words,sentence_id,labels
Hereditary,0,B-SpecificDisease
deficiency,0,I-SpecificDisease
of,0,I-SpecificDisease
the,0,I-SpecificDisease
fifth,0,I-SpecificDisease
component,0,I-SpecificDisease
of,0,I-SpecificDisease
complement,0,I-SpecificDisease
in,0,O
man,0,O
.,0,O
I,1,O
.,1,O
Clinical,2,O
",",2,O
immunochemical,2,O
",",2,O
and,2,O
family,2,O
studies,2,O
.,2,O
The,3,O
first,3,O
recognized,3,O
human,3,O
kindred,3,O
with,3,O
hereditary,3,B-SpecificDisease
deficiency,3,I-SpecificDisease
of,3,I-SpecificDisease
the,3,I-SpecificDisease
fifth,3,I-SpecificDisease
component,3,I-SpecificDisease
of,3,I-SpecificDisease
complement,3,I-SpecificDisease
(,3,O
C5,3,O
),3,O
is,3,O
described,3,O
.,3,O
The,4,O
proband,4,O
",",4,O
a,4,O
20-year-old,4,O
black,4,O
female,4,O
with,4,O
systemic,4,B-SpecificDisease
lupus,4,I-SpecificDisease
erythematosus,4,I-SpecificDisease
since,4,O
age,4,O
11,4,O
",",4,O
lacked,4,O
serum,4,O
hemolytic,4,O
complement,4,O
activity,4,O
",",4,O
even,4,O
during,4,O
remission,4,O
.,4,O
C5,5,O
was,5,O
undetectable,5,O
in,5,O
her,5,O
serum,5,O
by,5,O
both,5,O
immunodiffusion,5,O
and,5,O
hemolytic,5,O
assays,5,O
.,5,O
Other,6,O
complement,6,O
components,6,O
were,6,O
normal,6,O
during,6,O
remission,6,O
of,6,O
lupus,6,O
",",6,O
but,6,O
C1,6,O
",",6,O
C4,6,O
",",6,O
C2,6,O
",",6,O
and,6,O
C3,6,O
levels,6,O
fell,6,O
during,6,O
exacerbations,6,O
.,6,O
A,7,O
younger,7,O
half-sister,7,O
",",7,O
who,7,O
had,7,O
no,7,O
underlying,7,O
disease,7,O
",",7,O
was,7,O
also,7,O
found,7,O
to,7,O
lack,7,O
immunochemically,7,O
detectable,7,O
C5,7,O
.,7,O
By,8,O
hemolytic,8,O
assay,8,O
",",8,O
she,8,O
exhibited,8,O
1-2,8,O
%,8,O
of,8,O
the,8,O
normal,8,O
serum,8,O
C5,8,O
level,8,O
and,8,O
normal,8,O
concentrations,8,O
of,8,O
other,8,O
complement,8,O
components,8,O
.,8,O
C5,9,O
levels,9,O
of,9,O
other,9,O
family,9,O
members,9,O
were,9,O
either,9,O
normal,9,O
or,9,O
approximately,9,O
half-normal,9,O
",",9,O
consistent,9,O
with,9,O
autosomal,9,O
codominant,9,O
inheritance,9,O
of,9,O
the,9,O
gene,9,O
determining,9,O
C5,9,B-SpecificDisease
deficiency,9,I-SpecificDisease
.,9,O
Normal,10,O
hemolytic,10,O
titers,10,O
were,10,O
restored,10,O
to,10,O
both,10,O
homozygous,10,O
C5-deficient,10,B-Modifier
(,10,O
C5D,10,B-Modifier
),10,O
sera,10,O
by,10,O
addition,10,O
of,10,O
highly,10,O
purified,10,O
human,10,O
C5,10,O
.,10,O
In,11,O
specific,11,O
C5,11,O
titrations,11,O
",",11,O
however,11,O
",",11,O
it,11,O
was,11,O
noted,11,O
that,11,O
when,11,O
limited,11,O
amounts,11,O
of,11,O
C5,11,O
were,11,O
assayed,11,O
in,11,O
the,11,O
presence,11,O
of,11,O
low,11,O
dilutions,11,O
of,11,O
either,11,O
C5D,11,B-Modifier
serum,11,O
",",11,O
curving,11,O
rather,11,O
than,11,O
linear,11,O
dose-response,11,O
plots,11,O
were,11,O
consistently,11,O
obtained,11,O
",",11,O
suggesting,11,O
some,11,O
inhibitory,11,O
effect,11,O
.,11,O
Further,12,O
studies,12,O
suggested,12,O
that,12,O
low,12,O
dilutions,12,O
of,12,O
C5D,12,B-Modifier
serum,12,O
contain,12,O
a,12,O
factor,12,O
(,12,O
or,12,O
factors,12,O
),12,O
interfering,12,O
at,12,O
some,12,O
step,12,O
in,12,O
the,12,O
hemolytic,12,O
assay,12,O
of,12,O
C5,12,O
",",12,O
rather,12,O
than,12,O
a,12,O
true,12,O
C5,12,O
inhibitor,12,O
or,12,O
inactivator,12,O
.,12,O
Of,13,O
clinical,13,O
interest,13,O
are,13,O
(,13,O
a,13,O
),13,O
the,13,O
documentation,13,O
of,13,O
membranous,13,O
glomerulonephritis,13,B-SpecificDisease
",",13,O
vasculitis,13,B-SpecificDisease
",",13,O
and,13,O
arthritis,13,B-DiseaseClass
in,13,O
an,13,O
individual,13,O
lacking,13,O
C5,13,O
(,13,O
and,13,O
its,13,O
biologic,13,O
functions,13,O
),13,O
",",13,O
and,13,O
(,13,O
b,13,O
),13,O
a,13,O
remarkable,13,O
propensity,13,O
to,13,O
bacterial,13,B-DiseaseClass
infections,13,I-DiseaseClass
in,13,O
the,13,O
proband,13,O
",",13,O
even,13,O
during,13,O
periods,13,O
of,13,O
low-dose,13,O
or,13,O
alternate-day,13,O
corticosteroid,13,O
therapy,13,O
.,13,O
Other,14,O
observations,14,O
indicate,14,O
that,14,O
the,14,O
C5D,14,B-Modifier
state,14,O
is,14,O
compatible,14,O
with,14,O
normal,14,O
coagulation,14,O
function,14,O
and,14,O
the,14,O
capacity,14,O
to,14,O
mount,14,O
a,14,O
neutrophilic,14,O
leukocytosis,14,O
during,14,O
pyogenic,14,B-DiseaseClass
infection,14,I-DiseaseClass
..,14,O
Low,15,O
levels,15,O
of,15,O
beta,15,O
hexosaminidase,15,O
A,15,O
in,15,O
healthy,15,O
individuals,15,O
with,15,O
apparent,15,O
deficiency,15,O
of,15,O
this,15,O
enzyme,15,O
.,15,O
Appreciable,16,O
beta,16,O
hexosaminidase,16,O
A,16,O
(,16,O
hex,16,O
A,16,O
),16,O
activity,16,O
has,16,O
been,16,O
detected,16,O
in,16,O
cultured,16,O
skin,16,O
fibroblasts,16,O
and,16,O
melanoma,16,B-Modifier
tissue,16,O
from,16,O
healthy,16,O
individuals,16,O
previously,16,O
reported,16,O
as,16,O
having,16,O
deficiency,16,B-SpecificDisease
of,16,I-SpecificDisease
hex,16,I-SpecificDisease
A,16,I-SpecificDisease
activity,16,O
indistinguishable,16,O
from,16,O
that,16,O
of,16,O
patients,16,O
with,16,O
Tay-Sachs,16,B-SpecificDisease
disease,16,I-SpecificDisease
(,16,O
TSD,16,B-SpecificDisease
),16,O
.,16,O
Identification,17,O
and,17,O
quantitation,17,O
of,17,O
hex,17,O
A,17,O
",",17,O
amounting,17,O
to,17,O
3,17,O
.,17,O
5,18,O
%,18,O
-6,18,O
.,18,O
9,19,O
%,19,O
of,19,O
total,19,O
beta,19,O
hexosaminidase,19,O
activity,19,O
",",19,O
has,19,O
been,19,O
obtained,19,O
by,19,O
cellulose,19,O
acetate,19,O
gel,19,O
electrophoresis,19,O
",",19,O
DEAE-cellulose,19,O
ion-exchange,19,O
chromatography,19,O
",",19,O
radial,19,O
immunodiffusion,19,O
",",19,O
and,19,O
radioimmunoassay,19,O
.,19,O
Previous,20,O
family,20,O
studies,20,O
suggested,20,O
that,20,O
these,20,O
individuals,20,O
may,20,O
be,20,O
compound,20,O
heterozygotes,20,O
for,20,O
the,20,O
common,20,O
mutant,20,O
TSD,20,B-Modifier
gene,20,O
and,20,O
a,20,O
rare,20,O
(,20,O
allelic,20,O
),20,O
mutant,20,O
gene,20,O
.,20,O
Thus,21,O
",",21,O
the,21,O
postulated,21,O
rate,21,O
mutant,21,O
gene,21,O
appears,21,O
to,21,O
code,21,O
for,21,O
the,21,O
expression,21,O
of,21,O
low,21,O
amounts,21,O
of,21,O
hex,21,O
A.,21,O
Heterozygotes,21,O
for,21,O
the,21,O
rare,21,O
mutant,21,O
may,21,O
be,21,O
indistinguishable,21,O
from,21,O
heterozygotes,21,O
for,21,O
the,21,O
common,21,O
TSD,21,B-Modifier
mutant,21,O
.,21,O
However,22,O
",",22,O
direct,22,O
visualization,22,O
and,22,O
quantitation,22,O
of,22,O
hex,22,O
A,22,O
by,22,O
the,22,O
methods,22,O
described,22,O
may,22,O
prevent,22,O
false-positive,22,O
prenatal,22,O
diagnosis,22,O
of,22,O
TSD,22,B-SpecificDisease
in,22,O
fetuses,22,O
having,22,O
the,22,O
incomplete,22,O
hex,22,B-SpecificDisease
A,22,I-SpecificDisease
deficiency,22,I-SpecificDisease
of,22,O
the,22,O
type,22,O
described,22,O
in,22,O
the,22,O
four,22,O
healthy,22,O
individuals,22,O
The,23,O
chromosomal,23,O
order,23,O
of,23,O
genes,23,O
controlling,23,O
the,23,O
major,23,O
histocompatibility,23,O
complex,23,O
",",23,O
properdin,23,O
factor,23,O
B,23,O
",",23,O
and,23,O
deficiency,23,B-SpecificDisease
of,23,I-SpecificDisease
the,23,I-SpecificDisease
second,23,I-SpecificDisease
component,23,I-SpecificDisease
of,23,I-SpecificDisease
complement,23,I-SpecificDisease
.,23,O
The,24,O
relationship,24,O
of,24,O
the,24,O
genes,24,O
coding,24,O
for,24,O
HLA,24,O
to,24,O
those,24,O
coding,24,O
for,24,O
properdin,24,O
Factor,24,O
B,24,O
allotypes,24,O
and,24,O
for,24,O
deficiency,24,B-SpecificDisease
of,24,I-SpecificDisease
the,24,I-SpecificDisease
second,24,I-SpecificDisease
component,24,I-SpecificDisease
of,24,I-SpecificDisease
complement,24,I-SpecificDisease
(,24,O
C2,24,O
),24,O
was,24,O
studied,24,O
in,24,O
families,24,O
of,24,O
patients,24,O
with,24,O
connective,24,O
tissue,24,O
disorders,24,O
.,24,O
Patients,25,O
were,25,O
selected,25,O
because,25,O
they,25,O
were,25,O
heterozygous,25,O
or,25,O
homozygous,25,O
for,25,O
C2,25,B-SpecificDisease
deficiency,25,I-SpecificDisease
.,25,O
12,26,O
families,26,O
with,26,O
15,26,O
matings,26,O
informative,26,O
for,26,O
C2,26,B-SpecificDisease
deficiency,26,I-SpecificDisease
were,26,O
found,26,O
.,26,O
Of,27,O
57,27,O
informative,27,O
meioses,27,O
",",27,O
two,27,O
crossovers,27,O
were,27,O
noted,27,O
between,27,O
the,27,O
C2,27,B-Modifier
deficiency,27,I-Modifier
gene,27,O
and,27,O
the,27,O
HLA-B,27,O
gene,27,O
",",27,O
with,27,O
a,27,O
recombinant,27,O
fraction,27,O
of,27,O
0,27,O
.,27,O
035,28,O
.,28,O
A,29,O
lod,29,O
score,29,O
of,29,O
13,29,O
was,29,O
calculated,29,O
for,29,O
linkage,29,O
between,29,O
C2,29,B-SpecificDisease
deficiency,29,I-SpecificDisease
and,29,O
HLA-B,29,O
at,29,O
a,29,O
maximum,29,O
likelihood,29,O
value,29,O
of,29,O
the,29,O
recombinant,29,O
fraction,29,O
of,29,O
0,29,O
.,29,O
04,30,O
.,30,O
18,31,O
families,31,O
with,31,O
21,31,O
informative,31,O
matings,31,O
for,31,O
both,31,O
properdin,31,O
Factor,31,O
B,31,O
allotype,31,O
and,31,O
HLA-B,31,O
were,31,O
found,31,O
.,31,O
Of,32,O
72,32,O
informative,32,O
meioses,32,O
",",32,O
three,32,O
recombinants,32,O
were,32,O
found,32,O
",",32,O
giving,32,O
a,32,O
recombinant,32,O
fraction,32,O
of,32,O
0,32,O
.,32,O
042,33,O
.,33,O
A,34,O
lod,34,O
score,34,O
of,34,O
16,34,O
between,34,O
HLA-B,34,O
and,34,O
Factor,34,O
B,34,O
allotypes,34,O
was,34,O
calculated,34,O
at,34,O
a,34,O
maximum,34,O
likelihood,34,O
value,34,O
of,34,O
the,34,O
recombinant,34,O
fraction,34,O
of,34,O
0,34,O
.,34,O
04,35,O
.,35,O
A,36,O
crossover,36,O
was,36,O
shown,36,O
to,36,O
have,36,O
occurred,36,O
between,36,O
genes,36,O
for,36,O
Factor,36,O
B,36,O
and,36,O
HLA-D,36,O
",",36,O
in,36,O
which,36,O
HLA-D,36,O
segregared,36,O
with,36,O
HLA-A,36,O
and,36,O
B,36,O
.,36,O
These,37,O
studies,37,O
suggest,37,O
that,37,O
the,37,O
genes,37,O
for,37,O
Factor,37,O
B,37,O
and,37,O
C2,37,B-SpecificDisease
deficiency,37,I-SpecificDisease
are,37,O
located,37,O
outside,37,O
those,37,O
for,37,O
HLA,37,O
",",37,O
that,37,O
the,37,O
order,37,O
of,37,O
genese,37,O
is,37,O
HLA-A,37,O
",",37,O
-B,37,O
",",37,O
-D,37,O
",",37,O
Factor,37,O
B,37,O
allotype,37,O
",",37,O
C2,37,B-SpecificDisease
deficiency,37,I-SpecificDisease
",",37,O
that,37,O
the,37,O
genes,37,O
coding,37,O
for,37,O
C2,37,B-SpecificDisease
deficiency,37,I-SpecificDisease
and,37,O
Factor,37,O
B,37,O
allotypes,37,O
are,37,O
approximately,37,O
3,37,O
--,37,O
5,37,O
centimorgans,37,O
from,37,O
the,37,O
HLA-A,37,O
and,37,O
HLA-B,37,O
loci,37,O
",",37,O
and,37,O
that,37,O
the,37,O
apparent,37,O
lack,37,O
of,37,O
recombinants,37,O
between,37,O
the,37,O
Factor,37,O
B,37,O
gene,37,O
and,37,O
C2,37,B-Modifier
deficiency,37,I-Modifier
gene,37,O
suggests,37,O
that,37,O
these,37,O
two,37,O
genes,37,O
lie,37,O
in,37,O
close,37,O
proximity,37,O
to,37,O
one,37,O
another,37,O
.,37,O
Clustering,38,O
of,38,O
missense,38,O
mutations,38,O
in,38,O
the,38,O
ataxia-telangiectasia,38,B-Modifier
gene,38,O
in,38,O
a,38,O
sporadic,38,B-SpecificDisease
T-cell,38,I-SpecificDisease
leukaemia,38,I-SpecificDisease
.,38,O
Ataxia-telangiectasia,39,B-SpecificDisease
(,39,O
A-T,39,B-SpecificDisease
),39,O
is,39,O
a,39,O
recessive,39,B-DiseaseClass
multi-system,39,I-DiseaseClass
disorder,39,I-DiseaseClass
caused,39,O
by,39,O
mutations,39,O
in,39,O
the,39,O
ATM,39,O
gene,39,O
at,39,O
11q22-q23,39,O
(,39,O
ref,39,O
.,39,O
3,40,O
),40,O
.,40,O
The,41,O
risk,41,O
of,41,O
cancer,41,B-DiseaseClass
",",41,O
especially,41,O
lymphoid,41,B-DiseaseClass
neoplasias,41,I-DiseaseClass
",",41,O
is,41,O
substantially,41,O
elevated,41,O
in,41,O
A-T,41,B-Modifier
patients,41,O
and,41,O
has,41,O
long,41,O
been,41,O
associated,41,O
with,41,O
chromosomal,41,O
instability,41,O
.,41,O
By,42,O
analysing,42,O
tumour,42,B-Modifier
DNA,42,O
from,42,O
patients,42,O
with,42,O
sporadic,42,B-SpecificDisease
T-cell,42,I-SpecificDisease
prolymphocytic,42,I-SpecificDisease
leukaemia,42,I-SpecificDisease
(,42,O
T-PLL,42,B-SpecificDisease
),42,O
",",42,O
a,42,O
rare,42,O
clonal,42,B-DiseaseClass
malignancy,42,I-DiseaseClass
with,42,O
similarities,42,O
to,42,O
a,42,O
mature,42,B-SpecificDisease
T-cell,42,I-SpecificDisease
leukaemia,42,I-SpecificDisease
seen,42,O
in,42,O
A-T,42,B-SpecificDisease
",",42,O
we,42,O
demonstrate,42,O
a,42,O
high,42,O
frequency,42,O
of,42,O
ATM,42,O
mutations,42,O
in,42,O
T-PLL,42,B-SpecificDisease
.,42,O
In,43,O
marked,43,O
contrast,43,O
to,43,O
the,43,O
ATM,43,O
mutation,43,O
pattern,43,O
in,43,O
A-T,43,B-SpecificDisease
",",43,O
the,43,O
most,43,O
frequent,43,O
nucleotide,43,O
changes,43,O
in,43,O
this,43,O
leukaemia,43,B-DiseaseClass
were,43,O
missense,43,O
mutations,43,O
.,43,O
These,44,O
clustered,44,O
in,44,O
the,44,O
region,44,O
corresponding,44,O
to,44,O
the,44,O
kinase,44,O
domain,44,O
",",44,O
which,44,O
is,44,O
highly,44,O
conserved,44,O
in,44,O
ATM-related,44,O
proteins,44,O
in,44,O
mouse,44,O
",",44,O
yeast,44,O
and,44,O
Drosophila,44,O
.,44,O
The,45,O
resulting,45,O
amino-acid,45,O
substitutions,45,O
are,45,O
predicted,45,O
to,45,O
interfere,45,O
with,45,O
ATP,45,O
binding,45,O
or,45,O
substrate,45,O
recognition,45,O
.,45,O
Two,46,O
of,46,O
seventeen,46,O
mutated,46,O
T-PLL,46,B-SpecificDisease
samples,46,O
had,46,O
a,46,O
previously,46,O
reported,46,O
A-T,46,B-Modifier
allele,46,O
.,46,O
In,47,O
contrast,47,O
",",47,O
no,47,O
mutations,47,O
were,47,O
detected,47,O
in,47,O
the,47,O
p53,47,O
gene,47,O
",",47,O
suggesting,47,O
that,47,O
this,47,O
tumour,47,B-Modifier
suppressor,47,O
is,47,O
not,47,O
frequently,47,O
altered,47,O
in,47,O
this,47,O
leukaemia,47,B-DiseaseClass
.,47,O
Occasional,48,O
missense,48,O
mutations,48,O
in,48,O
ATM,48,O
were,48,O
also,48,O
found,48,O
in,48,O
tumour,48,B-Modifier
DNA,48,O
from,48,O
patients,48,O
with,48,O
B-cell,48,B-SpecificDisease
non-Hodgkins,48,I-SpecificDisease
lymphomas,48,I-SpecificDisease
(,48,O
B-NHL,48,B-SpecificDisease
),48,O
and,48,O
a,48,O
B-NHL,48,B-Modifier
cell,48,O
line,48,O
.,48,O
The,49,O
evidence,49,O
of,49,O
a,49,O
significant,49,O
proportion,49,O
of,49,O
loss-of-function,49,O
mutations,49,O
and,49,O
a,49,O
complete,49,O
absence,49,O
of,49,O
the,49,O
normal,49,O
copy,49,O
of,49,O
ATM,49,O
in,49,O
the,49,O
majority,49,O
of,49,O
mutated,49,O
tumours,49,B-DiseaseClass
establishes,49,O
somatic,49,O
inactivation,49,O
of,49,O
this,49,O
gene,49,O
in,49,O
the,49,O
pathogenesis,49,O
of,49,O
sporadic,49,B-SpecificDisease
T-PLL,49,I-SpecificDisease
and,49,O
suggests,49,O
that,49,O
ATM,49,O
acts,49,O
as,49,O
a,49,O
tumour,49,B-Modifier
suppressor,49,O
.,49,O
As,50,O
constitutional,50,O
DNA,50,O
was,50,O
not,50,O
available,50,O
",",50,O
a,50,O
putative,50,O
hereditary,50,O
predisposition,50,O
to,50,O
T-PLL,50,B-SpecificDisease
will,50,O
require,50,O
further,50,O
investigation,50,O
..,50,O
Myotonic,51,B-Modifier
dystrophy,51,I-Modifier
protein,51,O
kinase,51,O
is,51,O
involved,51,O
in,51,O
the,51,O
modulation,51,O
of,51,O
the,51,O
Ca2+,51,O
homeostasis,51,O
in,51,O
skeletal,51,O
muscle,51,O
cells,51,O
.,51,O
Myotonic,52,B-SpecificDisease
dystrophy,52,I-SpecificDisease
(,52,O
DM,52,B-SpecificDisease
),52,O
",",52,O
the,52,O
most,52,O
prevalent,52,O
muscular,52,B-DiseaseClass
disorder,52,I-DiseaseClass
in,52,O
adults,52,O
",",52,O
is,52,O
caused,52,O
by,52,O
(,52,O
CTG,52,O
),52,O
n-repeat,52,O
expansion,52,O
in,52,O
a,52,O
gene,52,O
encoding,52,O
a,52,O
protein,52,O
kinase,52,O
(,52,O
DM,52,B-Modifier
protein,52,O
kinase,52,O
;,52,O
DMPK,52,O
),52,O
and,52,O
involves,52,O
changes,52,O
in,52,O
cytoarchitecture,52,O
and,52,O
ion,52,O
homeostasis,52,O
.,52,O
To,53,O
obtain,53,O
clues,53,O
to,53,O
the,53,O
normal,53,O
biological,53,O
role,53,O
of,53,O
DMPK,53,O
in,53,O
cellular,53,O
ion,53,O
homeostasis,53,O
",",53,O
we,53,O
have,53,O
compared,53,O
the,53,O
resting,53,O
[,53,O
Ca2,53,O
+,53,O
],53,O
i,53,O
",",53,O
the,53,O
amplitude,53,O
and,53,O
shape,53,O
of,53,O
depolarization-induced,53,O
Ca2,53,O
+,53,O
transients,53,O
",",53,O
and,53,O
the,53,O
content,53,O
of,53,O
ATP-driven,53,O
ion,53,O
pumps,53,O
in,53,O
cultured,53,O
skeletal,53,O
muscle,53,O
cells,53,O
of,53,O
wild-type,53,O
and,53,O
DMPK,53,O
[,53,O
-/-,53,O
],53,O
knockout,53,O
mice,53,O
.,53,O
In,54,O
vitro-differentiated,54,O
DMPK,54,O
[,54,O
-/-,54,O
],54,O
myotubes,54,O
exhibit,54,O
a,54,O
higher,54,O
resting,54,O
[,54,O
Ca2,54,O
+,54,O
],54,O
i,54,O
than,54,O
do,54,O
wild-type,54,O
myotubes,54,O
because,54,O
of,54,O
an,54,O
altered,54,O
open,54,O
probability,54,O
of,54,O
voltage-dependent,54,O
l-type,54,O
Ca2,54,O
+,54,O
and,54,O
Na,54,O
+,54,O
channels,54,O
.,54,O
The,55,O
mutant,55,O
myotubes,55,O
exhibit,55,O
smaller,55,O
and,55,O
slower,55,O
Ca2,55,O
+,55,O
responses,55,O
upon,55,O
triggering,55,O
by,55,O
acetylcholine,55,O
or,55,O
high,55,O
external,55,O
K,55,O
+,55,O
.,55,O
In,56,O
addition,56,O
",",56,O
we,56,O
observed,56,O
that,56,O
these,56,O
Ca2,56,O
+,56,O
transients,56,O
partially,56,O
result,56,O
from,56,O
an,56,O
influx,56,O
of,56,O
extracellular,56,O
Ca2,56,O
+,56,O
through,56,O
the,56,O
l-type,56,O
Ca2,56,O
+,56,O
channel,56,O
.,56,O
Neither,57,O
the,57,O
content,57,O
nor,57,O
the,57,O
activity,57,O
of,57,O
Na,57,O
+/K,57,O
+,57,O
ATPase,57,O
and,57,O
sarcoplasmic,57,O
reticulum,57,O
Ca2,57,O
+,57,O
-ATPase,57,O
are,57,O
affected,57,O
by,57,O
DMPK,57,O
absence,57,O
.,57,O
In,58,O
conclusion,58,O
",",58,O
our,58,O
data,58,O
suggest,58,O
that,58,O
DMPK,58,O
is,58,O
involved,58,O
in,58,O
modulating,58,O
the,58,O
initial,58,O
events,58,O
of,58,O
excitation-contraction,58,O
coupling,58,O
in,58,O
skeletal,58,O
muscle,58,O
..,58,O
Constitutional,59,O
RB1-gene,59,O
mutations,59,O
in,59,O
patients,59,O
with,59,O
isolated,59,O
unilateral,59,B-SpecificDisease
retinoblastoma,59,I-SpecificDisease
.,59,O
In,60,O
most,60,O
patients,60,O
with,60,O
isolated,60,O
unilateral,60,B-SpecificDisease
retinoblastoma,60,I-SpecificDisease
",",60,O
tumor,60,B-Modifier
development,60,O
is,60,O
initiated,60,O
by,60,O
somatic,60,O
inactivation,60,O
of,60,O
both,60,O
alleles,60,O
of,60,O
the,60,O
RB1,60,O
gene,60,O
.,60,O
However,61,O
",",61,O
some,61,O
of,61,O
these,61,O
patients,61,O
can,61,O
transmit,61,O
retinoblastoma,61,B-Modifier
predisposition,61,O
to,61,O
their,61,O
offspring,61,O
.,61,O
To,62,O
determine,62,O
the,62,O
frequency,62,O
and,62,O
nature,62,O
of,62,O
constitutional,62,O
RB1-gene,62,O
mutations,62,O
in,62,O
patients,62,O
with,62,O
isolated,62,O
unilateral,62,B-SpecificDisease
retinoblastoma,62,I-SpecificDisease
",",62,O
we,62,O
analyzed,62,O
DNA,62,O
from,62,O
peripheral,62,O
blood,62,O
and,62,O
from,62,O
tumor,62,B-Modifier
tissue,62,O
.,62,O
The,63,O
analysis,63,O
of,63,O
tumors,63,B-DiseaseClass
from,63,O
54,63,O
(,63,O
71,63,O
%,63,O
),63,O
of,63,O
76,63,O
informative,63,O
patients,63,O
showed,63,O
loss,63,O
of,63,O
constitutional,63,O
heterozygosity,63,O
(,63,O
LOH,63,O
),63,O
at,63,O
intragenic,63,O
loci,63,O
.,63,O
Three,64,O
of,64,O
13,64,O
uninformative,64,O
patients,64,O
had,64,O
constitutional,64,O
deletions,64,O
.,64,O
For,65,O
39,65,O
randomly,65,O
selected,65,O
tumors,65,B-DiseaseClass
",",65,O
SSCP,65,O
",",65,O
hetero-duplex,65,O
analysis,65,O
",",65,O
sequencing,65,O
",",65,O
and,65,O
Southern,65,O
blot,65,O
analysis,65,O
were,65,O
used,65,O
to,65,O
identify,65,O
mutations,65,O
.,65,O
Mutations,66,O
were,66,O
detected,66,O
in,66,O
21,66,O
(,66,O
91,66,O
%,66,O
),66,O
of,66,O
23,66,O
tumors,66,B-DiseaseClass
with,66,O
LOH,66,O
.,66,O
In,67,O
6,67,O
(,67,O
38,67,O
%,67,O
),67,O
of,67,O
16,67,O
tumors,67,B-DiseaseClass
without,67,O
LOH,67,O
",",67,O
one,67,O
mutation,67,O
was,67,O
detected,67,O
",",67,O
and,67,O
in,67,O
9,67,O
(,67,O
56,67,O
%,67,O
),67,O
of,67,O
the,67,O
tumors,67,B-DiseaseClass
without,67,O
LOH,67,O
",",67,O
both,67,O
mutations,67,O
were,67,O
found,67,O
.,67,O
Thus,68,O
",",68,O
a,68,O
total,68,O
of,68,O
45,68,O
mutations,68,O
were,68,O
identified,68,O
in,68,O
tumors,68,B-DiseaseClass
of,68,O
36,68,O
patients,68,O
.,68,O
Thirty-nine,69,O
of,69,O
the,69,O
mutations-including,69,O
34,69,O
small,69,O
mutations,69,O
",",69,O
2,69,O
large,69,O
structural,69,O
alterations,69,O
",",69,O
and,69,O
hypermethylation,69,O
in,69,O
3,69,O
tumors-were,69,O
not,69,O
detected,69,O
in,69,O
the,69,O
corresponding,69,O
peripheral,69,O
blood,69,O
DNA,69,O
.,69,O
In,70,O
6,70,O
(,70,O
17,70,O
%,70,O
),70,O
of,70,O
the,70,O
36,70,O
patients,70,O
",",70,O
a,70,O
mutation,70,O
was,70,O
detected,70,O
in,70,O
constitutional,70,O
DNA,70,O
",",70,O
and,70,O
1,70,O
of,70,O
these,70,O
mutations,70,O
is,70,O
known,70,O
to,70,O
be,70,O
associated,70,O
with,70,O
reduced,70,O
expressivity,70,O
.,70,O
The,71,O
presence,71,O
of,71,O
a,71,O
constitutional,71,O
mutation,71,O
was,71,O
not,71,O
associated,71,O
with,71,O
an,71,O
early,71,O
age,71,O
at,71,O
treatment,71,O
.,71,O
In,72,O
1,72,O
patient,72,O
",",72,O
somatic,72,O
mosaicism,72,O
was,72,O
demonstrated,72,O
by,72,O
molecular,72,O
analysis,72,O
of,72,O
DNA,72,O
and,72,O
RNA,72,O
from,72,O
peripheral,72,O
blood,72,O
.,72,O
In,73,O
2,73,O
patients,73,O
without,73,O
a,73,O
detectable,73,O
mutation,73,O
in,73,O
peripheral,73,O
blood,73,O
",",73,O
mosaicism,73,O
was,73,O
suggested,73,O
because,73,O
1,73,O
of,73,O
the,73,O
patients,73,O
showed,73,O
multifocal,73,O
tumors,73,B-DiseaseClass
and,73,O
the,73,O
other,73,O
later,73,O
developed,73,O
bilateral,73,B-SpecificDisease
retinoblastoma,73,I-SpecificDisease
.,73,O
In,74,O
conclusion,74,O
",",74,O
our,74,O
results,74,O
emphasize,74,O
that,74,O
the,74,O
manifestation,74,O
and,74,O
transmissibility,74,O
of,74,O
retinoblastoma,74,B-SpecificDisease
depend,74,O
on,74,O
the,74,O
nature,74,O
of,74,O
the,74,O
first,74,O
mutation,74,O
",",74,O
its,74,O
time,74,O
in,74,O
development,74,O
",",74,O
and,74,O
the,74,O
number,74,O
and,74,O
types,74,O
of,74,O
cells,74,O
that,74,O
are,74,O
affected,74,O
..,74,O
Susceptibility,75,O
to,75,O
ankylosing,75,B-SpecificDisease
spondylitis,75,I-SpecificDisease
in,75,O
twins,75,O
:,75,O
the,75,O
role,75,O
of,75,O
genes,75,O
",",75,O
HLA,75,O
",",75,O
and,75,O
the,75,O
environment,75,O
.,75,O
OBJECTIVE,76,O
To,76,O
determine,76,O
the,76,O
relative,76,O
effects,76,O
of,76,O
genetic,76,O
and,76,O
environmental,76,O
factors,76,O
in,76,O
susceptibility,76,O
to,76,O
ankylosing,76,B-SpecificDisease
spondylitis,76,I-SpecificDisease
(,76,O
AS,76,B-SpecificDisease
),76,O
.,76,O
METHODS,77,O
Twins,77,O
with,77,O
AS,77,B-SpecificDisease
were,77,O
identified,77,O
from,77,O
the,77,O
Royal,77,O
National,77,O
Hospital,77,O
for,77,O
Rheumatic,77,B-DiseaseClass
Diseases,77,I-DiseaseClass
database,77,O
.,77,O
Clinical,78,O
and,78,O
radiographic,78,O
examinations,78,O
were,78,O
performed,78,O
to,78,O
establish,78,O
diagnoses,78,O
",",78,O
and,78,O
disease,78,O
severity,78,O
was,78,O
assessed,78,O
using,78,O
a,78,O
combination,78,O
of,78,O
validated,78,O
scoring,78,O
systems,78,O
.,78,O
HLA,79,O
typing,79,O
for,79,O
HLA-B27,79,O
",",79,O
HLA-B60,79,O
",",79,O
and,79,O
HLA-DR1,79,O
was,79,O
performed,79,O
by,79,O
polymerase,79,O
chain,79,O
reaction,79,O
with,79,O
sequence-specific,79,O
primers,79,O
",",79,O
and,79,O
zygosity,79,O
was,79,O
assessed,79,O
using,79,O
microsatellite,79,O
markers,79,O
.,79,O
Genetic,80,O
and,80,O
environmental,80,O
variance,80,O
components,80,O
were,80,O
assessed,80,O
with,80,O
the,80,O
program,80,O
Mx,80,O
",",80,O
using,80,O
data,80,O
from,80,O
this,80,O
and,80,O
previous,80,O
studies,80,O
of,80,O
twins,80,O
with,80,O
AS,80,B-SpecificDisease
.,80,O
RESULTS,81,O
Six,81,O
of,81,O
8,81,O
monozygotic,81,O
(,81,O
MZ,81,O
),81,O
twin,81,O
pairs,81,O
were,81,O
disease,81,O
concordant,81,O
",",81,O
compared,81,O
with,81,O
4,81,O
of,81,O
15,81,O
B27-positive,81,O
dizygotic,81,O
(,81,O
DZ,81,O
),81,O
twin,81,O
pairs,81,O
(,81,O
27,81,O
%,81,O
),81,O
and,81,O
4,81,O
of,81,O
32,81,O
DZ,81,O
twin,81,O
pairs,81,O
overall,81,O
(,81,O
12,81,O
.,81,O
5,82,O
%,82,O
),82,O
.,82,O
Nonsignificant,83,O
increases,83,O
in,83,O
similarity,83,O
with,83,O
regard,83,O
to,83,O
age,83,O
at,83,O
disease,83,O
onset,83,O
and,83,O
all,83,O
of,83,O
the,83,O
disease,83,O
severity,83,O
scores,83,O
assessed,83,O
were,83,O
noted,83,O
in,83,O
disease-concordant,83,O
MZ,83,O
twins,83,O
compared,83,O
with,83,O
concordant,83,O
DZ,83,O
twins,83,O
.,83,O
HLA-B27,84,O
and,84,O
B60,84,O
were,84,O
associated,84,O
with,84,O
the,84,O
disease,84,O
in,84,O
probands,84,O
",",84,O
and,84,O
the,84,O
rate,84,O
of,84,O
disease,84,O
concordance,84,O
was,84,O
significantly,84,O
increased,84,O
among,84,O
DZ,84,O
twin,84,O
pairs,84,O
in,84,O
which,84,O
the,84,O
co-twin,84,O
was,84,O
positive,84,O
for,84,O
both,84,O
B27,84,O
and,84,O
DR1,84,O
.,84,O
Additive,85,O
genetic,85,O
effects,85,O
were,85,O
estimated,85,O
to,85,O
contribute,85,O
97,85,O
%,85,O
of,85,O
the,85,O
population,85,O
variance,85,O
.,85,O
CONCLUSION,86,O
Susceptibility,86,O
to,86,O
AS,86,B-SpecificDisease
is,86,O
largely,86,O
genetically,86,O
determined,86,O
",",86,O
and,86,O
the,86,O
environmental,86,O
trigger,86,O
for,86,O
the,86,O
disease,86,O
is,86,O
probably,86,O
ubiquitous,86,O
.,86,O
HLA-B27,87,O
accounts,87,O
for,87,O
a,87,O
minority,87,O
of,87,O
the,87,O
overall,87,O
genetic,87,O
susceptibility,87,O
to,87,O
AS,87,B-SpecificDisease
.,87,O
Cell,88,O
cycle-dependent,88,O
colocalization,88,O
of,88,O
BARD1,88,O
and,88,O
BRCA1,88,O
proteins,88,O
in,88,O
discrete,88,O
nuclear,88,O
domains,88,O
.,88,O
Germ-line,89,O
mutations,89,O
of,89,O
the,89,O
BRCA1,89,O
gene,89,O
predispose,89,O
women,89,O
to,89,O
early-onset,89,O
breast,89,B-CompositeMention
and,89,I-CompositeMention
ovarian,89,I-CompositeMention
cancer,89,I-CompositeMention
by,89,O
compromising,89,O
the,89,O
genes,89,O
presumptive,89,O
function,89,O
as,89,O
a,89,O
tumor,89,B-Modifier
suppressor,89,O
.,89,O
Although,90,O
the,90,O
biochemical,90,O
properties,90,O
of,90,O
BRCA1,90,O
polypeptides,90,O
are,90,O
not,90,O
understood,90,O
",",90,O
their,90,O
expression,90,O
pattern,90,O
and,90,O
subcellular,90,O
localization,90,O
suggest,90,O
a,90,O
role,90,O
in,90,O
cell-cycle,90,O
regulation,90,O
.,90,O
When,91,O
resting,91,O
cells,91,O
are,91,O
induced,91,O
to,91,O
proliferate,91,O
",",91,O
the,91,O
steady-state,91,O
levels,91,O
of,91,O
BRCA1,91,O
increase,91,O
in,91,O
late,91,O
G1,91,O
and,91,O
reach,91,O
a,91,O
maximum,91,O
during,91,O
S,91,O
phase,91,O
.,91,O
Moreover,92,O
",",92,O
in,92,O
S,92,O
phase,92,O
cells,92,O
",",92,O
BRCA1,92,O
polypeptides,92,O
are,92,O
hyperphosphorylated,92,O
and,92,O
accumulate,92,O
into,92,O
discrete,92,O
subnuclear,92,O
foci,92,O
termed,92,O
``,92,O
BRCA1,92,O
nuclear,92,O
dots.,92,O
``,92,O
BRCA1,93,O
associates,93,O
in,93,O
vivo,93,O
with,93,O
a,93,O
structurally,93,O
related,93,O
protein,93,O
termed,93,O
BARD1,93,O
.,93,O
Here,94,O
we,94,O
show,94,O
that,94,O
the,94,O
steady-state,94,O
levels,94,O
of,94,O
BARD1,94,O
",",94,O
unlike,94,O
those,94,O
of,94,O
BRCA1,94,O
",",94,O
remain,94,O
relatively,94,O
constant,94,O
during,94,O
cell,94,O
cycle,94,O
progression,94,O
.,94,O
However,95,O
",",95,O
immunostaining,95,O
revealed,95,O
that,95,O
BARD1,95,O
resides,95,O
within,95,O
BRCA1,95,O
nuclear,95,O
dots,95,O
during,95,O
S,95,O
phase,95,O
of,95,O
the,95,O
cell,95,O
cycle,95,O
",",95,O
but,95,O
not,95,O
during,95,O
the,95,O
G1,95,O
phase,95,O
.,95,O
Nevertheless,96,O
",",96,O
BARD1,96,O
polypeptides,96,O
are,96,O
found,96,O
exclusively,96,O
in,96,O
the,96,O
nuclear,96,O
fractions,96,O
of,96,O
both,96,O
G1-,96,O
and,96,O
S-phase,96,O
cells,96,O
.,96,O
Therefore,97,O
",",97,O
progression,97,O
to,97,O
S,97,O
phase,97,O
is,97,O
accompanied,97,O
by,97,O
the,97,O
aggregation,97,O
of,97,O
nuclear,97,O
BARD1,97,O
polypeptides,97,O
into,97,O
BRCA1,97,O
nuclear,97,O
dots,97,O
.,97,O
This,98,O
cell,98,O
cycle-dependent,98,O
colocalization,98,O
of,98,O
BARD1,98,O
and,98,O
BRCA1,98,O
indicates,98,O
a,98,O
role,98,O
for,98,O
BARD1,98,O
in,98,O
BRCA1-mediated,98,O
tumor,98,B-Modifier
suppression,98,O
.,98,O
Ethnic,99,O
differences,99,O
in,99,O
the,99,O
HFE,99,O
codon,99,O
282,99,O
(,99,O
Cys/Tyr,99,O
),99,O
polymorphism,99,O
.,99,O
Recent,100,O
studies,100,O
have,100,O
shown,100,O
that,100,O
hereditary,100,B-SpecificDisease
hemochromatosis,100,I-SpecificDisease
(,100,O
HH,100,B-SpecificDisease
),100,O
is,100,O
likely,100,O
to,100,O
be,100,O
caused,100,O
by,100,O
homozygosity,100,O
for,100,O
a,100,O
Cys282Tyr,100,O
mutation,100,O
in,100,O
the,100,O
HFE,100,O
gene,100,O
located,100,O
4,100,O
.,100,O
5,101,O
Mb,101,O
telomeric,101,O
to,101,O
HLA-A,101,O
.,101,O
Population,102,O
studies,102,O
of,102,O
this,102,O
polymorphism,102,O
are,102,O
facilitated,102,O
by,102,O
the,102,O
fact,102,O
that,102,O
the,102,O
Cys282Tyr,102,O
mutation,102,O
creates,102,O
a,102,O
Rsal,102,O
restriction,102,O
site,102,O
.,102,O
We,103,O
have,103,O
studied,103,O
the,103,O
codon,103,O
282,103,O
(,103,O
Cys/Tyr,103,O
),103,O
polymorphism,103,O
in,103,O
different,103,O
ethnic,103,O
groups,103,O
.,103,O
In,104,O
agreement,104,O
with,104,O
previous,104,O
observations,104,O
the,104,O
Tyr,104,O
allele,104,O
appeared,104,O
to,104,O
be,104,O
rare,104,O
or,104,O
absent,104,O
in,104,O
Asiatic,104,O
(,104,O
Indian,104,O
",",104,O
Chinese,104,O
),104,O
populations,104,O
.,104,O
The,105,O
highest,105,O
allele,105,O
frequency,105,O
(,105,O
7,105,O
.,105,O
5,106,O
%,106,O
),106,O
was,106,O
found,106,O
in,106,O
Swedes,106,O
.,106,O
Saamis,107,O
(,107,O
2,107,O
%,107,O
),107,O
and,107,O
Mordvinians,107,O
(,107,O
1,107,O
.,107,O
8,108,O
%,108,O
),108,O
had,108,O
significantly,108,O
lower,108,O
frequencies,108,O
of,108,O
the,108,O
Tyr,108,O
allele,108,O
.,108,O
Comparisons,109,O
with,109,O
allele,109,O
frequencies,109,O
based,109,O
on,109,O
prevalence,109,O
estimates,109,O
of,109,O
HH,109,B-SpecificDisease
showed,109,O
some,109,O
disagreements,109,O
with,109,O
the,109,O
RFLP,109,O
data,109,O
",",109,O
particularly,109,O
in,109,O
Finns,109,O
.,109,O
The,110,O
newly,110,O
described,110,O
HFE,110,O
marker,110,O
provides,110,O
a,110,O
new,110,O
approach,110,O
to,110,O
the,110,O
screening,110,O
of,110,O
HH,110,B-SpecificDisease
as,110,O
well,110,O
as,110,O
studies,110,O
of,110,O
the,110,O
relationship,110,O
between,110,O
the,110,O
HFE,110,O
Tyr,110,O
allele,110,O
and,110,O
different,110,O
disorders,110,O
including,110,O
cancer,110,B-DiseaseClass
Autosomal,111,B-SpecificDisease
dominant,111,I-SpecificDisease
neurohypophyseal,111,I-SpecificDisease
diabetes,111,I-SpecificDisease
insipidus,111,I-SpecificDisease
associated,111,O
with,111,O
a,111,O
missense,111,O
mutation,111,O
encoding,111,O
Gly23,111,O
--,111,O
>,111,O
Val,111,O
in,111,O
neurophysin,111,O
II,111,O
.,111,O
Autosomal,112,B-SpecificDisease
dominant,112,I-SpecificDisease
neurohypophyseal,112,I-SpecificDisease
diabetes,112,I-SpecificDisease
insipidus,112,I-SpecificDisease
(,112,O
ADNDI,112,B-SpecificDisease
),112,O
is,112,O
an,112,O
inherited,112,B-DiseaseClass
disease,112,I-DiseaseClass
caused,112,O
by,112,O
progressive,112,O
degeneration,112,O
of,112,O
the,112,O
magnocellular,112,O
neurons,112,O
of,112,O
the,112,O
hypothalamus,112,O
leading,112,O
to,112,O
decreased,112,O
ability,112,O
to,112,O
produce,112,O
the,112,O
hormone,112,O
arginine,112,O
vasopressin,112,O
(,112,O
AVP,112,O
),112,O
.,112,O
Affected,113,O
individuals,113,O
are,113,O
not,113,O
symptomatic,113,O
at,113,O
birth,113,O
",",113,O
but,113,O
usually,113,O
develop,113,O
diabetes,113,B-SpecificDisease
insipidus,113,I-SpecificDisease
at,113,O
1-6,113,O
yr,113,O
of,113,O
age,113,O
.,113,O
The,114,O
genetic,114,O
locus,114,O
of,114,O
the,114,O
disease,114,O
is,114,O
the,114,O
AVP-neurophysin,114,O
II,114,O
(,114,O
NPII,114,O
),114,O
gene,114,O
",",114,O
and,114,O
mutations,114,O
that,114,O
cause,114,O
ADNDI,114,B-SpecificDisease
have,114,O
been,114,O
found,114,O
in,114,O
both,114,O
the,114,O
signal,114,O
peptide,114,O
of,114,O
the,114,O
prepro-AVP-NPII,114,O
precursor,114,O
and,114,O
within,114,O
NPII,114,O
itself,114,O
.,114,O
An,115,O
affected,115,O
girl,115,O
who,115,O
presented,115,O
at,115,O
9,115,O
months,115,O
of,115,O
age,115,O
and,115,O
her,115,O
similarly,115,O
affected,115,O
younger,115,O
brother,115,O
and,115,O
father,115,O
were,115,O
all,115,O
found,115,O
to,115,O
have,115,O
a,115,O
novel,115,O
missense,115,O
mutation,115,O
(,115,O
G1758,115,O
--,115,O
>,115,O
T,115,O
),115,O
encoding,115,O
the,115,O
amino,115,O
acid,115,O
substitution,115,O
Gly23,115,O
--,115,O
>,115,O
Val,115,O
within,115,O
NPII,115,O
.,115,O
The,116,O
mutation,116,O
was,116,O
confirmed,116,O
by,116,O
restriction,116,O
endonuclease,116,O
analysis,116,O
.,116,O
A,117,O
T1-weighted,117,O
magnetic,117,O
resonance,117,O
imaging,117,O
of,117,O
the,117,O
fathers,117,O
pituitary,117,O
gland,117,O
demonstrates,117,O
an,117,O
attenuated,117,O
posterior,117,O
pituitary,117,O
bright,117,O
spot,117,O
.,117,O
This,118,O
mutation,118,O
may,118,O
be,118,O
valuable,118,O
for,118,O
developing,118,O
models,118,O
of,118,O
dominantly,118,B-DiseaseClass
inherited,118,I-DiseaseClass
neurodegeneration,118,I-DiseaseClass
",",118,O
as,118,O
the,118,O
early,118,O
age,118,O
of,118,O
onset,118,O
of,118,O
symptoms,118,O
suggests,118,O
that,118,O
this,118,O
mutation,118,O
may,118,O
be,118,O
particularly,118,O
deleterious,118,O
to,118,O
the,118,O
magnocellular,118,O
neuron,118,O
..,118,O
Frequent,119,O
inactivation,119,O
of,119,O
PTEN/MMAC1,119,O
in,119,O
primary,119,O
prostate,119,B-SpecificDisease
cancer,119,I-SpecificDisease
.,119,O
Sporadic,120,B-SpecificDisease
prostate,120,I-SpecificDisease
carcinoma,120,I-SpecificDisease
is,120,O
the,120,O
most,120,O
common,120,O
male,120,B-DiseaseClass
cancer,120,I-DiseaseClass
in,120,O
the,120,O
Western,120,O
world,120,O
",",120,O
yet,120,O
many,120,O
of,120,O
the,120,O
major,120,O
genetic,120,O
events,120,O
involved,120,O
in,120,O
the,120,O
progression,120,O
of,120,O
this,120,O
often,120,O
fatal,120,O
cancer,120,B-DiseaseClass
remain,120,O
to,120,O
be,120,O
elucidated,120,O
.,120,O
Numerous,121,O
cytogenetic,121,O
and,121,O
allelotype,121,O
studies,121,O
have,121,O
reported,121,O
frequent,121,O
loss,121,O
of,121,O
heterozygosity,121,O
on,121,O
chromosomal,121,O
arm,121,O
10q,121,O
in,121,O
sporadic,121,B-SpecificDisease
prostate,121,I-SpecificDisease
cancer,121,I-SpecificDisease
.,121,O
Deletion,122,O
mapping,122,O
studies,122,O
have,122,O
unambiguously,122,O
identified,122,O
a,122,O
region,122,O
of,122,O
chromosome,122,O
10q23,122,O
to,122,O
be,122,O
the,122,O
minimal,122,O
area,122,O
of,122,O
loss,122,O
.,122,O
A,123,O
new,123,O
tumor,123,B-Modifier
suppressor,123,O
gene,123,O
",",123,O
PTEN/MMAC1,123,O
",",123,O
was,123,O
isolated,123,O
recently,123,O
at,123,O
this,123,O
region,123,O
of,123,O
chromosome,123,O
10q23,123,O
and,123,O
found,123,O
to,123,O
be,123,O
inactivated,123,O
by,123,O
mutation,123,O
in,123,O
three,123,O
prostate,123,B-Modifier
cancer,123,I-Modifier
cell,123,O
lines,123,O
.,123,O
We,124,O
screened,124,O
80,124,O
prostate,124,B-SpecificDisease
tumors,124,I-SpecificDisease
by,124,O
microsatellite,124,O
analysis,124,O
and,124,O
found,124,O
chromosome,124,O
10q23,124,O
to,124,O
be,124,O
deleted,124,O
in,124,O
23,124,O
cases,124,O
.,124,O
We,125,O
then,125,O
proceeded,125,O
with,125,O
sequence,125,O
analysis,125,O
of,125,O
the,125,O
entire,125,O
PTEN/MMAC1,125,O
coding,125,O
region,125,O
and,125,O
tested,125,O
for,125,O
homozygous,125,O
deletion,125,O
with,125,O
new,125,O
intragenic,125,O
markers,125,O
in,125,O
these,125,O
23,125,O
cases,125,O
with,125,O
10q23,125,O
loss,125,O
of,125,O
heterozygosity,125,O
.,125,O
The,126,O
identification,126,O
of,126,O
the,126,O
second,126,O
mutational,126,O
event,126,O
in,126,O
10,126,O
(,126,O
43,126,O
%,126,O
),126,O
tumors,126,B-DiseaseClass
establishes,126,O
PTEN/MMAC1,126,O
as,126,O
a,126,O
main,126,O
inactivation,126,O
target,126,O
of,126,O
10q,126,O
loss,126,O
in,126,O
sporadic,126,B-SpecificDisease
prostate,126,I-SpecificDisease
cancer,126,I-SpecificDisease
..,126,O
Risk,127,O
reversals,127,O
in,127,O
predictive,127,O
testing,127,O
for,127,O
Huntington,127,B-SpecificDisease
disease,127,I-SpecificDisease
.,127,O
The,128,O
first,128,O
predictive,128,O
testing,128,O
for,128,O
Huntington,128,B-SpecificDisease
disease,128,I-SpecificDisease
(,128,O
HD,128,B-SpecificDisease
),128,O
was,128,O
based,128,O
on,128,O
analysis,128,O
of,128,O
linked,128,O
polymorphic,128,O
DNA,128,O
markers,128,O
to,128,O
estimate,128,O
the,128,O
likelihood,128,O
of,128,O
inheriting,128,O
the,128,O
mutation,128,O
for,128,O
HD,128,B-SpecificDisease
.,128,O
Limits,129,O
to,129,O
accuracy,129,O
included,129,O
recombination,129,O
between,129,O
the,129,O
DNA,129,O
markers,129,O
and,129,O
the,129,O
mutation,129,O
",",129,O
pedigree,129,O
structure,129,O
",",129,O
and,129,O
whether,129,O
DNA,129,O
samples,129,O
were,129,O
available,129,O
from,129,O
family,129,O
members,129,O
.,129,O
With,130,O
direct,130,O
tests,130,O
for,130,O
the,130,O
HD,130,B-Modifier
mutation,130,O
",",130,O
we,130,O
have,130,O
assessed,130,O
the,130,O
accuracy,130,O
of,130,O
results,130,O
obtained,130,O
by,130,O
linkage,130,O
approaches,130,O
when,130,O
requested,130,O
to,130,O
do,130,O
so,130,O
by,130,O
the,130,O
test,130,O
individuals,130,O
.,130,O
For,131,O
six,131,O
such,131,O
individuals,131,O
",",131,O
there,131,O
was,131,O
significant,131,O
disparity,131,O
between,131,O
the,131,O
tests,131,O
.,131,O
Three,132,O
went,132,O
from,132,O
a,132,O
decreased,132,O
risk,132,O
to,132,O
an,132,O
increased,132,O
risk,132,O
",",132,O
while,132,O
in,132,O
another,132,O
three,132,O
the,132,O
risk,132,O
was,132,O
decreased,132,O
.,132,O
Knowledge,133,O
of,133,O
the,133,O
potential,133,O
reasons,133,O
for,133,O
these,133,O
changes,133,O
in,133,O
results,133,O
and,133,O
impact,133,O
of,133,O
these,133,O
risk,133,O
reversals,133,O
on,133,O
both,133,O
patients,133,O
and,133,O
the,133,O
counseling,133,O
team,133,O
can,133,O
assist,133,O
in,133,O
the,133,O
development,133,O
of,133,O
strategies,133,O
for,133,O
the,133,O
prevention,133,O
and,133,O
",",133,O
where,133,O
necessary,133,O
",",133,O
management,133,O
of,133,O
a,133,O
risk,133,O
reversal,133,O
in,133,O
any,133,O
predictive,133,O
testing,133,O
program,133,O
..,133,O
A,134,O
novel,134,O
common,134,O
missense,134,O
mutation,134,O
G301C,134,O
in,134,O
the,134,O
N-acetylgalactosamine-6-sulfate,134,O
sulfatase,134,O
gene,134,O
in,134,O
mucopolysaccharidosis,134,B-SpecificDisease
IVA,134,I-SpecificDisease
.,134,O
Mucopolysaccharidosis,135,B-SpecificDisease
IVA,135,I-SpecificDisease
(,135,O
MPS,135,B-SpecificDisease
IVA,135,I-SpecificDisease
),135,O
is,135,O
an,135,O
autosomal,135,B-DiseaseClass
recessive,135,I-DiseaseClass
lysosomal,135,I-DiseaseClass
storage,135,I-DiseaseClass
disorder,135,I-DiseaseClass
caused,135,O
by,135,O
a,135,O
genetic,135,B-DiseaseClass
defect,135,I-DiseaseClass
in,135,O
N-acetylgalactosamine-6-sulfate,135,O
sulfatase,135,O
(,135,O
GALNS,135,O
),135,O
.,135,O
In,136,O
previous,136,O
studies,136,O
",",136,O
we,136,O
have,136,O
found,136,O
two,136,O
common,136,O
mutations,136,O
in,136,O
Caucasians,136,O
and,136,O
Japanese,136,O
",",136,O
respectively,136,O
.,136,O
To,137,O
characterize,137,O
the,137,O
mutational,137,O
spectrum,137,O
in,137,O
various,137,O
ethnic,137,O
groups,137,O
",",137,O
mutations,137,O
in,137,O
the,137,O
GALNS,137,O
gene,137,O
in,137,O
Colombian,137,O
MPS,137,B-Modifier
IVA,137,I-Modifier
patients,137,O
were,137,O
investigated,137,O
",",137,O
and,137,O
genetic,137,O
backgrounds,137,O
were,137,O
extensively,137,O
analyzed,137,O
to,137,O
identify,137,O
racial,137,O
origin,137,O
",",137,O
based,137,O
on,137,O
mitochondrial,137,O
DNA,137,O
(,137,O
mtDNA,137,O
),137,O
lineages,137,O
.,137,O
Three,138,O
novel,138,O
missense,138,O
mutations,138,O
never,138,O
identified,138,O
previously,138,O
in,138,O
other,138,O
populations,138,O
and,138,O
found,138,O
in,138,O
16,138,O
out,138,O
of,138,O
19,138,O
Colombian,138,O
MPS,138,B-Modifier
IVA,138,I-Modifier
unrelated,138,O
alleles,138,O
account,138,O
for,138,O
84,138,O
.,138,O
2,139,O
%,139,O
of,139,O
the,139,O
alleles,139,O
in,139,O
this,139,O
study,139,O
.,139,O
The,140,O
G301C,140,O
and,140,O
S162F,140,O
mutations,140,O
account,140,O
for,140,O
68,140,O
.,140,O
4,141,O
%,141,O
and,141,O
10,141,O
.,141,O
5,142,O
%,142,O
of,142,O
mutations,142,O
",",142,O
respectively,142,O
",",142,O
whereas,142,O
the,142,O
remaining,142,O
F69V,142,O
is,142,O
limited,142,O
to,142,O
a,142,O
single,142,O
allele,142,O
.,142,O
The,143,O
skewed,143,O
prevalence,143,O
of,143,O
G301C,143,O
in,143,O
only,143,O
Colombian,143,O
patients,143,O
and,143,O
haplotype,143,O
analysis,143,O
by,143,O
restriction,143,O
fragment,143,O
length,143,O
polymorphisms,143,O
in,143,O
the,143,O
GALNS,143,O
gene,143,O
suggest,143,O
that,143,O
G301C,143,O
originated,143,O
from,143,O
a,143,O
common,143,O
ancestor,143,O
.,143,O
Investigation,144,O
of,144,O
the,144,O
genetic,144,O
background,144,O
by,144,O
means,144,O
of,144,O
mtDNA,144,O
lineages,144,O
indicate,144,O
that,144,O
all,144,O
our,144,O
patients,144,O
are,144,O
probably,144,O
of,144,O
native,144,O
American,144,O
descent,144,O
Low,145,O
frequency,145,O
of,145,O
BRCA1,145,O
germline,145,O
mutations,145,O
in,145,O
45,145,O
German,145,O
breast/ovarian,145,B-Modifier
cancer,145,I-Modifier
families,145,O
.,145,O
In,146,O
this,146,O
study,146,O
we,146,O
investigated,146,O
45,146,O
German,146,O
breast/ovarian,146,B-Modifier
cancer,146,I-Modifier
families,146,O
for,146,O
germline,146,O
mutations,146,O
in,146,O
the,146,O
BRCA1,146,O
gene,146,O
.,146,O
We,147,O
identified,147,O
four,147,O
germline,147,O
mutations,147,O
in,147,O
three,147,O
breast,147,B-Modifier
cancer,147,I-Modifier
families,147,O
and,147,O
in,147,O
one,147,O
breast-ovarian,147,B-Modifier
cancer,147,I-Modifier
family,147,O
.,147,O
among,148,O
these,148,O
were,148,O
one,148,O
frameshift,148,O
mutation,148,O
",",148,O
one,148,O
nonsense,148,O
mutation,148,O
",",148,O
one,148,O
novel,148,O
splice,148,O
site,148,O
mutation,148,O
",",148,O
and,148,O
one,148,O
missense,148,O
mutation,148,O
.,148,O
The,149,O
missense,149,O
mutation,149,O
was,149,O
also,149,O
found,149,O
in,149,O
2,149,O
.,149,O
8,150,O
%,150,O
of,150,O
the,150,O
general,150,O
population,150,O
",",150,O
suggesting,150,O
that,150,O
it,150,O
is,150,O
not,150,O
disease,150,O
associated,150,O
.,150,O
The,151,O
average,151,O
age,151,O
of,151,O
disease,151,O
onset,151,O
in,151,O
those,151,O
families,151,O
harbouring,151,O
causative,151,O
mutations,151,O
was,151,O
between,151,O
32,151,O
.,151,O
3,152,O
and,152,O
37,152,O
.,152,O
4,153,O
years,153,O
",",153,O
whereas,153,O
the,153,O
family,153,O
harbouring,153,O
the,153,O
missense,153,O
mutation,153,O
had,153,O
an,153,O
average,153,O
age,153,O
of,153,O
onset,153,O
of,153,O
51,153,O
.,153,O
2,154,O
years,154,O
.,154,O
These,155,O
findings,155,O
show,155,O
that,155,O
BRCA1,155,O
is,155,O
implicated,155,O
in,155,O
a,155,O
small,155,O
fraction,155,O
of,155,O
breast/ovarian,155,B-Modifier
cancer,155,I-Modifier
families,155,O
suggesting,155,O
the,155,O
involvement,155,O
of,155,O
another,155,O
susceptibility,155,O
gene,155,O
(,155,O
s,155,O
),155,O
Paternal,156,O
transmission,156,O
of,156,O
congenital,156,B-SpecificDisease
myotonic,156,I-SpecificDisease
dystrophy,156,I-SpecificDisease
.,156,O
We,157,O
report,157,O
a,157,O
rare,157,O
case,157,O
of,157,O
paternally,157,O
transmitted,157,O
congenital,157,B-SpecificDisease
myotonic,157,I-SpecificDisease
dystrophy,157,I-SpecificDisease
(,157,O
DM,157,B-SpecificDisease
),157,O
.,157,O
The,158,O
proband,158,O
is,158,O
a,158,O
23,158,O
year,158,O
old,158,O
",",158,O
mentally,158,B-Modifier
retarded,158,I-Modifier
male,158,O
who,158,O
suffers,158,O
severe,158,O
muscular,158,B-DiseaseClass
weakness,158,I-DiseaseClass
.,158,O
He,159,O
presented,159,O
with,159,O
respiratory,159,O
and,159,O
feeding,159,O
difficulties,159,O
at,159,O
birth,159,O
.,159,O
His,160,O
two,160,O
sibs,160,O
suffer,160,O
from,160,O
childhood,160,O
onset,160,O
DM,160,B-SpecificDisease
.,160,O
Their,161,O
late,161,O
father,161,O
had,161,O
the,161,O
adult,161,O
type,161,O
of,161,O
DM,161,B-SpecificDisease
",",161,O
with,161,O
onset,161,O
around,161,O
30,161,O
years,161,O
.,161,O
Only,162,O
six,162,O
other,162,O
cases,162,O
of,162,O
paternal,162,O
transmission,162,O
of,162,O
congenital,162,B-SpecificDisease
DM,162,I-SpecificDisease
have,162,O
been,162,O
reported,162,O
recently,162,O
.,162,O
We,163,O
review,163,O
the,163,O
sex,163,O
related,163,O
effects,163,O
on,163,O
transmission,163,O
of,163,O
congenital,163,B-SpecificDisease
DM,163,I-SpecificDisease
.,163,O
Decreased,164,O
fertility,164,O
of,164,O
males,164,O
with,164,O
adult,164,O
onset,164,O
DM,164,B-SpecificDisease
and,164,O
contraction,164,O
of,164,O
the,164,O
repeat,164,O
upon,164,O
male,164,O
transmission,164,O
contribute,164,O
to,164,O
the,164,O
almost,164,O
absent,164,O
occurrence,164,O
of,164,O
paternal,164,O
transmission,164,O
of,164,O
congenital,164,B-SpecificDisease
DM,164,I-SpecificDisease
.,164,O
Also,165,O
the,165,O
fathers,165,O
of,165,O
the,165,O
reported,165,O
congenitally,165,O
affected,165,O
children,165,O
showed,165,O
",",165,O
on,165,O
average,165,O
",",165,O
shorter,165,O
CTG,165,O
repeat,165,O
lengths,165,O
and,165,O
hence,165,O
less,165,O
severe,165,O
clinical,165,O
symptoms,165,O
than,165,O
the,165,O
mothers,165,O
of,165,O
children,165,O
with,165,O
congenital,165,B-SpecificDisease
DM,165,I-SpecificDisease
.,165,O
We,166,O
conclude,166,O
that,166,O
paternal,166,O
transmission,166,O
of,166,O
congenital,166,B-SpecificDisease
DM,166,I-SpecificDisease
is,166,O
rare,166,O
and,166,O
preferentially,166,O
occurs,166,O
with,166,O
onset,166,O
of,166,O
DM,166,B-SpecificDisease
past,166,O
30,166,O
years,166,O
in,166,O
the,166,O
father,166,O
..,166,O
The,167,O
RB1,167,O
gene,167,O
mutation,167,O
in,167,O
a,167,O
child,167,O
with,167,O
ectopic,167,B-SpecificDisease
intracranial,167,I-SpecificDisease
retinoblastoma,167,I-SpecificDisease
.,167,O
The,168,O
RB1,168,O
gene,168,O
mutation,168,O
was,168,O
investigated,168,O
in,168,O
a,168,O
child,168,O
with,168,O
ectopic,168,B-SpecificDisease
intracranial,168,I-SpecificDisease
retinoblastoma,168,I-SpecificDisease
using,168,O
DNA,168,O
obtained,168,O
from,168,O
both,168,O
the,168,O
pineal,168,O
and,168,O
retinal,168,O
tumours,168,O
of,168,O
the,168,O
patient,168,O
.,168,O
A,169,O
nonsense,169,O
mutation,169,O
in,169,O
exon,169,O
17,169,O
(,169,O
codon,169,O
556,169,O
),169,O
of,169,O
the,169,O
RB1,169,O
gene,169,O
was,169,O
found,169,O
to,169,O
be,169,O
present,169,O
homozygously,169,O
in,169,O
both,169,O
the,169,O
retinal,169,O
and,169,O
the,169,O
pineal,169,O
tumours,169,O
.,169,O
The,170,O
same,170,O
mutation,170,O
was,170,O
present,170,O
heterozygously,170,O
in,170,O
the,170,O
DNA,170,O
from,170,O
the,170,O
constitutional,170,O
cells,170,O
of,170,O
the,170,O
patient,170,O
",",170,O
proving,170,O
it,170,O
to,170,O
be,170,O
of,170,O
germline,170,O
origin,170,O
.,170,O
The,171,O
initial,171,O
mutation,171,O
was,171,O
shown,171,O
to,171,O
have,171,O
occurred,171,O
in,171,O
the,171,O
paternally,171,O
derived,171,O
RB1,171,O
allele,171,O
.,171,O
The,172,O
mutation,172,O
is,172,O
in,172,O
an,172,O
area,172,O
of,172,O
the,172,O
gene,172,O
that,172,O
encodes,172,O
the,172,O
protein-binding,172,O
region,172,O
known,172,O
as,172,O
the,172,O
pocket,172,O
region,172,O
and,172,O
has,172,O
been,172,O
detected,172,O
in,172,O
other,172,O
cases,172,O
of,172,O
retinoblastoma,172,B-SpecificDisease
..,172,O
The,173,O
tumor,173,B-Modifier
suppressor,173,O
gene,173,O
Smad4/Dpc4,173,O
is,173,O
required,173,O
for,173,O
gastrulation,173,O
and,173,O
later,173,O
for,173,O
anterior,173,O
development,173,O
of,173,O
the,173,O
mouse,173,O
embryo,173,O
.,173,O
Mutations,174,O
in,174,O
the,174,O
SMAD4/DPC4,174,O
tumor,174,B-Modifier
suppressor,174,O
gene,174,O
",",174,O
a,174,O
key,174,O
signal,174,O
transducer,174,O
in,174,O
most,174,O
TGFbeta-related,174,O
pathways,174,O
",",174,O
are,174,O
involved,174,O
in,174,O
50,174,O
%,174,O
of,174,O
pancreatic,174,B-SpecificDisease
cancers,174,I-SpecificDisease
.,174,O
Homozygous,175,O
Smad4,175,O
mutant,175,O
mice,175,O
die,175,O
before,175,O
day,175,O
7,175,O
.,175,O
5,176,O
of,176,O
embryogenesis,176,O
.,176,O
Mutant,177,O
embryos,177,O
have,177,O
reduced,177,O
size,177,O
",",177,O
fail,177,O
to,177,O
gastrulate,177,O
or,177,O
express,177,O
a,177,O
mesodermal,177,O
marker,177,O
",",177,O
and,177,O
show,177,O
abnormal,177,O
visceral,177,O
endoderm,177,O
development,177,O
.,177,O
Growth,178,B-DiseaseClass
retardation,178,I-DiseaseClass
of,178,O
the,178,O
Smad4-deficient,178,O
embryos,178,O
results,178,O
from,178,O
reduced,178,O
cell,178,O
proliferation,178,O
rather,178,O
than,178,O
increased,178,O
apoptosis,178,O
.,178,O
Aggregation,179,O
of,179,O
mutant,179,O
Smad4,179,O
ES,179,O
cells,179,O
with,179,O
wild-type,179,O
tetraploid,179,O
morulae,179,O
rescues,179,O
the,179,O
gastrulation,179,B-SpecificDisease
defect,179,I-SpecificDisease
.,179,O
These,180,O
results,180,O
indicate,180,O
that,180,O
Smad4,180,O
is,180,O
initially,180,O
required,180,O
for,180,O
the,180,O
differentiation,180,O
of,180,O
the,180,O
visceral,180,O
endoderm,180,O
and,180,O
that,180,O
the,180,O
gastrulation,180,B-SpecificDisease
defect,180,I-SpecificDisease
in,180,O
the,180,O
epiblast,180,O
is,180,O
secondary,180,O
and,180,O
non-cell,180,O
autonomous,180,O
.,180,O
Rescued,181,O
embryos,181,O
show,181,O
severe,181,O
anterior,181,O
truncations,181,O
",",181,O
indicating,181,O
a,181,O
second,181,O
important,181,O
role,181,O
for,181,O
Smad4,181,O
in,181,O
anterior,181,O
patterning,181,O
during,181,O
embryogenesis,181,O
.,181,O
Prevalence,182,O
of,182,O
p16,182,O
and,182,O
CDK4,182,O
germline,182,O
mutations,182,O
in,182,O
48,182,O
melanoma-prone,182,B-Modifier
families,182,O
in,182,O
France,182,O
.,182,O
The,183,O
French,183,O
Familial,183,B-Modifier
Melanoma,183,I-Modifier
Study,183,O
Group,183,O
.,183,O
Germline,184,O
mutations,184,O
in,184,O
the,184,O
p16,184,O
and,184,O
CDK4,184,O
genes,184,O
have,184,O
been,184,O
reported,184,O
in,184,O
a,184,O
subset,184,O
of,184,O
melanoma,184,B-Modifier
pedigrees,184,O
",",184,O
but,184,O
their,184,O
prevalence,184,O
is,184,O
not,184,O
well,184,O
known,184,O
.,184,O
We,185,O
searched,185,O
for,185,O
such,185,O
germline,185,O
mutations,185,O
in,185,O
48,185,O
French,185,O
melanoma-prone,185,B-Modifier
families,185,O
selected,185,O
according,185,O
to,185,O
two,185,O
major,185,O
criteria,185,O
families,185,O
with,185,O
at,185,O
least,185,O
three,185,O
affected,185,O
members,185,O
(,185,O
n,185,O
=,185,O
20,185,O
),185,O
or,185,O
families,185,O
with,185,O
two,185,O
affected,185,O
members,185,O
",",185,O
one,185,O
of,185,O
them,185,O
affected,185,O
before,185,O
the,185,O
age,185,O
of,185,O
50,185,O
(,185,O
n,185,O
=,185,O
28,185,O
),185,O
",",185,O
and,185,O
one,185,O
additional,185,O
minor,185,O
criterion,185,O
.,185,O
Sixteen,186,O
different,186,O
p16,186,O
germline,186,O
mutations,186,O
were,186,O
found,186,O
in,186,O
21,186,O
families,186,O
",",186,O
while,186,O
one,186,O
germline,186,O
mutation,186,O
",",186,O
Arg24His,186,O
",",186,O
was,186,O
detected,186,O
in,186,O
the,186,O
CDK4,186,O
gene,186,O
.,186,O
The,187,O
frequency,187,O
of,187,O
p16,187,O
gene,187,O
mutation,187,O
in,187,O
our,187,O
sample,187,O
(,187,O
44,187,O
%,187,O
),187,O
is,187,O
among,187,O
the,187,O
highest,187,O
rates,187,O
yet,187,O
reported,187,O
and,187,O
the,187,O
CDK4,187,O
mutation,187,O
is,187,O
the,187,O
second,187,O
mutation,187,O
detected,187,O
in,187,O
this,187,O
gene,187,O
worldwide,187,O
.,187,O
In,188,O
summary,188,O
",",188,O
our,188,O
results,188,O
show,188,O
frequent,188,O
involvement,188,O
of,188,O
the,188,O
p16,188,O
gene,188,O
in,188,O
familial,188,B-SpecificDisease
melanoma,188,I-SpecificDisease
and,188,O
confirm,188,O
the,188,O
role,188,O
of,188,O
the,188,O
CDK4,188,O
gene,188,O
as,188,O
a,188,O
melanoma-predisposing,188,B-Modifier
gene,188,O
..,188,O
Progression,189,O
of,189,O
somatic,189,O
CTG,189,O
repeat,189,O
length,189,O
heterogeneity,189,O
in,189,O
the,189,O
blood,189,O
cells,189,O
of,189,O
myotonic,189,B-Modifier
dystrophy,189,I-Modifier
patients,189,O
.,189,O
The,190,O
genetic,190,O
basis,190,O
of,190,O
myotonic,190,B-SpecificDisease
dystrophy,190,I-SpecificDisease
(,190,O
DM,190,B-SpecificDisease
),190,O
is,190,O
the,190,O
expansion,190,O
of,190,O
an,190,O
unstable,190,O
CTG,190,O
repeat,190,O
in,190,O
the,190,O
34,190,O
UTR,190,O
of,190,O
the,190,O
DM,190,B-Modifier
protein,190,O
kinase,190,O
gene,190,O
on,190,O
chromosome,190,O
19,190,O
.,190,O
One,191,O
of,191,O
the,191,O
principal,191,O
features,191,O
of,191,O
the,191,O
DM,191,B-Modifier
mutation,191,O
is,191,O
an,191,O
extraordinarily,191,O
high,191,O
level,191,O
of,191,O
somatic,191,O
mosaicism,191,O
",",191,O
due,191,O
to,191,O
an,191,O
extremely,191,O
high,191,O
degree,191,O
of,191,O
somatic,191,O
instability,191,O
both,191,O
within,191,O
and,191,O
between,191,O
different,191,O
tissues,191,O
.,191,O
This,192,O
instability,192,O
appears,192,O
to,192,O
be,192,O
biased,192,O
towards,192,O
further,192,O
expansion,192,O
and,192,O
continuous,192,O
throughout,192,O
the,192,O
life,192,O
of,192,O
an,192,O
individual,192,O
",",192,O
features,192,O
that,192,O
could,192,O
be,192,O
associated,192,O
with,192,O
the,192,O
progressive,192,O
nature,192,O
of,192,O
the,192,O
disease,192,O
.,192,O
Although,193,O
increasing,193,O
measured,193,O
allele,193,O
size,193,O
between,193,O
patients,193,O
clearly,193,O
correlates,193,O
with,193,O
an,193,O
increased,193,O
severity,193,O
of,193,O
symptoms,193,O
and,193,O
an,193,O
earlier,193,O
age,193,O
of,193,O
onset,193,O
",",193,O
this,193,O
correlation,193,O
is,193,O
not,193,O
precise,193,O
and,193,O
measured,193,O
allele,193,O
length,193,O
can,193,O
not,193,O
be,193,O
used,193,O
as,193,O
an,193,O
accurate,193,O
predictor,193,O
of,193,O
age,193,O
of,193,O
onset,193,O
.,193,O
In,194,O
order,194,O
to,194,O
further,194,O
characterize,194,O
the,194,O
dynamics,194,O
of,194,O
DM,194,B-Modifier
CTG,194,O
repeat,194,O
somatic,194,O
instability,194,O
",",194,O
we,194,O
have,194,O
studied,194,O
repeat,194,O
length,194,O
changes,194,O
over,194,O
time,194,O
in,194,O
111,194,O
myotonic,194,B-Modifier
dystrophy,194,I-Modifier
patients,194,O
with,194,O
varying,194,O
clinical,194,O
severity,194,O
and,194,O
CTG,194,O
repeat,194,O
size,194,O
over,194,O
time,194,O
intervals,194,O
of,194,O
1-7,194,O
years,194,O
.,194,O
We,195,O
have,195,O
found,195,O
a,195,O
direct,195,O
progression,195,O
of,195,O
the,195,O
size,195,O
heterogeneity,195,O
over,195,O
time,195,O
related,195,O
to,195,O
initial,195,O
CTG,195,O
repeat,195,O
size,195,O
and,195,O
the,195,O
time,195,O
interval,195,O
and,195,O
always,195,O
biased,195,O
towards,195,O
further,195,O
expansion,195,O
.,195,O
Attempts,196,O
to,196,O
mathematically,196,O
model,196,O
the,196,O
dynamics,196,O
have,196,O
proved,196,O
only,196,O
partially,196,O
successful,196,O
suggesting,196,O
that,196,O
individual,196,O
specific,196,O
genetic,196,O
and/or,196,O
environmental,196,O
factors,196,O
also,196,O
play,196,O
a,196,O
role,196,O
in,196,O
somatic,196,O
mosaicism,196,O
..,196,O
Aspartylglucosaminuria,197,B-SpecificDisease
among,197,O
Palestinian,197,O
Arabs,197,O
.,197,O
Aspartylglucosaminuria,198,B-SpecificDisease
(,198,O
AGU,198,B-SpecificDisease
),198,O
is,198,O
a,198,O
rare,198,O
disorder,198,B-DiseaseClass
of,198,I-DiseaseClass
glycoprotein,198,I-DiseaseClass
metabolism,198,I-DiseaseClass
caused,198,O
by,198,O
the,198,O
deficiency,198,B-SpecificDisease
of,198,I-SpecificDisease
the,198,I-SpecificDisease
lysosomal,198,I-SpecificDisease
enzyme,198,I-SpecificDisease
aspartylglucosaminidase,198,I-SpecificDisease
(,198,O
AGA,198,O
),198,O
.,198,O
AGU,199,B-SpecificDisease
is,199,O
inherited,199,O
as,199,O
an,199,O
autosomal,199,O
recessive,199,O
trait,199,O
and,199,O
occurs,199,O
with,199,O
a,199,O
high,199,O
frequency,199,O
in,199,O
Finland,199,O
because,199,O
of,199,O
a,199,O
founder,199,O
effect,199,O
.,199,O
While,200,O
very,200,O
few,200,O
patients,200,O
with,200,O
AGU,200,B-SpecificDisease
have,200,O
been,200,O
reported,200,O
from,200,O
non-Finnish,200,O
origin,200,O
",",200,O
we,200,O
diagnosed,200,O
the,200,O
disorder,200,O
in,200,O
8,200,O
patients,200,O
originating,200,O
from,200,O
3,200,O
unrelated,200,O
families,200,O
",",200,O
all,200,O
Palestinian,200,O
Arabs,200,O
from,200,O
the,200,O
region,200,O
of,200,O
Jerusalem,200,O
.,200,O
The,201,O
clinical,201,O
diagnosis,201,O
of,201,O
AGU,201,B-SpecificDisease
is,201,O
often,201,O
difficult,201,O
",",201,O
in,201,O
particular,201,O
early,201,O
in,201,O
the,201,O
course,201,O
of,201,O
the,201,O
disease,201,O
",",201,O
and,201,O
most,201,O
of,201,O
the,201,O
patients,201,O
are,201,O
diagnosed,201,O
after,201,O
the,201,O
age,201,O
of,201,O
5,201,O
years,201,O
.,201,O
However,202,O
",",202,O
since,202,O
these,202,O
patients,202,O
excrete,202,O
early,202,O
large,202,O
amounts,202,O
of,202,O
aspartylglucosamine,202,O
in,202,O
urine,202,O
",",202,O
biochemical,202,O
screening,202,O
is,202,O
easy,202,O
by,202,O
urine,202,O
chromatography,202,O
..,202,O
Detection,203,O
of,203,O
heterozygous,203,O
carriers,203,O
of,203,O
the,203,O
ataxia-telangiectasia,203,B-Modifier
(,203,O
ATM,203,O
),203,O
gene,203,O
by,203,O
G2,203,O
phase,203,O
chromosomal,203,O
radiosensitivity,203,O
of,203,O
peripheral,203,O
blood,203,O
lymphocytes,203,O
.,203,O
In,204,O
ataxia-telangiectasia,204,B-Modifier
(,204,O
A-T,204,B-Modifier
),204,O
patients,204,O
",",204,O
mutations,204,O
in,204,O
a,204,O
single,204,O
gene,204,O
",",204,O
ATM,204,O
",",204,O
result,204,O
in,204,O
an,204,O
autosomal,204,B-DiseaseClass
recessive,204,I-DiseaseClass
syndrome,204,I-DiseaseClass
that,204,O
embraces,204,O
a,204,O
variety,204,O
of,204,O
clinical,204,O
features,204,O
and,204,O
manifests,204,O
extreme,204,O
radiosensitivity,204,O
and,204,O
a,204,O
strong,204,O
pre-disposition,204,O
to,204,O
malignancy,204,B-DiseaseClass
.,204,O
Heterozygotes,205,O
for,205,O
the,205,O
ATM,205,O
gene,205,O
have,205,O
no,205,O
clinical,205,O
expression,205,O
of,205,O
A-T,205,B-SpecificDisease
but,205,O
may,205,O
be,205,O
cancer,205,B-Modifier
prone,205,O
with,205,O
a,205,O
moderate,205,O
increase,205,O
in,205,O
in,205,O
vitro,205,O
radiosensitivity,205,O
.,205,O
We,206,O
performed,206,O
a,206,O
blind,206,O
chromosomal,206,O
analysis,206,O
on,206,O
G2-phase,206,O
lymphocytes,206,O
from,206,O
7,206,O
unrelated,206,O
A-T,206,B-Modifier
patients,206,O
",",206,O
13,206,O
obligate,206,O
A-T,206,B-Modifier
heterozygotes,206,O
(,206,O
parents,206,O
of,206,O
the,206,O
patients,206,O
),206,O
",",206,O
and,206,O
14,206,O
normal,206,O
controls,206,O
following,206,O
X-irradiation,206,O
with,206,O
1,206,O
Gy,206,O
in,206,O
order,206,O
to,206,O
evaluate,206,O
this,206,O
cytogenetic,206,O
method,206,O
as,206,O
a,206,O
tool,206,O
for,206,O
detection,206,O
of,206,O
ATM,206,O
carriers,206,O
.,206,O
Both,207,O
A-T,207,B-Modifier
homozygotes,207,O
and,207,O
heterozygotes,207,O
showed,207,O
significantly,207,O
increased,207,O
levels,207,O
of,207,O
radiation-induced,207,O
chromatid,207,O
damage,207,O
relative,207,O
to,207,O
that,207,O
of,207,O
normal,207,O
controls,207,O
.,207,O
These,208,O
results,208,O
show,208,O
that,208,O
the,208,O
G2-phase,208,O
chromosomal,208,O
radiosensitivity,208,O
assay,208,O
can,208,O
be,208,O
used,208,O
for,208,O
the,208,O
detection,208,O
of,208,O
A-T,208,B-Modifier
heterozygotes,208,O
.,208,O
In,209,O
combination,209,O
with,209,O
molecular,209,O
genetic,209,O
analyses,209,O
",",209,O
this,209,O
test,209,O
may,209,O
be,209,O
of,209,O
value,209,O
in,209,O
studies,209,O
of,209,O
familial,209,B-CompositeMention
and,209,I-CompositeMention
sporadic,209,I-CompositeMention
cancers,209,I-CompositeMention
aimed,209,O
at,209,O
determination,209,O
of,209,O
the,209,O
potential,209,O
involvement,209,O
of,209,O
ATM,209,O
mutations,209,O
in,209,O
tumor,209,B-Modifier
risk,209,O
or,209,O
development,209,O
..,209,O
Ataxia-telangiectasia,210,B-SpecificDisease
:,210,O
identification,210,O
and,210,O
detection,210,O
of,210,O
founder-effect,210,O
mutations,210,O
in,210,O
the,210,O
ATM,210,O
gene,210,O
in,210,O
ethnic,210,O
populations,210,O
.,210,O
To,211,O
facilitate,211,O
the,211,O
evaluation,211,O
of,211,O
ATM,211,O
heterozygotes,211,O
for,211,O
susceptibility,211,O
to,211,O
other,211,O
diseases,211,O
",",211,O
such,211,O
as,211,O
breast,211,B-SpecificDisease
cancer,211,I-SpecificDisease
",",211,O
we,211,O
have,211,O
attempted,211,O
to,211,O
define,211,O
the,211,O
most,211,O
common,211,O
mutations,211,O
and,211,O
their,211,O
frequencies,211,O
in,211,O
ataxia-telangiectasia,211,B-Modifier
(,211,O
A-T,211,B-Modifier
),211,O
homozygotes,211,O
from,211,O
10,211,O
ethnic,211,O
populations,211,O
.,211,O
Both,212,O
genomic,212,O
mutations,212,O
and,212,O
their,212,O
effects,212,O
on,212,O
cDNA,212,O
were,212,O
characterized,212,O
.,212,O
Protein-truncation,213,O
testing,213,O
of,213,O
the,213,O
entire,213,O
ATM,213,O
cDNA,213,O
detected,213,O
92,213,O
(,213,O
66,213,O
%,213,O
),213,O
truncating,213,O
mutations,213,O
in,213,O
140,213,O
mutant,213,O
alleles,213,O
screened,213,O
.,213,O
The,214,O
haplotyping,214,O
of,214,O
patients,214,O
with,214,O
identical,214,O
mutations,214,O
indicates,214,O
that,214,O
almost,214,O
all,214,O
of,214,O
these,214,O
represent,214,O
common,214,O
ancestry,214,O
and,214,O
that,214,O
very,214,O
few,214,O
spontaneously,214,O
recurring,214,O
ATM,214,O
mutations,214,O
exist,214,O
.,214,O
Assays,215,O
requiring,215,O
minimal,215,O
amounts,215,O
of,215,O
genomic,215,O
DNA,215,O
were,215,O
designed,215,O
to,215,O
allow,215,O
rapid,215,O
screening,215,O
for,215,O
common,215,O
ethnic,215,O
mutations,215,O
.,215,O
These,216,O
rapid,216,O
assays,216,O
detected,216,O
mutations,216,O
in,216,O
76,216,O
%,216,O
of,216,O
Costa,216,O
Rican,216,O
patients,216,O
(,216,O
3,216,O
),216,O
",",216,O
50,216,O
%,216,O
of,216,O
Norwegian,216,O
patients,216,O
(,216,O
1,216,O
),216,O
",",216,O
25,216,O
%,216,O
of,216,O
Polish,216,O
patients,216,O
(,216,O
4,216,O
),216,O
",",216,O
and,216,O
14,216,O
%,216,O
of,216,O
Italian,216,O
patients,216,O
(,216,O
1,216,O
),216,O
",",216,O
as,216,O
well,216,O
as,216,O
in,216,O
patients,216,O
of,216,O
Amish/Mennonite,216,O
and,216,O
Irish,216,O
English,216,O
backgrounds,216,O
.,216,O
Additional,217,O
mutations,217,O
were,217,O
observed,217,O
in,217,O
Japanese,217,O
",",217,O
Utah,217,O
Mormon,217,O
",",217,O
and,217,O
African,217,O
American,217,O
patients,217,O
.,217,O
These,218,O
assays,218,O
should,218,O
facilitate,218,O
screening,218,O
for,218,O
A-T,218,B-Modifier
heterozygotes,218,O
in,218,O
the,218,O
populations,218,O
studied,218,O
..,218,O
The,219,O
von,219,B-Modifier
Hippel-Lindau,219,I-Modifier
tumor,219,I-Modifier
suppressor,219,O
gene,219,O
is,219,O
required,219,O
for,219,O
cell,219,O
cycle,219,O
exit,219,O
upon,219,O
serum,219,O
withdrawal,219,O
.,219,O
The,220,O
inactivation,220,O
of,220,O
the,220,O
von,220,B-Modifier
Hippel-Lindau,220,I-Modifier
(,220,I-Modifier
VHL,220,I-Modifier
),220,I-Modifier
tumor,220,I-Modifier
suppressor,220,O
gene,220,O
predisposes,220,O
affected,220,O
individuals,220,O
to,220,O
the,220,O
human,220,O
VHL,220,B-SpecificDisease
cancer,220,I-SpecificDisease
syndrome,220,I-SpecificDisease
and,220,O
is,220,O
associated,220,O
with,220,O
sporadic,220,B-SpecificDisease
renal,220,I-SpecificDisease
cell,220,I-SpecificDisease
carcinomas,220,I-SpecificDisease
(,220,O
RCC,220,B-SpecificDisease
),220,O
and,220,O
brain,220,B-SpecificDisease
hemangioblastomas,220,I-SpecificDisease
.,220,O
VHL-negative,221,O
786-0,221,O
RCC,221,B-Modifier
cells,221,O
are,221,O
tumorigenic,221,O
in,221,O
nude,221,O
mice,221,O
which,221,O
is,221,O
suppressed,221,O
by,221,O
the,221,O
reintroduction,221,O
of,221,O
VHL,221,B-SpecificDisease
.,221,O
Remarkably,222,O
",",222,O
this,222,O
occurs,222,O
without,222,O
affecting,222,O
the,222,O
growth,222,O
rate,222,O
and,222,O
cell,222,O
cycle,222,O
profile,222,O
of,222,O
these,222,O
cells,222,O
in,222,O
culture,222,O
.,222,O
The,223,O
786-0,223,O
cell,223,O
line,223,O
",",223,O
like,223,O
many,223,O
cancer,223,B-Modifier
cells,223,O
",",223,O
fails,223,O
to,223,O
exit,223,O
the,223,O
cell,223,O
cycle,223,O
upon,223,O
serum,223,O
withdrawal,223,O
.,223,O
Here,224,O
",",224,O
it,224,O
is,224,O
shown,224,O
that,224,O
reintroduction,224,O
of,224,O
the,224,O
wild-type,224,O
VHL,224,B-Modifier
gene,224,O
restores,224,O
the,224,O
ability,224,O
of,224,O
VHL-negative,224,O
RCC,224,B-Modifier
cancer,224,I-Modifier
cells,224,O
to,224,O
exit,224,O
the,224,O
cell,224,O
cycle,224,O
and,224,O
enter,224,O
G0/quiescence,224,O
in,224,O
low,224,O
serum,224,O
.,224,O
Both,225,O
VHL-positive,225,O
and,225,O
VHL-negative,225,O
RCC,225,B-Modifier
cells,225,O
exit,225,O
the,225,O
cell,225,O
cycle,225,O
by,225,O
contact,225,O
inhibition,225,O
.,225,O
The,226,O
cyclin-dependent,226,O
kinase,226,O
inhibitor,226,O
",",226,O
p27,226,O
",",226,O
accumulates,226,O
upon,226,O
serum,226,O
withdrawal,226,O
",",226,O
only,226,O
in,226,O
the,226,O
presence,226,O
of,226,O
VHL,226,B-SpecificDisease
",",226,O
as,226,O
a,226,O
result,226,O
of,226,O
the,226,O
stabilization,226,O
of,226,O
the,226,O
protein,226,O
.,226,O
We,227,O
propose,227,O
that,227,O
the,227,O
loss,227,O
of,227,O
wild-type,227,O
VHL,227,B-Modifier
gene,227,O
results,227,O
in,227,O
a,227,O
specific,227,O
cellular,227,O
defect,227,O
in,227,O
serum-dependent,227,O
growth,227,O
control,227,O
",",227,O
which,227,O
may,227,O
initiate,227,O
tumor,227,B-Modifier
formation,227,O
.,227,O
This,228,O
is,228,O
corrected,228,O
by,228,O
the,228,O
reintroduction,228,O
of,228,O
wild-type,228,O
VHL,228,B-SpecificDisease
",",228,O
implicating,228,O
VHL,228,B-SpecificDisease
as,228,O
the,228,O
first,228,O
tumor,228,B-Modifier
suppressor,228,O
involved,228,O
in,228,O
the,228,O
regulation,228,O
of,228,O
cell,228,O
cycle,228,O
exit,228,O
",",228,O
which,228,O
is,228,O
consistent,228,O
with,228,O
its,228,O
gatekeeper,228,O
function,228,O
in,228,O
the,228,O
kidney,228,O
..,228,O
Piebaldism,229,B-SpecificDisease
with,229,O
deafness,229,B-SpecificDisease
:,229,O
molecular,229,O
evidence,229,O
for,229,O
an,229,O
expanded,229,O
syndrome,229,O
.,229,O
In,230,O
a,230,O
South,230,O
African,230,O
girl,230,O
of,230,O
Xhosa,230,O
stock,230,O
with,230,O
severe,230,O
piebaldism,230,B-SpecificDisease
and,230,O
profound,230,O
congenital,230,O
sensorineural,230,B-SpecificDisease
deafness,230,I-SpecificDisease
we,230,O
identified,230,O
a,230,O
novel,230,O
missense,230,O
substitution,230,O
at,230,O
a,230,O
highly,230,O
conserved,230,O
residue,230,O
in,230,O
the,230,O
intracellular,230,O
kinase,230,O
domain,230,O
of,230,O
the,230,O
KIT,230,O
proto-oncogene,230,O
",",230,O
R796G,230,O
.,230,O
Though,231,O
auditory,231,B-DiseaseClass
anomalies,231,I-DiseaseClass
have,231,O
been,231,O
observed,231,O
in,231,O
mice,231,O
with,231,O
dominant,231,O
white,231,O
spotting,231,O
(,231,O
W,231,O
),231,O
due,231,O
to,231,O
KIT,231,O
mutations,231,O
",",231,O
deafness,231,B-SpecificDisease
is,231,O
not,231,O
typical,231,O
in,231,O
human,231,O
piebaldism,231,B-SpecificDisease
.,231,O
Thus,232,O
",",232,O
the,232,O
occurrence,232,O
of,232,O
sensorineural,232,B-SpecificDisease
deafness,232,I-SpecificDisease
in,232,O
this,232,O
patient,232,O
extends,232,O
considerably,232,O
the,232,O
phenotypic,232,O
range,232,O
of,232,O
piebaldism,232,B-SpecificDisease
due,232,O
to,232,O
KIT,232,O
gene,232,O
mutation,232,O
in,232,O
humans,232,O
and,232,O
tightens,232,O
the,232,O
clinical,232,O
similarity,232,O
between,232,O
piebaldism,232,B-SpecificDisease
and,232,O
the,232,O
various,232,O
forms,232,O
of,232,O
Waardenburg,232,B-SpecificDisease
syndrome,232,I-SpecificDisease
..,232,O
Cycloheximide,233,O
facilitates,233,O
the,233,O
identification,233,O
of,233,O
aberrant,233,O
transcripts,233,O
resulting,233,O
from,233,O
a,233,O
novel,233,O
splice-site,233,O
mutation,233,O
in,233,O
COL17A1,233,O
in,233,O
a,233,O
patient,233,O
with,233,O
generalized,233,O
atrophic,233,B-SpecificDisease
benign,233,I-SpecificDisease
epidermolysis,233,I-SpecificDisease
bullosa,233,I-SpecificDisease
.,233,O
Patients,234,O
with,234,O
generalized,234,O
atrophic,234,B-SpecificDisease
benign,234,I-SpecificDisease
epidermolysis,234,I-SpecificDisease
bullosa,234,I-SpecificDisease
often,234,O
show,234,O
decreased,234,O
expression,234,O
of,234,O
type,234,O
XVII,234,O
collagen,234,O
",",234,O
a,234,O
transmembrane,234,O
hemidesmosomal,234,O
protein,234,O
encoded,234,O
by,234,O
COL17A1,234,O
.,234,O
This,235,O
report,235,O
documents,235,O
a,235,O
novel,235,O
splice-site,235,O
mutation,235,O
in,235,O
COL17A1,235,O
in,235,O
a,235,O
patient,235,O
with,235,O
generalized,235,O
atrophic,235,B-SpecificDisease
benign,235,I-SpecificDisease
epidermolysis,235,I-SpecificDisease
bullosa,235,I-SpecificDisease
",",235,O
and,235,O
applies,235,O
a,235,O
new,235,O
methodology,235,O
to,235,O
define,235,O
and,235,O
characterize,235,O
the,235,O
resulting,235,O
mRNA,235,O
splice,235,O
variants,235,O
.,235,O
Mutational,236,O
analysis,236,O
of,236,O
COL17A1,236,O
identified,236,O
a,236,O
maternally,236,O
inherited,236,O
G-to-T,236,O
transversion,236,O
at,236,O
the,236,O
-1,236,O
position,236,O
of,236,O
exon,236,O
32,236,O
.,236,O
This,237,O
acceptor,237,O
splice-site,237,O
mutation,237,O
led,237,O
to,237,O
the,237,O
formation,237,O
of,237,O
aberrant,237,O
transcripts,237,O
present,237,O
at,237,O
extremely,237,O
low,237,O
levels,237,O
.,237,O
Based,238,O
on,238,O
our,238,O
recent,238,O
finding,238,O
that,238,O
cycloheximide,238,O
stabilized,238,O
mutant,238,O
COL17A1,238,O
transcripts,238,O
in,238,O
keratinocytes,238,O
homozygous,238,O
for,238,O
a,238,O
frameshift,238,O
mutation,238,O
",",238,O
the,238,O
effects,238,O
of,238,O
the,238,O
splice-site,238,O
mutation,238,O
on,238,O
splicing,238,O
of,238,O
COL17A1,238,O
transcripts,238,O
were,238,O
determined,238,O
using,238,O
reverse,238,O
transcriptase,238,O
polymerase,238,O
chain,238,O
reaction,238,O
of,238,O
total,238,O
RNA,238,O
from,238,O
keratinocytes,238,O
incubated,238,O
for,238,O
2,238,O
.,238,O
5,239,O
h,239,O
in,239,O
the,239,O
presence,239,O
or,239,O
absence,239,O
of,239,O
10,239,O
microg,239,O
cycloheximide,239,O
per,239,O
ml,239,O
.,239,O
Using,240,O
this,240,O
approach,240,O
",",240,O
an,240,O
abnormally,240,O
spliced,240,O
transcript,240,O
was,240,O
identified,240,O
that,240,O
contains,240,O
an,240,O
extra,240,O
264,240,O
bases,240,O
upstream,240,O
from,240,O
exon,240,O
32,240,O
",",240,O
resulting,240,O
in,240,O
a,240,O
premature,240,O
termination,240,O
codon,240,O
27,240,O
bp,240,O
downstream,240,O
from,240,O
the,240,O
cryptic,240,O
splice,240,O
site,240,O
.,240,O
Three,241,O
other,241,O
splice,241,O
variants,241,O
",",241,O
including,241,O
one,241,O
derived,241,O
from,241,O
the,241,O
skipping,241,O
of,241,O
exon,241,O
32,241,O
",",241,O
were,241,O
also,241,O
identified,241,O
.,241,O
These,242,O
results,242,O
indicate,242,O
the,242,O
usefulness,242,O
of,242,O
cycloheximide,242,O
treatment,242,O
in,242,O
evaluating,242,O
the,242,O
abnormal,242,O
processing,242,O
of,242,O
mRNA,242,O
due,242,O
to,242,O
splice-site,242,O
mutations,242,O
",",242,O
because,242,O
(,242,O
i,242,O
),242,O
aberrant,242,O
splicing,242,O
often,242,O
generates,242,O
a,242,O
premature,242,O
termination,242,O
codon,242,O
",",242,O
(,242,O
ii,242,O
),242,O
transcripts,242,O
with,242,O
premature,242,O
termination,242,O
codons,242,O
can,242,O
occur,242,O
at,242,O
low,242,O
or,242,O
undetectable,242,O
levels,242,O
due,242,O
to,242,O
nonsense-mediated,242,O
mRNA,242,O
decay,242,O
",",242,O
and,242,O
(,242,O
iii,242,O
),242,O
the,242,O
levels,242,O
of,242,O
these,242,O
transcripts,242,O
can,242,O
be,242,O
increased,242,O
by,242,O
cycloheximide,242,O
.,242,O
A,243,O
deletion,243,O
mutation,243,O
in,243,O
COL17A1,243,O
in,243,O
five,243,O
Austrian,243,O
families,243,O
with,243,O
generalized,243,O
atrophic,243,B-SpecificDisease
benign,243,I-SpecificDisease
epidermolysis,243,I-SpecificDisease
bullosa,243,I-SpecificDisease
represents,243,O
propagation,243,O
of,243,O
an,243,O
ancestral,243,O
allele,243,O
.,243,O
Patients,244,O
with,244,O
generalized,244,O
atrophic,244,B-SpecificDisease
benign,244,I-SpecificDisease
epidermolysis,244,I-SpecificDisease
bullosa,244,I-SpecificDisease
",",244,O
a,244,O
usually,244,O
nonlethal,244,O
form,244,O
of,244,O
junctional,244,B-SpecificDisease
epidermolysis,244,I-SpecificDisease
bullosa,244,I-SpecificDisease
",",244,O
have,244,O
generalized,244,O
blistering,244,B-SpecificDisease
",",244,O
nail,244,B-SpecificDisease
dystrophy,244,I-SpecificDisease
",",244,O
patchy,244,B-SpecificDisease
alopecia,244,I-SpecificDisease
",",244,O
and,244,O
dental,244,B-DiseaseClass
abnormalities,244,I-DiseaseClass
.,244,O
Skin,245,B-DiseaseClass
fragility,245,I-DiseaseClass
in,245,O
most,245,O
cases,245,O
is,245,O
due,245,O
to,245,O
mutations,245,O
in,245,O
the,245,O
gene,245,O
encoding,245,O
type,245,O
XVII,245,O
collagen,245,O
(,245,O
COL17A1,245,O
),245,O
.,245,O
Recently,246,O
",",246,O
we,246,O
reported,246,O
five,246,O
Austrian,246,O
families,246,O
with,246,O
generalized,246,O
atrophic,246,B-SpecificDisease
benign,246,I-SpecificDisease
epidermolysis,246,I-SpecificDisease
bullosa,246,I-SpecificDisease
who,246,O
share,246,O
the,246,O
same,246,O
COL17A1,246,O
mutation,246,O
.,246,O
Affected,247,O
individuals,247,O
in,247,O
three,247,O
families,247,O
are,247,O
homozygous,247,O
for,247,O
4003delTC,247,O
",",247,O
whereas,247,O
those,247,O
in,247,O
two,247,O
others,247,O
are,247,O
compound,247,O
heterozygotes,247,O
.,247,O
To,248,O
determine,248,O
if,248,O
the,248,O
occurrence,248,O
of,248,O
4003delTC,248,O
in,248,O
these,248,O
unrelated,248,O
families,248,O
signifies,248,O
propagation,248,O
of,248,O
an,248,O
ancestral,248,O
allele,248,O
or,248,O
a,248,O
mutational,248,O
hot,248,O
spot,248,O
",",248,O
haplotypes,248,O
were,248,O
determined,248,O
for,248,O
polymorphisms,248,O
both,248,O
within,248,O
and,248,O
flanking,248,O
COL17A1,248,O
.,248,O
Five,249,O
intragenic,249,O
polymorphisms,249,O
were,249,O
chosen,249,O
based,249,O
on,249,O
their,249,O
informativeness,249,O
.,249,O
One,250,O
of,250,O
these,250,O
",",250,O
not,250,O
previously,250,O
reported,250,O
",",250,O
was,250,O
2988,250,O
A,250,O
or,250,O
C,250,O
that,250,O
introduces,250,O
a,250,O
new,250,O
restriction,250,O
site,250,O
for,250,O
Eco0109,250,O
I,250,O
.,250,O
All,251,O
the,251,O
4003delTC,251,O
alleles,251,O
showed,251,O
the,251,O
same,251,O
haplotype,251,O
for,251,O
these,251,O
five,251,O
polymorphic,251,O
markers,251,O
.,251,O
Fourteen,252,O
microsatellite,252,O
polymorphisms,252,O
were,252,O
selected,252,O
based,252,O
on,252,O
their,252,O
high,252,O
heterozygosity,252,O
and,252,O
their,252,O
location,252,O
within,252,O
10q23-q25,252,O
near,252,O
COL17A1,252,O
.,252,O
Three,253,O
families,253,O
shared,253,O
microsatellite,253,O
polymorphisms,253,O
covering,253,O
at,253,O
most,253,O
19,253,O
cM,253,O
",",253,O
whereas,253,O
the,253,O
others,253,O
shared,253,O
smaller,253,O
regions,253,O
consistent,253,O
with,253,O
cross-over,253,O
events,253,O
during,253,O
passage,253,O
of,253,O
this,253,O
mutation,253,O
through,253,O
several,253,O
generations,253,O
.,253,O
These,254,O
results,254,O
indicate,254,O
that,254,O
4003delTC,254,O
occurs,254,O
on,254,O
a,254,O
single,254,O
ancestral,254,O
allele,254,O
..,254,O
The,255,O
haptoglobin-gene,255,O
deletion,255,O
responsible,255,O
for,255,O
anhaptoglobinemia,255,B-SpecificDisease
.,255,O
We,256,O
have,256,O
found,256,O
an,256,O
allelic,256,O
deletion,256,O
of,256,O
the,256,O
haptoglobin,256,O
(,256,O
Hp,256,O
),256,O
gene,256,O
from,256,O
an,256,O
individual,256,O
with,256,O
anhaptoglobinemia,256,B-SpecificDisease
.,256,O
The,257,O
Hp,257,O
gene,257,O
cluster,257,O
consists,257,O
of,257,O
coding,257,O
regions,257,O
of,257,O
the,257,O
alpha,257,O
chain,257,O
and,257,O
beta,257,O
chain,257,O
of,257,O
the,257,O
haptoglobin,257,O
gene,257,O
(,257,O
Hp,257,O
),257,O
and,257,O
of,257,O
the,257,O
alpha,257,O
chain,257,O
and,257,O
beta,257,O
chain,257,O
of,257,O
the,257,O
haptoglobin-related,257,O
gene,257,O
(,257,O
Hpr,257,O
),257,O
",",257,O
in,257,O
tandem,257,O
from,257,O
the,257,O
5,257,O
side,257,O
.,257,O
Southern,258,O
blot,258,O
and,258,O
PCR,258,O
analyses,258,O
have,258,O
indicated,258,O
that,258,O
the,258,O
individual,258,O
with,258,O
anhaptoglobinemia,258,B-SpecificDisease
was,258,O
homozygous,258,O
for,258,O
the,258,O
gene,258,O
deletion,258,O
and,258,O
that,258,O
the,258,O
gene,258,O
deletion,258,O
was,258,O
included,258,O
at,258,O
least,258,O
from,258,O
the,258,O
promoter,258,O
region,258,O
of,258,O
Hp,258,O
to,258,O
Hpr,258,O
alpha,258,O
but,258,O
not,258,O
to,258,O
Hpr,258,O
beta,258,O
(,258,O
Hpdel,258,O
),258,O
.,258,O
In,259,O
addition,259,O
",",259,O
we,259,O
found,259,O
seven,259,O
individuals,259,O
with,259,O
hypohaptoglobinemia,259,B-SpecificDisease
in,259,O
three,259,O
families,259,O
",",259,O
and,259,O
the,259,O
genotypes,259,O
of,259,O
six,259,O
of,259,O
the,259,O
seven,259,O
individuals,259,O
were,259,O
found,259,O
to,259,O
be,259,O
Hp2/Hpdel,259,O
.,259,O
The,260,O
phenotypes,260,O
and,260,O
genotypes,260,O
in,260,O
one,260,O
of,260,O
these,260,O
three,260,O
families,260,O
showed,260,O
the,260,O
father,260,O
to,260,O
be,260,O
hypohaptoglobinemic,260,B-Modifier
(,260,O
Hp2,260,O
),260,O
and,260,O
Hp2/Hpdel,260,O
",",260,O
the,260,O
mother,260,O
to,260,O
be,260,O
Hp2-1,260,O
and,260,O
Hp1/Hp2,260,O
",",260,O
one,260,O
of,260,O
the,260,O
two,260,O
children,260,O
to,260,O
be,260,O
hypohaptoglobinemic,260,B-Modifier
(,260,O
Hp2,260,O
),260,O
and,260,O
Hp2/Hpdel,260,O
",",260,O
and,260,O
the,260,O
other,260,O
child,260,O
to,260,O
be,260,O
Hp1,260,O
and,260,O
Hp1/Hpdel,260,O
",",260,O
showing,260,O
an,260,O
anomalous,260,O
inheritance,260,O
of,260,O
Hp,260,O
phenotypes,260,O
in,260,O
the,260,O
child,260,O
with,260,O
Hp1,260,O
.,260,O
The,261,O
Hp2/Hpdel,261,O
individuals,261,O
had,261,O
an,261,O
extremely,261,O
low,261,O
level,261,O
of,261,O
Hp,261,O
(,261,O
mean,261,O
+/-SD,261,O
=,261,O
0,261,O
.,261,O
049,262,O
+/-0,262,O
.,262,O
043,263,O
mg/ml,263,O
;,263,O
n,263,O
=,263,O
6,263,O
),263,O
",",263,O
compared,263,O
with,263,O
the,263,O
level,263,O
(,263,O
1,263,O
.,263,O
64,264,O
+/-1,264,O
.,264,O
07,265,O
mg/ml,265,O
),265,O
obtained,265,O
from,265,O
52,265,O
healthy,265,O
volunteers,265,O
having,265,O
phenotype,265,O
Hp2,265,O
",",265,O
whereas,265,O
the,265,O
serum,265,O
Hp,265,O
level,265,O
of,265,O
an,265,O
individual,265,O
with,265,O
Hp1/Hpdel,265,O
was,265,O
0,265,O
.,265,O
50,266,O
mg/ml,266,O
",",266,O
which,266,O
was,266,O
approximately,266,O
half,266,O
the,266,O
level,266,O
of,266,O
Hp,266,O
in,266,O
control,266,O
sera,266,O
from,266,O
the,266,O
Hp1,266,O
phenotype,266,O
(,266,O
1,266,O
.,266,O
26,267,O
+/-0,267,O
.,267,O
33,268,O
mg/ml,268,O
;,268,O
n,268,O
=,268,O
9,268,O
),268,O
",",268,O
showing,268,O
a,268,O
gene-dosage,268,O
effect,268,O
.,268,O
The,269,O
other,269,O
allele,269,O
(,269,O
Hp2,269,O
),269,O
of,269,O
individuals,269,O
with,269,O
Hp2/Hpdel,269,O
was,269,O
found,269,O
to,269,O
have,269,O
",",269,O
in,269,O
all,269,O
exons,269,O
",",269,O
no,269,O
mutation,269,O
",",269,O
by,269,O
DNA,269,O
sequencing,269,O
.,269,O
On,270,O
the,270,O
basis,270,O
of,270,O
the,270,O
present,270,O
study,270,O
",",270,O
the,270,O
mechanism,270,O
of,270,O
anhaptoglobinemia,270,B-SpecificDisease
and,270,O
the,270,O
mechanism,270,O
of,270,O
anomalous,270,O
inheritance,270,O
of,270,O
Hp,270,O
phenotypes,270,O
were,270,O
well,270,O
explained,270,O
.,270,O
However,271,O
",",271,O
the,271,O
mechanism,271,O
of,271,O
hypohaptoglobinemia,271,B-SpecificDisease
remains,271,O
unknown,271,O
ATM,272,O
mutations,272,O
and,272,O
phenotypes,272,O
in,272,O
ataxia-telangiectasia,272,B-Modifier
families,272,O
in,272,O
the,272,O
British,272,O
Isles,272,O
:,272,O
expression,272,O
of,272,O
mutant,272,O
ATM,272,O
and,272,O
the,272,O
risk,272,O
of,272,O
leukemia,272,B-SpecificDisease
",",272,O
lymphoma,272,B-SpecificDisease
",",272,O
and,272,O
breast,272,B-SpecificDisease
cancer,272,I-SpecificDisease
.,272,O
We,273,O
report,273,O
the,273,O
spectrum,273,O
of,273,O
59,273,O
ATM,273,O
mutations,273,O
observed,273,O
in,273,O
ataxia-telangiectasia,273,B-Modifier
(,273,O
A-T,273,B-Modifier
),273,O
patients,273,O
in,273,O
the,273,O
British,273,O
Isles,273,O
.,273,O
Of,274,O
51,274,O
ATM,274,O
mutations,274,O
identified,274,O
in,274,O
families,274,O
native,274,O
to,274,O
the,274,O
British,274,O
Isles,274,O
",",274,O
11,274,O
were,274,O
founder,274,O
mutations,274,O
",",274,O
and,274,O
2,274,O
of,274,O
these,274,O
11,274,O
conferred,274,O
a,274,O
milder,274,O
clinical,274,O
phenotype,274,O
with,274,O
respect,274,O
to,274,O
both,274,O
cerebellar,274,B-SpecificDisease
degeneration,274,I-SpecificDisease
and,274,O
cellular,274,O
features,274,O
.,274,O
We,275,O
report,275,O
",",275,O
in,275,O
two,275,O
A-T,275,B-Modifier
families,275,O
",",275,O
an,275,O
ATM,275,O
mutation,275,O
(,275,O
7271T,275,O
--,275,O
>,275,O
G,275,O
),275,O
that,275,O
may,275,O
be,275,O
associated,275,O
with,275,O
an,275,O
increased,275,O
risk,275,O
of,275,O
breast,275,B-SpecificDisease
cancer,275,I-SpecificDisease
in,275,O
both,275,O
homozygotes,275,O
and,275,O
heterozygotes,275,O
(,275,O
relative,275,O
risk,275,O
12,275,O
.,275,O
7,276,O
;,276,O
P,276,O
=,276,O
.,276,O
0025,277,O
),277,O
",",277,O
although,277,O
there,277,O
is,277,O
a,277,O
less,277,O
severe,277,O
A-T,277,B-Modifier
phenotype,277,O
in,277,O
terms,277,O
of,277,O
the,277,O
degree,277,O
of,277,O
cerebellar,277,B-SpecificDisease
degeneration,277,I-SpecificDisease
.,277,O
This,278,O
mutation,278,O
(,278,O
7271T,278,O
--,278,O
>,278,O
G,278,O
),278,O
also,278,O
allows,278,O
expression,278,O
of,278,O
full-length,278,O
ATM,278,O
protein,278,O
at,278,O
a,278,O
level,278,O
comparable,278,O
with,278,O
that,278,O
in,278,O
unaffected,278,O
individuals,278,O
.,278,O
In,279,O
addition,279,O
",",279,O
we,279,O
have,279,O
studied,279,O
18,279,O
A-T,279,B-Modifier
patients,279,O
",",279,O
in,279,O
15,279,O
families,279,O
",",279,O
who,279,O
developed,279,O
leukemia,279,B-SpecificDisease
",",279,O
lymphoma,279,B-SpecificDisease
",",279,O
preleukemic,279,O
T-cell,279,O
proliferation,279,O
",",279,O
or,279,O
Hodgkin,279,B-SpecificDisease
lymphoma,279,I-SpecificDisease
",",279,O
mostly,279,O
in,279,O
childhood,279,O
.,279,O
A,280,O
wide,280,O
variety,280,O
of,280,O
ATM,280,O
mutation,280,O
types,280,O
",",280,O
including,280,O
missense,280,O
mutations,280,O
and,280,O
in-frame,280,O
deletions,280,O
",",280,O
were,280,O
seen,280,O
in,280,O
these,280,O
patients,280,O
.,280,O
We,281,O
also,281,O
show,281,O
that,281,O
25,281,O
%,281,O
of,281,O
all,281,O
A-T,281,B-Modifier
patients,281,O
carried,281,O
in-frame,281,O
deletions,281,O
or,281,O
missense,281,O
mutations,281,O
",",281,O
many,281,O
of,281,O
which,281,O
were,281,O
also,281,O
associated,281,O
with,281,O
expression,281,O
of,281,O
mutant,281,O
ATM,281,O
protein,281,O
.,281,O
The,282,O
DMPK,282,O
gene,282,O
of,282,O
severely,282,O
affected,282,O
myotonic,282,B-Modifier
dystrophy,282,I-Modifier
patients,282,O
is,282,O
hypermethylated,282,O
proximal,282,O
to,282,O
the,282,O
largely,282,O
expanded,282,O
CTG,282,O
repeat,282,O
.,282,O
Using,283,O
methylation-sensitive,283,O
restriction,283,O
enzymes,283,O
",",283,O
we,283,O
characterized,283,O
the,283,O
methylation,283,O
pattern,283,O
on,283,O
the,283,O
5,283,O
side,283,O
of,283,O
the,283,O
CTG,283,O
repeat,283,O
in,283,O
the,283,O
DMPK,283,O
gene,283,O
of,283,O
normal,283,O
individuals,283,O
and,283,O
of,283,O
patients,283,O
affected,283,O
with,283,O
myotonic,283,B-SpecificDisease
dystrophy,283,I-SpecificDisease
",",283,O
showing,283,O
expansions,283,O
of,283,O
the,283,O
repetitive,283,O
sequence,283,O
.,283,O
The,284,O
gene,284,O
segment,284,O
analyzed,284,O
corresponds,284,O
to,284,O
the,284,O
genomic,284,O
SacI-HindIII,284,O
fragment,284,O
carrying,284,O
exons,284,O
11-15,284,O
.,284,O
There,285,O
is,285,O
constitutive,285,O
methylation,285,O
in,285,O
intron,285,O
12,285,O
at,285,O
restriction,285,O
sites,285,O
of,285,O
SacII,285,O
and,285,O
HhaI,285,O
",",285,O
localized,285,O
1,285,O
",",285,O
159-1,285,O
",",285,O
232,285,O
bp,285,O
upstream,285,O
of,285,O
the,285,O
CTG,285,O
repeat,285,O
",",285,O
whereas,285,O
most,285,O
",",285,O
if,285,O
not,285,O
all,285,O
",",285,O
of,285,O
the,285,O
other,285,O
sites,285,O
of,285,O
SacII,285,O
",",285,O
HhaI,285,O
",",285,O
and,285,O
HpaII,285,O
in,285,O
this,285,O
region,285,O
are,285,O
unmethylated,285,O
",",285,O
in,285,O
normal,285,O
individuals,285,O
and,285,O
most,285,O
of,285,O
the,285,O
patients,285,O
.,285,O
In,286,O
a,286,O
number,286,O
of,286,O
young,286,O
and,286,O
severely,286,O
affected,286,O
patients,286,O
",",286,O
however,286,O
",",286,O
complete,286,O
methylation,286,O
of,286,O
these,286,O
restriction,286,O
sites,286,O
was,286,O
found,286,O
in,286,O
the,286,O
mutated,286,O
allele,286,O
.,286,O
In,287,O
most,287,O
of,287,O
these,287,O
patients,287,O
",",287,O
the,287,O
onset,287,O
of,287,O
the,287,O
disease,287,O
was,287,O
congenital,287,O
.,287,O
Preliminary,288,O
in,288,O
vivo,288,O
footprinting,288,O
data,288,O
gave,288,O
evidence,288,O
for,288,O
protein-DNA,288,O
contact,288,O
in,288,O
normal,288,O
genes,288,O
at,288,O
an,288,O
Sp1,288,O
consensus,288,O
binding,288,O
site,288,O
upstream,288,O
of,288,O
the,288,O
CTG,288,O
repeat,288,O
and,288,O
for,288,O
a,288,O
significant,288,O
reduction,288,O
of,288,O
this,288,O
interaction,288,O
in,288,O
cells,288,O
with,288,O
a,288,O
hypermethylated,288,O
DMPK,288,O
gene,288,O
..,288,O
The,289,O
hemochromatosis,289,B-Modifier
gene,289,O
product,289,O
complexes,289,O
with,289,O
the,289,O
transferrin,289,O
receptor,289,O
and,289,O
lowers,289,O
its,289,O
affinity,289,O
for,289,O
ligand,289,O
binding,289,O
.,289,O
We,290,O
recently,290,O
reported,290,O
the,290,O
positional,290,O
cloning,290,O
of,290,O
a,290,O
candidate,290,O
gene,290,O
for,290,O
hereditary,290,B-SpecificDisease
hemochromatosis,290,I-SpecificDisease
called,290,O
HFE,290,O
.,290,O
The,291,O
gene,291,O
product,291,O
",",291,O
a,291,O
member,291,O
of,291,O
the,291,O
major,291,O
histocompatibility,291,O
complex,291,O
class,291,O
I-like,291,O
family,291,O
",",291,O
was,291,O
found,291,O
to,291,O
have,291,O
a,291,O
mutation,291,O
",",291,O
Cys-282,291,O
--,291,O
>,291,O
Tyr,291,O
(,291,O
C282Y,291,O
),291,O
",",291,O
in,291,O
85,291,O
%,291,O
of,291,O
patient,291,O
chromosomes,291,O
.,291,O
This,292,O
mutation,292,O
eliminates,292,O
the,292,O
ability,292,O
of,292,O
HFE,292,O
to,292,O
associate,292,O
with,292,O
beta2-microglobulin,292,O
(,292,O
beta2m,292,O
),292,O
and,292,O
prevents,292,O
cell-surface,292,O
expression,292,O
.,292,O
A,293,O
second,293,O
mutation,293,O
that,293,O
has,293,O
no,293,O
effect,293,O
on,293,O
beta2m,293,O
association,293,O
",",293,O
H63D,293,O
",",293,O
was,293,O
found,293,O
in,293,O
eight,293,O
out,293,O
of,293,O
nine,293,O
patients,293,O
heterozygous,293,O
for,293,O
the,293,O
C282Y,293,O
mutant,293,O
.,293,O
In,294,O
this,294,O
report,294,O
",",294,O
we,294,O
demonstrate,294,O
in,294,O
cultured,294,O
293,294,O
cells,294,O
overexpressing,294,O
wild-type,294,O
or,294,O
mutant,294,O
HFE,294,O
proteins,294,O
that,294,O
both,294,O
the,294,O
wild-type,294,O
and,294,O
H63D,294,O
HFE,294,O
proteins,294,O
form,294,O
stable,294,O
complexes,294,O
with,294,O
the,294,O
transferrin,294,O
receptor,294,O
(,294,O
TfR,294,O
),294,O
.,294,O
The,295,O
C282Y,295,O
mutation,295,O
nearly,295,O
completely,295,O
prevents,295,O
the,295,O
association,295,O
of,295,O
the,295,O
mutant,295,O
HFE,295,O
protein,295,O
with,295,O
the,295,O
TfR,295,O
.,295,O
Studies,296,O
on,296,O
cell-associated,296,O
transferrin,296,O
at,296,O
37,296,O
degrees,296,O
C,296,O
suggest,296,O
that,296,O
the,296,O
overexpressed,296,O
wild-type,296,O
HFE,296,O
protein,296,O
decreases,296,O
the,296,O
affinity,296,O
of,296,O
the,296,O
TfR,296,O
for,296,O
transferrin,296,O
.,296,O
The,297,O
overexpressed,297,O
H63D,297,O
protein,297,O
does,297,O
not,297,O
have,297,O
this,297,O
effect,297,O
",",297,O
providing,297,O
the,297,O
first,297,O
direct,297,O
evidence,297,O
for,297,O
a,297,O
functional,297,O
consequence,297,O
of,297,O
the,297,O
H63D,297,O
mutation,297,O
.,297,O
Addition,298,O
of,298,O
soluble,298,O
wild-type,298,O
HFE/beta2m,298,O
heterodimers,298,O
to,298,O
cultured,298,O
cells,298,O
also,298,O
decreased,298,O
the,298,O
apparent,298,O
affinity,298,O
of,298,O
the,298,O
TfR,298,O
for,298,O
its,298,O
ligand,298,O
under,298,O
steady-state,298,O
conditions,298,O
",",298,O
both,298,O
in,298,O
293,298,O
cells,298,O
and,298,O
in,298,O
HeLa,298,O
cells,298,O
.,298,O
Furthermore,299,O
",",299,O
at,299,O
4,299,O
degrees,299,O
C,299,O
",",299,O
the,299,O
added,299,O
soluble,299,O
complex,299,O
of,299,O
HFE/beta2m,299,O
inhibited,299,O
binding,299,O
of,299,O
transferrin,299,O
to,299,O
HeLa,299,O
cell,299,O
TfR,299,O
in,299,O
a,299,O
concentration-dependent,299,O
manner,299,O
.,299,O
Scatchard,300,O
plots,300,O
of,300,O
these,300,O
data,300,O
indicate,300,O
that,300,O
the,300,O
added,300,O
heterodimer,300,O
substantially,300,O
reduced,300,O
the,300,O
affinity,300,O
of,300,O
TfR,300,O
for,300,O
transferrin,300,O
.,300,O
These,301,O
results,301,O
establish,301,O
a,301,O
molecular,301,O
link,301,O
between,301,O
HFE,301,O
and,301,O
a,301,O
key,301,O
protein,301,O
involved,301,O
in,301,O
iron,301,O
transport,301,O
",",301,O
the,301,O
TfR,301,O
",",301,O
and,301,O
raise,301,O
the,301,O
possibility,301,O
that,301,O
alterations,301,O
in,301,O
this,301,O
regulatory,301,O
mechanism,301,O
may,301,O
play,301,O
a,301,O
role,301,O
in,301,O
the,301,O
pathogenesis,301,O
of,301,O
hereditary,301,B-SpecificDisease
hemochromatosis,301,I-SpecificDisease
..,301,O
Genomic,302,O
organization,302,O
of,302,O
the,302,O
UBE3A/E6-AP,302,O
gene,302,O
and,302,O
related,302,O
pseudogenes,302,O
.,302,O
The,303,O
UBE3A,303,O
gene,303,O
encodes,303,O
the,303,O
E6-AP,303,O
ubiquitin-protein,303,O
ligase,303,O
and,303,O
has,303,O
recently,303,O
been,303,O
shown,303,O
to,303,O
be,303,O
mutated,303,O
in,303,O
Angelman,303,B-Modifier
syndrome,303,I-Modifier
patients,303,O
who,303,O
lack,303,O
15q11-q13,303,O
deletions,303,O
or,303,O
chromosome,303,O
15,303,O
paternal,303,O
uniparental,303,B-SpecificDisease
disomy,303,I-SpecificDisease
.,303,O
Previous,304,O
UBE3A,304,O
cDNA,304,O
analysis,304,O
has,304,O
shown,304,O
a,304,O
coding,304,O
region,304,O
of,304,O
approximately,304,O
2,304,O
.,304,O
6,305,O
kb,305,O
and,305,O
a,305,O
3-untranslated,305,O
region,305,O
(,305,O
UTR,305,O
),305,O
of,305,O
<,305,O
50,305,O
bp,305,O
",",305,O
whereas,305,O
Northern,305,O
analysis,305,O
has,305,O
indicated,305,O
mRNA,305,O
sizes,305,O
of,305,O
5-8,305,O
kb,305,O
.,305,O
We,306,O
have,306,O
analyzed,306,O
additional,306,O
cDNA,306,O
clones,306,O
and,306,O
provide,306,O
evidence,306,O
for,306,O
an,306,O
additional,306,O
0,306,O
.,306,O
5,307,O
kb,307,O
of,307,O
5-UTR,307,O
and,307,O
>,307,O
2,307,O
kb,307,O
of,307,O
3-UTR,307,O
.,307,O
We,308,O
have,308,O
established,308,O
the,308,O
genomic,308,O
organization,308,O
of,308,O
UBE3A,308,O
and,308,O
the,308,O
sequence,308,O
of,308,O
intron-exon,308,O
borders,308,O
.,308,O
We,309,O
have,309,O
also,309,O
mapped,309,O
two,309,O
highly,309,O
homologous,309,O
processed,309,O
pseudogenes,309,O
",",309,O
UBE3AP1,309,O
and,309,O
UBE3AP2,309,O
",",309,O
to,309,O
chromosomes,309,O
2,309,O
and,309,O
21,309,O
",",309,O
respectively,309,O
",",309,O
and,309,O
determined,309,O
their,309,O
genomic,309,O
organization,309,O
.,309,O
These,310,O
results,310,O
will,310,O
form,310,O
the,310,O
basis,310,O
for,310,O
studies,310,O
of,310,O
mutation,310,O
and,310,O
imprinting,310,O
of,310,O
UBE3A,310,O
.,310,O
Mutation,311,O
spectrum,311,O
and,311,O
genotype-phenotype,311,O
analyses,311,O
in,311,O
Cowden,311,B-SpecificDisease
disease,311,I-SpecificDisease
and,311,O
Bannayan-Zonana,311,B-SpecificDisease
syndrome,311,I-SpecificDisease
",",311,O
two,311,O
hamartoma,311,B-DiseaseClass
syndromes,311,I-DiseaseClass
with,311,O
germline,311,O
PTEN,311,O
mutation,311,O
.,311,O
The,312,O
tumour,312,B-Modifier
suppressor,312,O
gene,312,O
PTEN,312,O
",",312,O
which,312,O
maps,312,O
to,312,O
10q23,312,O
.,312,O
3,313,O
and,313,O
encodes,313,O
a,313,O
403,313,O
amino,313,O
acid,313,O
dual,313,O
specificity,313,O
phosphatase,313,O
(,313,O
protein,313,O
tyrosine,313,O
phosphatase,313,O
;,313,O
PTPase,313,O
),313,O
",",313,O
was,313,O
shown,313,O
recently,313,O
to,313,O
play,313,O
a,313,O
broad,313,O
role,313,O
in,313,O
human,313,O
malignancy,313,B-DiseaseClass
.,313,O
Somatic,314,O
PTEN,314,O
deletions,314,O
and,314,O
mutations,314,O
were,314,O
observed,314,O
in,314,O
sporadic,314,O
breast,314,O
",",314,O
brain,314,O
",",314,O
prostate,314,O
and,314,O
kidney,314,O
cancer,314,O
cell,314,O
lines,314,O
and,314,O
in,314,O
several,314,O
primary,314,O
tumours,314,B-DiseaseClass
such,314,O
as,314,O
endometrial,314,B-SpecificDisease
carcinomas,314,I-SpecificDisease
",",314,O
malignant,314,B-SpecificDisease
melanoma,314,I-SpecificDisease
and,314,O
thyroid,314,B-SpecificDisease
tumours,314,I-SpecificDisease
.,314,O
In,315,O
addition,315,O
",",315,O
PTEN,315,O
was,315,O
identified,315,O
as,315,O
the,315,O
susceptibility,315,O
gene,315,O
for,315,O
two,315,O
hamartoma,315,B-DiseaseClass
syndromes,315,I-DiseaseClass
Cowden,315,B-SpecificDisease
disease,315,I-SpecificDisease
(,315,O
CD,315,B-SpecificDisease
;,315,O
MIM,315,O
158350,315,O
),315,O
and,315,O
Bannayan-Zonana,315,B-CompositeMention
(,315,I-CompositeMention
BZS,315,I-CompositeMention
),315,I-CompositeMention
or,315,I-CompositeMention
Ruvalcaba-Riley-Smith,315,I-CompositeMention
syndrome,315,I-CompositeMention
(,315,O
MIM,315,O
153480,315,O
),315,O
.,315,O
Constitutive,316,O
DNA,316,O
from,316,O
37,316,O
CD,316,B-Modifier
families,316,O
and,316,O
seven,316,O
BZS,316,B-Modifier
families,316,O
was,316,O
screened,316,O
for,316,O
germline,316,O
PTEN,316,O
mutations,316,O
.,316,O
PTEN,317,O
mutations,317,O
were,317,O
identified,317,O
in,317,O
30,317,O
of,317,O
37,317,O
(,317,O
81,317,O
%,317,O
),317,O
CD,317,B-Modifier
families,317,O
",",317,O
including,317,O
missense,317,O
and,317,O
nonsense,317,O
point,317,O
mutations,317,O
",",317,O
deletions,317,O
",",317,O
insertions,317,O
",",317,O
a,317,O
deletion/insertion,317,O
and,317,O
splice,317,O
site,317,O
mutations,317,O
.,317,O
These,318,O
mutations,318,O
were,318,O
scattered,318,O
over,318,O
the,318,O
entire,318,O
length,318,O
of,318,O
PTEN,318,O
",",318,O
with,318,O
the,318,O
exception,318,O
of,318,O
the,318,O
first,318,O
",",318,O
fourth,318,O
and,318,O
last,318,O
exons,318,O
.,318,O
A,319,O
hot,319,O
spot,319,O
for,319,O
PTEN,319,O
mutation,319,O
in,319,O
CD,319,B-SpecificDisease
was,319,O
identified,319,O
in,319,O
exon,319,O
5,319,O
that,319,O
contains,319,O
the,319,O
PTPase,319,O
core,319,O
motif,319,O
",",319,O
with,319,O
13,319,O
of,319,O
30,319,O
(,319,O
43,319,O
%,319,O
),319,O
CD,319,B-Modifier
mutations,319,O
identified,319,O
in,319,O
this,319,O
exon,319,O
.,319,O
Seven,320,O
of,320,O
30,320,O
(,320,O
23,320,O
%,320,O
),320,O
were,320,O
within,320,O
the,320,O
core,320,O
motif,320,O
",",320,O
the,320,O
majority,320,O
(,320,O
five,320,O
of,320,O
seven,320,O
),320,O
of,320,O
which,320,O
were,320,O
missense,320,O
mutations,320,O
",",320,O
possibly,320,O
pointing,320,O
to,320,O
the,320,O
functional,320,O
significance,320,O
of,320,O
this,320,O
region,320,O
.,320,O
Germline,321,O
PTEN,321,O
mutations,321,O
were,321,O
identified,321,O
in,321,O
four,321,O
of,321,O
seven,321,O
(,321,O
57,321,O
%,321,O
),321,O
BZS,321,B-Modifier
families,321,O
studied,321,O
.,321,O
Interestingly,322,O
",",322,O
none,322,O
of,322,O
these,322,O
mutations,322,O
was,322,O
observed,322,O
in,322,O
the,322,O
PTPase,322,O
core,322,O
motif,322,O
.,322,O
It,323,O
is,323,O
also,323,O
worthy,323,O
of,323,O
note,323,O
that,323,O
a,323,O
single,323,O
nonsense,323,O
point,323,O
mutation,323,O
",",323,O
R233X,323,O
",",323,O
was,323,O
observed,323,O
in,323,O
the,323,O
germline,323,O
DNA,323,O
from,323,O
two,323,O
unrelated,323,O
CD,323,B-Modifier
families,323,O
and,323,O
one,323,O
BZS,323,B-Modifier
family,323,O
.,323,O
Genotype-phenotype,324,O
studies,324,O
were,324,O
not,324,O
performed,324,O
on,324,O
this,324,O
small,324,O
group,324,O
of,324,O
BZS,324,B-Modifier
families,324,O
.,324,O
However,325,O
",",325,O
genotype-phenotype,325,O
analysis,325,O
inthe,325,O
group,325,O
of,325,O
CD,325,B-Modifier
families,325,O
revealed,325,O
two,325,O
possible,325,O
associations,325,O
worthy,325,O
of,325,O
follow-up,325,O
in,325,O
independent,325,O
analyses,325,O
.,325,O
The,326,O
first,326,O
was,326,O
an,326,O
association,326,O
noted,326,O
in,326,O
the,326,O
group,326,O
of,326,O
CD,326,B-Modifier
families,326,O
with,326,O
breast,326,B-DiseaseClass
disease,326,I-DiseaseClass
.,326,O
A,327,O
correlation,327,O
was,327,O
observed,327,O
between,327,O
the,327,O
presence/absence,327,O
of,327,O
a,327,O
PTEN,327,O
mutation,327,O
and,327,O
the,327,O
type,327,O
of,327,O
breast,327,O
involvement,327,O
(,327,O
unaffected,327,O
versus,327,O
benign,327,O
versus,327,O
malignant,327,O
),327,O
.,327,O
Specifically,328,O
and,328,O
more,328,O
directly,328,O
",",328,O
an,328,O
association,328,O
was,328,O
also,328,O
observed,328,O
between,328,O
the,328,O
presence,328,O
of,328,O
a,328,O
PTEN,328,O
mutation,328,O
and,328,O
malignant,328,B-DiseaseClass
breast,328,I-DiseaseClass
disease,328,I-DiseaseClass
.,328,O
Secondly,329,O
",",329,O
there,329,O
appeared,329,O
to,329,O
be,329,O
an,329,O
interdependent,329,O
association,329,O
between,329,O
mutations,329,O
upstream,329,O
and,329,O
within,329,O
the,329,O
PTPase,329,O
core,329,O
motif,329,O
",",329,O
the,329,O
core,329,O
motif,329,O
containing,329,O
the,329,O
majority,329,O
of,329,O
missense,329,O
mutations,329,O
",",329,O
and,329,O
the,329,O
involvement,329,O
of,329,O
all,329,O
major,329,O
organ,329,O
systems,329,O
(,329,O
central,329,O
nervous,329,O
system,329,O
",",329,O
thyroid,329,O
",",329,O
breast,329,O
",",329,O
skin,329,O
and,329,O
gastrointestinal,329,O
tract,329,O
),329,O
.,329,O
However,330,O
",",330,O
these,330,O
observations,330,O
would,330,O
need,330,O
to,330,O
be,330,O
confirmed,330,O
by,330,O
studying,330,O
a,330,O
larger,330,O
number,330,O
of,330,O
CD,330,B-Modifier
families,330,O
.,330,O
Molecular,331,O
defects,331,O
leading,331,O
to,331,O
human,331,O
complement,331,B-SpecificDisease
component,331,I-SpecificDisease
C6,331,I-SpecificDisease
deficiency,331,I-SpecificDisease
in,331,O
an,331,O
African-American,331,O
family,331,O
.,331,O
Complement,332,B-SpecificDisease
component,332,I-SpecificDisease
C6,332,I-SpecificDisease
deficiency,332,I-SpecificDisease
(,332,O
C6D,332,B-SpecificDisease
),332,O
was,332,O
diagnosed,332,O
in,332,O
a,332,O
16-year-old,332,O
African-American,332,O
male,332,O
with,332,O
meningococcal,332,B-SpecificDisease
meningitis,332,I-SpecificDisease
.,332,O
The,333,O
patients,333,O
father,333,O
and,333,O
two,333,O
brothers,333,O
also,333,O
had,333,O
C6D,333,B-SpecificDisease
",",333,O
but,333,O
gave,333,O
no,333,O
history,333,O
of,333,O
meningitis,333,B-SpecificDisease
or,333,O
other,333,O
neisserial,333,B-SpecificDisease
infection,333,I-SpecificDisease
.,333,O
By,334,O
using,334,O
exon-specific,334,O
polymerase,334,O
chain,334,O
reaction,334,O
(,334,O
PCR,334,O
),334,O
/single-strand,334,O
conformation,334,O
polymorphism,334,O
as,334,O
a,334,O
screening,334,O
step,334,O
and,334,O
nucleotide,334,O
sequencing,334,O
of,334,O
target,334,O
exons,334,O
",",334,O
we,334,O
determined,334,O
that,334,O
the,334,O
proband,334,O
was,334,O
a,334,O
compound,334,O
heterozygote,334,O
for,334,O
two,334,O
C6,334,O
gene,334,O
mutations,334,O
.,334,O
The,335,O
first,335,O
",",335,O
1195delC,335,O
located,335,O
in,335,O
exon,335,O
7,335,O
",",335,O
is,335,O
a,335,O
novel,335,O
mutation,335,O
",",335,O
while,335,O
the,335,O
second,335,O
",",335,O
1936delG,335,O
in,335,O
exon,335,O
12,335,O
",",335,O
has,335,O
been,335,O
described,335,O
before,335,O
to,335,O
cause,335,O
C6D,335,B-SpecificDisease
in,335,O
an,335,O
unrelated,335,O
African-American,335,O
individual,335,O
.,335,O
Both,336,O
mutations,336,O
result,336,O
in,336,O
premature,336,O
termination,336,O
codons,336,O
and,336,O
C6,336,O
null,336,O
alleles,336,O
.,336,O
Allele-specific,337,O
PCR,337,O
indicated,337,O
that,337,O
the,337,O
probands,337,O
two,337,O
brothers,337,O
also,337,O
inherited,337,O
the,337,O
1195delC,337,O
mutation,337,O
from,337,O
their,337,O
heterozygous,337,O
mother,337,O
and,337,O
the,337,O
1936delG,337,O
mutation,337,O
from,337,O
their,337,O
homozygous,337,O
father,337,O
..,337,O
PAX6,338,O
mutations,338,O
reviewed,338,O
.,338,O
Mutations,339,O
in,339,O
PAX6,339,O
are,339,O
responsible,339,O
for,339,O
human,339,O
aniridia,339,B-SpecificDisease
and,339,O
have,339,O
also,339,O
been,339,O
found,339,O
in,339,O
patients,339,O
with,339,O
Peters,339,B-SpecificDisease
anomaly,339,I-SpecificDisease
",",339,O
with,339,O
congenital,339,B-SpecificDisease
cataracts,339,I-SpecificDisease
",",339,O
with,339,O
autosomal,339,B-SpecificDisease
dominant,339,I-SpecificDisease
keratitis,339,I-SpecificDisease
",",339,O
and,339,O
with,339,O
isolated,339,B-SpecificDisease
foveal,339,I-SpecificDisease
hypoplasia,339,I-SpecificDisease
.,339,O
No,340,O
locus,340,O
other,340,O
than,340,O
chromosome,340,O
11p13,340,O
has,340,O
been,340,O
implicated,340,O
in,340,O
aniridia,340,B-SpecificDisease
",",340,O
and,340,O
PAX6,340,O
is,340,O
clearly,340,O
the,340,O
major,340,O
",",340,O
if,340,O
not,340,O
only,340,O
",",340,O
gene,340,O
responsible,340,O
.,340,O
Twenty-eight,341,O
percent,341,O
of,341,O
identified,341,O
PAX6,341,O
mutations,341,O
are,341,O
C-T,341,O
changes,341,O
at,341,O
CpG,341,O
dinucleotides,341,O
",",341,O
20,341,O
%,341,O
are,341,O
splicing,341,O
errors,341,O
",",341,O
and,341,O
more,341,O
than,341,O
30,341,O
%,341,O
are,341,O
deletion,341,O
or,341,O
insertion,341,O
events,341,O
.,341,O
There,342,O
is,342,O
a,342,O
noticeably,342,O
elevated,342,O
level,342,O
of,342,O
mutation,342,O
in,342,O
the,342,O
paired,342,O
domain,342,O
compared,342,O
with,342,O
the,342,O
rest,342,O
of,342,O
the,342,O
gene,342,O
.,342,O
Increased,343,O
mutation,343,O
in,343,O
the,343,O
homeodomain,343,O
is,343,O
accounted,343,O
for,343,O
by,343,O
the,343,O
hypermutable,343,O
CpG,343,O
dinucleotide,343,O
in,343,O
codon,343,O
240,343,O
.,343,O
Very,344,O
nearly,344,O
all,344,O
mutations,344,O
appear,344,O
to,344,O
cause,344,O
loss,344,O
of,344,O
function,344,O
of,344,O
the,344,O
mutant,344,O
allele,344,O
",",344,O
and,344,O
more,344,O
than,344,O
80,344,O
%,344,O
of,344,O
exonic,344,O
substitutions,344,O
result,344,O
in,344,O
nonsense,344,O
codons,344,O
.,344,O
In,345,O
a,345,O
gene,345,O
with,345,O
such,345,O
extraordinarily,345,O
high,345,O
sequence,345,O
conservation,345,O
throughout,345,O
evolution,345,O
",",345,O
there,345,O
are,345,O
presumed,345,O
undiscovered,345,O
missense,345,O
mutations,345,O
",",345,O
these,345,O
are,345,O
hypothesized,345,O
to,345,O
exist,345,O
in,345,O
as-yet,345,O
unidentified,345,O
phenotypes,345,O
..,345,O
Genetic,346,O
heterogeneity,346,O
and,346,O
penetrance,346,O
analysis,346,O
of,346,O
the,346,O
BRCA1,346,O
and,346,O
BRCA2,346,O
genes,346,O
in,346,O
breast,346,B-Modifier
cancer,346,I-Modifier
families,346,O
.,346,O
The,347,O
Breast,347,B-Modifier
Cancer,347,I-Modifier
Linkage,347,O
Consortium,347,O
.,347,O
The,348,O
contribution,348,O
of,348,O
BRCA1,348,O
and,348,O
BRCA2,348,O
to,348,O
inherited,348,B-SpecificDisease
breast,348,I-SpecificDisease
cancer,348,I-SpecificDisease
was,348,O
assessed,348,O
by,348,O
linkage,348,O
and,348,O
mutation,348,O
analysis,348,O
in,348,O
237,348,O
families,348,O
",",348,O
each,348,O
with,348,O
at,348,O
least,348,O
four,348,O
cases,348,O
of,348,O
breast,348,B-SpecificDisease
cancer,348,I-SpecificDisease
",",348,O
collected,348,O
by,348,O
the,348,O
Breast,348,B-Modifier
Cancer,348,I-Modifier
Linkage,348,O
Consortium,348,O
.,348,O
Families,349,O
were,349,O
included,349,O
without,349,O
regard,349,O
to,349,O
the,349,O
occurrence,349,O
of,349,O
ovarian,349,O
or,349,O
other,349,O
cancers,349,O
.,349,O
Overall,350,O
",",350,O
disease,350,O
was,350,O
linked,350,O
to,350,O
BRCA1,350,O
in,350,O
an,350,O
estimated,350,O
52,350,O
%,350,O
of,350,O
families,350,O
",",350,O
to,350,O
BRCA2,350,O
in,350,O
32,350,O
%,350,O
of,350,O
families,350,O
",",350,O
and,350,O
to,350,O
neither,350,O
gene,350,O
in,350,O
16,350,O
%,350,O
(,350,O
95,350,O
%,350,O
confidence,350,O
interval,350,O
[,350,O
CI,350,O
],350,O
6,350,O
%,350,O
-28,350,O
%,350,O
),350,O
",",350,O
suggesting,350,O
other,350,O
predisposition,350,O
genes,350,O
.,350,O
The,351,O
majority,351,O
(,351,O
81,351,O
%,351,O
),351,O
of,351,O
the,351,O
breast-ovarian,351,B-Modifier
cancer,351,I-Modifier
families,351,O
were,351,O
due,351,O
to,351,O
BRCA1,351,O
",",351,O
with,351,O
most,351,O
others,351,O
(,351,O
14,351,O
%,351,O
),351,O
due,351,O
to,351,O
BRCA2,351,O
.,351,O
Conversely,352,O
",",352,O
the,352,O
majority,352,O
of,352,O
families,352,O
with,352,O
male,352,O
and,352,O
female,352,O
breast,352,O
cancer,352,O
were,352,O
due,352,O
to,352,O
BRCA2,352,O
(,352,O
76,352,O
%,352,O
),352,O
.,352,O
The,353,O
largest,353,O
proportion,353,O
(,353,O
67,353,O
%,353,O
),353,O
of,353,O
families,353,O
due,353,O
to,353,O
other,353,O
genes,353,O
was,353,O
found,353,O
in,353,O
families,353,O
with,353,O
four,353,O
or,353,O
five,353,O
cases,353,O
of,353,O
female,353,O
breast,353,B-SpecificDisease
cancer,353,I-SpecificDisease
only,353,O
.,353,O
These,354,O
estimates,354,O
were,354,O
not,354,O
substantially,354,O
affected,354,O
either,354,O
by,354,O
changing,354,O
the,354,O
assumed,354,O
penetrance,354,O
model,354,O
for,354,O
BRCA1,354,O
or,354,O
by,354,O
including,354,O
or,354,O
excluding,354,O
BRCA1,354,O
mutation,354,O
data,354,O
.,354,O
Among,355,O
those,355,O
families,355,O
with,355,O
disease,355,O
due,355,O
to,355,O
BRCA1,355,O
that,355,O
were,355,O
tested,355,O
by,355,O
one,355,O
of,355,O
the,355,O
standard,355,O
screening,355,O
methods,355,O
",",355,O
mutations,355,O
were,355,O
detected,355,O
in,355,O
the,355,O
coding,355,O
sequence,355,O
or,355,O
splice,355,O
sites,355,O
in,355,O
an,355,O
estimated,355,O
63,355,O
%,355,O
(,355,O
95,355,O
%,355,O
CI,355,O
51,355,O
%,355,O
-77,355,O
%,355,O
),355,O
.,355,O
The,356,O
estimated,356,O
sensitivity,356,O
was,356,O
identical,356,O
for,356,O
direct,356,O
sequencing,356,O
and,356,O
other,356,O
techniques,356,O
.,356,O
The,357,O
penetrance,357,O
of,357,O
BRCA2,357,O
was,357,O
estimated,357,O
by,357,O
maximizing,357,O
the,357,O
LOD,357,O
score,357,O
in,357,O
BRCA2-mutation,357,O
families,357,O
",",357,O
over,357,O
all,357,O
possible,357,O
penetrance,357,O
functions,357,O
.,357,O
The,358,O
estimated,358,O
cumulative,358,O
risk,358,O
of,358,O
breast,358,B-SpecificDisease
cancer,358,I-SpecificDisease
reached,358,O
28,358,O
%,358,O
(,358,O
95,358,O
%,358,O
CI,358,O
9,358,O
%,358,O
-44,358,O
%,358,O
),358,O
by,358,O
age,358,O
50,358,O
years,358,O
and,358,O
84,358,O
%,358,O
(,358,O
95,358,O
%,358,O
CI,358,O
43,358,O
%,358,O
-95,358,O
%,358,O
),358,O
by,358,O
age,358,O
70,358,O
years,358,O
.,358,O
The,359,O
corresponding,359,O
ovarian,359,B-Modifier
cancer,359,I-Modifier
risks,359,O
were,359,O
0,359,O
.,359,O
4,360,O
%,360,O
(,360,O
95,360,O
%,360,O
CI,360,O
0,360,O
%,360,O
-1,360,O
%,360,O
),360,O
by,360,O
age,360,O
50,360,O
years,360,O
and,360,O
27,360,O
%,360,O
(,360,O
95,360,O
%,360,O
CI,360,O
0,360,O
%,360,O
-47,360,O
%,360,O
),360,O
by,360,O
age,360,O
70,360,O
years,360,O
.,360,O
The,361,O
lifetime,361,O
risk,361,O
of,361,O
breast,361,B-SpecificDisease
cancer,361,I-SpecificDisease
appears,361,O
similar,361,O
to,361,O
the,361,O
risk,361,O
in,361,O
BRCA1,361,O
carriers,361,O
",",361,O
but,361,O
there,361,O
was,361,O
some,361,O
suggestion,361,O
of,361,O
a,361,O
lower,361,O
risk,361,O
in,361,O
BRCA2,361,O
carriers,361,O
<,361,O
50,361,O
years,361,O
of,361,O
age,361,O
.,361,O
Eye,362,B-DiseaseClass
movement,362,I-DiseaseClass
abnormalities,362,I-DiseaseClass
correlate,362,O
with,362,O
genotype,362,O
in,362,O
autosomal,362,O
dominant,362,O
cerebellar,362,B-DiseaseClass
ataxia,362,I-DiseaseClass
type,362,I-DiseaseClass
I,362,I-DiseaseClass
.,362,O
We,363,O
compared,363,O
horizontal,363,O
eye,363,O
movements,363,O
(,363,O
visually,363,O
guided,363,O
saccades,363,O
",",363,O
antisaccades,363,O
",",363,O
and,363,O
smooth,363,O
pursuit,363,O
),363,O
in,363,O
control,363,O
subjects,363,O
(,363,O
n,363,O
=,363,O
14,363,O
),363,O
and,363,O
patients,363,O
with,363,O
three,363,O
forms,363,O
of,363,O
autosomal,363,O
dominant,363,O
cerebellar,363,B-DiseaseClass
ataxias,363,I-DiseaseClass
type,363,I-DiseaseClass
I,363,I-DiseaseClass
spinocerebellar,363,O
ataxias,363,O
1,363,O
and,363,O
2,363,O
(,363,O
SCA1,363,B-SpecificDisease
",",363,O
n,363,O
=,363,O
11,363,O
;,363,O
SCA2,363,B-SpecificDisease
",",363,O
n,363,O
=,363,O
10,363,O
),363,O
and,363,O
SCA3/Machado-Joseph,363,B-SpecificDisease
disease,363,I-SpecificDisease
(,363,O
MJD,363,B-SpecificDisease
),363,O
(,363,O
n,363,O
=,363,O
16,363,O
),363,O
.,363,O
In,364,O
SCA1,364,B-SpecificDisease
",",364,O
saccade,364,O
amplitude,364,O
was,364,O
significantly,364,O
increased,364,O
",",364,O
resulting,364,O
in,364,O
hypermetria,364,B-SpecificDisease
.,364,O
The,365,O
smooth,365,O
pursuit,365,O
gain,365,O
was,365,O
decreased,365,O
.,365,O
In,366,O
SCA2,366,B-SpecificDisease
",",366,O
saccade,366,O
velocity,366,O
was,366,O
markedly,366,O
decreased,366,O
.,366,O
The,367,O
percentage,367,O
of,367,O
errors,367,O
in,367,O
antisaccades,367,O
was,367,O
greatly,367,O
increased,367,O
and,367,O
was,367,O
significantly,367,O
correlated,367,O
with,367,O
age,367,O
at,367,O
disease,367,O
onset,367,O
.,367,O
In,368,O
addition,368,O
",",368,O
a,368,O
correlation,368,O
between,368,O
smooth,368,O
pursuit,368,O
gain,368,O
and,368,O
the,368,O
number,368,O
of,368,O
trinucleotide,368,O
repeats,368,O
was,368,O
found,368,O
.,368,O
In,369,O
SCA3,369,B-SpecificDisease
",",369,O
gaze-evoked,369,B-SpecificDisease
nystagmus,369,I-SpecificDisease
was,369,O
often,369,O
present,369,O
as,369,O
was,369,O
saccade,369,O
hypometria,369,O
and,369,O
smooth,369,O
pursuit,369,O
gain,369,O
was,369,O
markedly,369,O
decreased,369,O
.,369,O
Three,370,O
major,370,O
criteria,370,O
",",370,O
saccade,370,O
amplitude,370,O
",",370,O
saccade,370,O
velocity,370,O
",",370,O
and,370,O
presence,370,O
of,370,O
gaze-evoked,370,B-SpecificDisease
nystagmus,370,I-SpecificDisease
",",370,O
permitted,370,O
the,370,O
correct,370,O
assignment,370,O
of,370,O
90,370,O
%,370,O
of,370,O
the,370,O
SCA1,370,B-SpecificDisease
",",370,O
90,370,O
%,370,O
of,370,O
the,370,O
SCA2,370,B-SpecificDisease
",",370,O
and,370,O
93,370,O
%,370,O
of,370,O
the,370,O
patients,370,O
with,370,O
SCA3,370,B-SpecificDisease
to,370,O
their,370,O
genetically,370,O
confirmed,370,O
patient,370,O
group,370,O
and,370,O
",",370,O
therefore,370,O
",",370,O
may,370,O
help,370,O
orient,370,O
diagnoses,370,O
of,370,O
SCA1,370,B-SpecificDisease
",",370,O
SCA2,370,B-SpecificDisease
",",370,O
and,370,O
SCA3,370,B-SpecificDisease
at,370,O
early,370,O
clinical,370,O
stages,370,O
of,370,O
the,370,O
diseases,370,O
..,370,O
Genetic,371,O
basis,371,O
and,371,O
molecular,371,O
mechanism,371,O
for,371,O
idiopathic,371,B-SpecificDisease
ventricular,371,I-SpecificDisease
fibrillation,371,I-SpecificDisease
.,371,O
Ventricular,372,B-SpecificDisease
fibrillation,372,I-SpecificDisease
causes,372,O
more,372,O
than,372,O
300,372,O
",",372,O
000,372,O
sudden,372,O
deaths,372,O
each,372,O
year,372,O
in,372,O
the,372,O
USA,372,O
alone,372,O
.,372,O
In,373,O
approximately,373,O
5-12,373,O
%,373,O
of,373,O
these,373,O
cases,373,O
",",373,O
there,373,O
are,373,O
no,373,O
demonstrable,373,O
cardiac,373,O
or,373,O
non-cardiac,373,O
causes,373,O
to,373,O
account,373,O
for,373,O
the,373,O
episode,373,O
",",373,O
which,373,O
is,373,O
therefore,373,O
classified,373,O
as,373,O
idiopathic,373,B-SpecificDisease
ventricular,373,I-SpecificDisease
fibrillation,373,I-SpecificDisease
(,373,O
IVF,373,B-SpecificDisease
),373,O
.,373,O
A,374,O
distinct,374,O
group,374,O
of,374,O
IVF,374,B-Modifier
patients,374,O
has,374,O
been,374,O
found,374,O
to,374,O
present,374,O
with,374,O
a,374,O
characteristic,374,O
electrocardiographic,374,O
pattern,374,O
.,374,O
Because,375,O
of,375,O
the,375,O
small,375,O
size,375,O
of,375,O
most,375,O
pedigrees,375,O
and,375,O
the,375,O
high,375,O
incidence,375,O
of,375,O
sudden,375,B-SpecificDisease
death,375,I-SpecificDisease
",",375,O
however,375,O
",",375,O
molecular,375,O
genetic,375,O
studies,375,O
of,375,O
IVF,375,B-SpecificDisease
have,375,O
not,375,O
yet,375,O
been,375,O
done,375,O
.,375,O
Because,376,O
IVF,376,B-SpecificDisease
causes,376,O
cardiac,376,O
rhythm,376,O
disturbance,376,O
",",376,O
we,376,O
investigated,376,O
whether,376,O
malfunction,376,O
of,376,O
ion,376,O
channels,376,O
could,376,O
cause,376,O
the,376,O
disorder,376,O
by,376,O
studying,376,O
mutations,376,O
in,376,O
the,376,O
cardiac,376,O
sodium,376,O
channel,376,O
gene,376,O
SCN5A,376,O
.,376,O
We,377,O
have,377,O
now,377,O
identified,377,O
a,377,O
missense,377,O
mutation,377,O
",",377,O
a,377,O
splice-donor,377,O
mutation,377,O
",",377,O
and,377,O
a,377,O
frameshift,377,O
mutation,377,O
in,377,O
the,377,O
coding,377,O
region,377,O
of,377,O
SCN5A,377,O
in,377,O
three,377,O
IVF,377,B-Modifier
families,377,O
.,377,O
We,378,O
show,378,O
that,378,O
sodium,378,O
channels,378,O
with,378,O
the,378,O
missense,378,O
mutation,378,O
recover,378,O
from,378,O
inactivation,378,O
more,378,O
rapidly,378,O
than,378,O
normal,378,O
and,378,O
that,378,O
the,378,O
frameshift,378,O
mutation,378,O
causes,378,O
the,378,O
sodium,378,O
channel,378,O
to,378,O
be,378,O
non-functional,378,O
.,378,O
Our,379,O
results,379,O
indicate,379,O
that,379,O
mutations,379,O
in,379,O
cardiac,379,O
ion-channel,379,O
genes,379,O
contribute,379,O
to,379,O
the,379,O
risk,379,O
of,379,O
developing,379,O
IVF,379,B-SpecificDisease
..,379,O
Molecular,380,O
heterogeneity,380,O
in,380,O
mucopolysaccharidosis,380,B-SpecificDisease
IVA,380,I-SpecificDisease
in,380,O
Australia,380,O
and,380,O
Northern,380,O
Ireland,380,O
:,380,O
nine,380,O
novel,380,O
mutations,380,O
including,380,O
T312S,380,O
",",380,O
a,380,O
common,380,O
allele,380,O
that,380,O
confers,380,O
a,380,O
mild,380,O
phenotype,380,O
.,380,O
Mucopolysaccharidosis,381,B-SpecificDisease
IVA,381,I-SpecificDisease
(,381,O
MPS,381,B-SpecificDisease
IVA,381,I-SpecificDisease
),381,O
is,381,O
an,381,O
autosomal,381,B-DiseaseClass
recessive,381,I-DiseaseClass
lysosomal,381,I-DiseaseClass
storage,381,I-DiseaseClass
disorder,381,I-DiseaseClass
caused,381,O
by,381,O
a,381,O
genetic,381,B-DiseaseClass
defect,381,I-DiseaseClass
in,381,O
N-acetylgalactosamine-6-sulfate,381,O
sulfatase,381,O
(,381,O
GALNS,381,O
),381,O
.,381,O
Previous,382,O
studies,382,O
of,382,O
patients,382,O
from,382,O
a,382,O
British-Irish,382,O
population,382,O
showed,382,O
that,382,O
the,382,O
I113F,382,O
mutation,382,O
is,382,O
the,382,O
most,382,O
common,382,O
single,382,O
mutation,382,O
among,382,O
MPS,382,B-Modifier
IVA,382,I-Modifier
patients,382,O
and,382,O
produces,382,O
a,382,O
severe,382,O
clinical,382,O
phenotype,382,O
.,382,O
We,383,O
studied,383,O
mutations,383,O
in,383,O
the,383,O
GALNS,383,O
gene,383,O
from,383,O
23,383,O
additional,383,O
MPS,383,B-Modifier
IVA,383,I-Modifier
patients,383,O
(,383,O
15,383,O
from,383,O
Australia,383,O
",",383,O
8,383,O
from,383,O
Northern,383,O
Ireland,383,O
),383,O
",",383,O
with,383,O
various,383,O
clinical,383,O
phenotypes,383,O
(,383,O
severe,383,O
",",383,O
16,383,O
cases,383,O
;,383,O
intermediate,383,O
",",383,O
4,383,O
cases,383,O
;,383,O
mild,383,O
",",383,O
3,383,O
cases,383,O
),383,O
.,383,O
We,384,O
found,384,O
two,384,O
common,384,O
mutations,384,O
that,384,O
together,384,O
accounted,384,O
for,384,O
32,384,O
%,384,O
of,384,O
the,384,O
44,384,O
unrelated,384,O
alleles,384,O
in,384,O
these,384,O
patients,384,O
.,384,O
One,385,O
is,385,O
the,385,O
T312S,385,O
mutation,385,O
",",385,O
a,385,O
novel,385,O
mutation,385,O
found,385,O
exclusively,385,O
in,385,O
milder,385,O
patients,385,O
.,385,O
The,386,O
other,386,O
is,386,O
the,386,O
previously,386,O
described,386,O
I113F,386,O
that,386,O
produces,386,O
a,386,O
severe,386,O
phenotype,386,O
.,386,O
The,387,O
I113F,387,O
and,387,O
T312S,387,O
mutations,387,O
accounted,387,O
for,387,O
8,387,O
(,387,O
18,387,O
%,387,O
),387,O
and,387,O
6,387,O
(,387,O
14,387,O
%,387,O
),387,O
of,387,O
44,387,O
unrelated,387,O
alleles,387,O
",",387,O
respectively,387,O
.,387,O
The,388,O
relatively,388,O
high,388,O
residual,388,O
GALNS,388,O
activity,388,O
seen,388,O
when,388,O
the,388,O
T312S,388,O
mutant,388,O
cDNA,388,O
is,388,O
overexpressed,388,O
in,388,O
mutant,388,O
cells,388,O
provides,388,O
an,388,O
explanation,388,O
for,388,O
the,388,O
mild,388,O
phenotype,388,O
in,388,O
patients,388,O
with,388,O
this,388,O
mutation,388,O
.,388,O
The,389,O
distribution,389,O
and,389,O
relative,389,O
frequencies,389,O
of,389,O
the,389,O
I113F,389,O
and,389,O
T312S,389,O
mutations,389,O
in,389,O
Australia,389,O
corresponded,389,O
to,389,O
those,389,O
observed,389,O
in,389,O
Northern,389,O
Ireland,389,O
and,389,O
are,389,O
unique,389,O
to,389,O
these,389,O
two,389,O
populations,389,O
",",389,O
suggesting,389,O
that,389,O
both,389,O
mutations,389,O
were,389,O
probably,389,O
introduced,389,O
to,389,O
Australia,389,O
by,389,O
Irish,389,O
migrants,389,O
during,389,O
the,389,O
19th,389,O
century,389,O
.,389,O
Haplotype,390,O
analysis,390,O
using,390,O
6,390,O
RFLPs,390,O
provides,390,O
additional,390,O
data,390,O
that,390,O
the,390,O
I113F,390,O
mutation,390,O
originated,390,O
from,390,O
a,390,O
common,390,O
ancestor,390,O
.,390,O
The,391,O
other,391,O
9,391,O
novel,391,O
mutations,391,O
identified,391,O
in,391,O
these,391,O
23,391,O
patients,391,O
were,391,O
each,391,O
limited,391,O
to,391,O
a,391,O
single,391,O
family,391,O
.,391,O
These,392,O
data,392,O
provide,392,O
further,392,O
evidence,392,O
for,392,O
extensive,392,O
allelic,392,O
heterogeneity,392,O
in,392,O
MPS,392,B-SpecificDisease
IVA,392,I-SpecificDisease
in,392,O
British-Irish,392,O
patients,392,O
and,392,O
provide,392,O
evidence,392,O
for,392,O
their,392,O
transmission,392,O
to,392,O
Australia,392,O
by,392,O
British-Irish,392,O
migrants,392,O
..,392,O
Identification,393,O
of,393,O
constitutional,393,O
WT1,393,O
mutations,393,O
",",393,O
in,393,O
patients,393,O
with,393,O
isolated,393,O
diffuse,393,B-SpecificDisease
mesangial,393,I-SpecificDisease
sclerosis,393,I-SpecificDisease
",",393,O
and,393,O
analysis,393,O
of,393,O
genotype/phenotype,393,O
correlations,393,O
by,393,O
use,393,O
of,393,O
a,393,O
computerized,393,O
mutation,393,O
database,393,O
.,393,O
Constitutional,394,O
mutations,394,O
of,394,O
the,394,O
WT1,394,O
gene,394,O
",",394,O
encoding,394,O
a,394,O
zinc-finger,394,O
transcription,394,O
factor,394,O
involved,394,O
in,394,O
renal,394,O
and,394,O
gonadal,394,O
development,394,O
",",394,O
are,394,O
found,394,O
in,394,O
most,394,O
patients,394,O
with,394,O
Denys-Drash,394,B-SpecificDisease
syndrome,394,I-SpecificDisease
(,394,O
DDS,394,B-SpecificDisease
),394,O
",",394,O
or,394,O
diffuse,394,B-SpecificDisease
mesangial,394,I-SpecificDisease
sclerosis,394,I-SpecificDisease
(,394,O
DMS,394,B-SpecificDisease
),394,O
associated,394,O
with,394,O
pseudohermaphroditism,394,B-SpecificDisease
and/or,394,O
Wilms,394,B-SpecificDisease
tumor,394,I-SpecificDisease
(,394,O
WT,394,B-SpecificDisease
),394,O
.,394,O
Most,395,O
mutations,395,O
in,395,O
DDS,395,B-Modifier
patients,395,O
lie,395,O
in,395,O
exon,395,O
8,395,O
or,395,O
exon,395,O
9,395,O
",",395,O
encoding,395,O
zinc,395,O
finger,395,O
2,395,O
or,395,O
zinc,395,O
finger,395,O
3,395,O
",",395,O
respectively,395,O
",",395,O
with,395,O
a,395,O
hot,395,O
spot,395,O
(,395,O
R394W,395,O
),395,O
in,395,O
exon,395,O
9,395,O
.,395,O
We,396,O
analyzed,396,O
a,396,O
series,396,O
of,396,O
24,396,O
patients,396,O
",",396,O
10,396,O
with,396,O
isolated,396,B-SpecificDisease
DMS,396,I-SpecificDisease
(,396,O
IDMS,396,B-SpecificDisease
),396,O
",",396,O
10,396,O
with,396,O
DDS,396,B-SpecificDisease
",",396,O
and,396,O
4,396,O
with,396,O
urogenital,396,B-DiseaseClass
abnormalities,396,I-DiseaseClass
and/or,396,O
WT,396,B-SpecificDisease
.,396,O
We,397,O
report,397,O
WT1,397,O
heterozygous,397,O
mutations,397,O
in,397,O
16,397,O
patients,397,O
",",397,O
4,397,O
of,397,O
whom,397,O
presented,397,O
with,397,O
IDMS,397,B-SpecificDisease
.,397,O
One,398,O
male,398,O
and,398,O
two,398,O
female,398,O
IDMS,398,B-Modifier
patients,398,O
with,398,O
WT1,398,O
mutations,398,O
underwent,398,O
normal,398,O
puberty,398,O
.,398,O
Two,399,O
mutations,399,O
associated,399,O
with,399,O
IDMS,399,B-SpecificDisease
are,399,O
different,399,O
from,399,O
those,399,O
described,399,O
in,399,O
DDS,399,B-Modifier
patients,399,O
.,399,O
No,400,O
WT1,400,O
mutations,400,O
were,400,O
detected,400,O
in,400,O
the,400,O
six,400,O
other,400,O
IDMS,400,B-Modifier
patients,400,O
",",400,O
suggesting,400,O
genetic,400,O
heterogeneity,400,O
of,400,O
this,400,O
disease,400,O
.,400,O
We,401,O
analyzed,401,O
genotype/phenotype,401,O
correlations,401,O
",",401,O
on,401,O
the,401,O
basis,401,O
of,401,O
the,401,O
constitution,401,O
of,401,O
a,401,O
WT1,401,O
mutation,401,O
database,401,O
of,401,O
84,401,O
germ-line,401,O
mutations,401,O
",",401,O
to,401,O
compare,401,O
the,401,O
distribution,401,O
and,401,O
type,401,O
of,401,O
mutations,401,O
",",401,O
according,401,O
to,401,O
the,401,O
different,401,O
symptoms,401,O
.,401,O
This,402,O
demonstrated,402,O
(,402,O
1,402,O
),402,O
the,402,O
association,402,O
between,402,O
mutations,402,O
in,402,O
exons,402,O
8,402,O
and,402,O
9,402,O
and,402,O
DMS,402,B-SpecificDisease
;,402,O
(,402,O
2,402,O
),402,O
among,402,O
patients,402,O
with,402,O
DMS,402,B-SpecificDisease
",",402,O
a,402,O
higher,402,O
frequency,402,O
of,402,O
exon,402,O
8,402,O
mutations,402,O
among,402,O
46,402,O
",",402,O
XY,402,O
patients,402,O
with,402,O
female,402,O
phenotype,402,O
than,402,O
among,402,O
46,402,O
",",402,O
XY,402,O
patients,402,O
with,402,O
sexual,402,O
ambiguity,402,O
or,402,O
male,402,O
phenotype,402,O
;,402,O
and,402,O
(,402,O
3,402,O
),402,O
statistically,402,O
significant,402,O
evidence,402,O
that,402,O
mutations,402,O
in,402,O
exons,402,O
8,402,O
and,402,O
9,402,O
preferentially,402,O
affect,402,O
amino,402,O
acids,402,O
with,402,O
different,402,O
functions,402,O
..,402,O
The,403,O
185delAG,403,O
BRCA1,403,O
mutation,403,O
originated,403,O
before,403,O
the,403,O
dispersion,403,O
of,403,O
Jews,403,O
in,403,O
the,403,O
diaspora,403,O
and,403,O
is,403,O
not,403,O
limited,403,O
to,403,O
Ashkenazim,403,O
.,403,O
The,404,O
185delAG,404,O
mutation,404,O
in,404,O
BRCA1,404,O
is,404,O
detected,404,O
in,404,O
Ashkenazi,404,O
Jews,404,O
both,404,O
in,404,O
familial,404,B-CompositeMention
breast,404,I-CompositeMention
and,404,I-CompositeMention
ovarian,404,I-CompositeMention
cancer,404,I-CompositeMention
and,404,O
in,404,O
the,404,O
general,404,O
population,404,O
.,404,O
All,405,O
tested,405,O
Ashkenazi,405,O
mutation,405,O
carriers,405,O
share,405,O
the,405,O
same,405,O
allelic,405,O
pattern,405,O
at,405,O
the,405,O
BRCA1,405,O
locus,405,O
.,405,O
Our,406,O
previous,406,O
study,406,O
showed,406,O
that,406,O
this,406,O
Ashkenazi,406,O
mutation,406,O
also,406,O
occurs,406,O
in,406,O
Iraqi,406,O
Jews,406,O
with,406,O
a,406,O
similar,406,O
allelic,406,O
pattern,406,O
.,406,O
We,407,O
extended,407,O
our,407,O
analysis,407,O
to,407,O
other,407,O
non-Ashkenazi,407,O
subsets,407,O
354,407,O
of,407,O
Moroccan,407,O
origin,407,O
",",407,O
200,407,O
Yemenites,407,O
and,407,O
150,407,O
Iranian,407,O
Jews,407,O
.,407,O
Heteroduplex,408,O
analysis,408,O
complemented,408,O
by,408,O
direct,408,O
DNA,408,O
sequencing,408,O
of,408,O
abnormally,408,O
migrating,408,O
bands,408,O
were,408,O
employed,408,O
.,408,O
Four,409,O
of,409,O
Moroccan,409,O
origin,409,O
(,409,O
1,409,O
.,409,O
1,410,O
%,410,O
),410,O
and,410,O
none,410,O
of,410,O
the,410,O
Yemenites,410,O
or,410,O
Iranians,410,O
was,410,O
a,410,O
carrier,410,O
of,410,O
the,410,O
185delAG,410,O
mutation,410,O
.,410,O
BRCA1,411,O
allelic,411,O
patterns,411,O
were,411,O
determined,411,O
for,411,O
four,411,O
of,411,O
these,411,O
individuals,411,O
and,411,O
for,411,O
12,411,O
additional,411,O
non-Ashkenazi,411,O
185delAG,411,O
mutation,411,O
carriers,411,O
who,411,O
had,411,O
breast/ovarian,411,B-CompositeMention
cancer,411,I-CompositeMention
.,411,O
Six,412,O
non-Ashkenazi,412,O
individuals,412,O
shared,412,O
the,412,O
common,412,O
Ashkenazi,412,O
haplotype,412,O
",",412,O
four,412,O
had,412,O
a,412,O
closely,412,O
related,412,O
pattern,412,O
",",412,O
and,412,O
the,412,O
rest,412,O
(,412,O
n,412,O
=,412,O
6,412,O
),412,O
displayed,412,O
a,412,O
distinct,412,O
BRCA1,412,O
allelic,412,O
pattern,412,O
.,412,O
We,413,O
conclude,413,O
that,413,O
the,413,O
185delAG,413,O
BRCA1,413,O
mutation,413,O
occurs,413,O
in,413,O
some,413,O
non-Ashkenazi,413,O
populations,413,O
at,413,O
rates,413,O
comparable,413,O
with,413,O
that,413,O
of,413,O
Ashkenazim,413,O
.,413,O
The,414,O
majority,414,O
of,414,O
Jewish,414,O
185delAG,414,O
mutation,414,O
carriers,414,O
have,414,O
a,414,O
common,414,O
allelic,414,O
pattern,414,O
",",414,O
supporting,414,O
the,414,O
founder,414,O
effect,414,O
notion,414,O
",",414,O
but,414,O
dating,414,O
the,414,O
mutations,414,O
origin,414,O
to,414,O
an,414,O
earlier,414,O
date,414,O
than,414,O
currently,414,O
estimated,414,O
.,414,O
However,415,O
",",415,O
the,415,O
different,415,O
allelic,415,O
pattern,415,O
at,415,O
the,415,O
BRCA1,415,O
locus,415,O
even,415,O
in,415,O
some,415,O
Jewish,415,O
mutation,415,O
carriers,415,O
",",415,O
might,415,O
suggest,415,O
that,415,O
the,415,O
mutation,415,O
arose,415,O
independently,415,O
..,415,O
Crystal,416,O
structure,416,O
of,416,O
the,416,O
hemochromatosis,416,B-Modifier
protein,416,O
HFE,416,O
and,416,O
characterization,416,O
of,416,O
its,416,O
interaction,416,O
with,416,O
transferrin,416,O
receptor,416,O
.,416,O
HFE,417,O
is,417,O
an,417,O
MHC-related,417,O
protein,417,O
that,417,O
is,417,O
mutated,417,O
in,417,O
the,417,O
iron-overload,417,B-SpecificDisease
disease,417,I-SpecificDisease
hereditary,417,B-SpecificDisease
hemochromatosis,417,I-SpecificDisease
.,417,O
HFE,418,O
binds,418,O
to,418,O
transferrin,418,O
receptor,418,O
(,418,O
TfR,418,O
),418,O
and,418,O
reduces,418,O
its,418,O
affinity,418,O
for,418,O
iron-loaded,418,O
transferrin,418,O
",",418,O
implicating,418,O
HFE,418,O
in,418,O
iron,418,O
metabolism,418,O
.,418,O
The,419,O
2,419,O
.,419,O
6,420,O
A,420,O
crystal,420,O
structure,420,O
of,420,O
HFE,420,O
reveals,420,O
the,420,O
locations,420,O
of,420,O
hemochromatosis,420,B-Modifier
mutations,420,O
and,420,O
a,420,O
patch,420,O
of,420,O
histidines,420,O
that,420,O
could,420,O
be,420,O
involved,420,O
in,420,O
pH-dependent,420,O
interactions,420,O
.,420,O
We,421,O
also,421,O
demonstrate,421,O
that,421,O
soluble,421,O
TfR,421,O
and,421,O
HFE,421,O
bind,421,O
tightly,421,O
at,421,O
the,421,O
basic,421,O
pH,421,O
of,421,O
the,421,O
cell,421,O
surface,421,O
",",421,O
but,421,O
not,421,O
at,421,O
the,421,O
acidic,421,O
pH,421,O
of,421,O
intracellular,421,O
vesicles,421,O
.,421,O
TfR,422,O
HFE,422,O
stoichiometry,422,O
(,422,O
2,422,O
1,422,O
),422,O
differs,422,O
from,422,O
TfR,422,O
transferrin,422,O
stoichiometry,422,O
(,422,O
2,422,O
2,422,O
),422,O
",",422,O
implying,422,O
a,422,O
different,422,O
mode,422,O
of,422,O
binding,422,O
for,422,O
HFE,422,O
and,422,O
transferrin,422,O
to,422,O
TfR,422,O
",",422,O
consistent,422,O
with,422,O
our,422,O
demonstration,422,O
that,422,O
HFE,422,O
",",422,O
transferrin,422,O
",",422,O
and,422,O
TfR,422,O
form,422,O
a,422,O
ternary,422,O
complex,422,O
.,422,O
Identification,423,O
of,423,O
three,423,O
novel,423,O
mutations,423,O
and,423,O
a,423,O
high,423,O
frequency,423,O
of,423,O
the,423,O
Arg778Leu,423,O
mutation,423,O
in,423,O
Korean,423,O
patients,423,O
with,423,O
Wilson,423,B-SpecificDisease
disease,423,I-SpecificDisease
.,423,O
Four,424,O
mutations,424,O
--,424,O
R778L,424,O
",",424,O
A874V,424,O
",",424,O
L1083F,424,O
",",424,O
and,424,O
2304delC,424,O
--,424,O
in,424,O
the,424,O
copper-transporting,424,O
enzyme,424,O
",",424,O
P-type,424,O
ATPase,424,O
(,424,O
ATP7B,424,O
),424,O
",",424,O
were,424,O
identified,424,O
in,424,O
Korean,424,O
Patients,424,O
with,424,O
Wilson,424,B-SpecificDisease
disease,424,I-SpecificDisease
.,424,O
Arg778Leu,425,O
",",425,O
the,425,O
most,425,O
frequently,425,O
reported,425,O
mutation,425,O
of,425,O
this,425,O
enzyme,425,O
",",425,O
was,425,O
found,425,O
in,425,O
six,425,O
of,425,O
eight,425,O
unrelated,425,O
patients,425,O
studied,425,O
",",425,O
an,425,O
allele,425,O
frequency,425,O
of,425,O
37,425,O
.,425,O
5,426,O
%,426,O
",",426,O
which,426,O
is,426,O
considerably,426,O
higher,426,O
than,426,O
those,426,O
in,426,O
other,426,O
Asian,426,O
populations,426,O
.,426,O
The,427,O
novel,427,O
single,427,O
nucleotide,427,O
deletion,427,O
",",427,O
2304delC,427,O
",",427,O
was,427,O
found,427,O
in,427,O
one,427,O
patient,427,O
.,427,O
Since,428,O
a,428,O
mutation,428,O
at,428,O
cDNA,428,O
nucleotide,428,O
2302,428,O
(,428,O
2302insC,428,O
),428,O
had,428,O
been,428,O
previously,428,O
described,428,O
",",428,O
this,428,O
region,428,O
of,428,O
the,428,O
ATP7B,428,O
gene,428,O
may,428,O
be,428,O
susceptible,428,O
to,428,O
gene,428,O
rearrangements,428,O
causing,428,O
Wilson,428,B-SpecificDisease
disease,428,I-SpecificDisease
.,428,O
Disruption,429,O
of,429,O
splicing,429,O
regulated,429,O
by,429,O
a,429,O
CUG-binding,429,O
protein,429,O
in,429,O
myotonic,429,B-SpecificDisease
dystrophy,429,I-SpecificDisease
.,429,O
Myotonic,430,B-SpecificDisease
dystrophy,430,I-SpecificDisease
(,430,O
DM,430,B-SpecificDisease
),430,O
is,430,O
caused,430,O
by,430,O
a,430,O
CTG,430,O
expansion,430,O
in,430,O
the,430,O
3,430,O
untranslated,430,O
region,430,O
of,430,O
the,430,O
DM,430,B-Modifier
gene,430,O
.,430,O
One,431,O
model,431,O
of,431,O
DM,431,B-Modifier
pathogenesis,431,O
suggests,431,O
that,431,O
RNAs,431,O
from,431,O
the,431,O
expanded,431,O
allele,431,O
create,431,O
a,431,O
gain-of-function,431,O
mutation,431,O
by,431,O
the,431,O
inappropriate,431,O
binding,431,O
of,431,O
proteins,431,O
to,431,O
the,431,O
CUG,431,O
repeats,431,O
.,431,O
Data,432,O
presented,432,O
here,432,O
indicate,432,O
that,432,O
the,432,O
conserved,432,O
heterogeneous,432,O
nuclear,432,O
ribonucleoprotein,432,O
",",432,O
CUG-binding,432,O
protein,432,O
(,432,O
CUG-BP,432,O
),432,O
",",432,O
may,432,O
mediate,432,O
the,432,O
trans-dominant,432,O
effect,432,O
of,432,O
the,432,O
RNA,432,O
.,432,O
CUG-BP,433,O
was,433,O
found,433,O
to,433,O
bind,433,O
to,433,O
the,433,O
human,433,O
cardiac,433,O
troponin,433,O
T,433,O
(,433,O
cTNT,433,O
),433,O
pre-messenger,433,O
RNA,433,O
and,433,O
regulate,433,O
its,433,O
alternative,433,O
splicing,433,O
.,433,O
Splicing,434,O
of,434,O
cTNT,434,O
was,434,O
disrupted,434,O
in,434,O
DM,434,B-Modifier
striated,434,O
muscle,434,O
and,434,O
in,434,O
normal,434,O
cells,434,O
expressing,434,O
transcripts,434,O
that,434,O
contain,434,O
CUG,434,O
repeats,434,O
.,434,O
Altered,435,O
expression,435,O
of,435,O
genes,435,O
regulated,435,O
posttranscriptionally,435,O
by,435,O
CUG-BP,435,O
therefore,435,O
may,435,O
contribute,435,O
to,435,O
DM,435,B-Modifier
pathogenesis,435,O
..,435,O
Identification,436,O
of,436,O
a,436,O
novel,436,O
nonsense,436,O
mutation,436,O
and,436,O
a,436,O
missense,436,O
substitution,436,O
in,436,O
the,436,O
vasopressin-neurophysin,436,O
II,436,O
gene,436,O
in,436,O
two,436,O
Spanish,436,O
kindreds,436,O
with,436,O
familial,436,B-SpecificDisease
neurohypophyseal,436,I-SpecificDisease
diabetes,436,I-SpecificDisease
insipidus,436,I-SpecificDisease
.,436,O
Familial,437,B-SpecificDisease
neurohypophyseal,437,I-SpecificDisease
diabetes,437,I-SpecificDisease
insipidus,437,I-SpecificDisease
(,437,O
FNDI,437,B-SpecificDisease
),437,O
is,437,O
an,437,O
autosomal,437,B-DiseaseClass
dominant,437,I-DiseaseClass
disease,437,I-DiseaseClass
caused,437,O
by,437,O
deficiency,437,O
in,437,O
the,437,O
antidiuretic,437,O
hormone,437,O
arginine,437,O
vasopressin,437,O
(,437,O
AVP,437,O
),437,O
encoded,437,O
by,437,O
the,437,O
AVP-neurophysin,437,O
II,437,O
(,437,O
AVP-NPII,437,O
),437,O
gene,437,O
on,437,O
chromosome,437,O
20p13,437,O
.,437,O
In,438,O
this,438,O
study,438,O
",",438,O
we,438,O
analyzed,438,O
two,438,O
families,438,O
with,438,O
FNDI,438,B-SpecificDisease
using,438,O
direct,438,O
automated,438,O
fluorescent,438,O
",",438,O
solid,438,O
phase,438,O
",",438,O
single-stranded,438,O
DNA,438,O
sequencing,438,O
of,438,O
PCR-amplified,438,O
AVP-NPII,438,O
DNA,438,O
.,438,O
In,439,O
one,439,O
of,439,O
the,439,O
families,439,O
",",439,O
affected,439,O
individuals,439,O
presented,439,O
a,439,O
novel,439,O
nonsense,439,O
mutation,439,O
in,439,O
exon,439,O
3,439,O
of,439,O
the,439,O
gene,439,O
",",439,O
consisting,439,O
in,439,O
a,439,O
G,439,O
to,439,O
T,439,O
transition,439,O
at,439,O
nucleotide,439,O
2101,439,O
",",439,O
which,439,O
produces,439,O
a,439,O
stop,439,O
signal,439,O
in,439,O
codon,439,O
82,439,O
(,439,O
Glu,439,O
),439,O
of,439,O
NPII,439,O
.,439,O
The,440,O
premature,440,O
termination,440,O
eliminates,440,O
part,440,O
of,440,O
the,440,O
C-terminal,440,O
domain,440,O
of,440,O
NPII,440,O
",",440,O
including,440,O
a,440,O
cysteine,440,O
residue,440,O
in,440,O
position,440,O
85,440,O
",",440,O
which,440,O
could,440,O
be,440,O
involved,440,O
in,440,O
the,440,O
correct,440,O
folding,440,O
of,440,O
the,440,O
prohormone,440,O
.,440,O
In,441,O
the,441,O
second,441,O
family,441,O
",",441,O
a,441,O
G279A,441,O
substitution,441,O
at,441,O
position,441,O
-1,441,O
of,441,O
the,441,O
signal,441,O
peptide,441,O
was,441,O
observed,441,O
in,441,O
all,441,O
affected,441,O
individuals,441,O
.,441,O
This,442,O
missense,442,O
mutation,442,O
",",442,O
which,442,O
replaces,442,O
Ala,442,O
with,442,O
Thr,442,O
",",442,O
is,442,O
frequent,442,O
among,442,O
FNDI,442,B-Modifier
patients,442,O
and,442,O
is,442,O
thought,442,O
to,442,O
reduce,442,O
the,442,O
efficiency,442,O
of,442,O
cleavage,442,O
by,442,O
signal,442,O
peptidases,442,O
..,442,O
Genetic,443,O
heterogeneity,443,O
of,443,O
Saethre-Chotzen,443,B-SpecificDisease
syndrome,443,I-SpecificDisease
",",443,O
due,443,O
to,443,O
TWIST,443,O
and,443,O
FGFR,443,O
mutations,443,O
.,443,O
Thirty-two,444,O
unrelated,444,O
patients,444,O
with,444,O
features,444,O
of,444,O
Saethre-Chotzen,444,B-SpecificDisease
syndrome,444,I-SpecificDisease
",",444,O
a,444,O
common,444,O
autosomal,444,B-DiseaseClass
dominant,444,I-DiseaseClass
condition,444,I-DiseaseClass
of,444,O
craniosynostosis,444,B-SpecificDisease
and,444,O
limb,444,B-DiseaseClass
anomalies,444,I-DiseaseClass
",",444,O
were,444,O
screened,444,O
for,444,O
mutations,444,O
in,444,O
TWIST,444,O
",",444,O
FGFR2,444,O
",",444,O
and,444,O
FGFR3,444,O
.,444,O
Nine,445,O
novel,445,O
and,445,O
three,445,O
recurrent,445,O
TWIST,445,O
mutations,445,O
were,445,O
found,445,O
in,445,O
12,445,O
families,445,O
.,445,O
Seven,446,O
families,446,O
were,446,O
found,446,O
to,446,O
have,446,O
the,446,O
FGFR3,446,O
P250R,446,O
mutation,446,O
",",446,O
and,446,O
one,446,O
individual,446,O
was,446,O
found,446,O
to,446,O
have,446,O
an,446,O
FGFR2,446,O
VV269-270,446,O
deletion,446,O
.,446,O
To,447,O
date,447,O
",",447,O
our,447,O
detection,447,O
rate,447,O
for,447,O
TWIST,447,O
or,447,O
FGFR,447,O
mutations,447,O
is,447,O
68,447,O
%,447,O
in,447,O
our,447,O
Saethre-Chotzen,447,B-Modifier
syndrome,447,I-Modifier
patients,447,O
",",447,O
including,447,O
our,447,O
five,447,O
patients,447,O
elsewhere,447,O
reported,447,O
with,447,O
TWIST,447,O
mutations,447,O
.,447,O
More,448,O
than,448,O
35,448,O
different,448,O
TWIST,448,O
mutations,448,O
are,448,O
now,448,O
known,448,O
in,448,O
the,448,O
literature,448,O
.,448,O
The,449,O
most,449,O
common,449,O
phenotypic,449,O
features,449,O
",",449,O
present,449,O
in,449,O
more,449,O
than,449,O
a,449,O
third,449,O
of,449,O
our,449,O
patients,449,O
with,449,O
TWIST,449,O
mutations,449,O
",",449,O
are,449,O
coronal,449,B-SpecificDisease
synostosis,449,I-SpecificDisease
",",449,O
brachycephaly,449,B-SpecificDisease
",",449,O
low,449,B-SpecificDisease
frontal,449,I-SpecificDisease
hairline,449,I-SpecificDisease
",",449,O
facial,449,B-SpecificDisease
asymmetry,449,I-SpecificDisease
",",449,O
ptosis,449,B-SpecificDisease
",",449,O
hypertelorism,449,B-SpecificDisease
",",449,O
broad,449,B-SpecificDisease
great,449,I-SpecificDisease
toes,449,I-SpecificDisease
",",449,O
and,449,O
clinodactyly,449,B-SpecificDisease
.,449,O
Significant,450,O
intra-,450,O
and,450,O
interfamilial,450,O
phenotypic,450,O
variability,450,O
is,450,O
present,450,O
for,450,O
either,450,O
TWIST,450,O
mutations,450,O
or,450,O
FGFR,450,O
mutations,450,O
.,450,O
The,451,O
overlap,451,O
in,451,O
clinical,451,O
features,451,O
and,451,O
the,451,O
presence,451,O
",",451,O
in,451,O
the,451,O
same,451,O
genes,451,O
",",451,O
of,451,O
mutations,451,O
for,451,O
more,451,O
than,451,O
one,451,O
craniosynostotic,451,B-DiseaseClass
condition-such,451,O
as,451,O
Saethre-Chotzen,451,O
",",451,O
Crouzon,451,O
",",451,O
and,451,O
Pfeiffer,451,O
syndromes-support,451,O
the,451,O
hypothesis,451,O
that,451,O
TWIST,451,O
and,451,O
FGFRs,451,O
are,451,O
components,451,O
of,451,O
the,451,O
same,451,O
molecular,451,O
pathway,451,O
involved,451,O
in,451,O
the,451,O
modulation,451,O
of,451,O
craniofacial,451,O
and,451,O
limb,451,O
development,451,O
in,451,O
humans,451,O
..,451,O
Mutation,452,O
analysis,452,O
of,452,O
UBE3A,452,O
in,452,O
Angelman,452,B-Modifier
syndrome,452,I-Modifier
patients,452,O
.,452,O
Angelman,453,B-SpecificDisease
syndrome,453,I-SpecificDisease
(,453,O
AS,453,B-SpecificDisease
),453,O
is,453,O
caused,453,O
by,453,O
chromosome,453,O
15q11-q13,453,O
deletions,453,O
of,453,O
maternal,453,O
origin,453,O
",",453,O
by,453,O
paternal,453,O
uniparental,453,B-SpecificDisease
disomy,453,I-SpecificDisease
(,453,O
UPD,453,B-SpecificDisease
),453,O
15,453,O
",",453,O
by,453,O
imprinting,453,O
defects,453,O
",",453,O
and,453,O
by,453,O
mutations,453,O
in,453,O
the,453,O
UBE3A,453,O
gene,453,O
.,453,O
UBE3A,454,O
encodes,454,O
a,454,O
ubiquitin-protein,454,O
ligase,454,O
and,454,O
shows,454,O
brain-specific,454,O
imprinting,454,O
.,454,O
Here,455,O
we,455,O
describe,455,O
UBE3A,455,O
coding-region,455,O
mutations,455,O
detected,455,O
by,455,O
SSCP,455,O
analysis,455,O
in,455,O
13,455,O
AS,455,B-Modifier
individuals,455,O
or,455,O
families,455,O
.,455,O
Two,456,O
identical,456,O
de,456,O
novo,456,O
5-bp,456,O
duplications,456,O
in,456,O
exon,456,O
16,456,O
were,456,O
found,456,O
.,456,O
Among,457,O
the,457,O
other,457,O
11,457,O
unique,457,O
mutations,457,O
",",457,O
8,457,O
were,457,O
small,457,O
deletions,457,O
or,457,O
insertions,457,O
predicted,457,O
to,457,O
cause,457,O
frameshifts,457,O
",",457,O
1,457,O
was,457,O
a,457,O
mutation,457,O
to,457,O
a,457,O
stop,457,O
codon,457,O
",",457,O
1,457,O
was,457,O
a,457,O
missense,457,O
mutation,457,O
",",457,O
and,457,O
1,457,O
was,457,O
predicted,457,O
to,457,O
cause,457,O
insertion,457,O
of,457,O
an,457,O
isoleucine,457,O
in,457,O
the,457,O
hect,457,O
domain,457,O
of,457,O
the,457,O
UBE3A,457,O
protein,457,O
",",457,O
which,457,O
functions,457,O
in,457,O
E2,457,O
binding,457,O
and,457,O
ubiquitin,457,O
transfer,457,O
.,457,O
Eight,458,O
of,458,O
the,458,O
cases,458,O
were,458,O
familial,458,O
",",458,O
and,458,O
five,458,O
were,458,O
sporadic,458,O
.,458,O
In,459,O
two,459,O
familial,459,O
cases,459,O
and,459,O
one,459,O
sporadic,459,O
case,459,O
",",459,O
mosaicism,459,O
for,459,O
UBE3A,459,O
mutations,459,O
was,459,O
detected,459,O
in,459,O
the,459,O
mother,459,O
of,459,O
three,459,O
AS,459,B-Modifier
sons,459,O
",",459,O
in,459,O
the,459,O
maternal,459,O
grandfather,459,O
of,459,O
two,459,O
AS,459,B-Modifier
first,459,O
cousins,459,O
",",459,O
and,459,O
in,459,O
the,459,O
mother,459,O
of,459,O
an,459,O
AS,459,B-Modifier
daughter,459,O
.,459,O
The,460,O
frequencies,460,O
with,460,O
which,460,O
we,460,O
detected,460,O
mutations,460,O
were,460,O
5,460,O
(,460,O
14,460,O
%,460,O
),460,O
of,460,O
35,460,O
in,460,O
sporadic,460,O
cases,460,O
and,460,O
8,460,O
(,460,O
80,460,O
%,460,O
),460,O
of,460,O
10,460,O
in,460,O
familial,460,O
cases,460,O
..,460,O
The,461,O
hemochromatosis,461,B-Modifier
845,461,O
G,461,O
--,461,O
>,461,O
A,461,O
and,461,O
187,461,O
C,461,O
--,461,O
>,461,O
G,461,O
mutations,461,O
:,461,O
prevalence,461,O
in,461,O
non-Caucasian,461,O
populations,461,O
.,461,O
Hemochromatosis,462,B-SpecificDisease
",",462,O
the,462,O
inherited,462,B-DiseaseClass
disorder,462,I-DiseaseClass
of,462,I-DiseaseClass
iron,462,I-DiseaseClass
metabolism,462,I-DiseaseClass
",",462,O
leads,462,O
",",462,O
if,462,O
untreated,462,O
",",462,O
to,462,O
progressive,462,O
iron,462,B-SpecificDisease
overload,462,I-SpecificDisease
and,462,O
premature,462,B-SpecificDisease
death,462,I-SpecificDisease
.,462,O
The,463,O
hemochromatosis,463,B-Modifier
gene,463,O
",",463,O
HFE,463,O
",",463,O
recently,463,O
has,463,O
been,463,O
identified,463,O
",",463,O
and,463,O
characterization,463,O
of,463,O
this,463,O
gene,463,O
has,463,O
shown,463,O
that,463,O
it,463,O
contains,463,O
two,463,O
mutations,463,O
that,463,O
result,463,O
in,463,O
amino,463,O
acid,463,O
substitutions-cDNA,463,O
nucleotides,463,O
845,463,O
G,463,O
--,463,O
>,463,O
A,463,O
(,463,O
C282Y,463,O
),463,O
and,463,O
187,463,O
C,463,O
--,463,O
>,463,O
G,463,O
(,463,O
H63D,463,O
),463,O
.,463,O
Although,464,O
hemochromatosis,464,B-SpecificDisease
is,464,O
common,464,O
in,464,O
Caucasians,464,O
",",464,O
affecting,464,O
>,464,O
=,464,O
1/300,464,O
individuals,464,O
of,464,O
northern,464,O
European,464,O
origin,464,O
",",464,O
it,464,O
has,464,O
not,464,O
been,464,O
recognized,464,O
in,464,O
other,464,O
populations,464,O
.,464,O
The,465,O
present,465,O
study,465,O
used,465,O
PCR,465,O
and,465,O
restriction-enzyme,465,O
digestion,465,O
to,465,O
analyze,465,O
the,465,O
frequency,465,O
of,465,O
the,465,O
845,465,O
G,465,O
--,465,O
>,465,O
A,465,O
and,465,O
187,465,O
C,465,O
--,465,O
>,465,O
G,465,O
mutations,465,O
in,465,O
HLA-typed,465,O
samples,465,O
from,465,O
non-Caucasian,465,O
populations,465,O
",",465,O
comprising,465,O
Australian,465,O
Aboriginal,465,O
",",465,O
Chinese,465,O
",",465,O
and,465,O
Pacific,465,O
Islanders,465,O
.,465,O
Results,466,O
showed,466,O
that,466,O
the,466,O
845,466,O
G,466,O
--,466,O
>,466,O
A,466,O
mutation,466,O
was,466,O
present,466,O
in,466,O
these,466,O
populations,466,O
(,466,O
allele,466,O
frequency,466,O
0,466,O
.,466,O
32,467,O
%,467,O
),467,O
",",467,O
and,467,O
",",467,O
furthermore,467,O
",",467,O
it,467,O
was,467,O
always,467,O
seen,467,O
in,467,O
conjunction,467,O
with,467,O
HLA,467,O
haplotypes,467,O
common,467,O
in,467,O
Caucasians,467,O
",",467,O
suggesting,467,O
that,467,O
845,467,O
G,467,O
--,467,O
>,467,O
A,467,O
may,467,O
have,467,O
been,467,O
introduced,467,O
into,467,O
these,467,O
populations,467,O
by,467,O
Caucasian,467,O
admixture,467,O
.,467,O
187,468,O
C,468,O
--,468,O
>,468,O
G,468,O
was,468,O
present,468,O
at,468,O
an,468,O
allele,468,O
frequency,468,O
of,468,O
2,468,O
.,468,O
68,469,O
%,469,O
in,469,O
the,469,O
two,469,O
populations,469,O
analyzed,469,O
(,469,O
Australian,469,O
Aboriginal,469,O
and,469,O
Chinese,469,O
),469,O
.,469,O
In,470,O
the,470,O
Australian,470,O
Aboriginal,470,O
samples,470,O
",",470,O
187,470,O
C,470,O
--,470,O
>,470,O
G,470,O
was,470,O
found,470,O
to,470,O
be,470,O
associated,470,O
with,470,O
HLA,470,O
haplotypes,470,O
common,470,O
in,470,O
Caucasians,470,O
",",470,O
suggesting,470,O
that,470,O
it,470,O
was,470,O
introduced,470,O
by,470,O
recent,470,O
admixture,470,O
.,470,O
In,471,O
the,471,O
Chinese,471,O
samples,471,O
analyzed,471,O
",",471,O
187,471,O
C,471,O
--,471,O
>,471,O
G,471,O
was,471,O
present,471,O
in,471,O
association,471,O
with,471,O
a,471,O
wide,471,O
variety,471,O
of,471,O
HLA,471,O
haplotypes,471,O
",",471,O
showing,471,O
this,471,O
mutation,471,O
to,471,O
be,471,O
widespread,471,O
and,471,O
likely,471,O
to,471,O
predate,471,O
the,471,O
more,471,O
genetically,471,O
restricted,471,O
845,471,O
G,471,O
--,471,O
>,471,O
A,471,O
mutation,471,O
.,471,O
Genotype-phenotype,472,O
correlations,472,O
in,472,O
attenuated,472,B-SpecificDisease
adenomatous,472,I-SpecificDisease
polyposis,472,I-SpecificDisease
coli,472,I-SpecificDisease
.,472,O
Germ-line,473,O
mutations,473,O
of,473,O
the,473,O
tumor,473,B-Modifier
suppressor,473,O
APC,473,O
are,473,O
implicated,473,O
in,473,O
attenuated,473,B-SpecificDisease
adenomatous,473,I-SpecificDisease
polyposis,473,I-SpecificDisease
coli,473,I-SpecificDisease
(,473,O
AAPC,473,B-SpecificDisease
),473,O
",",473,O
a,473,O
variant,473,O
of,473,O
familial,473,B-SpecificDisease
adenomatous,473,I-SpecificDisease
polyposis,473,I-SpecificDisease
(,473,O
FAP,473,B-SpecificDisease
),473,O
.,473,O
AAPC,474,B-SpecificDisease
is,474,O
recognized,474,O
by,474,O
the,474,O
occurrence,474,O
of,474,O
<,474,O
100,474,O
colonic,474,B-SpecificDisease
adenomas,474,I-SpecificDisease
and,474,O
a,474,O
later,474,O
onset,474,O
of,474,O
colorectal,474,B-SpecificDisease
cancer,474,I-SpecificDisease
(,474,O
age,474,O
>,474,O
40,474,O
years,474,O
),474,O
.,474,O
The,475,O
aim,475,O
of,475,O
this,475,O
study,475,O
was,475,O
to,475,O
assess,475,O
genotype-phenotype,475,O
correlations,475,O
in,475,O
AAPC,475,B-Modifier
families,475,O
.,475,O
By,476,O
protein-truncation,476,O
test,476,O
(,476,O
PTT,476,O
),476,O
assay,476,O
",",476,O
the,476,O
entire,476,O
coding,476,O
region,476,O
of,476,O
the,476,O
APC,476,B-Modifier
gene,476,O
was,476,O
screened,476,O
in,476,O
affected,476,O
individuals,476,O
from,476,O
11,476,O
AAPC,476,B-Modifier
kindreds,476,O
",",476,O
and,476,O
their,476,O
phenotypic,476,O
differences,476,O
were,476,O
examined,476,O
.,476,O
Five,477,O
novel,477,O
germ-line,477,O
APC,477,B-Modifier
mutations,477,O
were,477,O
identified,477,O
in,477,O
seven,477,O
kindreds,477,O
.,477,O
Mutations,478,O
were,478,O
located,478,O
in,478,O
three,478,O
different,478,O
regions,478,O
of,478,O
the,478,O
APC,478,B-Modifier
gene,478,O
(,478,O
1,478,O
),478,O
at,478,O
the,478,O
5,478,O
end,478,O
spanning,478,O
exons,478,O
4,478,O
and,478,O
5,478,O
",",478,O
(,478,O
2,478,O
),478,O
within,478,O
exon,478,O
9,478,O
",",478,O
and,478,O
(,478,O
3,478,O
),478,O
at,478,O
the,478,O
3,478,O
distal,478,O
end,478,O
of,478,O
the,478,O
gene,478,O
.,478,O
Variability,479,O
in,479,O
the,479,O
number,479,O
of,479,O
colorectal,479,B-SpecificDisease
adenomas,479,I-SpecificDisease
was,479,O
most,479,O
apparent,479,O
in,479,O
individuals,479,O
with,479,O
mutations,479,O
in,479,O
region,479,O
1,479,O
",",479,O
and,479,O
upper-gastrointestinal,479,O
manifestations,479,O
were,479,O
more,479,O
severe,479,O
in,479,O
them,479,O
.,479,O
In,480,O
individuals,480,O
with,480,O
mutations,480,O
in,480,O
either,480,O
region,480,O
2,480,O
or,480,O
region,480,O
3,480,O
",",480,O
the,480,O
average,480,O
number,480,O
of,480,O
adenomas,480,B-DiseaseClass
tended,480,O
to,480,O
be,480,O
lower,480,O
than,480,O
those,480,O
in,480,O
individuals,480,O
with,480,O
mutations,480,O
in,480,O
region,480,O
1,480,O
",",480,O
although,480,O
age,480,O
at,480,O
diagnosis,480,O
was,480,O
similar,480,O
.,480,O
In,481,O
all,481,O
AAPC,481,B-Modifier
kindreds,481,O
",",481,O
a,481,O
predominance,481,O
of,481,O
right-sided,481,O
colorectal,481,B-SpecificDisease
adenomas,481,I-SpecificDisease
and,481,O
rectal,481,B-Modifier
polyp,481,I-Modifier
sparing,481,O
was,481,O
observed,481,O
.,481,O
No,482,O
desmoid,482,B-SpecificDisease
tumors,482,I-SpecificDisease
were,482,O
found,482,O
in,482,O
these,482,O
kindreds,482,O
.,482,O
Our,483,O
data,483,O
suggest,483,O
that,483,O
",",483,O
in,483,O
AAPC,483,B-Modifier
families,483,O
",",483,O
the,483,O
location,483,O
of,483,O
the,483,O
APC,483,B-Modifier
mutation,483,O
may,483,O
partially,483,O
predict,483,O
specific,483,O
phenotypic,483,O
expression,483,O
.,483,O
This,484,O
should,484,O
help,484,O
in,484,O
the,484,O
design,484,O
of,484,O
tailored,484,O
clinical-management,484,O
protocols,484,O
in,484,O
this,484,O
subset,484,O
of,484,O
FAP,484,B-Modifier
patients,484,O
..,484,O
Wilms,485,B-Modifier
',485,I-Modifier
tumor,485,I-Modifier
1,485,O
and,485,O
Dax-1,485,O
modulate,485,O
the,485,O
orphan,485,O
nuclear,485,O
receptor,485,O
SF-1,485,O
in,485,O
sex-specific,485,O
gene,485,O
expression,485,O
.,485,O
Products,486,O
of,486,O
steroidogenic,486,O
factor,486,O
1,486,O
(,486,O
SF-1,486,O
),486,O
and,486,O
Wilms,486,B-Modifier
tumor,486,I-Modifier
1,486,O
(,486,O
WT1,486,O
),486,O
genes,486,O
are,486,O
essential,486,O
for,486,O
mammalian,486,O
gonadogenesis,486,O
prior,486,O
to,486,O
sexual,486,O
differentiation,486,O
.,486,O
In,487,O
males,487,O
",",487,O
SF-1,487,O
participates,487,O
in,487,O
sexual,487,O
development,487,O
by,487,O
regulating,487,O
expression,487,O
of,487,O
the,487,O
polypeptide,487,O
hormone,487,O
Mullerian,487,O
inhibiting,487,O
substance,487,O
(,487,O
MIS,487,O
),487,O
.,487,O
Here,488,O
",",488,O
we,488,O
show,488,O
that,488,O
WT1,488,O
-KTS,488,O
isoforms,488,O
associate,488,O
and,488,O
synergize,488,O
with,488,O
SF-1,488,O
to,488,O
promote,488,O
MIS,488,O
expression,488,O
.,488,O
In,489,O
contrast,489,O
",",489,O
WT1,489,O
missense,489,O
mutations,489,O
",",489,O
associated,489,O
with,489,O
male,489,B-SpecificDisease
pseudohermaphroditism,489,I-SpecificDisease
in,489,O
Denys-Drash,489,B-SpecificDisease
syndrome,489,I-SpecificDisease
",",489,O
fail,489,O
to,489,O
synergize,489,O
with,489,O
SF-1,489,O
.,489,O
Additionally,490,O
",",490,O
the,490,O
X-linked,490,O
",",490,O
candidate,490,O
dosage-sensitive,490,O
sex-reversal,490,O
gene,490,O
",",490,O
Dax-1,490,O
",",490,O
antagonizes,490,O
synergy,490,O
between,490,O
SF-1,490,O
and,490,O
WT1,490,O
",",490,O
most,490,O
likely,490,O
through,490,O
a,490,O
direct,490,O
interaction,490,O
with,490,O
SF-1,490,O
.,490,O
We,491,O
propose,491,O
that,491,O
WT1,491,O
and,491,O
Dax-1,491,O
functionally,491,O
oppose,491,O
each,491,O
other,491,O
in,491,O
testis,491,O
development,491,O
by,491,O
modulating,491,O
SF-1-mediated,491,O
transactivation,491,O
..,491,O
A,492,O
mouse,492,O
model,492,O
for,492,O
Prader-Willi,492,B-SpecificDisease
syndrome,492,I-SpecificDisease
imprinting-centre,492,O
mutations,492,O
.,492,O
Imprinting,493,O
in,493,O
the,493,O
15q11-q13,493,O
region,493,O
involves,493,O
an,493,O
imprinting,493,O
centre,493,O
(,493,O
IC,493,O
),493,O
",",493,O
mapping,493,O
in,493,O
part,493,O
to,493,O
the,493,O
promoter,493,O
and,493,O
first,493,O
exon,493,O
of,493,O
SNRPN,493,O
.,493,O
Deletion,494,O
of,494,O
this,494,O
IC,494,O
abolishes,494,O
local,494,O
paternally,494,O
derived,494,O
gene,494,O
expression,494,O
and,494,O
results,494,O
in,494,O
Prader-Willi,494,B-SpecificDisease
syndrome,494,I-SpecificDisease
(,494,O
PWS,494,B-SpecificDisease
),494,O
.,494,O
We,495,O
have,495,O
created,495,O
two,495,O
deletion,495,O
mutations,495,O
in,495,O
mice,495,O
to,495,O
understand,495,O
PWS,495,B-SpecificDisease
and,495,O
the,495,O
mechanism,495,O
of,495,O
this,495,O
IC,495,O
.,495,O
Mice,496,O
harbouring,496,O
an,496,O
intragenic,496,O
deletion,496,O
in,496,O
Snrpn,496,O
are,496,O
phenotypically,496,O
normal,496,O
",",496,O
suggesting,496,O
that,496,O
mutations,496,O
of,496,O
SNRPN,496,O
are,496,O
not,496,O
sufficient,496,O
to,496,O
induce,496,O
PWS,496,B-SpecificDisease
.,496,O
Mice,497,O
with,497,O
a,497,O
larger,497,O
deletion,497,O
involving,497,O
both,497,O
Snrpn,497,O
and,497,O
the,497,O
putative,497,O
PWS-IC,497,O
lack,497,O
expression,497,O
of,497,O
the,497,O
imprinted,497,O
genes,497,O
Zfp127,497,O
(,497,O
mouse,497,O
homologue,497,O
of,497,O
ZNF127,497,O
),497,O
",",497,O
Ndn,497,O
and,497,O
Ipw,497,O
",",497,O
and,497,O
manifest,497,O
several,497,O
phenotypes,497,O
common,497,O
to,497,O
PWS,497,B-Modifier
infants,497,O
.,497,O
These,498,O
data,498,O
demonstrate,498,O
that,498,O
both,498,O
the,498,O
position,498,O
of,498,O
the,498,O
IC,498,O
and,498,O
its,498,O
role,498,O
in,498,O
the,498,O
coordinate,498,O
expression,498,O
of,498,O
genes,498,O
is,498,O
conserved,498,O
between,498,O
mouse,498,O
and,498,O
human,498,O
",",498,O
and,498,O
indicate,498,O
that,498,O
the,498,O
mouse,498,O
is,498,O
a,498,O
suitable,498,O
model,498,O
system,498,O
in,498,O
which,498,O
to,498,O
investigate,498,O
the,498,O
molecular,498,O
mechanisms,498,O
of,498,O
imprinting,498,O
in,498,O
this,498,O
region,498,O
of,498,O
the,498,O
genome,498,O
..,498,O
Mutations,499,O
of,499,O
the,499,O
ATM,499,O
gene,499,O
detected,499,O
in,499,O
Japanese,499,O
ataxia-telangiectasia,499,B-Modifier
patients,499,O
:,499,O
possible,499,O
preponderance,499,O
of,499,O
the,499,O
two,499,O
founder,499,O
mutations,499,O
4612del165,499,O
and,499,O
7883del5,499,O
.,499,O
The,500,O
ATM,500,O
(,500,O
A-T,500,O
",",500,O
mutated,500,O
),500,O
gene,500,O
on,500,O
human,500,O
chromosome,500,O
11q22,500,O
.,500,O
3,501,O
has,501,O
recently,501,O
been,501,O
identified,501,O
as,501,O
the,501,O
gene,501,O
responsible,501,O
for,501,O
the,501,O
human,501,O
recessive,501,B-DiseaseClass
disease,501,I-DiseaseClass
ataxia-telangiectasia,501,B-SpecificDisease
(,501,O
A-T,501,B-SpecificDisease
),501,O
.,501,O
In,502,O
order,502,O
to,502,O
define,502,O
the,502,O
types,502,O
of,502,O
disease-causing,502,O
ATM,502,O
mutations,502,O
in,502,O
Japanese,502,O
A-T,502,B-Modifier
patients,502,O
as,502,O
well,502,O
as,502,O
to,502,O
look,502,O
for,502,O
possible,502,O
mutational,502,O
hotspots,502,O
",",502,O
reverse-transcribed,502,O
RNA,502,O
derived,502,O
from,502,O
ten,502,O
patients,502,O
belonging,502,O
to,502,O
eight,502,O
unrelated,502,O
Japanese,502,O
A-T,502,B-Modifier
families,502,O
was,502,O
analyzed,502,O
for,502,O
mutations,502,O
by,502,O
the,502,O
restriction,502,O
endonuclease,502,O
fingerprinting,502,O
method,502,O
.,502,O
As,503,O
has,503,O
been,503,O
reported,503,O
by,503,O
others,503,O
",",503,O
mutations,503,O
that,503,O
lead,503,O
to,503,O
exon,503,O
skipping,503,O
or,503,O
premature,503,O
protein,503,O
truncation,503,O
were,503,O
also,503,O
predominant,503,O
in,503,O
our,503,O
mutants,503,O
.,503,O
Six,504,O
different,504,O
mutations,504,O
were,504,O
identified,504,O
on,504,O
12,504,O
of,504,O
the,504,O
16,504,O
alleles,504,O
examined,504,O
.,504,O
Four,505,O
were,505,O
deletions,505,O
involving,505,O
a,505,O
loss,505,O
of,505,O
a,505,O
single,505,O
exon,505,O
exon,505,O
7,505,O
",",505,O
exon,505,O
16,505,O
",",505,O
exon,505,O
33,505,O
or,505,O
exon,505,O
35,505,O
.,505,O
The,506,O
others,506,O
were,506,O
minute,506,O
deletions,506,O
",",506,O
4649delA,506,O
in,506,O
exon,506,O
33,506,O
and,506,O
7883del5,506,O
in,506,O
exon,506,O
55,506,O
.,506,O
The,507,O
mutations,507,O
4612del165,507,O
and,507,O
7883del5,507,O
were,507,O
found,507,O
in,507,O
more,507,O
than,507,O
two,507,O
unrelated,507,O
families,507,O
;,507,O
44,507,O
%,507,O
(,507,O
7,507,O
of,507,O
16,507,O
),507,O
of,507,O
the,507,O
mutant,507,O
alleles,507,O
had,507,O
one,507,O
of,507,O
the,507,O
two,507,O
mutations,507,O
.,507,O
The,508,O
4612del165,508,O
mutations,508,O
in,508,O
three,508,O
different,508,O
families,508,O
were,508,O
all,508,O
ascribed,508,O
to,508,O
the,508,O
same,508,O
T,508,O
--,508,O
>,508,O
A,508,O
substitution,508,O
at,508,O
the,508,O
splice,508,O
donor,508,O
site,508,O
in,508,O
intron,508,O
33,508,O
.,508,O
Microsatellite,509,O
genotyping,509,O
around,509,O
the,509,O
ATM,509,O
locus,509,O
also,509,O
indicated,509,O
that,509,O
a,509,O
common,509,O
haplotype,509,O
was,509,O
shared,509,O
by,509,O
the,509,O
mutant,509,O
alleles,509,O
in,509,O
both,509,O
mutations,509,O
.,509,O
This,510,O
suggests,510,O
that,510,O
these,510,O
two,510,O
founder,510,O
mutations,510,O
may,510,O
be,510,O
predominant,510,O
among,510,O
Japanese,510,O
ATM,510,O
mutant,510,O
alleles,510,O
.,510,O
W474C,511,O
amino,511,O
acid,511,O
substitution,511,O
affects,511,O
early,511,O
processing,511,O
of,511,O
the,511,O
alpha-subunit,511,O
of,511,O
beta-hexosaminidase,511,O
A,511,O
and,511,O
is,511,O
associated,511,O
with,511,O
subacute,511,O
G,511,B-SpecificDisease
(,511,I-SpecificDisease
M2,511,I-SpecificDisease
),511,I-SpecificDisease
gangliosidosis,511,I-SpecificDisease
.,511,O
Mutations,512,O
in,512,O
the,512,O
HEXA,512,O
gene,512,O
",",512,O
encoding,512,O
the,512,O
alpha-subunit,512,O
of,512,O
beta-hexosaminidase,512,O
A,512,O
(,512,O
Hex,512,O
A,512,O
),512,O
",",512,O
that,512,O
abolish,512,O
Hex,512,O
A,512,O
enzyme,512,O
activity,512,O
cause,512,O
Tay-Sachs,512,B-SpecificDisease
disease,512,I-SpecificDisease
(,512,O
TSD,512,B-SpecificDisease
),512,O
",",512,O
the,512,O
fatal,512,O
infantile,512,B-SpecificDisease
form,512,I-SpecificDisease
of,512,I-SpecificDisease
G,512,I-SpecificDisease
(,512,I-SpecificDisease
M2,512,I-SpecificDisease
),512,I-SpecificDisease
gangliosidosis,512,I-SpecificDisease
",",512,I-SpecificDisease
Type,512,I-SpecificDisease
1,512,I-SpecificDisease
.,512,O
Less,513,O
severe,513,O
",",513,O
subacute,513,O
(,513,O
juvenile-onset,513,O
),513,O
and,513,O
chronic,513,O
(,513,O
adult-onset,513,O
),513,O
variants,513,O
are,513,O
characterized,513,O
by,513,O
a,513,O
broad,513,O
spectrum,513,O
of,513,O
clinical,513,O
manifestations,513,O
and,513,O
are,513,O
associated,513,O
with,513,O
residual,513,O
levels,513,O
of,513,O
Hex,513,O
A,513,O
enzyme,513,O
activity,513,O
.,513,O
We,514,O
identified,514,O
a,514,O
1422,514,O
G,514,O
--,514,O
>,514,O
C,514,O
(,514,O
amino,514,O
acid,514,O
W474C,514,O
),514,O
substitution,514,O
in,514,O
the,514,O
first,514,O
position,514,O
of,514,O
exon,514,O
13,514,O
of,514,O
HEXA,514,O
of,514,O
a,514,O
non-Jewish,514,O
proband,514,O
who,514,O
manifested,514,O
a,514,O
subacute,514,O
variant,514,O
of,514,O
G,514,B-SpecificDisease
(,514,I-SpecificDisease
M2,514,I-SpecificDisease
),514,I-SpecificDisease
gangliosidosis,514,I-SpecificDisease
.,514,O
On,515,O
the,515,O
second,515,O
maternally,515,O
inherited,515,O
allele,515,O
",",515,O
we,515,O
identified,515,O
the,515,O
common,515,O
infantile,515,O
disease-causing,515,O
4-bp,515,O
insertion,515,O
",",515,O
+,515,O
TATC,515,O
1278,515,O
",",515,O
in,515,O
exon,515,O
11,515,O
.,515,O
Pulse-chase,516,O
analysis,516,O
using,516,O
proband,516,O
fibroblasts,516,O
revealed,516,O
that,516,O
the,516,O
W474C-containing,516,O
alpha-subunit,516,O
precursor,516,O
was,516,O
normally,516,O
synthesized,516,O
",",516,O
but,516,O
not,516,O
phosphorylated,516,O
or,516,O
secreted,516,O
",",516,O
and,516,O
the,516,O
mature,516,O
lysosomal,516,O
alpha-subunit,516,O
was,516,O
not,516,O
detected,516,O
.,516,O
When,517,O
the,517,O
W474C-containing,517,O
alpha-subunit,517,O
was,517,O
transiently,517,O
co-expressed,517,O
with,517,O
the,517,O
beta-subunit,517,O
to,517,O
produce,517,O
Hex,517,O
A,517,O
(,517,O
alphabeta,517,O
),517,O
in,517,O
COS-7,517,O
cells,517,O
",",517,O
the,517,O
mature,517,O
alpha-subunit,517,O
was,517,O
present,517,O
",",517,O
but,517,O
its,517,O
level,517,O
was,517,O
much,517,O
lower,517,O
than,517,O
that,517,O
from,517,O
normal,517,O
alpha-subunit,517,O
transfections,517,O
",",517,O
although,517,O
higher,517,O
than,517,O
in,517,O
those,517,O
cells,517,O
transfected,517,O
with,517,O
an,517,O
alpha-subunit,517,O
associated,517,O
with,517,O
infantile,517,O
TSD,517,B-SpecificDisease
.,517,O
Furthermore,518,O
",",518,O
the,518,O
precursor,518,O
level,518,O
of,518,O
the,518,O
W474C,518,O
alpha-subunit,518,O
was,518,O
found,518,O
to,518,O
accumulate,518,O
in,518,O
comparison,518,O
to,518,O
the,518,O
normal,518,O
alpha-subunit,518,O
precursor,518,O
levels,518,O
.,518,O
We,519,O
conclude,519,O
that,519,O
the,519,O
1422,519,O
G,519,O
--,519,O
>,519,O
C,519,O
mutation,519,O
is,519,O
the,519,O
cause,519,O
of,519,O
Hex,519,B-SpecificDisease
A,519,I-SpecificDisease
enzyme,519,I-SpecificDisease
deficiency,519,I-SpecificDisease
in,519,O
the,519,O
proband,519,O
.,519,O
The,520,O
resulting,520,O
W474C,520,O
substitution,520,O
clearly,520,O
interferes,520,O
with,520,O
alpha-subunit,520,O
processing,520,O
",",520,O
but,520,O
because,520,O
the,520,O
base,520,O
substitution,520,O
falls,520,O
at,520,O
the,520,O
first,520,O
position,520,O
of,520,O
exon,520,O
13,520,O
",",520,O
aberrant,520,O
splicing,520,O
may,520,O
also,520,O
contribute,520,O
to,520,O
Hex,520,B-SpecificDisease
A,520,I-SpecificDisease
deficiency,520,I-SpecificDisease
in,520,O
this,520,O
proband,520,O
..,520,O
Two,521,O
frequent,521,O
missense,521,O
mutations,521,O
in,521,O
Pendred,521,B-SpecificDisease
syndrome,521,I-SpecificDisease
.,521,O
Pendred,522,B-SpecificDisease
syndrome,522,I-SpecificDisease
is,522,O
an,522,O
autosomal,522,B-DiseaseClass
recessive,522,I-DiseaseClass
disorder,522,I-DiseaseClass
characterized,522,O
by,522,O
early,522,O
childhood,522,O
deafness,522,B-SpecificDisease
and,522,O
goiter,522,B-SpecificDisease
.,522,O
A,523,O
century,523,O
after,523,O
its,523,O
recognition,523,O
as,523,O
a,523,O
syndrome,523,O
by,523,O
Vaughan,523,O
Pendred,523,O
",",523,O
the,523,O
disease,523,O
gene,523,O
(,523,O
PDS,523,O
),523,O
was,523,O
mapped,523,O
to,523,O
chromosome,523,O
7q22-q31,523,O
.,523,O
1,524,O
and,524,O
",",524,O
recently,524,O
",",524,O
found,524,O
to,524,O
encode,524,O
a,524,O
putative,524,O
sulfate,524,O
transporter,524,O
.,524,O
We,525,O
performed,525,O
mutation,525,O
analysis,525,O
of,525,O
the,525,O
PDS,525,B-Modifier
gene,525,O
in,525,O
patients,525,O
from,525,O
14,525,O
Pendred,525,B-Modifier
families,525,O
originating,525,O
from,525,O
seven,525,O
countries,525,O
and,525,O
identified,525,O
all,525,O
mutations,525,O
.,525,O
The,526,O
mutations,526,O
include,526,O
three,526,O
single,526,O
base,526,O
deletions,526,O
",",526,O
one,526,O
splice,526,O
site,526,O
mutation,526,O
and,526,O
10,526,O
missense,526,O
mutations,526,O
.,526,O
One,527,O
missense,527,O
mutation,527,O
(,527,O
L236P,527,O
),527,O
was,527,O
found,527,O
in,527,O
a,527,O
homozygous,527,O
state,527,O
in,527,O
two,527,O
consanguineous,527,O
families,527,O
and,527,O
in,527,O
a,527,O
heterozygous,527,O
state,527,O
in,527,O
five,527,O
additional,527,O
non-consanguineous,527,O
families,527,O
.,527,O
Another,528,O
missense,528,O
mutation,528,O
(,528,O
T416P,528,O
),528,O
was,528,O
found,528,O
in,528,O
a,528,O
homozygous,528,O
state,528,O
in,528,O
one,528,O
family,528,O
and,528,O
in,528,O
a,528,O
heterozygous,528,O
state,528,O
in,528,O
four,528,O
families,528,O
.,528,O
Pendred,529,B-Modifier
patients,529,O
in,529,O
three,529,O
non-consanguineous,529,O
families,529,O
were,529,O
shown,529,O
to,529,O
be,529,O
compound,529,O
heterozygotes,529,O
for,529,O
L236P,529,O
and,529,O
T416P,529,O
.,529,O
In,530,O
total,530,O
",",530,O
one,530,O
or,530,O
both,530,O
of,530,O
these,530,O
mutations,530,O
were,530,O
found,530,O
in,530,O
nine,530,O
of,530,O
the,530,O
14,530,O
families,530,O
analyzed,530,O
.,530,O
The,531,O
identification,531,O
of,531,O
two,531,O
frequent,531,O
PDS,531,B-Modifier
mutations,531,O
will,531,O
facilitate,531,O
the,531,O
molecular,531,O
diagnosis,531,O
of,531,O
Pendred,531,B-SpecificDisease
syndrome,531,I-SpecificDisease
.,531,O
Insertional,532,O
mutation,532,O
by,532,O
transposable,532,O
element,532,O
",",532,O
L1,532,O
",",532,O
in,532,O
the,532,O
DMD,532,B-Modifier
gene,532,O
results,532,O
in,532,O
X-linked,532,B-SpecificDisease
dilated,532,I-SpecificDisease
cardiomyopathy,532,I-SpecificDisease
.,532,O
X-linked,533,B-SpecificDisease
dilated,533,I-SpecificDisease
cardiomyopathy,533,I-SpecificDisease
(,533,O
XLDCM,533,B-SpecificDisease
),533,O
is,533,O
a,533,O
clinical,533,O
phenotype,533,O
of,533,O
dystrophinopathy,533,B-DiseaseClass
which,533,O
is,533,O
characterized,533,O
by,533,O
preferential,533,O
myocardial,533,B-DiseaseClass
involvement,533,I-DiseaseClass
without,533,O
any,533,O
overt,533,O
clinical,533,O
signs,533,O
of,533,O
skeletal,533,B-SpecificDisease
myopathy,533,I-SpecificDisease
.,533,O
To,534,O
date,534,O
",",534,O
several,534,O
mutations,534,O
in,534,O
the,534,O
Duchenne,534,B-Modifier
muscular,534,I-Modifier
dystrophy,534,I-Modifier
gene,534,O
",",534,O
DMD,534,O
",",534,O
have,534,O
been,534,O
identified,534,O
in,534,O
patients,534,O
with,534,O
XLDCM,534,B-SpecificDisease
",",534,O
but,534,O
a,534,O
pathogenic,534,O
correlation,534,O
of,534,O
these,534,O
cardiospecific,534,O
mutations,534,O
in,534,O
DMD,534,O
with,534,O
the,534,O
XLDCM,534,B-Modifier
phenotype,534,O
has,534,O
remained,534,O
to,534,O
be,534,O
elucidated,534,O
.,534,O
We,535,O
report,535,O
here,535,O
the,535,O
identification,535,O
of,535,O
a,535,O
unique,535,O
de,535,O
novo,535,O
L1,535,O
insertion,535,O
in,535,O
the,535,O
muscle,535,O
exon,535,O
1,535,O
in,535,O
DMD,535,O
in,535,O
three,535,O
XLDCM,535,B-Modifier
patients,535,O
from,535,O
two,535,O
unrelated,535,O
Japanese,535,O
families,535,O
.,535,O
The,536,O
insertion,536,O
was,536,O
a,536,O
5-truncated,536,O
form,536,O
of,536,O
human,536,O
L1,536,O
inversely,536,O
integrated,536,O
in,536,O
the,536,O
5-untranslated,536,O
region,536,O
in,536,O
the,536,O
muscle,536,O
exon,536,O
1,536,O
",",536,O
which,536,O
affected,536,O
the,536,O
transcription,536,O
or,536,O
the,536,O
stability,536,O
of,536,O
the,536,O
muscle,536,O
form,536,O
of,536,O
dystrophin,536,O
transcripts,536,O
but,536,O
not,536,O
that,536,O
of,536,O
the,536,O
brain,536,O
or,536,O
Purkinje,536,O
cell,536,O
form,536,O
",",536,O
probably,536,O
due,536,O
to,536,O
its,536,O
unique,536,O
site,536,O
of,536,O
integration,536,O
.,536,O
We,537,O
speculate,537,O
that,537,O
this,537,O
insertion,537,O
of,537,O
an,537,O
L1,537,O
sequence,537,O
in,537,O
DMD,537,O
is,537,O
responsible,537,O
for,537,O
some,537,O
of,537,O
the,537,O
population,537,O
of,537,O
Japanese,537,O
patients,537,O
with,537,O
XLDCM,537,B-SpecificDisease
..,537,O
Severe,538,O
early-onset,538,O
obesity,538,B-SpecificDisease
",",538,O
adrenal,538,B-DiseaseClass
insufficiency,538,I-DiseaseClass
and,538,O
red,538,O
hair,538,O
pigmentation,538,O
caused,538,O
by,538,O
POMC,538,O
mutations,538,O
in,538,O
humans,538,O
.,538,O
Sequential,539,O
cleavage,539,O
of,539,O
the,539,O
precursor,539,O
protein,539,O
pre-pro-opiomelanocortin,539,O
(,539,O
POMC,539,O
),539,O
generates,539,O
the,539,O
melanocortin,539,O
peptides,539,O
adrenocorticotrophin,539,O
(,539,O
ACTH,539,O
),539,O
",",539,O
melanocyte-stimulating,539,O
hormones,539,O
(,539,O
MSH,539,O
),539,O
alpha,539,O
",",539,O
beta,539,O
and,539,O
gamma,539,O
as,539,O
well,539,O
as,539,O
the,539,O
opioid-receptor,539,O
ligand,539,O
beta-endorphin,539,O
.,539,O
While,540,O
a,540,O
few,540,O
cases,540,O
of,540,O
isolated,540,O
ACTH,540,O
deficiency,540,O
have,540,O
been,540,O
reported,540,O
(,540,O
OMIM,540,O
201400,540,O
),540,O
",",540,O
an,540,O
inherited,540,O
POMC,540,O
defect,540,O
has,540,O
not,540,O
been,540,O
described,540,O
so,540,O
far,540,O
.,540,O
Recent,541,O
studies,541,O
in,541,O
animal,541,O
models,541,O
elucidated,541,O
a,541,O
central,541,O
role,541,O
of,541,O
alpha-MSH,541,O
in,541,O
the,541,O
regulation,541,O
of,541,O
food,541,O
intake,541,O
by,541,O
activation,541,O
of,541,O
the,541,O
brain,541,O
melanocortin-4-receptor,541,O
(,541,O
MC4-R,541,O
;,541,O
refs,541,O
3-5,541,O
),541,O
and,541,O
the,541,O
linkage,541,O
of,541,O
human,541,O
obesity,541,B-SpecificDisease
to,541,O
chromosome,541,O
2,541,O
in,541,O
close,541,O
proximity,541,O
to,541,O
the,541,O
POMC,541,O
locus,541,O
",",541,O
led,541,O
to,541,O
the,541,O
proposal,541,O
of,541,O
an,541,O
association,541,O
of,541,O
POMC,541,O
with,541,O
human,541,O
obesity,541,B-SpecificDisease
.,541,O
The,542,O
dual,542,O
role,542,O
of,542,O
alpha-MSH,542,O
in,542,O
regulating,542,O
food,542,O
intake,542,O
and,542,O
influencing,542,O
hair,542,O
pigmentation,542,O
predicts,542,O
that,542,O
the,542,O
phenotype,542,O
associated,542,O
with,542,O
a,542,O
defect,542,O
in,542,O
POMC,542,O
function,542,O
would,542,O
include,542,O
obesity,542,B-SpecificDisease
",",542,O
alteration,542,O
in,542,O
pigmentation,542,O
and,542,O
ACTH,542,O
deficiency,542,O
.,542,O
The,543,O
observation,543,O
of,543,O
these,543,O
symptoms,543,O
in,543,O
two,543,O
probands,543,O
prompted,543,O
us,543,O
to,543,O
search,543,O
for,543,O
mutations,543,O
within,543,O
their,543,O
POMC,543,O
genes,543,O
.,543,O
Patient,544,O
1,544,O
was,544,O
found,544,O
to,544,O
be,544,O
a,544,O
compound,544,O
heterozygote,544,O
for,544,O
two,544,O
mutations,544,O
in,544,O
exon,544,O
3,544,O
(,544,O
G7013T,544,O
",",544,O
C7133delta,544,O
),544,O
which,544,O
interfere,544,O
with,544,O
appropriate,544,O
synthesis,544,O
of,544,O
ACTH,544,O
and,544,O
alpha-MSH,544,O
.,544,O
Patient,545,O
2,545,O
was,545,O
homozygous,545,O
for,545,O
a,545,O
mutation,545,O
in,545,O
exon,545,O
2,545,O
(,545,O
C3804A,545,O
),545,O
which,545,O
abolishes,545,O
POMC,545,O
translation,545,O
.,545,O
These,546,O
findings,546,O
represent,546,O
the,546,O
first,546,O
examples,546,O
of,546,O
a,546,O
genetic,546,B-DiseaseClass
defect,546,I-DiseaseClass
within,546,O
the,546,O
POMC,546,O
gene,546,O
and,546,O
define,546,O
a,546,O
new,546,O
monogenic,546,B-DiseaseClass
endocrine,546,I-DiseaseClass
disorder,546,I-DiseaseClass
resulting,546,O
in,546,O
early-onset,546,O
obesity,546,B-SpecificDisease
",",546,O
adrenal,546,B-DiseaseClass
insufficiency,546,I-DiseaseClass
and,546,O
red,546,O
hair,546,O
pigmentation,546,O
..,546,O
A,547,O
European,547,O
multicenter,547,O
study,547,O
of,547,O
phenylalanine,547,B-SpecificDisease
hydroxylase,547,I-SpecificDisease
deficiency,547,I-SpecificDisease
:,547,O
classification,547,O
of,547,O
105,547,O
mutations,547,O
and,547,O
a,547,O
general,547,O
system,547,O
for,547,O
genotype-based,547,O
prediction,547,O
of,547,O
metabolic,547,O
phenotype,547,O
.,547,O
Phenylketonuria,548,B-SpecificDisease
(,548,O
PKU,548,B-SpecificDisease
),548,O
and,548,O
mild,548,B-SpecificDisease
hyperphenylalaninemia,548,I-SpecificDisease
(,548,O
MHP,548,B-SpecificDisease
),548,O
are,548,O
allelic,548,B-DiseaseClass
disorders,548,I-DiseaseClass
caused,548,O
by,548,O
mutations,548,O
in,548,O
the,548,O
gene,548,O
encoding,548,O
phenylalanine,548,O
hydroxylase,548,O
(,548,O
PAH,548,O
),548,O
.,548,O
Previous,549,O
studies,549,O
have,549,O
suggested,549,O
that,549,O
the,549,O
highly,549,O
variable,549,O
metabolic,549,O
phenotypes,549,O
of,549,O
PAH,549,B-SpecificDisease
deficiency,549,I-SpecificDisease
correlate,549,O
with,549,O
PAH,549,O
genotypes,549,O
.,549,O
We,550,O
identified,550,O
both,550,O
causative,550,O
mutations,550,O
in,550,O
686,550,O
patients,550,O
from,550,O
seven,550,O
European,550,O
centers,550,O
.,550,O
On,551,O
the,551,O
basis,551,O
of,551,O
the,551,O
phenotypic,551,O
characteristics,551,O
of,551,O
297,551,O
functionally,551,O
hemizygous,551,O
patients,551,O
",",551,O
105,551,O
of,551,O
the,551,O
mutations,551,O
were,551,O
assigned,551,O
to,551,O
one,551,O
of,551,O
four,551,O
arbitrary,551,O
phenotype,551,O
categories,551,O
.,551,O
We,552,O
proposed,552,O
and,552,O
tested,552,O
a,552,O
simple,552,O
model,552,O
for,552,O
correlation,552,O
between,552,O
genotype,552,O
and,552,O
phenotypic,552,O
outcome,552,O
.,552,O
The,553,O
observed,553,O
phenotype,553,O
matched,553,O
the,553,O
predicted,553,O
phenotype,553,O
in,553,O
79,553,O
%,553,O
of,553,O
the,553,O
cases,553,O
",",553,O
and,553,O
in,553,O
only,553,O
5,553,O
of,553,O
184,553,O
patients,553,O
was,553,O
the,553,O
observed,553,O
phenotype,553,O
more,553,O
than,553,O
one,553,O
category,553,O
away,553,O
from,553,O
that,553,O
expected,553,O
.,553,O
Among,554,O
the,554,O
seven,554,O
contributing,554,O
centers,554,O
",",554,O
the,554,O
proportion,554,O
of,554,O
patients,554,O
for,554,O
whom,554,O
the,554,O
observed,554,O
phenotype,554,O
did,554,O
not,554,O
match,554,O
the,554,O
predicted,554,O
phenotype,554,O
was,554,O
4,554,O
%,554,O
-23,554,O
%,554,O
(,554,O
P,554,O
<,554,O
.,554,O
0001,555,O
),555,O
",",555,O
suggesting,555,O
that,555,O
differences,555,O
in,555,O
methods,555,O
used,555,O
for,555,O
mutation,555,O
detection,555,O
or,555,O
phenotype,555,O
classification,555,O
may,555,O
account,555,O
for,555,O
a,555,O
considerable,555,O
proportion,555,O
of,555,O
genotype-phenotype,555,O
inconsistencies,555,O
.,555,O
Our,556,O
data,556,O
indicate,556,O
that,556,O
the,556,O
PAH-mutation,556,O
genotype,556,O
is,556,O
the,556,O
main,556,O
determinant,556,O
of,556,O
metabolic,556,O
phenotype,556,O
in,556,O
most,556,O
patients,556,O
with,556,O
PAH,556,B-SpecificDisease
deficiency,556,I-SpecificDisease
.,556,O
In,557,O
the,557,O
present,557,O
study,557,O
",",557,O
the,557,O
classification,557,O
of,557,O
105,557,O
PAH,557,O
mutations,557,O
may,557,O
allow,557,O
the,557,O
prediction,557,O
of,557,O
the,557,O
biochemical,557,O
phenotype,557,O
in,557,O
>,557,O
10,557,O
",",557,O
000,557,O
genotypes,557,O
",",557,O
which,557,O
may,557,O
be,557,O
useful,557,O
for,557,O
the,557,O
management,557,O
of,557,O
hyperphenylalaninemia,557,B-SpecificDisease
in,557,O
newborns,557,O
.,557,O
Somatic,558,O
instability,558,O
of,558,O
the,558,O
CTG,558,O
repeat,558,O
in,558,O
mice,558,O
transgenic,558,O
for,558,O
the,558,O
myotonic,558,B-Modifier
dystrophy,558,I-Modifier
region,558,O
is,558,O
age,558,O
dependent,558,O
but,558,O
not,558,O
correlated,558,O
to,558,O
the,558,O
relative,558,O
intertissue,558,O
transcription,558,O
levels,558,O
and,558,O
proliferative,558,O
capacities,558,O
.,558,O
A,559,O
(,559,O
CTG,559,O
),559,O
nexpansion,559,O
in,559,O
the,559,O
3-untranslated,559,O
region,559,O
(,559,O
UTR,559,O
),559,O
of,559,O
the,559,O
DM,559,O
protein,559,O
kinase,559,O
gene,559,O
(,559,O
DMPK,559,O
),559,O
is,559,O
responsible,559,O
for,559,O
causing,559,O
myotonic,559,B-SpecificDisease
dystrophy,559,I-SpecificDisease
(,559,O
DM,559,B-SpecificDisease
),559,O
.,559,O
Major,560,O
instability,560,O
",",560,O
with,560,O
very,560,O
large,560,O
expansions,560,O
between,560,O
generations,560,O
and,560,O
high,560,O
levels,560,O
of,560,O
somatic,560,O
mosaicism,560,O
",",560,O
is,560,O
observed,560,O
in,560,O
patients,560,O
.,560,O
There,561,O
is,561,O
a,561,O
good,561,O
correlation,561,O
between,561,O
repeat,561,O
size,561,O
(,561,O
at,561,O
least,561,O
in,561,O
leucocytes,561,O
),561,O
",",561,O
clinical,561,O
severity,561,O
and,561,O
age,561,O
of,561,O
onset,561,O
.,561,O
The,562,O
trinucleotide,562,O
repeat,562,O
instability,562,O
mechanisms,562,O
involved,562,O
in,562,O
DM,562,B-SpecificDisease
and,562,O
other,562,O
human,562,O
genetic,562,B-DiseaseClass
diseases,562,I-DiseaseClass
are,562,O
unknown,562,O
.,562,O
We,563,O
studied,563,O
somatic,563,O
instability,563,O
by,563,O
measuring,563,O
the,563,O
CTG,563,O
repeat,563,O
length,563,O
at,563,O
several,563,O
ages,563,O
in,563,O
various,563,O
tissues,563,O
of,563,O
transgenic,563,O
mice,563,O
carrying,563,O
a,563,O
(,563,O
CTG,563,O
),563,O
55expansion,563,O
surrounded,563,O
by,563,O
45,563,O
kb,563,O
of,563,O
the,563,O
human,563,O
DM,563,B-Modifier
region,563,O
",",563,O
using,563,O
small-pool,563,O
PCR,563,O
.,563,O
These,564,O
mice,564,O
have,564,O
been,564,O
shown,564,O
to,564,O
reproduce,564,O
the,564,O
intergenerational,564,O
and,564,O
somatic,564,O
instability,564,O
of,564,O
the,564,O
55,564,O
CTG,564,O
repeat,564,O
suggesting,564,O
that,564,O
surrounding,564,O
sequences,564,O
and,564,O
the,564,O
chromatin,564,O
environment,564,O
are,564,O
involved,564,O
in,564,O
instability,564,O
mechanisms,564,O
.,564,O
As,565,O
observed,565,O
in,565,O
some,565,O
of,565,O
the,565,O
tissues,565,O
of,565,O
DM,565,B-Modifier
patients,565,O
",",565,O
there,565,O
is,565,O
a,565,O
tendency,565,O
for,565,O
repeat,565,O
length,565,O
and,565,O
somatic,565,O
mosaicism,565,O
to,565,O
increase,565,O
with,565,O
the,565,O
age,565,O
of,565,O
the,565,O
mouse,565,O
.,565,O
Furthermore,566,O
",",566,O
we,566,O
observed,566,O
no,566,O
correlation,566,O
between,566,O
the,566,O
somatic,566,O
mutation,566,O
rate,566,O
and,566,O
tissue,566,O
proliferation,566,O
capacity,566,O
.,566,O
The,567,O
somatic,567,O
mutation,567,O
rates,567,O
in,567,O
different,567,O
tissues,567,O
were,567,O
also,567,O
not,567,O
correlated,567,O
to,567,O
the,567,O
relative,567,O
inter-tissue,567,O
difference,567,O
in,567,O
transcriptional,567,O
levels,567,O
of,567,O
the,567,O
three,567,O
genes,567,O
(,567,O
DMAHP,567,O
",",567,O
DMPK,567,O
and,567,O
59,567,O
),567,O
surrounding,567,O
the,567,O
repeat,567,O
..,567,O
A,568,O
novel,568,O
missense,568,O
mutation,568,O
in,568,O
patients,568,O
from,568,O
a,568,O
retinoblastoma,568,B-Modifier
pedigree,568,O
showing,568,O
only,568,O
mild,568,O
expression,568,O
of,568,O
the,568,O
tumor,568,B-Modifier
phenotype,568,O
.,568,O
We,569,O
have,569,O
used,569,O
single,569,O
strand,569,O
conformation,569,O
polymorphism,569,O
analysis,569,O
to,569,O
study,569,O
the,569,O
27,569,O
exons,569,O
of,569,O
the,569,O
RB1,569,O
gene,569,O
in,569,O
individuals,569,O
from,569,O
a,569,O
family,569,O
showing,569,O
mild,569,O
expression,569,O
of,569,O
the,569,O
retinoblastoma,569,B-Modifier
phenotype,569,O
.,569,O
In,570,O
this,570,O
family,570,O
affected,570,O
individuals,570,O
developed,570,O
unilateral,570,B-DiseaseClass
tumors,570,I-DiseaseClass
and,570,O
",",570,O
as,570,O
a,570,O
result,570,O
of,570,O
linkage,570,O
analysis,570,O
",",570,O
unaffected,570,O
mutation,570,O
carriers,570,O
were,570,O
also,570,O
identified,570,O
within,570,O
the,570,O
pedigree,570,O
.,570,O
A,571,O
single,571,O
band,571,O
shift,571,O
using,571,O
SSCP,571,O
was,571,O
identified,571,O
in,571,O
exon,571,O
21,571,O
which,571,O
resulted,571,O
in,571,O
a,571,O
missense,571,O
mutation,571,O
converting,571,O
a,571,O
cys,571,O
--,571,O
>,571,O
arg,571,O
at,571,O
nucleotide,571,O
position,571,O
28,571,O
in,571,O
the,571,O
exon,571,O
.,571,O
The,572,O
mutation,572,O
destroyed,572,O
an,572,O
NdeI,572,O
restriction,572,O
enzyme,572,O
site,572,O
.,572,O
Analysis,573,O
of,573,O
all,573,O
family,573,O
members,573,O
demonstrated,573,O
that,573,O
the,573,O
missense,573,O
mutation,573,O
co-segregated,573,O
with,573,O
patients,573,O
with,573,O
tumors,573,B-DiseaseClass
or,573,O
who,573,O
",",573,O
as,573,O
a,573,O
result,573,O
of,573,O
linkage,573,O
analysis,573,O
had,573,O
been,573,O
predicted,573,O
to,573,O
carry,573,O
the,573,O
predisposing,573,O
mutation,573,O
.,573,O
These,574,O
observations,574,O
point,574,O
to,574,O
another,574,O
region,574,O
of,574,O
the,574,O
RB1,574,O
gene,574,O
where,574,O
mutations,574,O
only,574,O
modify,574,O
the,574,O
function,574,O
of,574,O
the,574,O
gene,574,O
and,574,O
raise,574,O
important,574,O
questions,574,O
for,574,O
genetic,574,O
counseling,574,O
in,574,O
families,574,O
with,574,O
these,574,O
distinctive,574,O
phenotypes,574,O
..,574,O
Maternal,575,B-DiseaseClass
disomy,575,I-DiseaseClass
and,575,O
Prader-Willi,575,B-SpecificDisease
syndrome,575,I-SpecificDisease
consistent,575,O
with,575,O
gamete,575,O
complementation,575,O
in,575,O
a,575,O
case,575,O
of,575,O
familial,575,O
translocation,575,O
(,575,O
3,575,O
;,575,O
15,575,O
),575,O
(,575,O
p25,575,O
;,575,O
q11.2,575,O
),575,O
.,575,O
Maternal,576,B-SpecificDisease
uniparental,576,I-SpecificDisease
disomy,576,I-SpecificDisease
(,576,I-SpecificDisease
UPD,576,I-SpecificDisease
),576,I-SpecificDisease
for,576,I-SpecificDisease
chromosome,576,I-SpecificDisease
15,576,I-SpecificDisease
is,576,O
responsible,576,O
for,576,O
an,576,O
estimated,576,O
30,576,O
%,576,O
of,576,O
cases,576,O
of,576,O
Prader-Willi,576,B-SpecificDisease
syndrome,576,I-SpecificDisease
(,576,O
PWS,576,B-SpecificDisease
),576,O
.,576,O
We,577,O
report,577,O
on,577,O
an,577,O
unusual,577,O
case,577,O
of,577,O
maternal,577,B-SpecificDisease
disomy,577,I-SpecificDisease
15,577,I-SpecificDisease
in,577,O
PWS,577,B-SpecificDisease
that,577,O
is,577,O
most,577,O
consistent,577,O
with,577,O
adjacent-1,577,O
segregation,577,O
of,577,O
a,577,O
paternal,577,O
t,577,O
(,577,O
3,577,O
;,577,O
15,577,O
),577,O
(,577,O
p25,577,O
;,577,O
q11,577,O
.,577,O
2,578,O
),578,O
with,578,O
simultaneous,578,O
maternal,578,O
meiotic,578,O
nondisjunction,578,O
for,578,O
chromosome,578,O
15,578,O
.,578,O
The,579,O
patient,579,O
(,579,O
J,579,O
.,579,O
B,580,O
.,580,O
),581,O
",",581,O
a,581,O
17-year-old,581,O
white,581,O
male,581,O
with,581,O
PWS,581,O
",",581,O
was,581,O
found,581,O
to,581,O
have,581,O
47,581,O
chromosomes,581,O
with,581,O
a,581,O
supernumerary,581,O
",",581,O
paternal,581,O
der,581,O
(,581,O
15,581,O
),581,O
consisting,581,O
of,581,O
the,581,O
short,581,O
arm,581,O
and,581,O
the,581,O
proximal,581,O
long,581,O
arm,581,O
of,581,O
chromosome,581,O
15,581,O
",",581,O
and,581,O
distal,581,O
chromosome,581,O
arm,581,O
3p,581,O
.,581,O
The,582,O
t,582,O
(,582,O
3,582,O
;,582,O
15,582,O
),582,O
was,582,O
present,582,O
in,582,O
the,582,O
balanced,582,O
state,582,O
in,582,O
the,582,O
patients,582,O
father,582,O
and,582,O
a,582,O
sister,582,O
.,582,O
Fluorescent,583,O
in,583,O
situ,583,O
hybridization,583,O
analysis,583,O
demonstrated,583,O
that,583,O
the,583,O
PWS,583,O
critical,583,O
region,583,O
resided,583,O
on,583,O
the,583,O
derivative,583,O
chromosome,583,O
3,583,O
and,583,O
that,583,O
there,583,O
was,583,O
no,583,O
deletion,583,O
of,583,O
the,583,O
PWS,583,O
region,583,O
on,583,O
the,583,O
normal,583,O
pair,583,O
of,583,O
15s,583,O
present,583,O
in,583,O
J,583,O
.,583,O
B.,584,O
Methylation,584,O
analysis,584,O
at,584,O
exon,584,O
alpha,584,O
of,584,O
the,584,O
small,584,O
nuclear,584,O
ribonucleoprotein-associated,584,O
polypeptide,584,O
N,584,O
(,584,O
SNRPN,584,O
),584,O
gene,584,O
showed,584,O
a,584,O
pattern,584,O
characteristic,584,O
of,584,O
only,584,O
the,584,O
maternal,584,O
chromosome,584,O
15,584,O
in,584,O
J,584,O
.,584,O
B.,585,O
Maternal,585,I-DiseaseClass
disomy,585,O
was,585,O
confirmed,585,O
by,585,O
polymerase,585,O
chain,585,O
reaction,585,O
analysis,585,O
of,585,O
microsatellite,585,O
repeats,585,O
at,585,O
the,585,O
gamma-aminobutyric,585,O
acid,585,O
receptor,585,O
beta3,585,O
subunit,585,O
(,585,O
GABRB3,585,O
),585,O
locus,585,O
.,585,O
A,586,O
niece,586,O
(,586,O
B,586,O
.,586,O
B,587,O
.,587,O
),587,O
with,588,O
45,588,O
chromosomes,588,O
and,588,O
the,588,O
derivative,588,O
3,588,O
but,588,O
without,588,O
the,588,O
der,588,O
(,588,O
15,588,O
),588,O
demonstrated,588,O
a,588,O
phenotype,588,O
consistent,588,O
with,588,O
that,588,O
reported,588,O
for,588,O
haploinsufficiency,588,O
of,588,O
distal,588,O
3,588,O
p.,588,O
Uniparental,588,I-DiseaseClass
disomy,588,O
associated,588,O
with,588,O
unbalanced,588,O
segregation,588,O
of,588,O
non-Robertsonian,588,O
translocations,588,O
has,588,O
been,588,O
reported,588,O
previously,588,O
but,588,O
has,588,O
not,588,O
",",588,O
to,588,O
our,588,O
knowledge,588,O
",",588,O
been,588,O
observed,588,O
in,588,O
a,588,O
case,588,O
of,588,O
PWS,588,O
.,588,O
Furthermore,589,O
",",589,O
our,589,O
findings,589,O
are,589,O
best,589,O
interpreted,589,O
as,589,O
true,589,O
gamete,589,O
complementation,589,O
resulting,589,O
in,589,O
maternal,589,I-SpecificDisease
UPD,589,I-SpecificDisease
15,589,O
and,589,O
PWS,589,O
Schwartz-Jampel,590,B-SpecificDisease
syndrome,590,I-SpecificDisease
type,590,I-SpecificDisease
2,590,I-SpecificDisease
and,590,O
Stuve-Wiedemann,590,B-SpecificDisease
syndrome,590,I-SpecificDisease
:,590,O
a,590,O
case,590,O
for,590,O
``,590,O
lumping,590,O
'',590,O
.,590,O
Recent,591,O
studies,591,O
demonstrated,591,O
the,591,O
existence,591,O
of,591,O
a,591,O
genetically,591,O
distinct,591,O
",",591,O
usually,591,O
lethal,591,O
form,591,O
of,591,O
the,591,O
Schwartz-Jampel,591,B-SpecificDisease
syndrome,591,I-SpecificDisease
(,591,O
SJS,591,B-SpecificDisease
),591,O
of,591,O
myotonia,591,B-SpecificDisease
and,591,O
skeletal,591,B-SpecificDisease
dysplasia,591,I-SpecificDisease
",",591,O
which,591,O
we,591,O
called,591,O
SJS,591,B-SpecificDisease
type,591,I-SpecificDisease
2,591,I-SpecificDisease
.,591,O
This,592,O
disorder,592,O
is,592,O
reminiscent,592,O
of,592,O
another,592,O
rare,592,O
condition,592,O
",",592,O
the,592,O
Stuve-Wiedemann,592,B-SpecificDisease
syndrome,592,I-SpecificDisease
(,592,O
SWS,592,B-SpecificDisease
),592,O
",",592,O
which,592,O
comprises,592,O
campomelia,592,B-SpecificDisease
at,592,O
birth,592,O
with,592,O
skeletal,592,B-SpecificDisease
dysplasia,592,I-SpecificDisease
",",592,O
contractures,592,B-SpecificDisease
",",592,O
and,592,O
early,592,B-SpecificDisease
death,592,I-SpecificDisease
.,592,O
To,593,O
test,593,O
for,593,O
possible,593,O
nosologic,593,O
identity,593,O
between,593,O
these,593,O
disorders,593,O
",",593,O
we,593,O
reviewed,593,O
the,593,O
literature,593,O
and,593,O
obtained,593,O
a,593,O
follow-up,593,O
of,593,O
the,593,O
only,593,O
two,593,O
surviving,593,O
patients,593,O
",",593,O
one,593,O
with,593,O
SJS,593,B-SpecificDisease
type,593,I-SpecificDisease
2,593,I-SpecificDisease
at,593,O
age,593,O
10,593,O
years,593,O
and,593,O
another,593,O
with,593,O
SWS,593,B-SpecificDisease
at,593,O
age,593,O
7,593,O
years,593,O
.,593,O
Patients,594,O
reported,594,O
as,594,O
having,594,O
either,594,O
neonatal,594,O
SJS,594,B-SpecificDisease
or,594,O
SWS,594,B-SpecificDisease
presented,594,O
a,594,O
combination,594,O
of,594,O
a,594,O
severe,594,O
",",594,O
prenatal-onset,594,O
neuromuscular,594,B-DiseaseClass
disorder,594,I-DiseaseClass
(,594,O
with,594,O
congenital,594,B-SpecificDisease
joint,594,I-SpecificDisease
contractures,594,I-SpecificDisease
",",594,O
respiratory,594,O
and,594,O
feeding,594,O
difficulties,594,O
",",594,O
tendency,594,O
to,594,O
hyperthermia,594,B-SpecificDisease
",",594,O
and,594,O
frequent,594,O
death,594,O
in,594,O
infancy,594,O
),594,O
with,594,O
a,594,O
distinct,594,O
campomelic-metaphyseal,594,B-SpecificDisease
skeletal,594,I-SpecificDisease
dysplasia,594,I-SpecificDisease
.,594,O
The,595,O
similarity,595,O
of,595,O
the,595,O
clinical,595,O
and,595,O
radiographic,595,O
findings,595,O
is,595,O
so,595,O
extensive,595,O
that,595,O
these,595,O
disorders,595,O
appear,595,O
to,595,O
be,595,O
a,595,O
single,595,O
entity,595,O
.,595,O
The,596,O
follow-up,596,O
observation,596,O
of,596,O
an,596,O
identical,596,O
and,596,O
unique,596,O
pattern,596,O
of,596,O
progressive,596,O
bone,596,B-SpecificDisease
dysplasia,596,I-SpecificDisease
in,596,O
the,596,O
two,596,O
patients,596,O
(,596,O
one,596,O
with,596,O
SJS,596,B-SpecificDisease
type,596,I-SpecificDisease
2,596,I-SpecificDisease
",",596,O
one,596,O
with,596,O
SWS,596,B-SpecificDisease
),596,O
surviving,596,O
beyond,596,O
infancy,596,O
adds,596,O
to,596,O
the,596,O
evidence,596,O
in,596,O
favor,596,O
of,596,O
identity,596,O
.,596,O
The,597,O
hypothesis,597,O
that,597,O
SWS,597,B-SpecificDisease
and,597,O
SJS,597,B-SpecificDisease
type,597,I-SpecificDisease
2,597,I-SpecificDisease
are,597,O
the,597,O
same,597,O
disorder,597,O
should,597,O
be,597,O
testable,597,O
by,597,O
molecular,597,O
methods,597,O
..,597,O
A,598,O
mouse,598,O
model,598,O
of,598,O
severe,598,O
von,598,B-SpecificDisease
Willebrand,598,I-SpecificDisease
disease,598,I-SpecificDisease
:,598,O
defects,598,O
in,598,O
hemostasis,598,O
and,598,O
thrombosis,598,B-SpecificDisease
.,598,O
von,599,B-SpecificDisease
Willebrand,599,I-SpecificDisease
factor,599,I-SpecificDisease
(,599,I-SpecificDisease
vWf,599,I-SpecificDisease
),599,I-SpecificDisease
deficiency,599,I-SpecificDisease
causes,599,O
severe,599,O
von,599,B-SpecificDisease
Willebrand,599,I-SpecificDisease
disease,599,I-SpecificDisease
in,599,O
humans,599,O
.,599,O
We,600,O
generated,600,O
a,600,O
mouse,600,O
model,600,O
for,600,O
this,600,O
disease,600,O
by,600,O
using,600,O
gene,600,O
targeting,600,O
.,600,O
vWf-deficient,601,B-Modifier
mice,601,O
appeared,601,O
normal,601,O
at,601,O
birth,601,O
;,601,O
they,601,O
were,601,O
viable,601,O
and,601,O
fertile,601,O
.,601,O
Neither,602,O
vWf,602,O
nor,602,O
vWf,602,O
propolypeptide,602,O
(,602,O
von,602,B-Modifier
Willebrand,602,I-Modifier
antigen,602,O
II,602,O
),602,O
were,602,O
detectable,602,O
in,602,O
plasma,602,O
",",602,O
platelets,602,O
",",602,O
or,602,O
endothelial,602,O
cells,602,O
of,602,O
the,602,O
homozygous,602,O
mutant,602,O
mice,602,O
.,602,O
The,603,O
mutant,603,O
mice,603,O
exhibited,603,O
defects,603,O
in,603,O
hemostasis,603,O
with,603,O
a,603,O
highly,603,O
prolonged,603,O
bleeding,603,O
time,603,O
and,603,O
spontaneous,603,O
bleeding,603,O
events,603,O
in,603,O
approximately,603,O
10,603,O
%,603,O
of,603,O
neonates,603,O
.,603,O
As,604,O
in,604,O
the,604,O
human,604,O
disease,604,O
",",604,O
the,604,O
factor,604,O
VIII,604,O
level,604,O
in,604,O
these,604,O
mice,604,O
was,604,O
reduced,604,O
strongly,604,O
as,604,O
a,604,O
result,604,O
of,604,O
the,604,O
lack,604,O
of,604,O
protection,604,O
provided,604,O
by,604,O
vWf,604,O
.,604,O
Defective,605,O
thrombosis,605,B-SpecificDisease
in,605,O
mutant,605,O
mice,605,O
was,605,O
also,605,O
evident,605,O
in,605,O
an,605,O
in,605,O
vivo,605,O
model,605,O
of,605,O
vascular,605,B-SpecificDisease
injury,605,I-SpecificDisease
.,605,O
In,606,O
this,606,O
model,606,O
",",606,O
the,606,O
exteriorized,606,O
mesentery,606,O
was,606,O
superfused,606,O
with,606,O
ferric,606,O
chloride,606,O
and,606,O
the,606,O
accumulation,606,O
of,606,O
fluorescently,606,O
labeled,606,O
platelets,606,O
was,606,O
observed,606,O
by,606,O
intravital,606,O
microscopy,606,O
.,606,O
We,607,O
conclude,607,O
that,607,O
these,607,O
mice,607,O
very,607,O
closely,607,O
mimic,607,O
severe,607,O
human,607,O
von,607,B-SpecificDisease
Willebrand,607,I-SpecificDisease
disease,607,I-SpecificDisease
and,607,O
will,607,O
be,607,O
very,607,O
useful,607,O
for,607,O
investigating,607,O
the,607,O
role,607,O
of,607,O
vWf,607,O
in,607,O
normal,607,O
physiology,607,O
and,607,O
in,607,O
disease,607,O
models,607,O
..,607,O
Oral,608,O
contraceptives,608,O
and,608,O
the,608,O
risk,608,O
of,608,O
hereditary,608,B-SpecificDisease
ovarian,608,I-SpecificDisease
cancer,608,I-SpecificDisease
.,608,O
Hereditary,609,B-Modifier
Ovarian,609,I-Modifier
Cancer,609,I-Modifier
Clinical,609,O
Study,609,O
Group,609,O
.,609,O
BACKGROUND,610,O
Women,610,O
with,610,O
mutations,610,O
in,610,O
either,610,O
the,610,O
BRCA1,610,O
or,610,O
the,610,O
BRCA2,610,O
gene,610,O
have,610,O
a,610,O
high,610,O
lifetime,610,O
risk,610,O
of,610,O
ovarian,610,B-SpecificDisease
cancer,610,I-SpecificDisease
.,610,O
Oral,611,O
contraceptives,611,O
protect,611,O
against,611,O
ovarian,611,B-SpecificDisease
cancer,611,I-SpecificDisease
in,611,O
general,611,O
",",611,O
but,611,O
it,611,O
is,611,O
not,611,O
known,611,O
whether,611,O
they,611,O
also,611,O
protect,611,O
against,611,O
hereditary,611,B-SpecificDisease
forms,611,I-SpecificDisease
of,611,I-SpecificDisease
ovarian,611,I-SpecificDisease
cancer,611,I-SpecificDisease
.,611,O
METHODS,612,O
We,612,O
enrolled,612,O
207,612,O
women,612,O
with,612,O
hereditary,612,B-SpecificDisease
ovarian,612,I-SpecificDisease
cancer,612,I-SpecificDisease
and,612,O
161,612,O
of,612,O
their,612,O
sisters,612,O
as,612,O
controls,612,O
in,612,O
a,612,O
case-control,612,O
study,612,O
.,612,O
All,613,O
the,613,O
patients,613,O
carried,613,O
a,613,O
pathogenic,613,O
mutation,613,O
in,613,O
either,613,O
BRCA1,613,O
(,613,O
179,613,O
women,613,O
),613,O
or,613,O
BRCA2,613,O
(,613,O
28,613,O
women,613,O
),613,O
.,613,O
The,614,O
control,614,O
women,614,O
were,614,O
enrolled,614,O
regardless,614,O
of,614,O
whether,614,O
or,614,O
not,614,O
they,614,O
had,614,O
either,614,O
mutation,614,O
.,614,O
Lifetime,615,O
histories,615,O
of,615,O
oral-contraceptive,615,O
use,615,O
were,615,O
obtained,615,O
by,615,O
interview,615,O
or,615,O
by,615,O
written,615,O
questionnaire,615,O
and,615,O
were,615,O
compared,615,O
between,615,O
patients,615,O
and,615,O
control,615,O
women,615,O
",",615,O
after,615,O
adjustment,615,O
for,615,O
year,615,O
of,615,O
birth,615,O
and,615,O
parity,615,O
.,615,O
RESULTS,616,O
The,616,O
adjusted,616,O
odds,616,O
ratio,616,O
for,616,O
ovarian,616,B-SpecificDisease
cancer,616,I-SpecificDisease
associated,616,O
with,616,O
any,616,O
past,616,O
use,616,O
of,616,O
oral,616,O
contraceptives,616,O
was,616,O
0,616,O
.,616,O
5,617,O
(,617,O
95,617,O
percent,617,O
confidence,617,O
interval,617,O
",",617,O
0,617,O
.,617,O
3,618,O
to,618,O
0,618,O
.,618,O
8,619,O
),619,O
.,619,O
The,620,O
risk,620,O
decreased,620,O
with,620,O
increasing,620,O
duration,620,O
of,620,O
use,620,O
(,620,O
P,620,O
for,620,O
trend,620,O
",",620,O
<,620,O
0,620,O
.,620,O
001,621,O
),621,O
;,621,O
use,621,O
for,621,O
six,621,O
or,621,O
more,621,O
years,621,O
was,621,O
associated,621,O
with,621,O
a,621,O
60,621,O
percent,621,O
reduction,621,O
in,621,O
risk,621,O
.,621,O
Oral-contraceptive,622,O
use,622,O
protected,622,O
against,622,O
ovarian,622,B-SpecificDisease
cancer,622,I-SpecificDisease
both,622,O
for,622,O
carriers,622,O
of,622,O
the,622,O
BRCA1,622,O
mutation,622,O
(,622,O
odds,622,O
ratio,622,O
",",622,O
0,622,O
.,622,O
5,623,O
;,623,O
95,623,O
percent,623,O
confidence,623,O
interval,623,O
",",623,O
0,623,O
.,623,O
3,624,O
to,624,O
0,624,O
.,624,O
9,625,O
),625,O
and,625,O
for,625,O
carriers,625,O
of,625,O
the,625,O
BRCA2,625,O
mutation,625,O
(,625,O
odds,625,O
ratio,625,O
",",625,O
0,625,O
.,625,O
4,626,O
;,626,O
95,626,O
percent,626,O
confidence,626,O
interval,626,O
",",626,O
0,626,O
.,626,O
2,627,O
to,627,O
1,627,O
.,627,O
1,628,O
),628,O
.,628,O
CONCLUSIONS,629,O
Oral-contraceptive,629,O
use,629,O
may,629,O
reduce,629,O
the,629,O
risk,629,O
of,629,O
ovarian,629,B-SpecificDisease
cancer,629,I-SpecificDisease
in,629,O
women,629,O
with,629,O
pathogenic,629,O
mutations,629,O
in,629,O
the,629,O
BRCA1,629,O
or,629,O
BRCA2,629,O
gene,629,O
A,630,O
Japanese,630,O
family,630,O
with,630,O
adrenoleukodystrophy,630,B-SpecificDisease
with,630,O
a,630,O
codon,630,O
291,630,O
deletion,630,O
:,630,O
a,630,O
clinical,630,O
",",630,O
biochemical,630,O
",",630,O
pathological,630,O
",",630,O
and,630,O
genetic,630,O
report,630,O
.,630,O
We,631,O
report,631,O
a,631,O
Japanese,631,O
family,631,O
with,631,O
adrenoleukodystrophy,631,B-SpecificDisease
(,631,O
ALD,631,B-SpecificDisease
),631,O
with,631,O
a,631,O
three,631,O
base,631,O
pair,631,O
deletion,631,O
(,631,O
delGAG,631,O
291,631,O
),631,O
in,631,O
the,631,O
ALD,631,B-Modifier
gene,631,O
.,631,O
A,632,O
variety,632,O
of,632,O
phenotypes,632,O
were,632,O
observed,632,O
within,632,O
this,632,O
family,632,O
.,632,O
While,633,O
the,633,O
proband,633,O
(,633,O
patient,633,O
1,633,O
),633,O
was,633,O
classified,633,O
as,633,O
having,633,O
a,633,O
rare,633,O
intermediate,633,O
type,633,O
of,633,O
adult,633,O
cerebral,633,O
and,633,O
cerebello-brain,633,O
stem,633,O
forms,633,O
",",633,O
his,633,O
younger,633,O
brother,633,O
(,633,O
patient,633,O
2,633,O
),633,O
and,633,O
nephew,633,O
(,633,O
patient,633,O
3,633,O
),633,O
had,633,O
a,633,O
childhood,633,O
ALD,633,B-Modifier
type,633,O
.,633,O
Another,634,O
nephew,634,O
(,634,O
patient,634,O
4,634,O
),634,O
of,634,O
patient,634,O
1,634,O
was,634,O
classified,634,O
as,634,O
having,634,O
an,634,O
adolescent,634,O
form,634,O
.,634,O
The,635,O
tau,635,O
level,635,O
in,635,O
the,635,O
cerebrospinal,635,O
fluid,635,O
(,635,O
CSF,635,O
),635,O
in,635,O
patient,635,O
1,635,O
was,635,O
as,635,O
high,635,O
as,635,O
that,635,O
of,635,O
patients,635,O
with,635,O
Alzheimers,635,B-SpecificDisease
disease,635,I-SpecificDisease
(,635,O
AD,635,B-SpecificDisease
),635,O
.,635,O
His,636,O
brain,636,O
magnetic,636,O
resonance,636,O
image,636,O
(,636,O
MRI,636,O
),636,O
showed,636,O
abnormalities,636,B-DiseaseClass
in,636,I-DiseaseClass
the,636,I-DiseaseClass
bilateral,636,I-DiseaseClass
cerebellar,636,I-DiseaseClass
hemispheres,636,I-DiseaseClass
and,636,O
brain,636,O
stem,636,O
",",636,O
but,636,O
not,636,O
in,636,O
the,636,O
cerebral,636,O
white,636,O
matter,636,O
",",636,O
where,636,O
marked,636,O
reductions,636,O
of,636,O
the,636,O
cerebral,636,O
blood,636,O
flow,636,O
and,636,O
oxygen,636,O
metabolism,636,O
were,636,O
clearly,636,O
demonstrated,636,O
by,636,O
positron,636,O
emission,636,O
tomography,636,O
(,636,O
PET,636,O
),636,O
.,636,O
In,637,O
patients,637,O
2,637,O
and,637,O
3,637,O
",",637,O
the,637,O
autopsy,637,O
findings,637,O
showed,637,O
massive,637,O
demyelination,637,B-DiseaseClass
of,637,I-DiseaseClass
the,637,I-DiseaseClass
cerebral,637,I-DiseaseClass
white,637,I-DiseaseClass
matter,637,I-DiseaseClass
with,637,O
sparing,637,O
of,637,O
the,637,O
U-fibers,637,O
",",637,O
compatible,637,O
with,637,O
the,637,O
findings,637,O
of,637,O
childhood,637,O
ALD,637,B-SpecificDisease
.,637,O
Oleic,638,O
and,638,O
erucic,638,O
acids,638,O
(,638,O
Lorenzos,638,O
Oil,638,O
),638,O
were,638,O
administered,638,O
to,638,O
patients,638,O
1,638,O
and,638,O
4,638,O
",",638,O
but,638,O
sufficient,638,O
effectiveness,638,O
was,638,O
not,638,O
obtained,638,O
.,638,O
The,639,O
findings,639,O
in,639,O
this,639,O
family,639,O
suggest,639,O
that,639,O
delGAG291,639,O
is,639,O
part,639,O
of,639,O
the,639,O
cause,639,O
of,639,O
Japanese,639,O
ALD,639,B-SpecificDisease
with,639,O
phenotypic,639,O
variations,639,O
.,639,O
Moreover,640,O
",",640,O
although,640,O
the,640,O
scale,640,O
of,640,O
the,640,O
study,640,O
is,640,O
limited,640,O
",",640,O
there,640,O
is,640,O
a,640,O
possibility,640,O
that,640,O
PET,640,O
can,640,O
detect,640,O
an,640,O
insidious,640,B-DiseaseClass
lesion,640,I-DiseaseClass
which,640,O
is,640,O
undetectable,640,O
by,640,O
computed,640,O
tomogram,640,O
(,640,O
CT,640,O
),640,O
or,640,O
MRI,640,O
analysis,640,O
",",640,O
and,640,O
that,640,O
the,640,O
higher,640,O
level,640,O
of,640,O
tau,640,O
reflects,640,O
the,640,O
process,640,O
of,640,O
neuronal,640,B-DiseaseClass
degeneration,640,I-DiseaseClass
in,640,O
ALD,640,B-SpecificDisease
.,640,O
Lorenzos,641,O
Oil,641,O
should,641,O
be,641,O
given,641,O
in,641,O
the,641,O
early,641,O
stage,641,O
..,641,O
Nonsense,642,O
mutation,642,O
in,642,O
exon,642,O
4,642,O
of,642,O
human,642,O
complement,642,O
C9,642,O
gene,642,O
is,642,O
the,642,O
major,642,O
cause,642,O
of,642,O
Japanese,642,O
complement,642,B-SpecificDisease
C9,642,I-SpecificDisease
deficiency,642,I-SpecificDisease
.,642,O
Deficiency,643,B-SpecificDisease
of,643,I-SpecificDisease
the,643,I-SpecificDisease
ninth,643,I-SpecificDisease
component,643,I-SpecificDisease
of,643,I-SpecificDisease
human,643,I-SpecificDisease
complement,643,I-SpecificDisease
(,643,O
C9,643,O
),643,O
is,643,O
the,643,O
most,643,O
common,643,O
complement,643,B-DiseaseClass
deficiency,643,I-DiseaseClass
in,643,O
Japan,643,O
but,643,O
is,643,O
rare,643,O
in,643,O
other,643,O
countries,643,O
.,643,O
We,644,O
studied,644,O
the,644,O
molecular,644,O
basis,644,O
of,644,O
C9,644,B-SpecificDisease
deficiency,644,I-SpecificDisease
in,644,O
four,644,O
Japanese,644,O
C9-deficient,644,B-Modifier
patients,644,O
who,644,O
had,644,O
suffered,644,O
from,644,O
meningococcal,644,B-SpecificDisease
meningitis,644,I-SpecificDisease
.,644,O
Direct,645,O
sequencing,645,O
of,645,O
amplified,645,O
C9,645,O
cDNA,645,O
and,645,O
DNA,645,O
revealed,645,O
a,645,O
nonsense,645,O
substitution,645,O
(,645,O
CGA,645,O
--,645,O
>,645,O
TGA,645,O
),645,O
at,645,O
codon,645,O
95,645,O
in,645,O
exon,645,O
4,645,O
in,645,O
the,645,O
four,645,O
C9-deficient,645,B-Modifier
individuals,645,O
.,645,O
An,646,O
allele-specific,646,O
polymerase,646,O
chain,646,O
reaction,646,O
system,646,O
designed,646,O
to,646,O
detect,646,O
exclusively,646,O
only,646,O
one,646,O
of,646,O
the,646,O
normal,646,O
and,646,O
mutant,646,O
alleles,646,O
indicated,646,O
that,646,O
all,646,O
the,646,O
four,646,O
patients,646,O
were,646,O
homozygous,646,O
for,646,O
the,646,O
mutation,646,O
in,646,O
exon,646,O
4,646,O
and,646,O
that,646,O
the,646,O
parents,646,O
of,646,O
patient,646,O
2,646,O
were,646,O
heterozygous,646,O
.,646,O
The,647,O
common,647,O
mutation,647,O
at,647,O
codon,647,O
95,647,O
in,647,O
exon,647,O
4,647,O
might,647,O
be,647,O
responsible,647,O
for,647,O
most,647,O
Japanese,647,O
C9,647,B-SpecificDisease
deficiency,647,I-SpecificDisease
..,647,O
BRCA1,648,O
required,648,O
for,648,O
transcription-coupled,648,O
repair,648,O
of,648,O
oxidative,648,O
DNA,648,O
damage,648,O
.,648,O
The,649,O
breast,649,B-Modifier
and,649,I-Modifier
ovarian,649,I-Modifier
cancer,649,I-Modifier
susceptibility,649,O
gene,649,O
BRCA1,649,O
encodes,649,O
a,649,O
zinc,649,O
finger,649,O
protein,649,O
of,649,O
unknown,649,O
function,649,O
.,649,O
Association,650,O
of,650,O
the,650,O
BRCA1,650,O
protein,650,O
with,650,O
the,650,O
DNA,650,O
repair,650,O
protein,650,O
Rad51,650,O
and,650,O
changes,650,O
in,650,O
the,650,O
phosphorylation,650,O
and,650,O
cellular,650,O
localization,650,O
of,650,O
the,650,O
protein,650,O
after,650,O
exposure,650,O
to,650,O
DNA-damaging,650,O
agents,650,O
are,650,O
consistent,650,O
with,650,O
a,650,O
role,650,O
for,650,O
BRCA1,650,O
in,650,O
DNA,650,O
repair,650,O
.,650,O
Here,651,O
",",651,O
it,651,O
is,651,O
shown,651,O
that,651,O
mouse,651,O
embryonic,651,O
stem,651,O
cells,651,O
deficient,651,B-Modifier
in,651,I-Modifier
BRCA1,651,I-Modifier
are,651,O
defective,651,O
in,651,O
the,651,O
ability,651,O
to,651,O
carry,651,O
out,651,O
transcription-coupled,651,O
repair,651,O
of,651,O
oxidative,651,O
DNA,651,O
damage,651,O
",",651,O
and,651,O
are,651,O
hypersensitive,651,O
to,651,O
ionizing,651,O
radiation,651,O
and,651,O
hydrogen,651,O
peroxide,651,O
.,651,O
These,652,O
results,652,O
suggest,652,O
that,652,O
BRCA1,652,O
participates,652,O
",",652,O
directly,652,O
or,652,O
indirectly,652,O
",",652,O
in,652,O
transcription-coupled,652,O
repair,652,O
of,652,O
oxidative,652,O
DNA,652,O
damage,652,O
..,652,O
Truncation,653,O
mutations,653,O
in,653,O
the,653,O
transactivation,653,O
region,653,O
of,653,O
PAX6,653,O
result,653,O
in,653,O
dominant-negative,653,O
mutants,653,O
.,653,O
PAX6,654,O
is,654,O
a,654,O
transcription,654,O
factor,654,O
with,654,O
two,654,O
DNA-binding,654,O
domains,654,O
(,654,O
paired,654,O
box,654,O
and,654,O
homeobox,654,O
),654,O
and,654,O
a,654,O
proline-serine-threonine,654,O
(,654,O
PST,654,O
),654,O
-rich,654,O
transactivation,654,O
domain,654,O
.,654,O
PAX6,655,O
regulates,655,O
eye,655,O
development,655,O
in,655,O
animals,655,O
ranging,655,O
from,655,O
jellyfish,655,O
to,655,O
Drosophila,655,O
to,655,O
humans,655,O
.,655,O
Heterozygous,656,O
mutations,656,O
in,656,O
the,656,O
human,656,O
PAX6,656,O
gene,656,O
result,656,O
in,656,O
various,656,O
phenotypes,656,O
",",656,O
including,656,O
aniridia,656,B-SpecificDisease
",",656,O
Peters,656,B-SpecificDisease
anomaly,656,I-SpecificDisease
",",656,O
autosomal,656,B-SpecificDisease
dominant,656,I-SpecificDisease
keratitis,656,I-SpecificDisease
",",656,O
and,656,O
familial,656,B-SpecificDisease
foveal,656,I-SpecificDisease
dysplasia,656,I-SpecificDisease
.,656,O
It,657,O
is,657,O
believed,657,O
that,657,O
the,657,O
mutated,657,O
allele,657,O
of,657,O
PAX6,657,O
produces,657,O
an,657,O
inactive,657,O
protein,657,O
and,657,O
aniridia,657,B-SpecificDisease
is,657,O
caused,657,O
due,657,O
to,657,O
genetic,657,O
haploinsufficiency,657,O
.,657,O
However,658,O
",",658,O
several,658,O
truncation,658,O
mutations,658,O
have,658,O
been,658,O
found,658,O
to,658,O
occur,658,O
in,658,O
the,658,O
C-terminal,658,O
half,658,O
of,658,O
PAX6,658,O
in,658,O
patients,658,O
with,658,O
Aniridia,658,B-SpecificDisease
resulting,658,O
in,658,O
mutant,658,O
proteins,658,O
that,658,O
retain,658,O
the,658,O
DNA-binding,658,O
domains,658,O
but,658,O
have,658,O
lost,658,O
most,658,O
of,658,O
the,658,O
transactivation,658,O
domain,658,O
.,658,O
It,659,O
is,659,O
not,659,O
clear,659,O
whether,659,O
such,659,O
mutants,659,O
really,659,O
behave,659,O
as,659,O
loss-of-function,659,O
mutants,659,O
as,659,O
predicted,659,O
by,659,O
haploinsufficiency,659,O
.,659,O
Contrary,660,O
to,660,O
this,660,O
theory,660,O
",",660,O
our,660,O
data,660,O
showed,660,O
that,660,O
these,660,O
mutants,660,O
are,660,O
dominant-negative,660,O
in,660,O
transient,660,O
transfection,660,O
assays,660,O
when,660,O
they,660,O
are,660,O
coexpressed,660,O
with,660,O
wild-type,660,O
PAX6,660,O
.,660,O
We,661,O
found,661,O
that,661,O
the,661,O
dominant-negative,661,O
effects,661,O
result,661,O
from,661,O
the,661,O
enhanced,661,O
DNA,661,O
binding,661,O
ability,661,O
of,661,O
these,661,O
mutants,661,O
.,661,O
Kinetic,662,O
studies,662,O
of,662,O
binding,662,O
and,662,O
dissociation,662,O
revealed,662,O
that,662,O
various,662,O
truncation,662,O
mutants,662,O
have,662,O
3-5-fold,662,O
higher,662,O
affinity,662,O
to,662,O
various,662,O
DNA-binding,662,O
sites,662,O
when,662,O
compared,662,O
with,662,O
the,662,O
wild-type,662,O
PAX6,662,O
.,662,O
These,663,O
results,663,O
provide,663,O
a,663,O
new,663,O
insight,663,O
into,663,O
the,663,O
role,663,O
of,663,O
mutant,663,O
PAX6,663,O
in,663,O
causing,663,O
aniridia,663,B-SpecificDisease
..,663,O
Reversal,664,O
of,664,O
severe,664,O
hypertrophic,664,B-SpecificDisease
cardiomyopathy,664,I-SpecificDisease
and,664,O
excellent,664,O
neuropsychologic,664,O
outcome,664,O
in,664,O
very-long-chain,664,B-SpecificDisease
acyl-coenzyme,664,I-SpecificDisease
A,664,I-SpecificDisease
dehydrogenase,664,I-SpecificDisease
deficiency,664,I-SpecificDisease
.,664,O
Very-long-chain,665,B-SpecificDisease
acyl-coenzyme,665,I-SpecificDisease
A,665,I-SpecificDisease
dehydrogenase,665,I-SpecificDisease
(,665,I-SpecificDisease
VLCAD,665,I-SpecificDisease
),665,I-SpecificDisease
deficiency,665,I-SpecificDisease
is,665,O
a,665,O
disorder,665,O
of,665,O
fatty,665,O
acid,665,O
beta,665,O
oxidation,665,O
that,665,O
reportedly,665,O
has,665,O
high,665,O
rates,665,O
of,665,O
morbidity,665,O
and,665,O
mortality,665,O
.,665,O
We,666,O
describe,666,O
the,666,O
outcome,666,O
of,666,O
a,666,O
5-year-old,666,O
girl,666,O
with,666,O
VLCAD,666,B-SpecificDisease
deficiency,666,I-SpecificDisease
who,666,O
was,666,O
first,666,O
seen,666,O
at,666,O
5,666,O
months,666,O
of,666,O
age,666,O
with,666,O
severe,666,O
hypertrophic,666,B-SpecificDisease
cardiomyopathy,666,I-SpecificDisease
",",666,O
hepatomegaly,666,B-SpecificDisease
",",666,O
encephalopathy,666,B-DiseaseClass
",",666,O
and,666,O
hypotonia,666,B-SpecificDisease
.,666,O
Biochemical,667,O
studies,667,O
indicated,667,O
VLCAD,667,B-SpecificDisease
deficiency,667,I-SpecificDisease
caused,667,O
by,667,O
a,667,O
stable,667,O
yet,667,O
inactive,667,O
enzyme,667,O
.,667,O
Molecular,668,O
genetic,668,O
analysis,668,O
of,668,O
her,668,O
VLCAD,668,O
gene,668,O
revealed,668,O
a,668,O
T1372C,668,O
(,668,O
F458L,668,O
),668,O
missense,668,O
mutation,668,O
and,668,O
a,668,O
1668,668,O
ACAG,668,O
1669,668,O
splice,668,O
site,668,O
mutation,668,O
.,668,O
After,669,O
initial,669,O
treatment,669,O
with,669,O
intravenous,669,O
glucose,669,O
and,669,O
carnitine,669,O
",",669,O
the,669,O
patient,669,O
has,669,O
thrived,669,O
on,669,O
a,669,O
low-fat,669,O
diet,669,O
supplemented,669,O
with,669,O
medium-chain,669,O
triglyceride,669,O
oil,669,O
and,669,O
carnitine,669,O
and,669,O
avoidance,669,O
of,669,O
fasting,669,O
.,669,O
Her,670,O
ventricular,670,O
hypertrophy,670,O
resolved,670,O
significantly,670,O
over,670,O
1,670,O
year,670,O
",",670,O
and,670,O
cognitively,670,O
",",670,O
she,670,O
is,670,O
in,670,O
the,670,O
superior,670,O
range,670,O
for,670,O
age,670,O
.,670,O
Clinical,671,O
recognition,671,O
of,671,O
VLCAD,671,B-SpecificDisease
deficiency,671,I-SpecificDisease
is,671,O
important,671,O
because,671,O
it,671,O
is,671,O
one,671,O
of,671,O
the,671,O
few,671,O
directly,671,O
treatable,671,O
causes,671,O
of,671,O
cardiomyopathy,671,B-DiseaseClass
in,671,O
children,671,O
..,671,O
Cloning,672,O
of,672,O
a,672,O
novel,672,O
member,672,O
of,672,O
the,672,O
low-density,672,O
lipoprotein,672,O
receptor,672,O
family,672,O
.,672,O
A,673,O
gene,673,O
encoding,673,O
a,673,O
novel,673,O
transmembrane,673,O
protein,673,O
was,673,O
identified,673,O
by,673,O
DNA,673,O
sequence,673,O
analysis,673,O
within,673,O
the,673,O
insulin-dependent,673,B-Modifier
diabetes,673,I-Modifier
mellitus,673,I-Modifier
(,673,O
IDDM,673,B-Modifier
),673,O
locus,673,O
IDDM4,673,O
on,673,O
chromosome,673,O
11q13,673,O
.,673,O
Based,674,O
on,674,O
its,674,O
chromosomal,674,O
position,674,O
",",674,O
this,674,O
gene,674,O
is,674,O
a,674,O
candidate,674,O
for,674,O
conferring,674,O
susceptibility,674,O
to,674,O
diabetes,674,B-DiseaseClass
.,674,O
The,675,O
gene,675,O
",",675,O
termed,675,O
low-density,675,O
lipoprotein,675,O
receptor,675,O
related,675,O
protein,675,O
5,675,O
(,675,O
LRP5,675,O
),675,O
",",675,O
encodes,675,O
a,675,O
protein,675,O
of,675,O
1615,675,O
amino,675,O
acids,675,O
that,675,O
contains,675,O
conserved,675,O
modules,675,O
which,675,O
are,675,O
characteristic,675,O
of,675,O
the,675,O
low-density,675,O
lipoprotein,675,O
(,675,O
LDL,675,O
),675,O
receptor,675,O
family,675,O
.,675,O
These,676,O
modules,676,O
include,676,O
a,676,O
putative,676,O
signal,676,O
peptide,676,O
for,676,O
protein,676,O
export,676,O
",",676,O
four,676,O
epidermal,676,O
growth,676,O
factor,676,O
(,676,O
EGF,676,O
),676,O
repeats,676,O
with,676,O
associated,676,O
spacer,676,O
domains,676,O
",",676,O
three,676,O
LDL-receptor,676,O
(,676,O
LDLR,676,O
),676,O
repeats,676,O
",",676,O
a,676,O
single,676,O
transmembrane,676,O
spanning,676,O
domain,676,O
",",676,O
and,676,O
a,676,O
cytoplasmic,676,O
domain,676,O
.,676,O
The,677,O
encoded,677,O
protein,677,O
has,677,O
a,677,O
unique,677,O
organization,677,O
of,677,O
EGF,677,O
and,677,O
LDLR,677,O
repeats,677,O
;,677,O
therefore,677,O
",",677,O
LRP5,677,O
likely,677,O
represents,677,O
a,677,O
new,677,O
category,677,O
of,677,O
the,677,O
LDLR,677,O
family,677,O
.,677,O
Both,678,O
human,678,O
and,678,O
mouse,678,O
LRP5,678,O
cDNAs,678,O
have,678,O
been,678,O
isolated,678,O
and,678,O
the,678,O
encoded,678,O
mature,678,O
proteins,678,O
are,678,O
95,678,O
%,678,O
identical,678,O
",",678,O
indicating,678,O
a,678,O
high,678,O
degree,678,O
of,678,O
evolutionary,678,O
conservation,678,O
..,678,O
The,679,O
APC,679,B-Modifier
variants,679,O
I1307K,679,O
and,679,O
E1317Q,679,O
are,679,O
associated,679,O
with,679,O
colorectal,679,B-DiseaseClass
tumors,679,I-DiseaseClass
",",679,O
but,679,O
not,679,O
always,679,O
with,679,O
a,679,O
family,679,O
history,679,O
.,679,O
Classical,680,O
familial,680,B-SpecificDisease
adenomatous,680,I-SpecificDisease
polyposis,680,I-SpecificDisease
(,680,O
FAP,680,B-SpecificDisease
),680,O
is,680,O
a,680,O
high-penetrance,680,O
autosomal,680,B-DiseaseClass
dominant,680,I-DiseaseClass
disease,680,I-DiseaseClass
that,680,O
predisposes,680,O
to,680,O
hundreds,680,O
or,680,O
thousands,680,O
of,680,O
colorectal,680,O
adenomas,680,O
and,680,O
carcinoma,680,O
and,680,O
that,680,O
results,680,O
from,680,O
truncating,680,O
mutations,680,O
in,680,O
the,680,O
APC,680,B-Modifier
gene,680,O
.,680,O
A,681,O
variant,681,O
of,681,O
FAP,681,B-SpecificDisease
is,681,O
attenuated,681,B-SpecificDisease
adenomatous,681,I-SpecificDisease
polyposis,681,I-SpecificDisease
coli,681,I-SpecificDisease
",",681,O
which,681,O
results,681,O
from,681,O
germ-line,681,O
mutations,681,O
in,681,O
the,681,O
5,681,O
and,681,O
3,681,O
regions,681,O
of,681,O
the,681,O
APC,681,B-Modifier
gene,681,O
.,681,O
Attenuated,682,B-Modifier
adenomatous,682,I-Modifier
polyposis,682,I-Modifier
coli,682,I-Modifier
patients,682,O
have,682,O
``,682,O
multiple,682,O
``,682,O
colorectal,682,B-SpecificDisease
adenomas,682,I-SpecificDisease
(,682,O
typically,682,O
fewer,682,O
than,682,O
100,682,O
),682,O
without,682,O
the,682,O
florid,682,O
phenotype,682,O
of,682,O
classical,682,O
FAP,682,B-SpecificDisease
.,682,O
Another,683,O
group,683,O
of,683,O
patients,683,O
with,683,O
multiple,683,O
adenomas,683,B-DiseaseClass
has,683,O
no,683,O
mutations,683,O
in,683,O
the,683,O
APC,683,B-Modifier
gene,683,O
",",683,O
and,683,O
their,683,O
phenotype,683,O
probably,683,O
results,683,O
from,683,O
variation,683,O
at,683,O
a,683,O
locus,683,O
",",683,O
or,683,O
loci,683,O
",",683,O
elsewhere,683,O
in,683,O
the,683,O
genome,683,O
.,683,O
Recently,684,O
",",684,O
however,684,O
",",684,O
a,684,O
missense,684,O
variant,684,O
of,684,O
APC,684,B-SpecificDisease
(,684,O
I1307K,684,O
),684,O
was,684,O
described,684,O
that,684,O
confers,684,O
an,684,O
increased,684,O
risk,684,O
of,684,O
colorectal,684,B-SpecificDisease
tumors,684,I-SpecificDisease
",",684,O
including,684,O
multiple,684,O
adenomas,684,B-DiseaseClass
",",684,O
in,684,O
Ashkenazim,684,O
.,684,O
We,685,O
have,685,O
studied,685,O
a,685,O
set,685,O
of,685,O
164,685,O
patients,685,O
with,685,O
multiple,685,O
colorectal,685,O
adenomas,685,O
and/or,685,O
carcinoma,685,O
and,685,O
analyzed,685,O
codons,685,O
1263-1377,685,O
(,685,O
exon,685,O
15G,685,O
),685,O
of,685,O
the,685,O
APC,685,B-Modifier
gene,685,O
for,685,O
germ-line,685,O
variants,685,O
.,685,O
Three,686,O
patients,686,O
with,686,O
the,686,O
I1307K,686,O
allele,686,O
were,686,O
detected,686,O
",",686,O
each,686,O
of,686,O
Ashkenazi,686,O
descent,686,O
.,686,O
Four,687,O
patients,687,O
had,687,O
a,687,O
germ-line,687,O
E1317Q,687,O
missense,687,O
variant,687,O
of,687,O
APC,687,O
that,687,O
was,687,O
not,687,O
present,687,O
in,687,O
controls,687,O
;,687,O
one,687,O
of,687,O
these,687,O
individuals,687,O
had,687,O
an,687,O
unusually,687,O
large,687,O
number,687,O
of,687,O
metaplastic,687,B-SpecificDisease
polyps,687,I-SpecificDisease
of,687,I-SpecificDisease
the,687,I-SpecificDisease
colorectum,687,I-SpecificDisease
.,687,O
There,688,O
is,688,O
increasing,688,O
evidence,688,O
that,688,O
there,688,O
exist,688,O
germ-line,688,O
variants,688,O
of,688,O
the,688,O
APC,688,B-Modifier
gene,688,O
that,688,O
predispose,688,O
to,688,O
the,688,O
development,688,O
of,688,O
multiple,688,O
colorectal,688,O
adenomas,688,O
and,688,O
carcinoma,688,O
",",688,O
but,688,O
without,688,O
the,688,O
florid,688,O
phenotype,688,O
of,688,O
classical,688,O
FAP,688,B-SpecificDisease
",",688,O
and,688,O
possibly,688,O
with,688,O
importance,688,O
for,688,O
colorectal,688,B-SpecificDisease
cancer,688,I-SpecificDisease
risk,688,O
in,688,O
the,688,O
general,688,O
population,688,O
..,688,O
Genomic,689,O
structure,689,O
of,689,O
the,689,O
human,689,O
congenital,689,B-Modifier
chloride,689,I-Modifier
diarrhea,689,I-Modifier
(,689,O
CLD,689,B-Modifier
),689,O
gene,689,O
.,689,O
Congenital,690,B-SpecificDisease
chloride,690,I-SpecificDisease
diarrhea,690,I-SpecificDisease
(,690,O
CLD,690,B-SpecificDisease
),690,O
is,690,O
caused,690,O
by,690,O
mutations,690,O
in,690,O
a,690,O
gene,690,O
which,690,O
encodes,690,O
an,690,O
intestinal,690,O
anion,690,O
transporter,690,O
.,690,O
We,691,O
report,691,O
here,691,O
the,691,O
complete,691,O
genomic,691,O
organization,691,O
of,691,O
the,691,O
human,691,O
CLD,691,B-Modifier
gene,691,O
which,691,O
spans,691,O
approximately,691,O
39kb,691,O
",",691,O
and,691,O
comprises,691,O
21,691,O
exons,691,O
.,691,O
All,692,O
exon/intron,692,O
boundaries,692,O
conform,692,O
to,692,O
the,692,O
GT/AG,692,O
rule,692,O
.,692,O
An,693,O
analysis,693,O
of,693,O
the,693,O
putative,693,O
promoter,693,O
region,693,O
sequence,693,O
shows,693,O
a,693,O
putative,693,O
TATA,693,O
box,693,O
and,693,O
predicts,693,O
multiple,693,O
transcription,693,O
factor,693,O
binding,693,O
sites,693,O
.,693,O
The,694,O
genomic,694,O
structure,694,O
was,694,O
determined,694,O
using,694,O
DNA,694,O
from,694,O
several,694,O
sources,694,O
including,694,O
multiple,694,O
large-insert,694,O
libaries,694,O
and,694,O
genomic,694,O
DNA,694,O
from,694,O
Finnish,694,O
CLD,694,B-Modifier
patients,694,O
and,694,O
controls,694,O
.,694,O
Exon-specific,695,O
primers,695,O
developed,695,O
in,695,O
this,695,O
study,695,O
will,695,O
facilitate,695,O
mutation,695,O
screening,695,O
studies,695,O
of,695,O
patients,695,O
with,695,O
the,695,O
disease,695,O
.,695,O
Genomic,696,O
sequencing,696,O
of,696,O
a,696,O
BAC,696,O
clone,696,O
H_RG364P16,696,O
revealed,696,O
the,696,O
presence,696,O
of,696,O
another,696,O
",",696,O
highly,696,O
homologous,696,O
gene,696,O
3,696,O
of,696,O
the,696,O
CLD,696,B-Modifier
gene,696,O
",",696,O
with,696,O
a,696,O
similar,696,O
genomic,696,O
structure,696,O
",",696,O
recently,696,O
identified,696,O
as,696,O
the,696,O
Pendred,696,B-Modifier
syndrome,696,I-Modifier
gene,696,O
(,696,O
PDS,696,B-SpecificDisease
),696,O
..,696,O
The,697,O
APCI1307K,697,O
allele,697,O
and,697,O
cancer,697,B-Modifier
risk,697,O
in,697,O
a,697,O
community-based,697,O
study,697,O
of,697,O
Ashkenazi,697,O
Jews,697,O
.,697,O
Mutations,698,O
in,698,O
APC,698,O
are,698,O
classically,698,O
associated,698,O
with,698,O
familial,698,B-SpecificDisease
adenomatous,698,I-SpecificDisease
polyposis,698,I-SpecificDisease
(,698,O
FAP,698,B-SpecificDisease
),698,O
",",698,O
a,698,O
highly,698,O
penetrant,698,O
autosomal,698,B-DiseaseClass
dominant,698,I-DiseaseClass
disorder,698,I-DiseaseClass
characterized,698,O
by,698,O
multiple,698,O
intestinal,698,O
polyps,698,B-DiseaseClass
and,698,O
",",698,O
without,698,O
surgical,698,O
intervention,698,O
",",698,O
the,698,O
development,698,O
of,698,O
colorectal,698,B-SpecificDisease
cancer,698,I-SpecificDisease
(,698,O
CRC,698,B-SpecificDisease
),698,O
.,698,O
APC,699,B-SpecificDisease
is,699,O
a,699,O
tumour-suppressor,699,O
gene,699,O
",",699,O
and,699,O
somatic,699,O
loss,699,O
occurs,699,O
in,699,O
tumours,699,B-DiseaseClass
.,699,O
The,700,O
germline,700,O
T-to-A,700,O
transversion,700,O
responsible,700,O
for,700,O
the,700,O
APC,700,O
I1307K,700,O
allele,700,O
converts,700,O
the,700,O
wild-type,700,O
sequence,700,O
to,700,O
a,700,O
homopolymer,700,O
tract,700,O
(,700,O
A8,700,O
),700,O
that,700,O
is,700,O
genetically,700,O
unstable,700,O
and,700,O
prone,700,O
to,700,O
somatic,700,O
mutation,700,O
.,700,O
The,701,O
I1307K,701,O
allele,701,O
was,701,O
found,701,O
in,701,O
6,701,O
.,701,O
1,702,O
%,702,O
of,702,O
unselected,702,O
Ashkenazi,702,O
Jews,702,O
and,702,O
higher,702,O
proportions,702,O
of,702,O
Ashkenazim,702,O
with,702,O
family,702,O
or,702,O
personal,702,O
histories,702,O
of,702,O
CRC,702,B-SpecificDisease
(,702,O
ref,702,O
.,702,O
2,703,O
),703,O
.,703,O
To,704,O
evaluate,704,O
the,704,O
role,704,O
of,704,O
I1307K,704,O
in,704,O
cancer,704,B-DiseaseClass
",",704,O
we,704,O
genotyped,704,O
5,704,O
",",704,O
081,704,O
Ashkenazi,704,O
volunteers,704,O
in,704,O
a,704,O
community,704,O
survey,704,O
.,704,O
Risk,705,O
of,705,O
developing,705,O
colorectal,705,O
",",705,O
breast,705,O
and,705,O
other,705,O
cancers,705,O
were,705,O
compared,705,O
between,705,O
genotyped,705,O
I1307K,705,O
carriers,705,O
and,705,O
non-carriers,705,O
and,705,O
their,705,O
first-degree,705,O
relatives,705,O
.,705,O
Sperm,706,O
DNA,706,O
analysis,706,O
in,706,O
a,706,O
Friedreich,706,B-Modifier
ataxia,706,I-Modifier
premutation,706,O
carrier,706,O
suggests,706,O
both,706,O
meiotic,706,O
and,706,O
mitotic,706,O
expansion,706,O
in,706,O
the,706,O
FRDA,706,B-Modifier
gene,706,O
.,706,O
Friedreich,707,B-SpecificDisease
ataxia,707,I-SpecificDisease
is,707,O
usually,707,O
caused,707,O
by,707,O
an,707,O
expansion,707,O
of,707,O
a,707,O
GAA,707,O
trinucleotide,707,O
repeat,707,O
in,707,O
intron,707,O
1,707,O
of,707,O
the,707,O
FRDA,707,B-Modifier
gene,707,O
.,707,O
Occasionally,708,O
",",708,O
a,708,O
fully,708,O
expanded,708,O
allele,708,O
has,708,O
been,708,O
found,708,O
to,708,O
arise,708,O
from,708,O
a,708,O
premutation,708,O
of,708,O
100,708,O
or,708,O
less,708,O
triplet,708,O
repeats,708,O
.,708,O
We,709,O
have,709,O
examined,709,O
the,709,O
sperm,709,O
DNA,709,O
of,709,O
a,709,O
premutation,709,O
carrier,709,O
.,709,O
This,710,O
mans,710,O
leucocyte,710,O
DNA,710,O
showed,710,O
one,710,O
normal,710,O
allele,710,O
and,710,O
one,710,O
allele,710,O
of,710,O
approximately,710,O
100,710,O
repeats,710,O
.,710,O
His,711,O
sperm,711,O
showed,711,O
an,711,O
expanded,711,O
allele,711,O
in,711,O
a,711,O
tight,711,O
range,711,O
centering,711,O
on,711,O
a,711,O
size,711,O
of,711,O
approximately,711,O
320,711,O
trinucleotide,711,O
repeats,711,O
.,711,O
His,712,O
affected,712,O
son,712,O
has,712,O
repeat,712,O
sizes,712,O
of,712,O
1040,712,O
and,712,O
540,712,O
.,712,O
These,713,O
data,713,O
suggest,713,O
that,713,O
expansion,713,O
occurs,713,O
in,713,O
two,713,O
stages,713,O
",",713,O
the,713,O
first,713,O
during,713,O
meiosis,713,O
followed,713,O
by,713,O
a,713,O
second,713,O
mitotic,713,O
expansion,713,O
.,713,O
We,714,O
also,714,O
show,714,O
that,714,O
in,714,O
all,714,O
informative,714,O
carrier,714,O
father,714,O
to,714,O
affected,714,O
child,714,O
transmissions,714,O
",",714,O
with,714,O
the,714,O
notable,714,O
exception,714,O
of,714,O
the,714,O
premutation,714,O
carrier,714,O
",",714,O
the,714,O
expansion,714,O
size,714,O
decreases,714,O
..,714,O
The,715,O
R496H,715,O
mutation,715,O
of,715,O
arylsulfatase,715,O
A,715,O
does,715,O
not,715,O
cause,715,O
metachromatic,715,B-SpecificDisease
leukodystrophy,715,I-SpecificDisease
.,715,O
Deficiency,716,B-SpecificDisease
of,716,I-SpecificDisease
arylsulfatase,716,I-SpecificDisease
A,716,I-SpecificDisease
(,716,O
ARSA,716,O
),716,O
enzyme,716,O
activity,716,O
causes,716,O
metachromatic,716,B-SpecificDisease
leukodystrophy,716,I-SpecificDisease
(,716,O
MLD,716,B-SpecificDisease
),716,O
.,716,O
A,717,O
number,717,O
of,717,O
ARSA,717,O
gene,717,O
mutations,717,O
responsible,717,O
for,717,O
MLD,717,B-SpecificDisease
have,717,O
been,717,O
identified,717,O
.,717,O
Recently,718,O
",",718,O
the,718,O
R496H,718,O
mutation,718,O
of,718,O
ARSA,718,O
was,718,O
proposed,718,O
to,718,O
be,718,O
a,718,O
cause,718,O
of,718,O
MLD,718,B-SpecificDisease
(,718,O
Draghia,718,O
et,718,O
al.,718,O
",",718,O
1997,718,O
),718,O
.,718,O
We,719,O
have,719,O
investigated,719,O
the,719,O
R496H,719,O
mutation,719,O
and,719,O
found,719,O
this,719,O
mutation,719,O
at,719,O
a,719,O
relatively,719,O
high,719,O
frequency,719,O
in,719,O
an,719,O
African,719,O
American,719,O
population,719,O
(,719,O
f,719,O
=,719,O
0,719,O
.,719,O
09,720,O
",",720,O
n,720,O
=,720,O
61,720,O
subjects,720,O
),720,O
.,720,O
The,721,O
ARSA,721,O
enzyme,721,O
activity,721,O
in,721,O
subjects,721,O
with,721,O
and,721,O
without,721,O
the,721,O
R496H,721,O
mutation,721,O
was,721,O
determined,721,O
and,721,O
found,721,O
to,721,O
be,721,O
normal,721,O
.,721,O
It,722,O
is,722,O
therefore,722,O
concluded,722,O
that,722,O
the,722,O
R496H,722,O
mutation,722,O
of,722,O
ARSA,722,O
does,722,O
not,722,O
negatively,722,O
influence,722,O
the,722,O
activity,722,O
of,722,O
ARSA,722,O
and,722,O
is,722,O
not,722,O
a,722,O
cause,722,O
of,722,O
MLD,722,B-SpecificDisease
Down-regulation,723,O
of,723,O
transmembrane,723,O
carbonic,723,O
anhydrases,723,O
in,723,O
renal,723,B-Modifier
cell,723,I-Modifier
carcinoma,723,I-Modifier
cell,723,O
lines,723,O
by,723,O
wild-type,723,O
von,723,B-Modifier
Hippel-Lindau,723,I-Modifier
transgenes,723,O
.,723,O
To,724,O
discover,724,O
genes,724,O
involved,724,O
in,724,O
von,724,B-Modifier
Hippel-Lindau,724,I-Modifier
(,724,O
VHL,724,B-Modifier
),724,O
-mediated,724,O
carcinogenesis,724,O
",",724,O
we,724,O
used,724,O
renal,724,B-Modifier
cell,724,I-Modifier
carcinoma,724,I-Modifier
cell,724,O
lines,724,O
stably,724,O
transfected,724,O
with,724,O
wild-type,724,O
VHL-expressing,724,O
transgenes,724,O
.,724,O
Large-scale,725,O
RNA,725,O
differential,725,O
display,725,O
technology,725,O
applied,725,O
to,725,O
these,725,O
cell,725,O
lines,725,O
identified,725,O
several,725,O
differentially,725,O
expressed,725,O
genes,725,O
",",725,O
including,725,O
an,725,O
alpha,725,O
carbonic,725,O
anhydrase,725,O
gene,725,O
",",725,O
termed,725,O
CA12,725,O
.,725,O
The,726,O
deduced,726,O
protein,726,O
sequence,726,O
was,726,O
classified,726,O
as,726,O
a,726,O
one-pass,726,O
transmembrane,726,O
CA,726,O
possessing,726,O
an,726,O
apparently,726,O
intact,726,O
catalytic,726,O
domain,726,O
in,726,O
the,726,O
extracellular,726,O
CA,726,O
module,726,O
.,726,O
Reintroduced,727,O
wild-type,727,O
VHL,727,B-SpecificDisease
strongly,727,O
inhibited,727,O
the,727,O
overexpression,727,O
of,727,O
the,727,O
CA12,727,O
gene,727,O
in,727,O
the,727,O
parental,727,O
renal,727,B-Modifier
cell,727,I-Modifier
carcinoma,727,I-Modifier
cell,727,O
lines,727,O
.,727,O
Similar,728,O
results,728,O
were,728,O
obtained,728,O
with,728,O
CA9,728,O
",",728,O
encoding,728,O
another,728,O
transmembrane,728,O
CA,728,O
with,728,O
an,728,O
intact,728,O
catalytic,728,O
domain,728,O
.,728,O
Although,729,O
both,729,O
domains,729,O
of,729,O
the,729,O
VHL,729,B-Modifier
protein,729,O
contribute,729,O
to,729,O
regulation,729,O
of,729,O
CA12,729,O
expression,729,O
",",729,O
the,729,O
elongin,729,O
binding,729,O
domain,729,O
alone,729,O
could,729,O
effectively,729,O
regulate,729,O
CA9,729,O
expression,729,O
.,729,O
We,730,O
mapped,730,O
CA12,730,O
and,730,O
CA9,730,O
loci,730,O
to,730,O
chromosome,730,O
bands,730,O
15q22,730,O
and,730,O
17q21,730,O
.,730,O
2,731,O
respectively,731,O
",",731,O
regions,731,O
prone,731,O
to,731,O
amplification,731,O
in,731,O
some,731,O
human,731,O
cancers,731,B-DiseaseClass
.,731,O
Additional,732,O
experiments,732,O
are,732,O
needed,732,O
to,732,O
define,732,O
the,732,O
role,732,O
of,732,O
CA,732,O
IX,732,O
and,732,O
CA,732,O
XII,732,O
enzymes,732,O
in,732,O
the,732,O
regulation,732,O
of,732,O
pH,732,O
in,732,O
the,732,O
extracellular,732,O
microenvironment,732,O
and,732,O
its,732,O
potential,732,O
impact,732,O
on,732,O
cancer,732,B-Modifier
cell,732,O
growth,732,O
.,732,O
A,733,O
gene,733,O
encoding,733,O
a,733,O
transmembrane,733,O
protein,733,O
is,733,O
mutated,733,O
in,733,O
patients,733,O
with,733,O
diabetes,733,B-SpecificDisease
mellitus,733,I-SpecificDisease
and,733,O
optic,733,B-SpecificDisease
atrophy,733,I-SpecificDisease
(,733,O
Wolfram,733,B-SpecificDisease
syndrome,733,I-SpecificDisease
),733,O
.,733,O
Wolfram,734,B-SpecificDisease
syndrome,734,I-SpecificDisease
(,734,O
WFS,734,B-SpecificDisease
;,734,O
OMIM,734,O
222300,734,O
),734,O
is,734,O
an,734,O
autosomal,734,B-DiseaseClass
recessive,734,I-DiseaseClass
neurodegenerative,734,I-DiseaseClass
disorder,734,I-DiseaseClass
defined,734,O
by,734,O
young-onset,734,O
non-immune,734,O
insulin-dependent,734,B-SpecificDisease
diabetes,734,I-SpecificDisease
mellitus,734,I-SpecificDisease
and,734,O
progressive,734,O
optic,734,B-SpecificDisease
atrophy,734,I-SpecificDisease
.,734,O
Linkage,735,O
to,735,O
markers,735,O
on,735,O
chromosome,735,O
4p,735,O
was,735,O
confirmed,735,O
in,735,O
five,735,O
families,735,O
.,735,O
On,736,O
the,736,O
basis,736,O
of,736,O
meiotic,736,O
recombinants,736,O
and,736,O
disease-associated,736,O
haplotypes,736,O
",",736,O
the,736,O
WFS,736,B-Modifier
gene,736,O
was,736,O
localized,736,O
to,736,O
a,736,O
BAC/P1,736,O
contig,736,O
of,736,O
less,736,O
than,736,O
250,736,O
kb,736,O
.,736,O
Mutations,737,O
in,737,O
a,737,O
novel,737,O
gene,737,O
(,737,O
WFS1,737,O
),737,O
encoding,737,O
a,737,O
putative,737,O
transmembrane,737,O
protein,737,O
were,737,O
found,737,O
in,737,O
all,737,O
affected,737,O
individuals,737,O
in,737,O
six,737,O
WFS,737,B-Modifier
families,737,O
",",737,O
and,737,O
these,737,O
mutations,737,O
were,737,O
associated,737,O
with,737,O
the,737,O
disease,737,O
phenotype,737,O
.,737,O
WFS1,738,O
appears,738,O
to,738,O
function,738,O
in,738,O
survival,738,O
of,738,O
islet,738,O
beta-cells,738,O
and,738,O
neurons,738,O
..,738,O
Stable,739,O
interaction,739,O
between,739,O
the,739,O
products,739,O
of,739,O
the,739,O
BRCA1,739,O
and,739,O
BRCA2,739,O
tumor,739,B-Modifier
suppressor,739,O
genes,739,O
in,739,O
mitotic,739,O
and,739,O
meiotic,739,O
cells,739,O
.,739,O
BRCA1,740,O
and,740,O
BRCA2,740,O
account,740,O
for,740,O
most,740,O
cases,740,O
of,740,O
familial,740,O
",",740,O
early,740,O
onset,740,O
breast,740,B-CompositeMention
and/or,740,I-CompositeMention
ovarian,740,I-CompositeMention
cancer,740,I-CompositeMention
and,740,O
encode,740,O
products,740,O
that,740,O
each,740,O
interact,740,O
with,740,O
hRAD51,740,O
.,740,O
Results,741,O
presented,741,O
here,741,O
show,741,O
that,741,O
BRCA1,741,O
and,741,O
BRCA2,741,O
coexist,741,O
in,741,O
a,741,O
biochemical,741,O
complex,741,O
and,741,O
colocalize,741,O
in,741,O
subnuclear,741,O
foci,741,O
in,741,O
somatic,741,O
cells,741,O
and,741,O
on,741,O
the,741,O
axial,741,O
elements,741,O
of,741,O
developing,741,O
synaptonemal,741,O
complexes,741,O
.,741,O
Like,742,O
BRCA1,742,O
and,742,O
RAD51,742,O
",",742,O
BRCA2,742,O
relocates,742,O
to,742,O
PCNA,742,O
+,742,O
replication,742,O
sites,742,O
following,742,O
exposure,742,O
of,742,O
S,742,O
phase,742,O
cells,742,O
to,742,O
hydroxyurea,742,O
or,742,O
UV,742,O
irradiation,742,O
.,742,O
Thus,743,O
",",743,O
BRCA1,743,O
and,743,O
BRCA2,743,O
participate,743,O
",",743,O
together,743,O
",",743,O
in,743,O
a,743,O
pathway,743,O
(,743,O
s,743,O
),743,O
associated,743,O
with,743,O
the,743,O
activation,743,O
of,743,O
double-strand,743,O
break,743,O
repair,743,O
and/or,743,O
homologous,743,O
recombination,743,O
.,743,O
Dysfunction,744,O
of,744,O
this,744,O
pathway,744,O
may,744,O
be,744,O
a,744,O
general,744,O
phenomenon,744,O
in,744,O
the,744,O
majority,744,O
of,744,O
cases,744,O
of,744,O
hereditary,744,B-CompositeMention
breast,744,I-CompositeMention
and/or,744,I-CompositeMention
ovarian,744,I-CompositeMention
cancer,744,I-CompositeMention
..,744,O
A,745,O
novel,745,O
Arg362Ser,745,O
mutation,745,O
in,745,O
the,745,O
sterol,745,O
27-hydroxylase,745,O
gene,745,O
(,745,O
CYP27,745,O
),745,O
:,745,O
its,745,O
effects,745,O
on,745,O
pre-mRNA,745,O
splicing,745,O
and,745,O
enzyme,745,O
activity,745,O
.,745,O
A,746,O
novel,746,O
C,746,O
to,746,O
A,746,O
mutation,746,O
in,746,O
the,746,O
sterol,746,O
27-hydroxylase,746,O
gene,746,O
(,746,O
CYP27,746,O
),746,O
was,746,O
identified,746,O
by,746,O
sequencing,746,O
amplified,746,O
CYP27,746,O
gene,746,O
products,746,O
from,746,O
a,746,O
patient,746,O
with,746,O
cerebrotendinous,746,B-SpecificDisease
xanthomatosis,746,I-SpecificDisease
(,746,O
CTX,746,B-SpecificDisease
),746,O
.,746,O
The,747,O
mutation,747,O
changed,747,O
the,747,O
adrenodoxin,747,O
cofactor,747,O
binding,747,O
residue,747,O
362Arg,747,O
to,747,O
362Ser,747,O
(,747,O
CGT,747,O
362Arg,747,O
to,747,O
AGT,747,O
362Ser,747,O
),747,O
",",747,O
and,747,O
was,747,O
responsible,747,O
for,747,O
deficiency,747,O
in,747,O
the,747,O
sterol,747,O
27-hydroxylase,747,O
activity,747,O
",",747,O
as,747,O
confirmed,747,O
by,747,O
expression,747,O
of,747,O
mutant,747,O
cDNA,747,O
into,747,O
COS-1,747,O
cells,747,O
.,747,O
Quantitative,748,O
analysis,748,O
showed,748,O
that,748,O
the,748,O
expression,748,O
of,748,O
CYP27,748,O
gene,748,O
mRNA,748,O
in,748,O
the,748,O
patient,748,O
represented,748,O
52,748,O
.,748,O
5,749,O
%,749,O
of,749,O
the,749,O
normal,749,O
level,749,O
.,749,O
As,750,O
the,750,O
mutation,750,O
occurred,750,O
at,750,O
the,750,O
penultimate,750,O
nucleotide,750,O
of,750,O
exon,750,O
6,750,O
(,750,O
-2,750,O
position,750,O
of,750,O
exon,750,O
6-intron,750,O
6,750,O
splice,750,O
site,750,O
),750,O
of,750,O
the,750,O
gene,750,O
",",750,O
we,750,O
hypothesized,750,O
that,750,O
the,750,O
mutation,750,O
may,750,O
partially,750,O
affect,750,O
the,750,O
normal,750,O
splicing,750,O
efficiency,750,O
in,750,O
exon,750,O
6,750,O
and,750,O
cause,750,O
alternative,750,O
splicing,750,O
elsewhere,750,O
",",750,O
which,750,O
resulted,750,O
in,750,O
decreased,750,O
transcript,750,O
in,750,O
the,750,O
patient,750,O
.,750,O
Transfection,751,O
of,751,O
constructed,751,O
minigenes,751,O
",",751,O
with,751,O
or,751,O
without,751,O
the,751,O
mutation,751,O
",",751,O
into,751,O
COS-1,751,O
cells,751,O
confirmed,751,O
that,751,O
the,751,O
mutant,751,O
minigene,751,O
was,751,O
responsible,751,O
for,751,O
a,751,O
mRNA,751,O
species,751,O
alternatively,751,O
spliced,751,O
at,751,O
an,751,O
activated,751,O
cryptic,751,O
5,751,O
splice,751,O
site,751,O
88,751,O
bp,751,O
upstream,751,O
from,751,O
the,751,O
3,751,O
end,751,O
of,751,O
exon,751,O
6,751,O
.,751,O
Our,752,O
data,752,O
suggest,752,O
that,752,O
the,752,O
C,752,O
to,752,O
A,752,O
mutation,752,O
at,752,O
the,752,O
penultimate,752,O
nucleotide,752,O
of,752,O
exon,752,O
6,752,O
of,752,O
the,752,O
CYP27,752,O
gene,752,O
not,752,O
only,752,O
causes,752,O
the,752,O
deficiency,752,B-SpecificDisease
in,752,I-SpecificDisease
the,752,I-SpecificDisease
sterol,752,I-SpecificDisease
27-hydroxylase,752,I-SpecificDisease
activity,752,I-SpecificDisease
",",752,O
but,752,O
also,752,O
partially,752,O
leads,752,O
to,752,O
alternative,752,O
pre-mRNA,752,O
splicing,752,O
of,752,O
the,752,O
gene,752,O
.,752,O
To,753,O
our,753,O
knowledge,753,O
",",753,O
this,753,O
is,753,O
the,753,O
first,753,O
report,753,O
regarding,753,O
effects,753,O
on,753,O
pre-mRNA,753,O
splicing,753,O
of,753,O
a,753,O
mutation,753,O
at,753,O
the,753,O
-2,753,O
position,753,O
of,753,O
a,753,O
5,753,O
splice,753,O
site,753,O
.,753,O
ATM,754,O
germline,754,O
mutations,754,O
in,754,O
classical,754,O
ataxia-telangiectasia,754,B-Modifier
patients,754,O
in,754,O
the,754,O
Dutch,754,O
population,754,O
.,754,O
Germline,755,O
mutations,755,O
in,755,O
the,755,O
ATM,755,O
gene,755,O
are,755,O
responsible,755,O
for,755,O
the,755,O
autosomal,755,B-DiseaseClass
recessive,755,I-DiseaseClass
disorder,755,I-DiseaseClass
ataxia-telangiectasia,755,B-SpecificDisease
(,755,O
A-T,755,B-SpecificDisease
),755,O
.,755,O
In,756,O
our,756,O
study,756,O
",",756,O
we,756,O
have,756,O
determined,756,O
the,756,O
ATM,756,O
mutation,756,O
spectrum,756,O
in,756,O
19,756,O
classical,756,O
A-T,756,B-Modifier
patients,756,O
",",756,O
including,756,O
some,756,O
immigrant,756,O
populations,756,O
",",756,O
as,756,O
well,756,O
as,756,O
12,756,O
of,756,O
Dutch,756,O
ethnic,756,O
origin,756,O
.,756,O
Both,757,O
the,757,O
protein,757,O
truncation,757,O
test,757,O
(,757,O
PTT,757,O
),757,O
and,757,O
the,757,O
restriction,757,O
endonuclease,757,O
fingerprinting,757,O
(,757,O
REF,757,O
),757,O
method,757,O
were,757,O
used,757,O
and,757,O
compared,757,O
for,757,O
their,757,O
detection,757,O
efficiency,757,O
",",757,O
identifying,757,O
76,757,O
%,757,O
and,757,O
60,757,O
%,757,O
of,757,O
the,757,O
mutations,757,O
",",757,O
respectively,757,O
.,757,O
Most,758,O
patients,758,O
were,758,O
found,758,O
to,758,O
be,758,O
compound,758,O
heterozygote,758,O
.,758,O
Seventeen,759,O
mutations,759,O
were,759,O
distinct,759,O
",",759,O
of,759,O
which,759,O
10,759,O
were,759,O
not,759,O
reported,759,O
previously,759,O
.,759,O
Mutations,760,O
are,760,O
small,760,O
deletions,760,O
or,760,O
point,760,O
mutations,760,O
frequently,760,O
affecting,760,O
splice,760,O
sites,760,O
.,760,O
Moreover,761,O
",",761,O
a,761,O
16,761,O
.,761,O
7-kb,762,O
genomic,762,O
deletion,762,O
of,762,O
the,762,O
3,762,O
end,762,O
of,762,O
the,762,O
gene,762,O
",",762,O
most,762,O
likely,762,O
a,762,O
result,762,O
of,762,O
recombination,762,O
between,762,O
two,762,O
LINE,762,O
elements,762,O
",",762,O
was,762,O
identified,762,O
.,762,O
The,763,O
most,763,O
frequently,763,O
found,763,O
mutation,763,O
",",763,O
identified,763,O
in,763,O
three,763,O
unrelated,763,O
Turkish,763,O
A-T,763,B-Modifier
individuals,763,O
",",763,O
was,763,O
previously,763,O
described,763,O
to,763,O
be,763,O
a,763,O
Turkish,763,O
A-T,763,B-Modifier
founder,763,O
mutation,763,O
.,763,O
The,764,O
presence,764,O
of,764,O
a,764,O
founder,764,O
mutation,764,O
among,764,O
relatively,764,O
small,764,O
ethnic,764,O
population,764,O
groups,764,O
in,764,O
Western,764,O
Europe,764,O
could,764,O
indicate,764,O
a,764,O
high,764,O
carrier,764,O
frequency,764,O
in,764,O
such,764,O
communities,764,O
.,764,O
In,765,O
patients,765,O
of,765,O
Dutch,765,O
ethnic,765,O
origin,765,O
",",765,O
however,765,O
",",765,O
no,765,O
significant,765,O
founder,765,O
effect,765,O
could,765,O
be,765,O
identified,765,O
.,765,O
The,766,O
observed,766,O
genetic,766,O
heterogeneity,766,O
including,766,O
the,766,O
relative,766,O
high,766,O
percentage,766,O
of,766,O
splice-site,766,O
mutations,766,O
had,766,O
no,766,O
reflection,766,O
on,766,O
the,766,O
phenotype,766,O
.,766,O
All,767,O
patients,767,O
manifested,767,O
classical,767,O
A-T,767,B-SpecificDisease
and,767,O
increased,767,O
cellular,767,O
radioresistant,767,O
DNA,767,O
synthesis,767,O
.,767,O
Determination,768,O
of,768,O
the,768,O
genomic,768,O
structure,768,O
of,768,O
the,768,O
COL4A4,768,O
gene,768,O
and,768,O
of,768,O
novel,768,O
mutations,768,O
causing,768,O
autosomal,768,B-SpecificDisease
recessive,768,I-SpecificDisease
Alport,768,I-SpecificDisease
syndrome,768,I-SpecificDisease
.,768,O
Autosomal,769,B-SpecificDisease
recessive,769,I-SpecificDisease
Alport,769,I-SpecificDisease
syndrome,769,I-SpecificDisease
is,769,O
a,769,O
progressive,769,O
hematuric,769,B-SpecificDisease
glomerulonephritis,769,I-SpecificDisease
characterized,769,O
by,769,O
glomerular,769,B-DiseaseClass
basement,769,I-DiseaseClass
membrane,769,I-DiseaseClass
abnormalities,769,I-DiseaseClass
and,769,O
associated,769,O
with,769,O
mutations,769,O
in,769,O
either,769,O
the,769,O
COL4A3,769,O
or,769,O
the,769,O
COL4A4,769,O
gene,769,O
",",769,O
which,769,O
encode,769,O
the,769,O
alpha3,769,O
and,769,O
alpha4,769,O
type,769,O
IV,769,O
collagen,769,O
chains,769,O
",",769,O
respectively,769,O
.,769,O
To,770,O
date,770,O
",",770,O
mutation,770,O
screening,770,O
in,770,O
the,770,O
two,770,O
genes,770,O
has,770,O
been,770,O
hampered,770,O
by,770,O
the,770,O
lack,770,O
of,770,O
genomic,770,O
structure,770,O
information,770,O
.,770,O
We,771,O
report,771,O
here,771,O
the,771,O
complete,771,O
characterization,771,O
of,771,O
the,771,O
48,771,O
exons,771,O
of,771,O
the,771,O
COL4A4,771,O
gene,771,O
",",771,O
a,771,O
comprehensive,771,O
gene,771,O
screen,771,O
",",771,O
and,771,O
the,771,O
subsequent,771,O
detection,771,O
of,771,O
10,771,O
novel,771,O
mutations,771,O
in,771,O
eight,771,O
patients,771,O
diagnosed,771,O
with,771,O
autosomal,771,B-SpecificDisease
recessive,771,I-SpecificDisease
Alport,771,I-SpecificDisease
syndrome,771,I-SpecificDisease
.,771,O
Furthermore,772,O
",",772,O
we,772,O
identified,772,O
a,772,O
glycine,772,O
to,772,O
alanine,772,O
substitution,772,O
in,772,O
the,772,O
collagenous,772,O
domain,772,O
that,772,O
is,772,O
apparently,772,O
silent,772,O
in,772,O
the,772,O
heterozygous,772,O
carriers,772,O
",",772,O
in,772,O
11,772,O
.,772,O
5,773,O
%,773,O
of,773,O
all,773,O
control,773,O
individuals,773,O
",",773,O
and,773,O
in,773,O
one,773,O
control,773,O
individual,773,O
homozygous,773,O
for,773,O
this,773,O
glycine,773,O
substitution,773,O
.,773,O
There,774,O
has,774,O
been,774,O
no,774,O
previous,774,O
finding,774,O
of,774,O
a,774,O
glycine,774,O
substitution,774,O
that,774,O
is,774,O
not,774,O
associated,774,O
with,774,O
any,774,O
obvious,774,O
phenotype,774,O
in,774,O
homozygous,774,O
individuals,774,O
.,774,O
Founder,775,O
BRCA1,775,O
and,775,O
BRCA2,775,O
mutations,775,O
in,775,O
French,775,O
Canadian,775,O
breast,775,B-Modifier
and,775,I-Modifier
ovarian,775,I-Modifier
cancer,775,I-Modifier
families,775,O
.,775,O
We,776,O
have,776,O
identified,776,O
four,776,O
mutations,776,O
in,776,O
each,776,O
of,776,O
the,776,O
breast,776,B-Modifier
cancer-susceptibility,776,O
genes,776,O
",",776,O
BRCA1,776,O
and,776,O
BRCA2,776,O
",",776,O
in,776,O
French,776,O
Canadian,776,O
breast,776,B-Modifier
cancer,776,I-Modifier
and,776,O
breast/ovarian,776,B-Modifier
cancer,776,I-Modifier
families,776,O
from,776,O
Quebec,776,O
.,776,O
To,777,O
identify,777,O
founder,777,O
effects,777,O
",",777,O
we,777,O
examined,777,O
independently,777,O
ascertained,777,O
French,777,O
Canadian,777,O
cancer,777,B-Modifier
families,777,O
for,777,O
the,777,O
distribution,777,O
of,777,O
these,777,O
eight,777,O
mutations,777,O
.,777,O
Mutations,778,O
were,778,O
found,778,O
in,778,O
41,778,O
of,778,O
97,778,O
families,778,O
.,778,O
Six,779,O
of,779,O
eight,779,O
mutations,779,O
were,779,O
observed,779,O
at,779,O
least,779,O
twice,779,O
.,779,O
The,780,O
BRCA1,780,O
C4446T,780,O
mutation,780,O
was,780,O
the,780,O
most,780,O
common,780,O
mutation,780,O
found,780,O
",",780,O
followed,780,O
by,780,O
the,780,O
BRCA2,780,O
8765delAG,780,O
mutation,780,O
.,780,O
Together,781,O
",",781,O
these,781,O
mutations,781,O
were,781,O
found,781,O
in,781,O
28,781,O
of,781,O
41,781,O
families,781,O
identified,781,O
to,781,O
have,781,O
a,781,O
mutation,781,O
.,781,O
The,782,O
odds,782,O
of,782,O
detection,782,O
of,782,O
any,782,O
of,782,O
the,782,O
four,782,O
BRCA1,782,O
mutations,782,O
was,782,O
18,782,O
.,782,O
7x,783,O
greater,783,O
if,783,O
one,783,O
or,783,O
more,783,O
cases,783,O
of,783,O
ovarian,783,B-SpecificDisease
cancer,783,I-SpecificDisease
were,783,O
also,783,O
present,783,O
in,783,O
the,783,O
family,783,O
.,783,O
The,784,O
odds,784,O
of,784,O
detection,784,O
of,784,O
any,784,O
of,784,O
the,784,O
four,784,O
BRCA2,784,O
mutations,784,O
was,784,O
5,784,O
.,784,O
3x,785,O
greater,785,O
if,785,O
there,785,O
were,785,O
at,785,O
least,785,O
five,785,O
cases,785,O
of,785,O
breast,785,B-SpecificDisease
cancer,785,I-SpecificDisease
in,785,O
the,785,O
family,785,O
.,785,O
Interestingly,786,O
",",786,O
the,786,O
presence,786,O
of,786,O
a,786,O
breast,786,B-Modifier
cancer,786,I-Modifier
case,786,O
<,786,O
36,786,O
years,786,O
of,786,O
age,786,O
was,786,O
strongly,786,O
predictive,786,O
of,786,O
the,786,O
presence,786,O
of,786,O
any,786,O
of,786,O
the,786,O
eight,786,O
mutations,786,O
screened,786,O
.,786,O
Carriers,787,O
of,787,O
the,787,O
same,787,O
mutation,787,O
",",787,O
from,787,O
different,787,O
families,787,O
",",787,O
shared,787,O
similar,787,O
haplotypes,787,O
",",787,O
indicating,787,O
that,787,O
the,787,O
mutant,787,O
alleles,787,O
were,787,O
likely,787,O
to,787,O
be,787,O
identical,787,O
by,787,O
descent,787,O
for,787,O
a,787,O
mutation,787,O
in,787,O
the,787,O
founder,787,O
population,787,O
.,787,O
The,788,O
identification,788,O
of,788,O
common,788,O
BRCA1,788,O
and,788,O
BRCA2,788,O
mutations,788,O
will,788,O
facilitate,788,O
carrier,788,O
detection,788,O
in,788,O
French,788,O
Canadian,788,O
breast,788,B-Modifier
cancer,788,I-Modifier
and,788,O
breast/ovarian,788,B-Modifier
cancer,788,I-Modifier
families,788,O
.,788,O
Are,789,O
Dp71,789,O
and,789,O
Dp140,789,O
brain,789,O
dystrophin,789,O
isoforms,789,O
related,789,O
to,789,O
cognitive,789,B-DiseaseClass
impairment,789,I-DiseaseClass
in,789,O
Duchenne,789,B-SpecificDisease
muscular,789,I-SpecificDisease
dystrophy,789,I-SpecificDisease
?,789,O
Molecular,790,O
study,790,O
and,790,O
neuropsychological,790,O
analysis,790,O
were,790,O
performed,790,O
concurrently,790,O
on,790,O
49,790,O
patients,790,O
with,790,O
Duchenne,790,B-SpecificDisease
muscular,790,I-SpecificDisease
dystrophy,790,I-SpecificDisease
(,790,O
DMD,790,B-SpecificDisease
),790,O
in,790,O
order,790,O
to,790,O
find,790,O
a,790,O
molecular,790,O
explanation,790,O
for,790,O
the,790,O
cognitive,790,B-DiseaseClass
impairment,790,I-DiseaseClass
observed,790,O
in,790,O
most,790,O
DMD,790,B-Modifier
patients,790,O
.,790,O
Complete,791,O
analysis,791,O
of,791,O
the,791,O
dystrophin,791,O
gene,791,O
was,791,O
performed,791,O
to,791,O
define,791,O
the,791,O
localization,791,O
of,791,O
deletions,791,O
and,791,O
duplications,791,O
in,791,O
relation,791,O
to,791,O
the,791,O
different,791,O
DMD,791,B-Modifier
promoters,791,O
.,791,O
Qualitative,792,O
analysis,792,O
of,792,O
the,792,O
Dp71,792,O
transcript,792,O
and,792,O
testing,792,O
for,792,O
the,792,O
specific,792,O
first,792,O
exon,792,O
of,792,O
Dp140,792,O
were,792,O
also,792,O
carried,792,O
out,792,O
.,792,O
Neuropsychological,793,O
analysis,793,O
assessed,793,O
verbal,793,O
and,793,O
visuospatial,793,O
intelligence,793,O
",",793,O
verbal,793,O
memory,793,O
",",793,O
and,793,O
reading,793,O
skills,793,O
.,793,O
Comparison,794,O
of,794,O
molecular,794,O
and,794,O
psychometric,794,O
findings,794,O
demonstrated,794,O
that,794,O
deletions,794,O
and,794,O
duplications,794,O
that,794,O
were,794,O
localized,794,O
in,794,O
the,794,O
distal,794,O
part,794,O
of,794,O
the,794,O
gene,794,O
seemed,794,O
to,794,O
be,794,O
preferentially,794,O
associated,794,O
with,794,O
cognitive,794,B-DiseaseClass
impairment,794,I-DiseaseClass
.,794,O
Two,795,O
altered,795,O
Dp71,795,O
transcripts,795,O
and,795,O
two,795,O
deleted,795,O
Dp140,795,O
DNA,795,O
sequences,795,O
were,795,O
found,795,O
in,795,O
four,795,O
patients,795,O
with,795,O
severe,795,O
cerebral,795,B-DiseaseClass
dysfunction,795,I-DiseaseClass
.,795,O
These,796,O
findings,796,O
suggest,796,O
that,796,O
some,796,O
sequences,796,O
located,796,O
in,796,O
the,796,O
distal,796,O
part,796,O
of,796,O
the,796,O
gene,796,O
and,796,O
",",796,O
in,796,O
particular,796,O
",",796,O
some,796,O
DMD,796,B-Modifier
isoforms,796,O
expressed,796,O
in,796,O
the,796,O
brain,796,O
may,796,O
be,796,O
related,796,O
to,796,O
the,796,O
cognitive,796,B-DiseaseClass
impairment,796,I-DiseaseClass
associated,796,O
with,796,O
DMD,796,B-SpecificDisease
..,796,O
I1307K,797,O
APC,797,O
and,797,O
hMLH1,797,O
mutations,797,O
in,797,O
a,797,O
non-Jewish,797,O
family,797,O
with,797,O
hereditary,797,B-SpecificDisease
non-polyposis,797,I-SpecificDisease
colorectal,797,I-SpecificDisease
cancer,797,I-SpecificDisease
.,797,O
We,798,O
describe,798,O
a,798,O
French,798,O
Canadian,798,O
hereditary,798,B-Modifier
non-polyposis,798,I-Modifier
colorectal,798,I-Modifier
cancer,798,I-Modifier
(,798,O
HNPCC,798,B-Modifier
),798,O
kindred,798,O
which,798,O
carries,798,O
a,798,O
novel,798,O
truncating,798,O
mutation,798,O
in,798,O
hMLH1,798,O
.,798,O
Interestingly,799,O
",",799,O
the,799,O
I1307K,799,O
APC,799,O
polymorphism,799,O
",",799,O
associated,799,O
with,799,O
an,799,O
increased,799,O
risk,799,O
of,799,O
colorectal,799,B-SpecificDisease
cancer,799,I-SpecificDisease
",",799,O
is,799,O
also,799,O
present,799,O
in,799,O
this,799,O
family,799,O
.,799,O
The,800,O
I1307K,800,O
polymorphism,800,O
has,800,O
previously,800,O
only,800,O
been,800,O
identified,800,O
in,800,O
individuals,800,O
of,800,O
self-reported,800,O
Ashkenazi,800,O
Jewish,800,O
origins,800,O
.,800,O
In,801,O
addition,801,O
",",801,O
in,801,O
this,801,O
family,801,O
",",801,O
there,801,O
appears,801,O
to,801,O
be,801,O
no,801,O
relationship,801,O
between,801,O
the,801,O
I1307K,801,O
polymorphism,801,O
and,801,O
the,801,O
presence,801,O
or,801,O
absence,801,O
of,801,O
cancer,801,B-DiseaseClass
..,801,O
Identification,802,O
of,802,O
a,802,O
novel,802,O
mutation,802,O
of,802,O
the,802,O
CPO,802,O
gene,802,O
in,802,O
a,802,O
Japanese,802,O
hereditary,802,B-Modifier
coproporphyria,802,I-Modifier
family,802,O
.,802,O
Hereditary,803,B-SpecificDisease
coproporphyria,803,I-SpecificDisease
(,803,O
HCP,803,B-SpecificDisease
),803,O
is,803,O
an,803,O
autosomal,803,B-DiseaseClass
dominant,803,I-DiseaseClass
disease,803,I-DiseaseClass
characterized,803,O
by,803,O
a,803,O
deficiency,803,B-SpecificDisease
of,803,I-SpecificDisease
coproporphyrinogen,803,I-SpecificDisease
oxidase,803,I-SpecificDisease
(,803,O
CPO,803,O
),803,O
caused,803,O
by,803,O
a,803,O
mutation,803,O
in,803,O
the,803,O
CPO,803,O
gene,803,O
.,803,O
Only,804,O
11,804,O
mutations,804,O
of,804,O
the,804,O
gene,804,O
have,804,O
been,804,O
reported,804,O
in,804,O
HCP,804,B-Modifier
patients,804,O
.,804,O
We,805,O
report,805,O
another,805,O
mutation,805,O
in,805,O
a,805,O
Japanese,805,O
family,805,O
.,805,O
Polymerase,806,O
chain,806,O
reaction-single,806,O
strand,806,O
conformational,806,O
polymorphism,806,O
and,806,O
direct,806,O
sequence,806,O
analyses,806,O
demonstrated,806,O
a,806,O
C,806,O
to,806,O
T,806,O
substitution,806,O
in,806,O
exon,806,O
1,806,O
of,806,O
the,806,O
CPO,806,O
gene,806,O
at,806,O
nucleotide,806,O
position,806,O
85,806,O
",",806,O
which,806,O
lies,806,O
in,806,O
the,806,O
putative,806,O
presequence,806,O
for,806,O
targeting,806,O
to,806,O
mitochondria,806,O
.,806,O
This,807,O
mutation,807,O
changes,807,O
the,807,O
codon,807,O
for,807,O
glutamine,807,O
to,807,O
a,807,O
termination,807,O
codon,807,O
at,807,O
amino,807,O
acid,807,O
position,807,O
29,807,O
.,807,O
MaeI,808,O
restriction,808,O
analysis,808,O
showed,808,O
two,808,O
other,808,O
carriers,808,O
in,808,O
the,808,O
family,808,O
.,808,O
The,809,O
C-T,809,O
mutation,809,O
is,809,O
located,809,O
within,809,O
a,809,O
recently,809,O
proposed,809,O
putative,809,O
alternative,809,O
translation,809,O
initiation,809,O
codon,809,O
(,809,O
TIC-1,809,O
),809,O
",",809,O
supporting,809,O
that,809,O
TIC-1,809,O
is,809,O
the,809,O
real,809,O
TIC,809,O
rather,809,O
than,809,O
TIC-2,809,O
..,809,O
Human,810,B-SpecificDisease
complement,810,I-SpecificDisease
factor,810,I-SpecificDisease
H,810,I-SpecificDisease
deficiency,810,I-SpecificDisease
associated,810,O
with,810,O
hemolytic,810,B-SpecificDisease
uremic,810,I-SpecificDisease
syndrome,810,I-SpecificDisease
.,810,O
This,811,O
study,811,O
reports,811,O
on,811,O
six,811,O
cases,811,O
of,811,O
deficiency,811,B-SpecificDisease
in,811,I-SpecificDisease
the,811,I-SpecificDisease
human,811,I-SpecificDisease
complement,811,I-SpecificDisease
regulatory,811,I-SpecificDisease
protein,811,I-SpecificDisease
Factor,811,I-SpecificDisease
H,811,I-SpecificDisease
(,811,O
FH,811,O
),811,O
in,811,O
the,811,O
context,811,O
of,811,O
an,811,O
acute,811,B-SpecificDisease
renal,811,I-SpecificDisease
disease,811,I-SpecificDisease
.,811,O
Five,812,O
of,812,O
the,812,O
cases,812,O
were,812,O
observed,812,O
in,812,O
children,812,O
presenting,812,O
with,812,O
idiopathic,812,O
hemolytic,812,B-SpecificDisease
uremic,812,I-SpecificDisease
syndrome,812,I-SpecificDisease
(,812,O
HUS,812,B-SpecificDisease
),812,O
.,812,O
Two,813,O
of,813,O
the,813,O
children,813,O
exhibited,813,O
a,813,O
homozygous,813,O
deficiency,813,O
characterized,813,O
by,813,O
the,813,O
absence,813,O
of,813,O
the,813,O
150-kD,813,O
form,813,O
of,813,O
Factor,813,O
H,813,O
and,813,O
the,813,O
presence,813,O
",",813,O
upon,813,O
immunoblotting,813,O
",",813,O
of,813,O
the,813,O
42-kD,813,O
Factor,813,O
H-like,813,O
protein,813,O
1,813,O
(,813,O
FHL-1,813,O
),813,O
and,813,O
other,813,O
FH-related,813,O
protein,813,O
(,813,O
FHR,813,O
),813,O
bands,813,O
.,813,O
Southern,814,O
blot,814,O
and,814,O
PCR,814,O
analysis,814,O
of,814,O
DNA,814,O
of,814,O
one,814,O
patient,814,O
with,814,O
homozygous,814,O
deficiency,814,O
ruled,814,O
out,814,O
the,814,O
presence,814,O
of,814,O
a,814,O
large,814,O
deletion,814,O
of,814,O
the,814,O
FH,814,O
gene,814,O
as,814,O
the,814,O
underlying,814,O
defect,814,O
for,814,O
the,814,O
deficiency,814,O
.,814,O
The,815,O
other,815,O
four,815,O
children,815,O
presented,815,O
with,815,O
heterozygous,815,O
deficiency,815,O
and,815,O
exhibited,815,O
a,815,O
normal,815,O
immunoblotting,815,O
pattern,815,O
of,815,O
proteins,815,O
of,815,O
the,815,O
FH,815,O
family,815,O
.,815,O
Factor,816,B-SpecificDisease
H,816,I-SpecificDisease
deficiency,816,I-SpecificDisease
is,816,O
the,816,O
only,816,O
complement,816,B-DiseaseClass
deficiency,816,I-DiseaseClass
associated,816,O
with,816,O
HUS,816,B-SpecificDisease
.,816,O
These,817,O
observations,817,O
suggest,817,O
a,817,O
role,817,O
for,817,O
FH,817,O
and/or,817,O
FH,817,O
receptors,817,O
in,817,O
the,817,O
pathogenesis,817,O
of,817,O
idiopathic,817,O
HUS,817,B-SpecificDisease
..,817,O
Further,818,O
evidence,818,O
for,818,O
a,818,O
major,818,O
ancient,818,O
mutation,818,O
underlying,818,O
myotonic,818,B-SpecificDisease
dystrophy,818,I-SpecificDisease
from,818,O
linkage,818,O
disequilibrium,818,O
studies,818,O
in,818,O
the,818,O
Japanese,818,O
population,818,O
.,818,O
The,819,O
myotonic,819,B-Modifier
dystrophy,819,I-Modifier
(,819,O
DM,819,B-Modifier
),819,O
mutation,819,O
is,819,O
an,819,O
unstable,819,O
(,819,O
CTG,819,O
),819,O
n,819,O
repeat,819,O
",",819,O
present,819,O
at,819,O
a,819,O
copy,819,O
number,819,O
of,819,O
5-37,819,O
repeats,819,O
on,819,O
normal,819,O
chromosomes,819,O
but,819,O
amplified,819,O
to,819,O
50-3000,819,O
copies,819,O
on,819,O
DM,819,B-Modifier
chromosomes,819,O
.,819,O
Previous,820,O
findings,820,O
in,820,O
Caucasian,820,O
populations,820,O
of,820,O
a,820,O
DM,820,B-Modifier
founder,820,O
chromosome,820,O
raise,820,O
a,820,O
question,820,O
about,820,O
the,820,O
molecular,820,O
events,820,O
involved,820,O
in,820,O
the,820,O
expansion,820,O
mutation,820,O
.,820,O
To,821,O
investigate,821,O
whether,821,O
a,821,O
founder,821,O
chromosome,821,O
for,821,O
the,821,O
DM,821,B-Modifier
mutation,821,O
exists,821,O
in,821,O
the,821,O
Japanese,821,O
population,821,O
",",821,O
we,821,O
genotyped,821,O
families,821,O
using,821,O
polymorphic,821,O
markers,821,O
near,821,O
the,821,O
(,821,O
CTG,821,O
),821,O
n,821,O
repeat,821,O
region,821,O
and,821,O
constructed,821,O
haplotypes,821,O
.,821,O
Six,822,O
different,822,O
haplotypes,822,O
were,822,O
found,822,O
and,822,O
DM,822,B-Modifier
alleles,822,O
were,822,O
always,822,O
haplotype,822,O
A,822,O
.,822,O
To,823,O
find,823,O
an,823,O
origin,823,O
of,823,O
the,823,O
(,823,O
CTG,823,O
),823,O
n,823,O
repeat,823,O
mutation,823,O
and,823,O
to,823,O
investigate,823,O
the,823,O
mechanism,823,O
of,823,O
the,823,O
expansion,823,O
mutation,823,O
in,823,O
the,823,O
Japanese,823,O
population,823,O
we,823,O
have,823,O
studied,823,O
90,823,O
Japanese,823,O
DM,823,B-Modifier
families,823,O
comprising,823,O
190,823,O
affected,823,O
and,823,O
130,823,O
unaffected,823,O
members,823,O
.,823,O
The,824,O
results,824,O
suggest,824,O
that,824,O
a,824,O
few,824,O
common,824,O
ancestral,824,O
mutations,824,O
in,824,O
both,824,O
Caucasian,824,O
and,824,O
Japanese,824,O
populations,824,O
have,824,O
originated,824,O
by,824,O
expansion,824,O
of,824,O
an,824,O
ancestral,824,O
n,824,O
=,824,O
5,824,O
repeat,824,O
to,824,O
n,824,O
=,824,O
19-37,824,O
copies,824,O
.,824,O
These,825,O
data,825,O
support,825,O
multistep,825,O
models,825,O
of,825,O
triplet,825,O
repeat,825,O
expansion,825,O
that,825,O
have,825,O
been,825,O
proposed,825,O
for,825,O
both,825,O
DM,825,B-SpecificDisease
and,825,O
Friedreichs,825,B-SpecificDisease
ataxia,825,I-SpecificDisease
..,825,O
The,826,O
molecular,826,O
basis,826,O
of,826,O
C6,826,B-SpecificDisease
deficiency,826,I-SpecificDisease
in,826,O
the,826,O
western,826,O
Cape,826,O
",",826,O
South,826,O
Africa,826,O
.,826,O
Deficiency,827,B-SpecificDisease
of,827,I-SpecificDisease
the,827,I-SpecificDisease
sixth,827,I-SpecificDisease
component,827,I-SpecificDisease
of,827,I-SpecificDisease
human,827,I-SpecificDisease
complement,827,I-SpecificDisease
(,827,O
C6,827,O
),827,O
has,827,O
been,827,O
reported,827,O
in,827,O
a,827,O
number,827,O
of,827,O
families,827,O
from,827,O
the,827,O
western,827,O
Cape,827,O
",",827,O
South,827,O
Africa,827,O
.,827,O
Meningococcal,828,B-SpecificDisease
disease,828,I-SpecificDisease
is,828,O
endemic,828,O
in,828,O
the,828,O
Cape,828,O
and,828,O
almost,828,O
all,828,O
pedigrees,828,O
of,828,O
total,828,O
C6,828,B-SpecificDisease
deficiency,828,I-SpecificDisease
(,828,O
C6Q0,828,O
),828,O
have,828,O
been,828,O
ascertained,828,O
because,828,O
of,828,O
recurrent,828,O
disease,828,O
.,828,O
We,829,O
have,829,O
sequenced,829,O
the,829,O
expressed,829,O
exons,829,O
of,829,O
the,829,O
C6,829,O
gene,829,O
from,829,O
selected,829,O
cases,829,O
and,829,O
have,829,O
found,829,O
three,829,O
molecular,829,O
defects,829,O
leading,829,O
to,829,O
total,829,O
deficiency,829,O
879delG,829,O
",",829,O
which,829,O
is,829,O
the,829,O
common,829,O
defect,829,O
in,829,O
the,829,O
Cape,829,O
and,829,O
hitherto,829,O
unreported,829,O
",",829,O
and,829,O
1195delC,829,O
and,829,O
1936delG,829,O
",",829,O
which,829,O
have,829,O
been,829,O
previously,829,O
reported,829,O
in,829,O
African-Americans,829,O
.,829,O
We,830,O
also,830,O
show,830,O
that,830,O
the,830,O
879delG,830,O
and,830,O
1195delC,830,O
defects,830,O
are,830,O
associated,830,O
with,830,O
characteristic,830,O
C6/C7,830,O
region,830,O
DNA,830,O
marker,830,O
haplotypes,830,O
",",830,O
although,830,O
small,830,O
variations,830,O
were,830,O
observed,830,O
.,830,O
The,831,O
1936delG,831,O
defect,831,O
was,831,O
observed,831,O
only,831,O
once,831,O
in,831,O
the,831,O
Cape,831,O
",",831,O
but,831,O
its,831,O
associated,831,O
haplotype,831,O
could,831,O
be,831,O
deduced,831,O
.,831,O
The,832,O
data,832,O
from,832,O
the,832,O
haplotypes,832,O
indicate,832,O
that,832,O
these,832,O
three,832,O
molecular,832,O
defects,832,O
account,832,O
for,832,O
the,832,O
defects,832,O
in,832,O
all,832,O
the,832,O
38,832,O
unrelated,832,O
C6Q0,832,O
individuals,832,O
we,832,O
have,832,O
studied,832,O
from,832,O
the,832,O
Cape,832,O
.,832,O
We,833,O
have,833,O
also,833,O
observed,833,O
the,833,O
879delG,833,O
defect,833,O
in,833,O
two,833,O
Dutch,833,O
C6-deficient,833,B-Modifier
kindreds,833,O
",",833,O
but,833,O
the,833,O
879delG,833,O
defect,833,O
in,833,O
the,833,O
Cape,833,O
probably,833,O
did,833,O
not,833,O
come,833,O
from,833,O
The,833,O
Netherlands,833,O
..,833,O
Complement,834,B-SpecificDisease
C7,834,I-SpecificDisease
deficiency,834,I-SpecificDisease
:,834,O
seven,834,O
further,834,O
molecular,834,O
defects,834,O
and,834,O
their,834,O
associated,834,O
marker,834,O
haplotypes,834,O
.,834,O
Seven,835,O
further,835,O
molecular,835,O
bases,835,O
of,835,O
C7,835,B-SpecificDisease
deficiency,835,I-SpecificDisease
are,835,O
described,835,O
.,835,O
All,836,O
these,836,O
new,836,O
molecular,836,O
defects,836,O
involve,836,O
single-nucleotide,836,O
events,836,O
",",836,O
deletions,836,O
and,836,O
substitutions,836,O
",",836,O
some,836,O
of,836,O
which,836,O
alter,836,O
splice,836,O
sites,836,O
",",836,O
and,836,O
others,836,O
codons,836,O
.,836,O
They,837,O
are,837,O
distributed,837,O
along,837,O
the,837,O
C7,837,O
gene,837,O
",",837,O
but,837,O
predominantly,837,O
towards,837,O
the,837,O
3,837,O
end,837,O
.,837,O
All,838,O
were,838,O
found,838,O
in,838,O
compound,838,O
heterozygous,838,O
individuals,838,O
.,838,O
The,839,O
C6/C7,839,O
marker,839,O
haplotypes,839,O
associated,839,O
with,839,O
most,839,O
C7,839,B-SpecificDisease
defects,839,I-SpecificDisease
are,839,O
tabulated,839,O
..,839,O
A,840,O
genome-wide,840,O
search,840,O
for,840,O
chromosomal,840,O
loci,840,O
linked,840,O
to,840,O
mental,840,O
health,840,O
wellness,840,O
in,840,O
relatives,840,O
at,840,O
high,840,O
risk,840,O
for,840,O
bipolar,840,B-SpecificDisease
affective,840,I-SpecificDisease
disorder,840,I-SpecificDisease
among,840,O
the,840,O
Old,840,O
Order,840,O
Amish,840,O
.,840,O
Bipolar,841,B-SpecificDisease
affective,841,I-SpecificDisease
disorder,841,I-SpecificDisease
(,841,O
BPAD,841,B-SpecificDisease
;,841,O
manic-depressive,841,B-SpecificDisease
illness,841,I-SpecificDisease
),841,O
is,841,O
characterized,841,O
by,841,O
episodes,841,O
of,841,O
mania,841,B-SpecificDisease
and/or,841,O
hypomania,841,B-SpecificDisease
interspersed,841,O
with,841,O
periods,841,O
of,841,O
depression,841,B-SpecificDisease
.,841,O
Compelling,842,O
evidence,842,O
supports,842,O
a,842,O
significant,842,O
genetic,842,O
component,842,O
in,842,O
the,842,O
susceptibility,842,O
to,842,O
develop,842,O
BPAD,842,B-SpecificDisease
.,842,O
To,843,O
date,843,O
",",843,O
however,843,O
",",843,O
linkage,843,O
studies,843,O
have,843,O
attempted,843,O
only,843,O
to,843,O
identify,843,O
chromosomal,843,O
loci,843,O
that,843,O
cause,843,O
or,843,O
increase,843,O
the,843,O
risk,843,O
of,843,O
developing,843,O
BPAD,843,B-SpecificDisease
.,843,O
To,844,O
determine,844,O
whether,844,O
there,844,O
could,844,O
be,844,O
protective,844,O
alleles,844,O
that,844,O
prevent,844,O
or,844,O
reduce,844,O
the,844,O
risk,844,O
of,844,O
developing,844,O
BPAD,844,B-SpecificDisease
",",844,O
similar,844,O
to,844,O
what,844,O
is,844,O
observed,844,O
in,844,O
other,844,O
genetic,844,B-DiseaseClass
disorders,844,I-DiseaseClass
",",844,O
we,844,O
used,844,O
mental,844,O
health,844,O
wellness,844,O
(,844,O
absence,844,O
of,844,O
any,844,O
psychiatric,844,B-DiseaseClass
disorder,844,I-DiseaseClass
),844,O
as,844,O
the,844,O
phenotype,844,O
in,844,O
our,844,O
genome-wide,844,O
linkage,844,O
scan,844,O
of,844,O
several,844,O
large,844,O
multigeneration,844,O
Old,844,O
Order,844,O
Amish,844,O
pedigrees,844,O
exhibiting,844,O
an,844,O
extremely,844,O
high,844,O
incidence,844,O
of,844,O
BPAD,844,B-SpecificDisease
.,844,O
We,845,O
have,845,O
found,845,O
strong,845,O
evidence,845,O
for,845,O
a,845,O
locus,845,O
on,845,O
chromosome,845,O
4p,845,O
at,845,O
D4S2949,845,O
(,845,O
maximum,845,O
GENEHUNTER-PLUS,845,O
nonparametric,845,O
linkage,845,O
score,845,O
=,845,O
4,845,O
.,845,O
05,846,O
",",846,O
P,846,O
=,846,O
5,846,O
.,846,O
22,847,O
x,847,O
10,847,O
(,847,O
-4,847,O
),847,O
;,847,O
SIBPAL,847,O
Pempirical,847,O
value,847,O
<,847,O
3,847,O
x,847,O
10,847,O
(,847,O
-5,847,O
),847,O
),847,O
and,847,O
suggestive,847,O
evidence,847,O
for,847,O
a,847,O
locus,847,O
on,847,O
chromosome,847,O
4q,847,O
at,847,O
D4S397,847,O
(,847,O
maximum,847,O
GENEHUNTER-PLUS,847,O
nonparametric,847,O
linkage,847,O
score,847,O
=,847,O
3,847,O
.,847,O
29,848,O
",",848,O
P,848,O
=,848,O
2,848,O
.,848,O
57,849,O
x,849,O
10,849,O
(,849,O
-3,849,O
),849,O
;,849,O
SIBPAL,849,O
Pempirical,849,O
value,849,O
<,849,O
1,849,O
x,849,O
10,849,O
(,849,O
-3,849,O
),849,O
),849,O
that,849,O
are,849,O
linked,849,O
to,849,O
mental,849,O
health,849,O
wellness,849,O
.,849,O
These,850,O
findings,850,O
are,850,O
consistent,850,O
with,850,O
the,850,O
hypothesis,850,O
that,850,O
certain,850,O
alleles,850,O
could,850,O
prevent,850,O
or,850,O
modify,850,O
the,850,O
clinical,850,O
manifestations,850,O
of,850,O
BPAD,850,B-SpecificDisease
and,850,O
perhaps,850,O
other,850,O
related,850,O
affective,850,B-DiseaseClass
disorders,850,I-DiseaseClass
.,850,O
Segregation,851,O
distortion,851,O
in,851,O
myotonic,851,B-SpecificDisease
dystrophy,851,I-SpecificDisease
.,851,O
Myotonic,852,B-SpecificDisease
dystrophy,852,I-SpecificDisease
(,852,O
DM,852,B-SpecificDisease
),852,O
is,852,O
an,852,O
autosomal,852,B-DiseaseClass
dominant,852,I-DiseaseClass
disease,852,I-DiseaseClass
which,852,O
",",852,O
in,852,O
the,852,O
typical,852,O
pedigree,852,O
",",852,O
shows,852,O
a,852,O
three,852,O
generation,852,O
anticipation,852,O
cascade,852,O
.,852,O
This,853,O
results,853,O
in,853,O
infertility,853,B-SpecificDisease
and,853,O
congenital,853,B-SpecificDisease
myotonic,853,I-SpecificDisease
dystrophy,853,I-SpecificDisease
(,853,O
CDM,853,B-SpecificDisease
),853,O
with,853,O
the,853,O
disappearance,853,O
of,853,O
DM,853,B-SpecificDisease
in,853,O
that,853,O
pedigree,853,O
.,853,O
The,854,O
concept,854,O
of,854,O
segregation,854,O
distortion,854,O
",",854,O
where,854,O
there,854,O
is,854,O
preferential,854,O
transmission,854,O
of,854,O
the,854,O
larger,854,O
allele,854,O
at,854,O
the,854,O
DM,854,B-Modifier
locus,854,O
",",854,O
has,854,O
been,854,O
put,854,O
forward,854,O
to,854,O
explain,854,O
partially,854,O
the,854,O
maintenance,854,O
of,854,O
DM,854,B-SpecificDisease
in,854,O
the,854,O
population,854,O
.,854,O
In,855,O
a,855,O
survey,855,O
of,855,O
DM,855,B-SpecificDisease
in,855,O
Northern,855,O
Ireland,855,O
",",855,O
59,855,O
pedigrees,855,O
were,855,O
ascertained,855,O
.,855,O
Sibships,856,O
where,856,O
the,856,O
status,856,O
of,856,O
all,856,O
the,856,O
members,856,O
had,856,O
been,856,O
identified,856,O
were,856,O
examined,856,O
to,856,O
determine,856,O
the,856,O
transmission,856,O
of,856,O
the,856,O
DM,856,B-Modifier
expansion,856,O
from,856,O
affected,856,O
parents,856,O
to,856,O
their,856,O
offspring,856,O
.,856,O
Where,857,O
the,857,O
transmitting,857,O
parent,857,O
was,857,O
male,857,O
",",857,O
58,857,O
.,857,O
3,858,O
%,858,O
of,858,O
the,858,O
offspring,858,O
were,858,O
affected,858,O
",",858,O
and,858,O
in,858,O
the,858,O
case,858,O
of,858,O
a,858,O
female,858,O
transmitting,858,O
parent,858,O
",",858,O
68,858,O
.,858,O
7,859,O
%,859,O
were,859,O
affected,859,O
.,859,O
Studies,860,O
on,860,O
meiotic,860,O
drive,860,O
in,860,O
DM,860,B-SpecificDisease
have,860,O
shown,860,O
increased,860,O
transmission,860,O
of,860,O
the,860,O
larger,860,O
allele,860,O
at,860,O
the,860,O
DM,860,B-Modifier
locus,860,O
in,860,O
non-DM,860,O
heterozygotes,860,O
for,860,O
CTGn,860,O
.,860,O
This,861,O
study,861,O
provides,861,O
further,861,O
evidence,861,O
that,861,O
the,861,O
DM,861,B-Modifier
expansion,861,O
tends,861,O
to,861,O
be,861,O
transmitted,861,O
preferentially,861,O
.,861,O
Diagnosis,862,O
of,862,O
hemochromatosis,862,B-SpecificDisease
.,862,O
If,863,O
untreated,863,O
",",863,O
hemochromatosis,863,B-SpecificDisease
can,863,O
cause,863,O
serious,863,O
illness,863,O
and,863,O
early,863,B-SpecificDisease
death,863,I-SpecificDisease
",",863,O
but,863,O
the,863,O
disease,863,O
is,863,O
still,863,O
substantially,863,O
under-diagnosed,863,O
.,863,O
The,864,O
cornerstone,864,O
of,864,O
screening,864,O
and,864,O
case,864,O
detection,864,O
is,864,O
the,864,O
measurement,864,O
of,864,O
serum,864,O
transferrin,864,O
saturation,864,O
and,864,O
the,864,O
serum,864,O
ferritin,864,O
level,864,O
.,864,O
Once,865,O
the,865,O
diagnosis,865,O
is,865,O
suspected,865,O
",",865,O
physicians,865,O
must,865,O
use,865,O
serum,865,O
ferritin,865,O
levels,865,O
and,865,O
hepatic,865,O
iron,865,O
stores,865,O
on,865,O
liver,865,O
biopsy,865,O
specimens,865,O
to,865,O
assess,865,O
patients,865,O
for,865,O
the,865,O
presence,865,O
of,865,O
iron,865,B-SpecificDisease
overload,865,I-SpecificDisease
.,865,O
Liver,866,O
biopsy,866,O
is,866,O
also,866,O
used,866,O
to,866,O
establish,866,O
the,866,O
presence,866,O
or,866,O
absence,866,O
of,866,O
cirrhosis,866,B-SpecificDisease
",",866,O
which,866,O
can,866,O
affect,866,O
prognosis,866,O
and,866,O
management,866,O
.,866,O
A,867,O
DNA-based,867,O
test,867,O
for,867,O
the,867,O
HFE,867,O
gene,867,O
is,867,O
commercially,867,O
available,867,O
",",867,O
but,867,O
its,867,O
place,867,O
in,867,O
the,867,O
diagnosis,867,O
of,867,O
hemochromatosis,867,B-SpecificDisease
is,867,O
still,867,O
being,867,O
evaluated,867,O
.,867,O
Currently,868,O
",",868,O
the,868,O
most,868,O
useful,868,O
role,868,O
for,868,O
this,868,O
test,868,O
is,868,O
in,868,O
the,868,O
detection,868,O
of,868,O
hemochromatosis,868,B-SpecificDisease
in,868,O
the,868,O
family,868,O
members,868,O
of,868,O
patients,868,O
with,868,O
a,868,O
proven,868,O
case,868,O
of,868,O
the,868,O
disease,868,O
.,868,O
It,869,O
is,869,O
crucial,869,O
to,869,O
diagnose,869,O
hemochromatosis,869,B-SpecificDisease
before,869,O
hepatic,869,B-SpecificDisease
cirrhosis,869,I-SpecificDisease
develops,869,O
because,869,O
phlebotomy,869,O
therapy,869,O
can,869,O
avert,869,O
serious,869,O
chronic,869,O
disease,869,O
and,869,O
can,869,O
even,869,O
lead,869,O
to,869,O
normal,869,O
life,869,O
expectancy,869,O
..,869,O
Prevalence,870,O
of,870,O
the,870,O
I1307K,870,O
APC,870,B-Modifier
gene,870,O
variant,870,O
in,870,O
Israeli,870,O
Jews,870,O
of,870,O
differing,870,O
ethnic,870,O
origin,870,O
and,870,O
risk,870,O
for,870,O
colorectal,870,B-SpecificDisease
cancer,870,I-SpecificDisease
.,870,O
BACKGROUND,871,O
&,871,O
AIMS,871,O
Israeli,871,O
Jews,871,O
of,871,O
European,871,O
birth,871,O
",",871,O
i.,871,O
e.,871,O
",",871,O
Ashkenazim,871,O
",",871,O
have,871,O
the,871,O
highest,871,O
colorectal,871,B-Modifier
cancer,871,I-Modifier
incidence,871,O
of,871,O
any,871,O
Israeli,871,O
ethnic,871,O
group,871,O
.,871,O
The,872,O
I1307K,872,O
APC,872,B-Modifier
gene,872,O
variant,872,O
was,872,O
found,872,O
in,872,O
6,872,O
.,872,O
1,873,O
%,873,O
of,873,O
American,873,O
Jews,873,O
",",873,O
28,873,O
%,873,O
of,873,O
their,873,O
familial,873,O
colorectal,873,B-Modifier
cancer,873,I-Modifier
cases,873,O
",",873,O
but,873,O
not,873,O
in,873,O
non-Jews,873,O
.,873,O
We,874,O
assessed,874,O
the,874,O
I1307K,874,O
prevalence,874,O
in,874,O
Israeli,874,O
Jews,874,O
of,874,O
differing,874,O
ethnic,874,O
origin,874,O
and,874,O
risk,874,O
for,874,O
colorectal,874,B-SpecificDisease
cancer,874,I-SpecificDisease
.,874,O
METHODS,875,O
DNA,875,O
samples,875,O
from,875,O
500,875,O
unrelated,875,O
Jews,875,O
of,875,O
European,875,O
or,875,O
non-European,875,O
origin,875,O
",",875,O
with,875,O
or,875,O
without,875,O
a,875,O
personal,875,O
and/or,875,O
family,875,O
history,875,O
of,875,O
neoplasia,875,B-DiseaseClass
",",875,O
were,875,O
examined,875,O
for,875,O
the,875,O
I1307K,875,O
variant,875,O
by,875,O
the,875,O
allele-specific,875,O
oligonucleotide,875,O
(,875,O
ASO,875,O
),875,O
method,875,O
.,875,O
RESULTS,876,O
In,876,O
persons,876,O
at,876,O
average,876,O
risk,876,O
for,876,O
colorectal,876,B-SpecificDisease
cancer,876,I-SpecificDisease
",",876,O
I1307K,876,O
was,876,O
found,876,O
in,876,O
5,876,O
.,876,O
0,877,O
%,877,O
of,877,O
120,877,O
European,877,O
and,877,O
1,877,O
.,877,O
6,878,O
%,878,O
of,878,O
188,878,O
non-European,878,O
Jews,878,O
(,878,O
P,878,O
=,878,O
0,878,O
.,878,O
08,879,O
),879,O
.,879,O
It,880,O
occurred,880,O
in,880,O
15,880,O
.,880,O
4,881,O
%,881,O
of,881,O
52,881,O
Ashkenazi,881,O
Israelis,881,O
with,881,O
familial,881,O
cancer,881,B-DiseaseClass
(,881,O
P,881,O
=,881,O
0,881,O
.,881,O
02,882,O
),882,O
and,882,O
was,882,O
not,882,O
detected,882,O
in,882,O
51,882,O
non-European,882,O
Jews,882,O
at,882,O
increased,882,O
cancer,882,B-Modifier
risk,882,O
.,882,O
Colorectal,883,B-SpecificDisease
neoplasia,883,I-SpecificDisease
occurred,883,O
personally,883,O
or,883,O
in,883,O
the,883,O
families,883,O
of,883,O
13,883,O
of,883,O
20,883,O
Ashkenazi,883,O
I1307K,883,O
carriers,883,O
",",883,O
8,883,O
of,883,O
whom,883,O
also,883,O
had,883,O
a,883,O
personal,883,O
or,883,O
family,883,O
history,883,O
of,883,O
noncolonic,883,O
neoplasia,883,B-DiseaseClass
.,883,O
CONCLUSIONS,884,O
The,884,O
I1307K,884,O
APC,884,O
variant,884,O
may,884,O
represent,884,O
a,884,O
susceptibility,884,O
gene,884,O
for,884,O
colorectal,884,O
",",884,O
or,884,O
other,884,O
",",884,O
cancers,884,O
in,884,O
Ashkenazi,884,O
Jews,884,O
",",884,O
and,884,O
partially,884,O
explains,884,O
the,884,O
higher,884,O
incidence,884,O
of,884,O
colorectal,884,B-SpecificDisease
cancer,884,I-SpecificDisease
in,884,O
European,884,O
Israelis,884,O
.,884,O
Systematic,885,O
analysis,885,O
of,885,O
coproporphyrinogen,885,O
oxidase,885,O
gene,885,O
defects,885,O
in,885,O
hereditary,885,B-SpecificDisease
coproporphyria,885,I-SpecificDisease
and,885,O
mutation,885,O
update,885,O
.,885,O
Hereditary,886,B-SpecificDisease
coproporphyria,886,I-SpecificDisease
(,886,O
HC,886,B-SpecificDisease
),886,O
is,886,O
an,886,O
acute,886,O
hepatic,886,B-SpecificDisease
porphyria,886,I-SpecificDisease
with,886,O
autosomal,886,O
dominant,886,O
inheritance,886,O
caused,886,O
by,886,O
deficient,886,B-SpecificDisease
activity,886,I-SpecificDisease
of,886,I-SpecificDisease
coproporphyrinogen,886,I-SpecificDisease
III,886,I-SpecificDisease
oxidase,886,I-SpecificDisease
(,886,O
CPO,886,O
),886,O
.,886,O
Clinical,887,O
manifestations,887,O
of,887,O
the,887,O
disease,887,O
are,887,O
characterized,887,O
by,887,O
acute,887,O
attacks,887,O
of,887,O
neurological,887,B-DiseaseClass
dysfunction,887,I-DiseaseClass
often,887,O
precipitated,887,O
by,887,O
drugs,887,O
",",887,O
fasting,887,O
",",887,O
cyclical,887,O
hormonal,887,O
changes,887,O
",",887,O
or,887,O
infectious,887,B-DiseaseClass
diseases,887,I-DiseaseClass
.,887,O
Skin,888,O
photosensitivity,888,O
may,888,O
also,888,O
be,888,O
present,888,O
.,888,O
The,889,O
seven,889,O
exons,889,O
",",889,O
the,889,O
exon/intron,889,O
boundaries,889,O
and,889,O
part,889,O
of,889,O
3,889,O
noncoding,889,O
sequence,889,O
of,889,O
the,889,O
CPO,889,O
gene,889,O
were,889,O
systematically,889,O
analyzed,889,O
by,889,O
an,889,O
exon-by-exon,889,O
denaturing,889,O
gradient,889,O
gel,889,O
electrophoresis,889,O
(,889,O
DGGE,889,O
),889,O
strategy,889,O
followed,889,O
by,889,O
direct,889,O
sequencing,889,O
in,889,O
seven,889,O
unrelated,889,O
heterozygous,889,O
HC,889,B-Modifier
patients,889,O
from,889,O
France,889,O
",",889,O
Holland,889,O
",",889,O
and,889,O
Czech,889,O
Republic,889,O
.,889,O
Seven,890,O
novel,890,O
mutations,890,O
and,890,O
two,890,O
new,890,O
polymorphisms,890,O
were,890,O
detected,890,O
.,890,O
Among,891,O
these,891,O
mutations,891,O
two,891,O
are,891,O
missense,891,O
(,891,O
G197W,891,O
",",891,O
W427R,891,O
),891,O
",",891,O
two,891,O
are,891,O
nonsense,891,O
(,891,O
Q306X,891,O
",",891,O
Q385X,891,O
),891,O
",",891,O
two,891,O
are,891,O
small,891,O
deletions,891,O
(,891,O
662de14bp,891,O
;,891,O
1168del3bp,891,O
removing,891,O
a,891,O
glycine,891,O
at,891,O
position,891,O
390,891,O
),891,O
",",891,O
and,891,O
one,891,O
is,891,O
a,891,O
splicing,891,O
mutation,891,O
(,891,O
IVS1-15c,891,O
--,891,O
>,891,O
g,891,O
),891,O
which,891,O
creates,891,O
a,891,O
new,891,O
acceptor,891,O
splice,891,O
site,891,O
.,891,O
The,892,O
pathological,892,O
significance,892,O
of,892,O
the,892,O
point,892,O
mutations,892,O
G197W,892,O
",",892,O
W427R,892,O
",",892,O
and,892,O
the,892,O
in-frame,892,O
deletion,892,O
390delGly,892,O
were,892,O
assessed,892,O
by,892,O
their,892,O
respective,892,O
expression,892,O
in,892,O
a,892,O
prokaryotic,892,O
system,892,O
using,892,O
site-directed,892,O
mutagenesis,892,O
.,892,O
These,893,O
mutations,893,O
resulted,893,O
in,893,O
the,893,O
absence,893,O
or,893,O
a,893,O
dramatic,893,O
decrease,893,O
of,893,O
CPO,893,O
activity,893,O
.,893,O
The,894,O
two,894,O
polymorphisms,894,O
were,894,O
localized,894,O
in,894,O
noncoding,894,O
part,894,O
of,894,O
the,894,O
gene,894,O
1,894,O
),894,O
a,894,O
C/G,894,O
polymorphism,894,O
in,894,O
the,894,O
promotor,894,O
region,894,O
",",894,O
142,894,O
bp,894,O
upstream,894,O
from,894,O
the,894,O
transcriptional,894,O
initiation,894,O
site,894,O
(,894,O
-142C/G,894,O
),894,O
",",894,O
and,894,O
2,894,O
),894,O
a,894,O
6,894,O
bp,894,O
deletion,894,O
polymorphism,894,O
in,894,O
the,894,O
3,894,O
noncoding,894,O
part,894,O
of,894,O
the,894,O
CPO,894,O
gene,894,O
",",894,O
574,894,O
bp,894,O
downstream,894,O
of,894,O
the,894,O
last,894,O
base,894,O
of,894,O
the,894,O
normal,894,O
termination,894,O
codon,894,O
(,894,O
+,894,O
574,894,O
delATTCTT,894,O
),894,O
.,894,O
Five,895,O
intragenic,895,O
dimorphisms,895,O
are,895,O
now,895,O
well,895,O
characterized,895,O
and,895,O
the,895,O
high,895,O
degree,895,O
of,895,O
allelic,895,O
heterogeneity,895,O
in,895,O
HC,895,B-SpecificDisease
is,895,O
demonstrated,895,O
with,895,O
seven,895,O
new,895,O
different,895,O
mutations,895,O
making,895,O
a,895,O
total,895,O
of,895,O
nineteen,895,O
CPO,895,O
gene,895,B-DiseaseClass
defects,895,I-DiseaseClass
reported,895,O
so,895,O
far,895,O
..,895,O
Coincidence,896,O
of,896,O
two,896,O
novel,896,O
arylsulfatase,896,O
A,896,O
alleles,896,O
and,896,O
mutation,896,O
459+1G,896,O
>,896,O
A,896,O
within,896,O
a,896,O
family,896,O
with,896,O
metachromatic,896,B-SpecificDisease
leukodystrophy,896,I-SpecificDisease
:,896,O
molecular,896,O
basis,896,O
of,896,O
phenotypic,896,O
heterogeneity,896,O
.,896,O
In,897,O
a,897,O
family,897,O
with,897,O
three,897,O
siblings,897,O
",",897,O
one,897,O
developed,897,O
classical,897,O
late,897,O
infantile,897,O
metachromatic,897,B-SpecificDisease
leukodystrophy,897,I-SpecificDisease
(,897,O
MLD,897,B-SpecificDisease
),897,O
",",897,O
fatal,897,O
at,897,O
age,897,O
5,897,O
years,897,O
",",897,O
with,897,O
deficient,897,O
arylsulfatase,897,O
A,897,O
(,897,O
ARSA,897,O
),897,O
activity,897,O
and,897,O
increased,897,O
galactosylsulfatide,897,O
(,897,O
GS,897,O
),897,O
excretion,897,O
.,897,O
The,898,O
two,898,O
other,898,O
siblings,898,O
",",898,O
apparently,898,O
healthy,898,O
at,898,O
12,898,O
(,898,O
1/2,898,O
),898,O
and,898,O
15,898,O
years,898,O
",",898,O
respectively,898,O
",",898,O
and,898,O
their,898,O
father,898,O
",",898,O
apparently,898,O
healthy,898,O
as,898,O
well,898,O
",",898,O
presented,898,O
ARSA,898,O
and,898,O
GS,898,O
values,898,O
within,898,O
the,898,O
range,898,O
of,898,O
MLD,898,B-Modifier
patients,898,O
.,898,O
Mutation,899,O
screening,899,O
and,899,O
sequence,899,O
analysis,899,O
disclosed,899,O
the,899,O
involvement,899,O
of,899,O
three,899,O
different,899,O
ARSA,899,O
mutations,899,O
being,899,O
the,899,O
molecular,899,O
basis,899,O
of,899,O
intrafamilial,899,O
phenotypic,899,O
heterogeneity,899,O
.,899,O
The,900,O
late,900,O
infantile,900,O
patient,900,O
inherited,900,O
from,900,O
his,900,O
mother,900,O
the,900,O
frequent,900,O
0-type,900,O
mutation,900,O
459,900,O
+,900,O
1G,900,O
>,900,O
A,900,O
",",900,O
and,900,O
from,900,O
his,900,O
father,900,O
a,900,O
novel,900,O
",",900,O
single,900,O
basepair,900,O
microdeletion,900,O
of,900,O
guanine,900,O
at,900,O
nucleotide,900,O
7,900,O
in,900,O
exon,900,O
1,900,O
(,900,O
7delG,900,O
),900,O
.,900,O
The,901,O
two,901,O
clinically,901,O
unaffected,901,O
siblings,901,O
carried,901,O
the,901,O
maternal,901,O
mutation,901,O
459,901,O
+,901,O
1G,901,O
>,901,O
A,901,O
and,901,O
",",901,O
on,901,O
their,901,O
paternal,901,O
allele,901,O
",",901,O
a,901,O
novel,901,O
cytosine,901,O
to,901,O
thymidine,901,O
transition,901,O
at,901,O
nucleotide,901,O
2435,901,O
in,901,O
exon,901,O
8,901,O
",",901,O
resulting,901,O
in,901,O
substitution,901,O
of,901,O
alanine,901,O
464,901,O
by,901,O
valine,901,O
(,901,O
A464V,901,O
),901,O
.,901,O
The,902,O
fathers,902,O
genotype,902,O
thus,902,O
was,902,O
7delG/A464V,902,O
.,902,O
Mutation,903,O
A464V,903,O
was,903,O
not,903,O
found,903,O
in,903,O
18,903,O
unrelated,903,O
MLD,903,B-Modifier
patients,903,O
and,903,O
50,903,O
controls,903,O
.,903,O
A464V,904,O
",",904,O
although,904,O
clearly,904,O
modifying,904,O
ARSA,904,O
and,904,O
GS,904,O
levels,904,O
",",904,O
apparently,904,O
bears,904,O
little,904,O
significance,904,O
for,904,O
clinical,904,O
manifestation,904,O
of,904,O
MLD,904,B-SpecificDisease
",",904,O
mimicking,904,O
the,904,O
frequent,904,O
ARSA,904,O
pseudodeficiency,904,O
allele,904,O
.,904,O
Our,905,O
results,905,O
demonstrate,905,O
that,905,O
in,905,O
certain,905,O
genetic,905,O
conditions,905,O
MLD-like,905,B-Modifier
ARSA,905,O
and,905,O
GS,905,O
values,905,O
need,905,O
not,905,O
be,905,O
paralleled,905,O
by,905,O
clinical,905,O
disease,905,O
",",905,O
a,905,O
finding,905,O
with,905,O
serious,905,O
diagnostic,905,O
and,905,O
prognostic,905,O
implications,905,O
.,905,O
Moreover,906,O
",",906,O
further,906,O
ARSA,906,O
alleles,906,O
functionally,906,O
similar,906,O
to,906,O
A464V,906,O
might,906,O
exist,906,O
which,906,O
",",906,O
together,906,O
with,906,O
0-type,906,O
mutations,906,O
",",906,O
may,906,O
cause,906,O
pathological,906,O
ARSA,906,O
and,906,O
GS,906,O
levels,906,O
",",906,O
but,906,O
not,906,O
clinical,906,O
outbreak,906,O
of,906,O
the,906,O
disease,906,O
..,906,O
Human,907,O
MLH1,907,O
deficiency,907,O
predisposes,907,O
to,907,O
hematological,907,B-DiseaseClass
malignancy,907,I-DiseaseClass
and,907,O
neurofibromatosis,907,B-SpecificDisease
type,907,I-SpecificDisease
1,907,I-SpecificDisease
.,907,O
Heterozygous,908,O
germ-line,908,O
mutations,908,O
in,908,O
the,908,O
DNA,908,O
mismatch,908,O
repair,908,O
genes,908,O
lead,908,O
to,908,O
hereditary,908,B-SpecificDisease
nonpolyposis,908,I-SpecificDisease
colorectal,908,I-SpecificDisease
cancer,908,I-SpecificDisease
.,908,O
The,909,O
disease,909,O
susceptibility,909,O
of,909,O
individuals,909,O
who,909,O
constitutionally,909,O
lack,909,O
both,909,O
wild-type,909,O
alleles,909,O
is,909,O
unknown,909,O
.,909,O
We,910,O
have,910,O
identified,910,O
three,910,O
offspring,910,O
in,910,O
a,910,O
hereditary,910,B-Modifier
nonpolyposis,910,I-Modifier
colorectal,910,I-Modifier
cancer,910,I-Modifier
family,910,O
who,910,O
developed,910,O
hematological,910,B-DiseaseClass
malignancy,910,I-DiseaseClass
at,910,O
a,910,O
very,910,O
early,910,O
age,910,O
",",910,O
and,910,O
at,910,O
least,910,O
two,910,O
of,910,O
them,910,O
displayed,910,O
signs,910,O
of,910,O
neurofibromatosis,910,B-SpecificDisease
type,910,I-SpecificDisease
1,910,I-SpecificDisease
(,910,O
NF1,910,B-SpecificDisease
),910,O
.,910,O
DNA,911,O
sequence,911,O
analysis,911,O
and,911,O
allele-specific,911,O
amplification,911,O
in,911,O
two,911,O
siblings,911,O
revealed,911,O
a,911,O
homozygous,911,O
MLH1,911,O
mutation,911,O
(,911,O
C676T,911,O
--,911,O
>,911,O
Arg226Stop,911,O
),911,O
.,911,O
Thus,912,O
",",912,O
a,912,O
homozygous,912,O
germ-line,912,O
MLH1,912,O
mutation,912,O
and,912,O
consequent,912,O
mismatch,912,O
repair,912,O
deficiency,912,O
results,912,O
in,912,O
a,912,O
mutator,912,O
phenotype,912,O
characterized,912,O
by,912,O
leukemia,912,B-DiseaseClass
and/or,912,O
lymphoma,912,B-DiseaseClass
associated,912,O
with,912,O
neurofibromatosis,912,B-SpecificDisease
type,912,I-SpecificDisease
1,912,I-SpecificDisease
..,912,O
Missense,913,O
mutations,913,O
in,913,O
the,913,O
most,913,O
ancient,913,O
residues,913,O
of,913,O
the,913,O
PAX6,913,O
paired,913,O
domain,913,O
underlie,913,O
a,913,O
spectrum,913,O
of,913,O
human,913,O
congenital,913,B-DiseaseClass
eye,913,I-DiseaseClass
malformations,913,I-DiseaseClass
.,913,O
Mutations,914,O
of,914,O
the,914,O
human,914,O
PAX6,914,O
gene,914,O
underlie,914,O
aniridia,914,B-SpecificDisease
(,914,O
congenital,914,B-SpecificDisease
absence,914,I-SpecificDisease
of,914,I-SpecificDisease
the,914,I-SpecificDisease
iris,914,I-SpecificDisease
),914,O
",",914,O
a,914,O
rare,914,O
dominant,914,O
malformation,914,B-DiseaseClass
of,914,I-DiseaseClass
the,914,I-DiseaseClass
eye,914,I-DiseaseClass
.,914,O
The,915,O
spectrum,915,O
of,915,O
PAX6,915,O
mutations,915,O
in,915,O
aniridia,915,B-Modifier
patients,915,O
is,915,O
highly,915,O
biased,915,O
",",915,O
with,915,O
92,915,O
%,915,O
of,915,O
all,915,O
reported,915,O
mutations,915,O
leading,915,O
to,915,O
premature,915,O
truncation,915,O
of,915,O
the,915,O
protein,915,O
(,915,O
nonsense,915,O
",",915,O
splicing,915,O
",",915,O
insertions,915,O
and,915,O
deletions,915,O
),915,O
and,915,O
just,915,O
2,915,O
%,915,O
leading,915,O
to,915,O
substitution,915,O
of,915,O
one,915,O
amino,915,O
acid,915,O
by,915,O
another,915,O
(,915,O
missense,915,O
),915,O
.,915,O
The,916,O
extraordinary,916,O
conservation,916,O
of,916,O
the,916,O
PAX6,916,O
protein,916,O
at,916,O
the,916,O
amino,916,O
acid,916,O
level,916,O
amongst,916,O
vertebrates,916,O
predicts,916,O
that,916,O
pathological,916,O
missense,916,O
mutations,916,O
should,916,O
in,916,O
fact,916,O
be,916,O
common,916,O
even,916,O
though,916,O
they,916,O
are,916,O
hardly,916,O
ever,916,O
seen,916,O
in,916,O
aniridia,916,B-Modifier
patients,916,O
.,916,O
This,917,O
indicates,917,O
that,917,O
there,917,O
is,917,O
a,917,O
heavy,917,O
ascertainment,917,O
bias,917,O
in,917,O
the,917,O
selection,917,O
of,917,O
patients,917,O
for,917,O
PAX6,917,O
mutation,917,O
analysis,917,O
and,917,O
that,917,O
the,917,O
missing,917,O
PAX6,917,O
missense,917,O
mutations,917,O
frequently,917,O
may,917,O
underlie,917,O
phenotypes,917,O
distinct,917,O
from,917,O
textbook,917,O
aniridia,917,B-SpecificDisease
.,917,O
Here,918,O
we,918,O
present,918,O
four,918,O
novel,918,O
PAX6,918,O
missense,918,O
mutations,918,O
",",918,O
two,918,O
in,918,O
association,918,O
with,918,O
atypical,918,O
phenotypes,918,O
ectopia,918,B-SpecificDisease
pupillae,918,I-SpecificDisease
(,918,O
displaced,918,B-SpecificDisease
pupils,918,I-SpecificDisease
),918,O
and,918,O
congenital,918,B-SpecificDisease
nystagmus,918,I-SpecificDisease
(,918,O
searching,918,B-SpecificDisease
gaze,918,I-SpecificDisease
),918,O
",",918,O
and,918,O
two,918,O
in,918,O
association,918,O
with,918,O
more,918,O
recognizable,918,O
aniridia,918,B-Modifier
phenotypes,918,O
.,918,O
Strikingly,919,O
",",919,O
all,919,O
four,919,O
mutations,919,O
are,919,O
located,919,O
within,919,O
the,919,O
PAX6,919,O
paired,919,O
domain,919,O
and,919,O
affect,919,O
amino,919,O
acids,919,O
which,919,O
are,919,O
highly,919,O
conserved,919,O
in,919,O
all,919,O
known,919,O
paired,919,O
domain,919,O
proteins,919,O
.,919,O
Our,920,O
results,920,O
support,920,O
the,920,O
hypothesis,920,O
that,920,O
the,920,O
under-representation,920,O
of,920,O
missense,920,O
mutations,920,O
is,920,O
caused,920,O
by,920,O
ascertainment,920,O
bias,920,O
and,920,O
suggest,920,O
that,920,O
a,920,O
substantial,920,O
burden,920,O
of,920,O
PAX6,920,B-DiseaseClass
-related,920,I-DiseaseClass
disease,920,I-DiseaseClass
remains,920,O
to,920,O
be,920,O
uncovered,920,O
..,920,O
Distribution,921,O
of,921,O
emerin,921,O
and,921,O
lamins,921,O
in,921,O
the,921,O
heart,921,O
and,921,O
implications,921,O
for,921,O
Emery-Dreifuss,921,B-SpecificDisease
muscular,921,I-SpecificDisease
dystrophy,921,I-SpecificDisease
.,921,O
Emerin,922,O
is,922,O
a,922,O
nuclear,922,O
membrane,922,O
protein,922,O
which,922,O
is,922,O
missing,922,O
or,922,O
defective,922,O
in,922,O
Emery-Dreifuss,922,B-SpecificDisease
muscular,922,I-SpecificDisease
dystrophy,922,I-SpecificDisease
(,922,O
EDMD,922,B-SpecificDisease
),922,O
.,922,O
It,923,O
is,923,O
one,923,O
member,923,O
of,923,O
a,923,O
family,923,O
of,923,O
lamina-associated,923,O
proteins,923,O
which,923,O
includes,923,O
LAP1,923,O
",",923,O
LAP2,923,O
and,923,O
lamin,923,O
B,923,O
receptor,923,O
(,923,O
LBR,923,O
),923,O
.,923,O
A,924,O
panel,924,O
of,924,O
16,924,O
monoclonal,924,O
antibodies,924,O
(,924,O
mAbs,924,O
),924,O
has,924,O
been,924,O
mapped,924,O
to,924,O
six,924,O
specific,924,O
sites,924,O
throughout,924,O
the,924,O
emerin,924,O
molecule,924,O
using,924,O
phage-displayed,924,O
peptide,924,O
libraries,924,O
and,924,O
has,924,O
been,924,O
used,924,O
to,924,O
localize,924,O
emerin,924,O
in,924,O
human,924,O
and,924,O
rabbit,924,O
heart,924,O
.,924,O
Several,925,O
mAbs,925,O
against,925,O
different,925,O
emerin,925,O
epitopes,925,O
did,925,O
not,925,O
recognize,925,O
intercalated,925,O
discs,925,O
in,925,O
the,925,O
heart,925,O
",",925,O
though,925,O
they,925,O
recognized,925,O
cardiomyocyte,925,O
nuclei,925,O
strongly,925,O
",",925,O
both,925,O
at,925,O
the,925,O
rim,925,O
and,925,O
in,925,O
intranuclear,925,O
spots,925,O
or,925,O
channels,925,O
.,925,O
A,926,O
polyclonal,926,O
rabbit,926,O
antiserum,926,O
against,926,O
emerin,926,O
did,926,O
recognize,926,O
both,926,O
nuclear,926,O
membrane,926,O
and,926,O
intercalated,926,O
discs,926,O
but,926,O
",",926,O
after,926,O
affinity,926,O
purification,926,O
against,926,O
a,926,O
pure-emerin,926,O
band,926,O
on,926,O
a,926,O
western,926,O
blot,926,O
",",926,O
it,926,O
stained,926,O
only,926,O
the,926,O
nuclear,926,O
membrane,926,O
.,926,O
These,927,O
results,927,O
would,927,O
not,927,O
be,927,O
expected,927,O
if,927,O
immunostaining,927,O
at,927,O
intercalated,927,O
discs,927,O
were,927,O
due,927,O
to,927,O
a,927,O
product,927,O
of,927,O
the,927,O
emerin,927,O
gene,927,O
and,927,O
",",927,O
therefore,927,O
",",927,O
cast,927,O
some,927,O
doubt,927,O
upon,927,O
the,927,O
hypothesis,927,O
that,927,O
cardiac,927,B-DiseaseClass
defects,927,I-DiseaseClass
in,927,O
EDMD,927,B-SpecificDisease
are,927,O
caused,927,O
by,927,O
absence,927,O
of,927,O
emerin,927,O
from,927,O
intercalated,927,O
discs,927,O
.,927,O
Although,928,O
emerin,928,O
was,928,O
abundant,928,O
in,928,O
the,928,O
membranes,928,O
of,928,O
cardiomyocyte,928,O
nuclei,928,O
",",928,O
it,928,O
was,928,O
absent,928,O
from,928,O
many,928,O
non-myocyte,928,O
cells,928,O
in,928,O
the,928,O
heart,928,O
.,928,O
This,929,O
distribution,929,O
of,929,O
emerin,929,O
was,929,O
similar,929,O
to,929,O
that,929,O
of,929,O
lamin,929,O
A,929,O
",",929,O
a,929,O
candidate,929,O
gene,929,O
for,929,O
an,929,O
autosomal,929,O
form,929,O
of,929,O
EDMD,929,B-SpecificDisease
.,929,O
In,930,O
contrast,930,O
",",930,O
lamin,930,O
B1,930,O
was,930,O
absent,930,O
from,930,O
cardiomyocyte,930,O
nuclei,930,O
",",930,O
showing,930,O
that,930,O
lamin,930,O
B1,930,O
is,930,O
not,930,O
essential,930,O
for,930,O
localization,930,O
of,930,O
emerin,930,O
to,930,O
the,930,O
nuclear,930,O
lamina,930,O
.,930,O
Lamin,931,O
B1,931,O
is,931,O
also,931,O
almost,931,O
completely,931,O
absent,931,O
from,931,O
skeletal,931,O
muscle,931,O
nuclei,931,O
.,931,O
In,932,O
EDMD,932,B-SpecificDisease
",",932,O
the,932,O
additional,932,O
absence,932,O
of,932,O
lamin,932,O
B1,932,O
from,932,O
heart,932,O
and,932,O
skeletal,932,O
muscle,932,O
nuclei,932,O
which,932,O
already,932,O
lack,932,O
emerin,932,O
may,932,O
offer,932,O
an,932,O
alternative,932,O
explanation,932,O
of,932,O
why,932,O
these,932,O
tissues,932,O
are,932,O
particularly,932,O
affected,932,O
..,932,O
Genetic,933,O
mapping,933,O
of,933,O
the,933,O
copper,933,B-Modifier
toxicosis,933,I-Modifier
locus,933,O
in,933,O
Bedlington,933,O
terriers,933,O
to,933,O
dog,933,O
chromosome,933,O
10,933,O
",",933,O
in,933,O
a,933,O
region,933,O
syntenic,933,O
to,933,O
human,933,O
chromosome,933,O
region,933,O
2p13-p16,933,O
.,933,O
Abnormal,934,O
hepatic,934,B-SpecificDisease
copper,934,I-SpecificDisease
accumulation,934,I-SpecificDisease
is,934,O
recognized,934,O
as,934,O
an,934,O
inherited,934,B-DiseaseClass
disorder,934,I-DiseaseClass
in,934,O
man,934,O
",",934,O
mouse,934,O
",",934,O
rat,934,O
and,934,O
dog,934,O
.,934,O
The,935,O
major,935,O
cause,935,O
of,935,O
hepatic,935,B-SpecificDisease
copper,935,I-SpecificDisease
accumulation,935,I-SpecificDisease
in,935,O
man,935,O
is,935,O
a,935,O
dysfunctional,935,O
ATP7B,935,O
gene,935,O
",",935,O
causing,935,O
Wilson,935,B-SpecificDisease
disease,935,I-SpecificDisease
(,935,O
WD,935,B-SpecificDisease
),935,O
.,935,O
Mutations,936,O
in,936,O
the,936,O
ATP7B,936,O
genes,936,O
have,936,O
also,936,O
been,936,O
demonstrated,936,O
in,936,O
mouse,936,O
and,936,O
rat,936,O
.,936,O
The,937,O
ATP7B,937,O
gene,937,O
has,937,O
been,937,O
excluded,937,O
in,937,O
the,937,O
much,937,O
rarer,937,O
human,937,O
copper,937,B-SpecificDisease
overload,937,I-SpecificDisease
disease,937,O
non-Indian,937,B-SpecificDisease
childhood,937,I-SpecificDisease
cirrhosis,937,I-SpecificDisease
",",937,O
indicating,937,O
genetic,937,O
heterogeneity,937,O
.,937,O
By,938,O
investigating,938,O
the,938,O
common,938,O
autosomal,938,O
recessive,938,O
copper,938,B-SpecificDisease
toxicosis,938,I-SpecificDisease
(,938,O
CT,938,B-SpecificDisease
),938,O
in,938,O
Bedlington,938,O
terriers,938,O
",",938,O
we,938,O
have,938,O
identified,938,O
a,938,O
new,938,O
locus,938,O
involved,938,O
in,938,O
progressive,938,O
liver,938,B-DiseaseClass
disease,938,I-DiseaseClass
.,938,O
We,939,O
examined,939,O
whether,939,O
the,939,O
WD,939,B-Modifier
gene,939,O
ATP7B,939,O
was,939,O
also,939,O
causative,939,O
for,939,O
CT,939,B-SpecificDisease
by,939,O
investigating,939,O
the,939,O
chromosomal,939,O
co-localization,939,O
of,939,O
ATP7B,939,O
and,939,O
C04107,939,O
",",939,O
using,939,O
fluorescence,939,O
in,939,O
situ,939,O
hybridization,939,O
(,939,O
FISH,939,O
),939,O
.,939,O
C04107,940,O
is,940,O
an,940,O
anonymous,940,O
microsatellite,940,O
marker,940,O
closely,940,O
linked,940,O
to,940,O
CT,940,B-SpecificDisease
.,940,O
However,941,O
",",941,O
BAC,941,O
clones,941,O
containing,941,O
ATP7B,941,O
and,941,O
C04107,941,O
mapped,941,O
to,941,O
the,941,O
canine,941,O
chromosome,941,O
regions,941,O
CFA22q11,941,O
and,941,O
CFA10q26,941,O
",",941,O
respectively,941,O
",",941,O
demonstrating,941,O
that,941,O
WD,941,B-SpecificDisease
can,941,O
not,941,O
be,941,O
homologous,941,O
to,941,O
CT,941,B-SpecificDisease
.,941,O
The,942,O
copper,942,O
transport,942,O
genes,942,O
CTR1,942,O
and,942,O
CTR2,942,O
were,942,O
also,942,O
excluded,942,O
as,942,O
candidate,942,O
genes,942,O
for,942,O
CT,942,B-SpecificDisease
since,942,O
they,942,O
both,942,O
mapped,942,O
to,942,O
canine,942,O
chromosome,942,O
region,942,O
CFA11q22,942,O
.,942,O
2-22,943,O
.,943,O
5,944,O
.,944,O
A,945,O
transcribed,945,O
sequence,945,O
identified,945,O
from,945,O
the,945,O
C04107-containing,945,O
BAC,945,O
was,945,O
found,945,O
to,945,O
be,945,O
homologous,945,O
to,945,O
a,945,O
gene,945,O
expressed,945,O
from,945,O
human,945,O
chromosome,945,O
2p13-p16,945,O
",",945,O
a,945,O
region,945,O
devoid,945,O
of,945,O
any,945,O
positional,945,O
candidate,945,O
genes,945,O
.,945,O
Molecular,946,O
analysis,946,O
of,946,O
the,946,O
APC,946,B-Modifier
gene,946,O
in,946,O
205,946,O
families,946,O
:,946,O
extended,946,O
genotype-phenotype,946,O
correlations,946,O
in,946,O
FAP,946,B-SpecificDisease
and,946,O
evidence,946,O
for,946,O
the,946,O
role,946,O
of,946,O
APC,946,B-Modifier
amino,946,O
acid,946,O
changes,946,O
in,946,O
colorectal,946,B-Modifier
cancer,946,I-Modifier
predisposition,946,O
.,946,O
BACKGROUND/AIMS,947,O
The,947,O
development,947,O
of,947,O
colorectal,947,B-SpecificDisease
cancer,947,I-SpecificDisease
and,947,O
a,947,O
variable,947,O
range,947,O
of,947,O
extracolonic,947,O
manifestations,947,O
in,947,O
familial,947,B-SpecificDisease
adenomatous,947,I-SpecificDisease
polyposis,947,I-SpecificDisease
(,947,O
FAP,947,B-SpecificDisease
),947,O
is,947,O
the,947,O
result,947,O
of,947,O
the,947,O
dominant,947,O
inheritance,947,O
of,947,O
adenomatous,947,B-Modifier
polyposis,947,I-Modifier
coli,947,I-Modifier
(,947,O
APC,947,B-Modifier
),947,O
gene,947,O
mutations,947,O
.,947,O
In,948,O
this,948,O
study,948,O
",",948,O
direct,948,O
mutation,948,O
analysis,948,O
of,948,O
the,948,O
APC,948,B-Modifier
gene,948,O
was,948,O
performed,948,O
to,948,O
determine,948,O
genotype-phenotype,948,O
correlations,948,O
for,948,O
nine,948,O
extracolonic,948,O
manifestations,948,O
and,948,O
to,948,O
investigate,948,O
the,948,O
incidence,948,O
of,948,O
APC,948,B-Modifier
mutations,948,O
in,948,O
non-FAP,948,O
colorectal,948,B-SpecificDisease
cancer,948,I-SpecificDisease
.,948,O
METHODS,949,O
The,949,O
APC,949,B-Modifier
gene,949,O
was,949,O
analysed,949,O
in,949,O
190,949,O
unrelated,949,O
FAP,949,B-Modifier
and,949,O
15,949,O
non-FAP,949,O
colorectal,949,B-Modifier
cancer,949,I-Modifier
patients,949,O
using,949,O
denaturing,949,O
gradient,949,O
gel,949,O
electrophoresis,949,O
",",949,O
the,949,O
protein,949,O
truncation,949,O
test,949,O
",",949,O
and,949,O
direct,949,O
sequencing,949,O
.,949,O
RESULTS,950,O
Chain,950,O
terminating,950,O
signals,950,O
were,950,O
only,950,O
identified,950,O
in,950,O
patients,950,O
belonging,950,O
to,950,O
the,950,O
FAP,950,B-Modifier
group,950,O
(,950,O
105,950,O
patients,950,O
),950,O
.,950,O
Amino,951,O
acid,951,O
changes,951,O
were,951,O
identified,951,O
in,951,O
four,951,O
patients,951,O
",",951,O
three,951,O
of,951,O
whom,951,O
belonged,951,O
to,951,O
the,951,O
non-FAP,951,O
group,951,O
of,951,O
colorectal,951,B-Modifier
cancer,951,I-Modifier
patients,951,O
.,951,O
Genotype-phenotype,952,O
correlations,952,O
identified,952,O
significant,952,O
differences,952,O
in,952,O
the,952,O
nature,952,O
of,952,O
certain,952,O
extracolonic,952,O
manifestations,952,O
in,952,O
FAP,952,B-Modifier
patients,952,O
belonging,952,O
to,952,O
three,952,O
mutation,952,O
subgroups,952,O
.,952,O
CONCLUSIONS,953,O
Extended,953,O
genotype-phenotype,953,O
correlations,953,O
made,953,O
in,953,O
this,953,O
study,953,O
may,953,O
have,953,O
the,953,O
potential,953,O
to,953,O
determine,953,O
the,953,O
most,953,O
appropriate,953,O
surveillance,953,O
and,953,O
prophylactic,953,O
treatment,953,O
regimens,953,O
for,953,O
those,953,O
patients,953,O
with,953,O
mutations,953,O
associated,953,O
with,953,O
life,953,O
threatening,953,O
conditions,953,O
.,953,O
This,954,O
study,954,O
also,954,O
provided,954,O
evidence,954,O
for,954,O
the,954,O
pathological,954,O
nature,954,O
of,954,O
amino,954,O
acid,954,O
changes,954,O
in,954,O
APC,954,O
associated,954,O
with,954,O
both,954,O
FAP,954,B-Modifier
and,954,O
non-FAP,954,O
colorectal,954,B-Modifier
cancer,954,I-Modifier
patients,954,O
..,954,O
Inherited,955,B-SpecificDisease
colorectal,955,I-SpecificDisease
polyposis,955,I-SpecificDisease
and,955,O
cancer,955,B-Modifier
risk,955,O
of,955,O
the,955,O
APC,955,O
I1307K,955,O
polymorphism,955,O
.,955,O
Germ-line,956,O
and,956,O
somatic,956,O
truncating,956,O
mutations,956,O
of,956,O
the,956,O
APC,956,B-Modifier
gene,956,O
are,956,O
thought,956,O
to,956,O
initiate,956,O
colorectal,956,B-Modifier
tumor,956,I-Modifier
formation,956,O
in,956,O
familial,956,B-SpecificDisease
adenomatous,956,I-SpecificDisease
polyposis,956,I-SpecificDisease
syndrome,956,I-SpecificDisease
and,956,O
sporadic,956,O
colorectal,956,O
carcinogenesis,956,O
",",956,O
respectively,956,O
.,956,O
Recently,957,O
",",957,O
an,957,O
isoleucine,957,O
--,957,O
>,957,O
lysine,957,O
polymorphism,957,O
at,957,O
codon,957,O
1307,957,O
(,957,O
I1307K,957,O
),957,O
of,957,O
the,957,O
APC,957,B-Modifier
gene,957,O
has,957,O
been,957,O
identified,957,O
in,957,O
6,957,O
%,957,O
-7,957,O
%,957,O
of,957,O
the,957,O
Ashkenazi,957,O
Jewish,957,O
population,957,O
.,957,O
To,958,O
assess,958,O
the,958,O
risk,958,O
of,958,O
this,958,O
common,958,O
APC,958,B-Modifier
allelic,958,O
variant,958,O
in,958,O
colorectal,958,O
carcinogenesis,958,O
",",958,O
we,958,O
have,958,O
analyzed,958,O
a,958,O
large,958,O
cohort,958,O
of,958,O
unselected,958,O
Ashkenazi,958,O
Jewish,958,O
subjects,958,O
with,958,O
adenomatous,958,B-SpecificDisease
polyps,958,I-SpecificDisease
and,958,O
.,958,O
or,959,O
colorectal,959,B-SpecificDisease
cancer,959,I-SpecificDisease
",",959,I-SpecificDisease
for,959,O
the,959,O
APC,959,O
I1307K,959,O
polymorphism,959,O
.,959,O
The,960,O
APC,960,O
I1307K,960,O
allele,960,O
was,960,O
identified,960,O
in,960,O
48,960,O
(,960,O
10,960,O
.,960,O
1,961,O
%,961,O
),961,O
of,961,O
476,961,O
patients,961,O
.,961,O
Compared,962,O
with,962,O
the,962,O
frequency,962,O
in,962,O
two,962,O
separate,962,O
population,962,O
control,962,O
groups,962,O
",",962,O
the,962,O
APC,962,O
I1307K,962,O
allele,962,O
is,962,O
associated,962,O
with,962,O
an,962,O
estimated,962,O
relative,962,O
risk,962,O
of,962,O
1,962,O
.,962,O
5-1,963,O
.,963,O
7,964,O
for,964,O
colorectal,964,B-SpecificDisease
neoplasia,964,I-SpecificDisease
(,964,O
both,964,O
P,964,O
=,964,O
.,964,O
01,965,O
),965,O
.,965,O
Furthermore,966,O
",",966,O
compared,966,O
with,966,O
noncarriers,966,O
",",966,O
APC,966,O
I1307K,966,O
carriers,966,O
had,966,O
increased,966,O
numbers,966,O
of,966,O
adenomas,966,B-DiseaseClass
and,966,O
colorectal,966,B-SpecificDisease
cancers,966,I-SpecificDisease
per,966,O
patient,966,O
(,966,O
P,966,O
=,966,O
.,966,O
03,967,O
),967,O
",",967,O
as,967,O
well,967,O
as,967,O
a,967,O
younger,967,O
age,967,O
at,967,O
diagnosis,967,O
.,967,O
We,968,O
conclude,968,O
that,968,O
the,968,O
APC,968,O
I1307K,968,O
variant,968,O
leads,968,O
to,968,O
increased,968,O
adenoma,968,B-Modifier
formation,968,O
and,968,O
directly,968,O
contributes,968,O
to,968,O
3,968,O
%,968,O
-4,968,O
%,968,O
of,968,O
all,968,O
Ashkenazi,968,O
Jewish,968,O
colorectal,968,B-SpecificDisease
cancer,968,I-SpecificDisease
.,968,O
The,969,O
estimated,969,O
relative,969,O
risk,969,O
for,969,O
carriers,969,O
may,969,O
justify,969,O
specific,969,O
clinical,969,O
screening,969,O
for,969,O
the,969,O
360,969,O
",",969,O
000,969,O
Americans,969,O
expected,969,O
to,969,O
harbor,969,O
this,969,O
allele,969,O
",",969,O
and,969,O
genetic,969,O
testing,969,O
in,969,O
the,969,O
setting,969,O
of,969,O
long-term-outcome,969,O
studies,969,O
may,969,O
impact,969,O
significantly,969,O
on,969,O
colorectal,969,B-Modifier
cancer,969,I-Modifier
prevention,969,O
in,969,O
this,969,O
population,969,O
.,969,O
Localization,970,O
of,970,O
human,970,O
BRCA1,970,O
and,970,O
its,970,O
loss,970,O
in,970,O
high-grade,970,O
",",970,O
non-inherited,970,B-SpecificDisease
breast,970,I-SpecificDisease
carcinomas,970,I-SpecificDisease
.,970,O
Although,971,O
the,971,O
link,971,O
between,971,O
the,971,O
BRCA1,971,O
tumour-suppressor,971,B-Modifier
gene,971,O
and,971,O
hereditary,971,B-CompositeMention
breast,971,I-CompositeMention
and,971,I-CompositeMention
ovarian,971,I-CompositeMention
cancer,971,I-CompositeMention
is,971,O
established,971,O
",",971,O
the,971,O
role,971,O
",",971,O
if,971,O
any,971,O
",",971,O
of,971,O
BRCA1,971,O
in,971,O
non-familial,971,B-DiseaseClass
cancers,971,I-DiseaseClass
is,971,O
unclear,971,O
.,971,O
BRCA1,972,O
mutations,972,O
are,972,O
rare,972,O
in,972,O
sporadic,972,B-DiseaseClass
cancers,972,I-DiseaseClass
",",972,O
but,972,O
loss,972,O
of,972,O
BRCA1,972,O
resulting,972,O
from,972,O
reduced,972,O
expression,972,O
or,972,O
incorrect,972,O
subcellular,972,O
localization,972,O
is,972,O
postulated,972,O
to,972,O
be,972,O
important,972,O
in,972,O
non-familial,972,O
breast,972,O
and,972,O
ovarian,972,O
cancers,972,O
.,972,O
Epigenetic,973,O
loss,973,O
",",973,O
however,973,O
",",973,O
has,973,O
not,973,O
received,973,O
general,973,O
acceptance,973,O
due,973,O
to,973,O
controversy,973,O
regarding,973,O
the,973,O
subcellular,973,O
localization,973,O
of,973,O
BRCA1,973,O
proteins,973,O
",",973,O
reports,973,O
of,973,O
which,973,O
have,973,O
ranged,973,O
from,973,O
exclusively,973,O
nuclear,973,O
",",973,O
to,973,O
conditionally,973,O
nuclear,973,O
",",973,O
to,973,O
the,973,O
ER/golgi,973,O
",",973,O
to,973,O
cytoplasmic,973,O
invaginations,973,O
into,973,O
the,973,O
nucleus,973,O
.,973,O
In,974,O
an,974,O
attempt,974,O
to,974,O
resolve,974,O
this,974,O
issue,974,O
",",974,O
we,974,O
have,974,O
comprehensively,974,O
characterized,974,O
19,974,O
anti-BRCA1,974,O
antibodies,974,O
.,974,O
These,975,O
reagents,975,O
detect,975,O
a,975,O
220-kD,975,O
protein,975,O
localized,975,O
in,975,O
discrete,975,O
nuclear,975,O
foci,975,O
in,975,O
all,975,O
epithelial,975,O
cell,975,O
lines,975,O
",",975,O
including,975,O
those,975,O
derived,975,O
from,975,O
breast,975,B-SpecificDisease
malignancies,975,I-SpecificDisease
.,975,O
Immunohistochemical,976,O
staining,976,O
of,976,O
human,976,O
breast,976,O
specimens,976,O
also,976,O
revealed,976,O
BRCA1,976,O
nuclear,976,O
foci,976,O
in,976,O
benign,976,O
breast,976,O
",",976,O
invasive,976,B-DiseaseClass
lobular,976,I-DiseaseClass
cancers,976,I-DiseaseClass
and,976,O
low-grade,976,B-SpecificDisease
ductal,976,I-SpecificDisease
carcinomas,976,I-SpecificDisease
.,976,O
Conversely,977,O
",",977,O
BRCA1,977,O
expression,977,O
was,977,O
reduced,977,O
or,977,O
undetectable,977,O
in,977,O
the,977,O
majority,977,O
of,977,O
high-grade,977,O
",",977,O
ductal,977,B-SpecificDisease
carcinomas,977,I-SpecificDisease
",",977,O
suggesting,977,O
that,977,O
absence,977,O
of,977,O
BRCA1,977,O
may,977,O
contribute,977,O
to,977,O
the,977,O
pathogenesis,977,O
of,977,O
a,977,O
significant,977,O
percentage,977,O
of,977,O
sporadic,977,B-SpecificDisease
breast,977,I-SpecificDisease
cancers,977,I-SpecificDisease
..,977,O
